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Emerging respiratory virus infections
S28 Avian inﬂuenza virus infections in humans
R.A.M. Fouchier
Rotterdam, NL
Objectives: Recently a novel paramyxovirus isolated from children
with respiratory tract disease was identiﬁed that was named
human metapneumovirus (hMPV) and classiﬁed as a member of
the metapneumovirus genus. We investigated the impact of
hMPV infections and developed new tools and reagents for
applied and fundamental research.
Methods: A large collection of hMPV isolates was generated, origi-
nating from different geographical locations from 1980 onwards.
Sequence analyses were performed to study the genetic diversity
of hMPV. Antigenic variation was measured with postinfection
animal sera. A reverse genetics system was developed to produce
recombinant hMPV. Improved diagnostic tests for hMPV were
designed.
Results: Retrospective studies revealed that approximately 7% of
the samples collected from individuals suffering from respiratory
tract disease where positive for hMPV. HMPV was detected pri-
marily in very young children and immunocompromised indivi-
duals and mostly in January and February. Clinical symptoms
associated with hMPV infection in young children were found to
be similar to those observed for RSV infections. In the 2000 and
2001 winter seasons in the Netherlands, only RSV was found to be
associated with respiratory tract illnesses more frequently in an
academic hospital setting. Sequence information on the fusion and
attachment surface glycoproteins revealed that there are two main
genetic lineages of hMPV (A and B) each of which, can be sepa-
rated in two sublineages (A1, A2, B1 and B2). Virus neutralization
experiments using animal sera indicated that the two main
lineages represent different hMPV serotypes. We have sequenced
the full-length genome of prototype strains representing each of
these four genetic lineages. For both serotypes a prototype virus
isolate was selected for which minigenome reporter systems were
made and subsequently infectious recombinant hMPVs were res-
cued. We also developed and evaluated new diagnostic assays for
detection of hMPV strains from all genetic lineages with equal spe-
ciﬁcity and sensitivity.
Conclusions: hMPV is an important viral pathogen. Young chil-
dren, immunocompromised individuals and frail elderly are at
risk for serious hMPV-associated disease. The genetic and anti-
genic heterogeneity of hMPV isolates should be taken into account
for the development of diagnostic tests and evaluation of future
vaccines. The applied and fundamental research on hMPV will
beneﬁt from the newly developed tools and reagents.
Sushi delights and leisure-related exposure
S39 Sushi and Sashimi risks
Y. Nawa
Miyazaki, JP
‘Sushi’ and ‘Sashimi’ are the traditional Japanese dishes served
with soya sauce dipping (3S Japanese food culture). Among three
major types of ‘Sushi’ dishes, Nigiri, a piece of sliced raw ﬁsh ﬁl-
let on vinegered rice ball, is the commonest dish served at Sushi
bars. ‘Sashimi’ is an assorted dish of sliced raw ﬁsh ﬁllets. Along
with the popularization of Japanese dishes, ‘Sushi’ and ‘Sashimi’
are thought to be responsible in causing ﬁsh-borne parasitic zoo-
noses, especially anisakiasis, which is caused by infection with
either herring worm, Anisakis sp. or cod worm, Pseudoterranova
decipiens. The larval stages of them reside in the muscles and/or
visceral organs of an array of marine ﬁshes and squid. Human
infection occurs by ingesting un-cooked/under-cooked marine
products. However, apparent increase in anisakiasis cases in
Japan and some other countries is related more to advances in
diagnosis by endoscopy than to the epidemiological outbreak by
commercialization of ‘Sushi’. In addition, ﬁsh species used for
‘Sushi’ or ‘Sashimi’ are less contaminated with, or free from, Ani-
sakis larvae. Of course, we should remind the high risk of infec-
tion with ﬁsh tapeworm (Diphyllobothrium) by ingesting salmon,
which is commonly served as ‘Sushi’ and ‘Sashimi’. The ﬁsh spe-
cies having heavy burden of Anisakis larvae are cod, herring,
mackerel and squids, which are cheap and mainly consumed at
home. Concerning the risk of ﬁsh-borne parasitic zoonoses, we
should pay more attention to the fresh- or brackish-water ﬁshes.
Gnathostoma larvae, which cause creeping disease, are common in
the muscle of snakehead, cat ﬁsh, or tilapia. The disease is ende-
mic in Asia, especially in Thailand and Japan. Recently an out-
break of this disease was reported from Mexico. Cultivation of
tilapia in dam-lakes and its usage in traditional ﬁsh dishes,
‘Cebiche’ and ‘Callos’, are responsible for the outbreak. Consump-
tion of freshwater crabs in Asia is at risk of infection with Parago-
nimus, a lung ﬂuke. Many small ﬁshes in fresh- or brackish-water
carry metacercariae of minute intestinal ﬂukes such as Metagoni-
mus, Heterophyes, etc. In Asia, liver ﬂuke larvae are found in fresh-
water ﬁshes. Those ﬂukes are usually harmless, but heavy infec-
tion occasionally causes serious GI symptoms. In conclusion,
‘Sushi’ and ‘Sashimi’ are rather at low risk of infection with zoo-
notic parasites. We need more attention on local ethnic dishes pre-
pared by local freshwater ﬁshes.
S41 Worms in south-east Asia: watch out what you eat
and where you bath
S. Odermatt-Biays, P. Odermatt
Vientiane, LAO
In the last decade south-east Asia has become an attractive place
for tourists. Various activities are nowadays possible, reaching
from beach holidays to eco-tourism exploring remote natural
areas or visiting ethnic minorities. In south-east Asia a very fre-
quent habit is the consumption of uncooked or partially-cooked
foodstuff which favours the transmission of various parasites. As
a result of the consumption of raw ﬁsh, opisthorchiasis is very
common disease in the region. Although most liver ﬂukes infec-
tions are asymptomatic, signiﬁcant disease can be associated:
obstructive jaundice, cholangitis, cholecysticis, cholelithiasis and
specially cholangiocarcinoma have a high incidence in the region
and contribute to the mortality. Less frequently, ingestion of raw
ﬁsh can transmit gnathostoma or Angiostrongylus sp. These para-
sites are causes of eosinophilic meningitis and can also be found in
frogs, snails and reptiles. Consumption of fresh rice ﬁeld crabs
enables the infection with Paragonimus sp.. The transmission takes
place mostly is mountainous regions. Traditional medicine of eth-
nic groups can contribute to transmission as raw crab meat is
given to children as fever-decreasing remedy. Erratic localization
of eggs can cause neurological disease. Various dishes include
inadequately cooked pork. A total of 120 epidemics of trichinello-
sis have been reported from 1962 to 2000 in Thailand, mostly in
the North in Mong, Yao and Karen communities, involving 6700
patients and 97 death. In Laos, Thailand and north of Vietnam,
recent studies have shown that cysticercosis is much more com-
mon than anticipated. Since the 1990s, fascioliasis is an emerging
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disease in central provinces of Vietnam. Is it due to a raise of con-
sumption of raw aquatic plants? Recent economic development
enable the commercialization of cattle which favours the establish-
ment of the transmission cycle. Schistosomiasis mekongi, is focally
transmitted along the Mekong river in northern Cambodia and
southern Laos. Although successful control programmes are
implemented, transmission still occurs in certain areas; S. mekongi
may lead to severe disease. A case of cerebral schistosomiasis has
recently been reported in an exposed traveller. Prevention of
food-borne parasitic infections should be an integral part in the
counselling of travellers to south-east Asia and recommendations
concerning the bathing in the Mekong river.
S42 Swimmer’s itch: an emerging water-borne disease
L. Kolarova
Prague, CZ
Swimmer’s itch (cercarial dermatitis) is a common, noncommunic-
able infection that is widely neglected. The disease represents an
allergic immune response which develops after repeated contacts
of mammals (including man) with schistosome larval stages (cer-
cariae). The most known causative agent of the disease are cercar-
iae of the bird schistosome genus Trichobilharzia the life-cycle of
which is connected with fresh-water bodies all over the world.
In the past, it has been assumed that the parasites die soon after
the penetration into the noncompatible host skin. However, recent
observations on bird schistosomes showed that the immature
ﬂukes are able to escape from the skin and migrate further to inter-
nal organs where they can survive for several days and even weeks
in mammals under certain circumstances. And depending on the
species, particular schistosomes can cause severe tissue injuries
either in the lungs or in the central nervous system (CNS) of these
type of hosts. Our studies on Trichobilharzia infections showed
that the involvement of internal organs during bird schistosome
infections in mammals is dependent on the host-immune status.
During primary T. regenti infection of immunocompetent mice, the
parasites evoked acute inﬂammatory reaction in the skin and the
CNS involving focal oedema and cellular inﬁltration of the tissues.
Challenge infections resulted in the development of extensive
inﬂammatory foci in the host skin which precluded the subsequent
migration of the schistosomula to the CNS. However, during pri-
mary and challenge infections of immunodeﬁcient hosts (SCID
mice), no signiﬁcant immune response against the parasites in any
of examined host organs was detected; however, in contrast to
immunocompetent mice, the infections were frequently manifested
by severe neurological symptoms. Moreover, the studies on mice
with various immune status showed that the deﬁciency in T- and
B-cell immune response mice can lead to longer survival of the
parasites in SCID mice. Our results showed that the infection of
mammals with bird schistosomes may cause more serious pro-
blems than just cercarial dermatitis alone in certain cases. The cos-
mopolitan occurrence of T. cercariae and increasing exposures of
humans to these parasites show the necessity to intensify the stu-
dies on these parasites.
Intervention to improve antibiotic prescription
O47 Improving the management of inpatients with
community-acquired pneumonia: controlled before and after
study
G. Barlow, D. Nathwani, F. Williams, S. Ogston, K. Lowden,
J. Winter, M. Jones, P. Slane, E. Myers, F. Sullivan, N. Stevens,
R. Duffy, P.G. Davey
Dundee, UK
Objectives: Community-acquired pneumonia is a common cause of
acute medical admission. We have previously identiﬁed time to
antibiotic administration and antibiotic appropriateness as poten-
tially important quality improvement targets (Clin Infect Dis 2002;
34: 218–223). The aim of the project was to implement a quality
improvement intervention and to evaluate its impact on processes
and outcomes of care.
Methods: Preimplementation, qualitative and quantitative methods
identiﬁed barriers to the efﬁcient delivery of appropriate antibio-
tics. These data were used to design a targeted intervention (wall-
based pathways, promotional posters, implementation packs, edu-
cational sessions and audit and feedback). Process of care and
outcomes were compared at one study and one control hospital
over two winters (2001/02 and 2002/03), before and after the
intervention. The primary outcome was the proportion of patients
receiving appropriate antibiotics (British Thoracic Society deﬁni-
tion) within 4 h of admission. Cost effectiveness analysis was per-
formed from the hospital’s perspective.
Results: The proportion of patients receiving appropriate antibio-
tics within 4 h increased by 70% at the study hospital: from 33%
(60/181) to 56% (118/209) vs. a 10% increase at the control hospi-
tal: from 32% (19/60) to 36% (19/53). Unadjusted absolute
change (study – control) ¼ 20%, P < 0.01; adjusted absolute
change ¼ 17%, P ¼ 0.035. This difference was mostly because of
an improvement in ‘door to antibiotic time’, the proportion of
patients receiving appropriate antibiotics by BTS criteria improved
similarly at both hospitals. The improvement in door to needle
time was not associated with any signiﬁcant difference in length
of hospital stay or mortality between the study and control hospi-
tals (P ¼ 0.4 adjusted for severity). The cost per additional patient
receiving appropriate antibiotics within 4 h was £1776 for a pro-
ject with full evaluation but could be reduced to £132 by imple-
menting the intervention without full evaluation. Costs would
also be substantially reduced if outcomes could be evaluated from
electronic medical records.
Conclusions: The intervention signiﬁcantly improved the quality of
initial care, but at notable cost. Costs would fall considerably if
routinely collected electronic data were available. This is the sec-
ond intervention study that has failed to show an association
between decreased door to needle time and improved outcome of
CAP.
O48 The path of least resistance: the value of educating
patients and professionals about antimicrobial resistance
G. Madle, P. Kostkova, J. Mani-Saada, J. Weinberg
London, UK
Objectives: To evaluate the impact of a digital library on changing
patient and professional knowledge and attitudes to antimicrobial
prescribing.
Methods: Research has shown that patient expectation and the
perceived expectation by the doctor inﬂuences general practice
prescribing of antibiotics. Both the SMAC report ‘The Path of
Least Resistance in 1997’, and the House of Lords report in 1998
highlighted the importance of educating the public about antimi-
crobial resistance as part of the strategy to contain it. So how
can we provide timely access to quality-controlled information
for both professionals and patients and know that it is making a
difference to their knowledge and attitudes? The National Elec-
tronic Library for Health (NeLH) is a freely accessible Internet
gateway to the best available evidence. At City we are
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developing the infection specialist library (NeLI). The key value
of the library lies in the quality appraisal of documents by
expert reviewers. One aim of NeLH is to provide health care
professionals and the public with knowledge and know-how to
support health care related decisions. But does NeLI have any
inﬂuence on user knowledge and attitudes about antimicrobial
resistance? We used pre and postuse questionnaires to evaluate
the impact of NeLI on users.
Results: The study was conducted in several different locations. At
the Science Museum, London 177 visitors completed both ques-
tionnaires. There were statistically signiﬁcant increases in knowl-
edge and reductions in expectation of receiving antibiotics for
acute otitis media (AOM). The most signiﬁcant change was from
10 to 46% of users correctly saying that people cannot become
resistant to antibiotics. The percentage of users agreeing that doc-
tors should usually prescribe antibiotics for a child with AOM fell
from 51 to 33% and for those agreeing that they would expect an
antibiotic for themselves or their child with AOM fell from 59 to
30%. Similar results were obtained with a smaller group at Not-
tingham City Hospital. The study has recently been repeated at
Oxford University Medical School and results will be available for
the conference presentation.
Conclusion: To summarise, there were signiﬁcant improvements
in user knowledge about antibiotics, after using the site users
had a reduced expectation of receiving antibiotics for AOM.
Internet resources can be effective tools in improving health out-
comes.
O49 Attitudes to antibiotic prescribing, resistance and
laboratory investigations amongst practitioners and patients in
the Grampian region of Scotland
I.M. Gould, F.M. MacKenzie, L. Shepherd
Aberdeen, UK
Objectives: Patient pressure and difﬁculties in accessing laboratory
facilities are often put forward as reasons for inappropriate anti-
biotic prescribing in the community. Community general practi-
tioners (GPs) and patients were questioned to establish their
perception of appropriate prescribing, the existence of resistance
problems and the use of laboratory investigations to facilitate pre-
scribing.
Methods: The Grampian region of Scotland operates an accelerated
bacteriology laboratory examination (ABLE) service, ensuring
overnight processing of samples in order to allow informed anti-
biotic prescribing. During an audit of use of the service and of
antibiotic prescribing, we distributed questionnaires to both GPs
and patients. Questions related to attitudes and knowledge of
antibiotic prescribing and resistance and feedback on the ABLE
service. Results were entered in an Excel spreadsheet and ana-
lysed by SPSS.
Results: A total of 49 GPs responded (response rate 90%). 89%
thought that reducing prescribing reduces resistance but only
38% considered resistance a problem in their own practice. 92%
used the ABLE service, but only 8% daily and 47% weekly. 67%
said they combined the service with a delayed prescription. 53%
thought it decreased antibiotic prescription rates. 701 patients
were surveyed. 23% expected antibiotic for a sore throat, 36% for
a chesty cough, 35% for earache and 17% for sinusitis. Notably,
expectations were markedly lower for their children. 88% thought
the ABLE service was a good idea. 50% thought resistance a big
problem and 74% wanted more information on antibiotic resis-
tance in the form of a leaﬂet.
Conclusions: Acceptance of the ABLE service and awareness of
antibiotic resistance was high. Patient expectations of antibio-
tics were low compared with the literature and provide a good
grounding for further improvements in antibiotic prescribing
based on decreased patient pressure and increased use of
ABLE. Both GPs and patients seem well placed to maintain
recent improvements in antibiotic prescribing in the Grampian
region.
O50 Antimicrobial usage and resistance trends among
Gram-negative nosocomial bacteria: a 4-year follow-up study in
a Belgian hospital
Y. Glupczynski, B. Delaere, C. Baude, P. Gillet, Y. DeGheldre,
J.D. Hecq
Yvoir, Belgium
Objective: An increase of extended-spectrum beta-lactamase
(ESBL) producing Enterobacter aerogenes (E.a.) and multi-resistant
Pseudomonas aeruginosa (PSA) was documented in our hospital
during the 1998–2000 period. In 2001, an antibiotic policy aimed
to control the usage of broad-spectrum antibiotics was instituted.
We aimed to compare the antimicrobial usage and the prevalence
of resistance among nosocomial Gram-negative bacilli (GNB) iso-
lates between 2000 and 2003 in order to evaluate the relationship
between antibiotic use and resistance prevalence in nosocomial
infections.
Methods: Resistance data were collected from all GNB strains iso-
lated from nosocomial infections. Antibiotic consumption data
were monitored with the ABCCalc software according to the
ATC/WHO 2003 methodology and data were expressed in pre-
scribed daily doses (PDDs)/100 bed instead of deﬁned daily doses
(DDDs).
Results: The global antibiotic consumption decreased by 14%
(50.9 PDDs in 2003 vs. 58.8 in 2000), the largest decrease being
noted for the ﬂuoroquinolones (FQs) (7.0–4.5 PDDs; -36%),
especially the parenteral formulations (2.9–0.8 PDDs; -72%).
Decreased usage was also recorded for cefuroxime (7.6–5.2
PDDs), ceftazidime (1.9–1.0 PDDs) and meropenem (2.2–0.8
PDDs) while the use of cefepime increased from 2.2 to 2.9 PDDs.
No changes were observed for ureidopenicillins, aminoglycosides
and glycopeptides. A decline in resistance was observed
through the study period for beta-lactams (piperacillin/tazobac-
tam 15%, cefuroxime 14%, ceftazidime 9%), ciproﬂoxacin
(19%) and amikacin (8%) among Enterobacteriaceae isolates.
These lower resistance rates were essentially linked to a marked
reduction in the proportion ESBL-producing E.a. over time (14.3–
7.6%; 49%). In PSA, the proportion of multi-resistant strains
ﬂuctuated but did not vary signiﬁcantly, the only trend observed
being a lowering in resistance rates to gentamicin (17%) and
tobramycin (8%) while no changes were recorded for other anti-
pseudomonal agents.
Conclusions: The enforcement of a controlled antibiotic policy
led to a signiﬁcant decrease in the consumption of broad-spec-
trum antibiotics. A direct relationship could be observed
between the decreased usage of FQs over time and a marked
decline in the number of ESBL-producing E.a. isolates. Our
study illustrates that controlled usage of broad spectrum anti-
biotics may have a positive impact on the epidemiology of
nosocomial bacteria.
O51 Interventions to improve vancomycin prescribing – a
useful exercise or a waste of time?
F.M. Fitzpatrick, R. Crowley, H. Humphreys, E. Smyth
Dublin, IRL
Therapeutic drug monitoring has become a standard of care in
patients on vancomycin, despite controversary regarding its role
in preventing toxicity and optimizing outcome. Informal obser-
vations by the clinical microbiology team in our institution, sug-
gested that patients were not receiving all doses of vancomycin
prescribed. As a consequence, we conducted a prospective audit
of vancomycin usage and assessed the impact of therapeutic
drug monitoring on administration of vancomycin in our institu-
tion. The initial month-long audit revealed that the majority of
patients (51/54) were prescribed vancomycin appropriately.
However patients received only 725 of 1007 prescribed doses
(72%). Reasons for failure to administer 282 doses included no
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i.m. access (3%) and toxic levels (39%). However in the
remaining 58% the antibiotic was withheld inappropriately
either awaiting level results or for no apparent reason. This
study highlighted the confusion among health care professionals
about administration and laboratory monitoring of vancomycin.
As a consequence, our department undertook several measures
in order to improve vancomycin prescribing and laboratory
monitoring. These measures included feedback of audit ﬁndings
to medical, nursing, pharmacy and management staff at hospi-
tal-wide educational meetings, changes in laboratory computer
and phlebotomy practices and changes in microbiology depart-
ment policy with regard to level ordering, frequency and inter-
pretation of levels. One of the changes that we undertook was
to abolish random, peak and trough testing options in favour
of a single predose level. This simpliﬁed level ordering, which
was a major source of confusion among medical staff. A second
audit of practice is currently underway. This presentation will
discuss the success or otherwise of our interventations and
highlight problems that we identiﬁed whilst attempting to
improve vancomycin prescribing and level ordering in our insti-
tution.
O52 A computerised decision support system (TREAT)
to reduce inappropriate antibiotic therapy of bacterial infections
E. Tacconelli, M. Paul, M.A. Cataldo, N. Almanasreh,
A. Zalounina, A. Nielsen, S. Andreassen, U. Frank, R. Cauda,
L. Leibovici
Rome, I; Petah-Tiqva, IL; Freiburg, D; Aalborg, DK
Background: Inappropriate empirical therapy of bacterial infections
is associated with an increase in fatality rate. TREAT is a compu-
terised decision support system (DSS) for antibiotic treatment of
bacterial infections in in-patients. It looks at risk factors for infec-
tions, local distribution and susceptibilities of bacteria, and then
balances the beneﬁt of antibiotic treatment against its costs to
advice on a drug.
Objectives: To improve the percentage of appropriate antibiotic
treatments by using the TREAT system in clinical practice.
Methods: A multi-centre observational clinical trial has been per-
formed at three University hospitals. All consecutive adult
patients for whom antibiotic treatment was started have been
included over a 7-month study period. The following variables
were collected before starting antibiotic therapy, at the availability
of microbiological result, and at ﬁnal diagnosis: comorbidies, risk
factors for infections and pathogens, clinical and microbiological
data, physicians’ chosen therapy and TREAT advice. Primary out-
come was the percentage of appropriate empirical antibiotic treat-
ment, deﬁned as antibiotic treatment matching the susceptibility
of the isolated pathogen. Test-based conﬁdence intervals (CI) at
95% were used to determinate the signiﬁcance of the relative risk
(RR).
Results: During the observational trial, 1203 patients were
enrolled. Infections were acquired in the community in 70% of
cases. The most frequent outcome diagnosis were: pneumonia
(24%) and septicaemia (11%). Signiﬁcant clinical isolates were
available in 352 patients (29%) with the most frequent being:
E. coli (36%), S. aureus (17%), and P. aeruginosa (16%). Appropri-
ate antibiotic treatment was given by TREAT to 63% of patients,
compared with 56% of treatments prescribed by physicians (OR
0.33, 95%CI 0.07–0.53, P 0.01). The use of the programme led to
signiﬁcant decrease in inappropriate treatment from 38 to 28%.
The overall cost of treatment prescribed by TREAT was 58%
(95% CI, 56–59%) of the treatment cost prescribed by physicians.
The direct antibiotic cost per patient for 1 day was 17.5 Euro for
TREAT vs. 31 Euro for physicians.
Conclusions: TREAT achieved a signiﬁcant increase in appropriate
empirical antibiotic treatment of patients with bacterial infections.
These results seem to suggest that computerised DSS using local
data can streamline appropriateness of antibiotic therapy and
reduce hospital costs.
O53 Impact of an intervention programme to reduce
inappropriate antibiotic prescriptions in south-eastern France
B. Dunais, H. Carsenti Dellamonica, M. Roussel Delvallez
Nice, Lille, F
Background: France has very high pneumococcal resistance and
antibiotic consumption rates. Nasopharyngeal (NP) nonpenicillin-
susceptible pneumococcal (NPSP) carriage rates in children’s day-
care centres in the Alpes Maritimes (AM) and Nord (N) areas
reached 60 and 72%, respectively, during Winter 1999. A local
intervention programme was implemented in AM in 2000 to
reduce antibiotic prescriptions in paediatric upper respiratory
tract infections (URTI).
Methods: Resistance data and guidelines were provided to general
practitioners and paediatricians in AM during peer-conducted
academic detailing visits. Parents received an information leaﬂet
on bacterial resistance. A new cross-sectional survey of NPSP car-
riage was conducted in AM and N during Winter 2002. NP sam-
ples were collected and parents were questioned about AB
treatment during the past 3 months.
Results: Between 1999 and 2002, among SP carriers, the proportion
of NPSP remained stable in AM: + 0.02% (ns). In N it increased
by 19% (P ¼ 0.01). Between 1999 and 2002, the proportion of
treated children in AM decreased by 18% (P ¼ 0.03) and
remained stable in Nord: +2.2%, (ns). Sentinel surveillance of
URTI did not show differential epidemic contexts between the
two areas.
Conclusions: Academic detailing visits promoting prudent antibio-
tic use appear to have been effective in reducing prescription rates
for children attending day care.
O54 Implementation of multidisciplinary antibiotic
management teams in Belgian hospitals: pilot phase evaluation,
2002–03
L. Sourdeau, M.J. Struelens, W.E. Peetermans, C. Suetens and the
Hospital Care Working Group of Belgian Antibiotic Policy Coordi-
nation Commitee (BAPCOC)
Objectives: To analyse the interventions undertaken by Belgian
hospitals during a pilot phase of supporting local antibiotic man-
agers (AM) and multidisciplinary antibiotic management teams
(AMT).
Methods: In 2002–03, the Belgian government subsidised the part-
time activities of AMs in 35 hospitals selected based on the pre-
sence of an operational AMT. The activities described in the ﬁrst
8-month progress reports were analysed according to national
guidelines for AMTs.
Material: The pilot hospitals had a median capacity of 654 (range,
154–1597) beds; 18 hospitals comprised several sites. Their regio-
nal distribution was representative of population size, with 18
hospitals located in Flanders, 11 in Wallonia and six in Brussels;
17 were general hospitals, eight teaching hospitals and 10 general
hospitals with teaching beds.
Results: AMs were trained as internists (28), microbiologists (13)
and hospital pharmacists (13). In 18 hospitals the AM also served
as infection-control physician. On average, AMTs included 10
members who met every 6 weeks. The pilot ﬁnancing scheme
allowed the implementation of 175 antibiotic management inter-
ventions, with a mean of ﬁve interventions per hospital. More
interventions were launched in large size and teaching hospitals.
All hospitals irrespective of size or afﬁliation had undertaken a
wide range of measures: review of formulary (29), implementation
of new clinical guidelines (24), restricted access to select antibiotics
(25), improvement of susceptibility-testing methods (12), develop-
ment of antibiotic consumption database (35) and analysis of anti-
bacterial susceptibility data (31). Updated guidelines addressed
mainly urinary tract infection (14), pneumonia (14) and meningitis
(10) and indications for use of speciﬁc drugs (14). Use of
glycopeptides, carbapenems, ﬂuoro-quinolones, cefepime and
ceftazidime was restricted in respectively 16, 12, 12, 12 and 10
hospitals.
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Conclusion: All hospitals that received ﬁnancial incentive under
the AMT pilot scheme have developed multiple antibiotic policy
interventions independently of the hospital size and teaching sta-
tus. Extension to all Belgian hospitals appears warranted. Further
analysis is planned to monitor the impact of this scheme on the
use of antibiotics and trends of antibiotic resistance.
O55 Antimicrobial availability for oncology patients with
advanced malignancy in Latin America: WHO/PAHO Medical
Oncology Survey Report 2000–2002
A. Safdar, I. Torres, C. Cleeland, K. Rolston
Houston, USA
Objective: Evaluate availability of major classes of antimicrobials
to physicians providing health care to patients with advanced
cancer in Latin America.
Methods: A cross-sectional descriptive analytic survey was con-
ducted from March 2000 to November 2002. The self-administered
anonymous survey was approved by institutional review board of
The University of Texas M. D. Anderson Cancer Center. The six
major groups of antimicrobials surveyed included: aminoglyco-
sides, antifungals, beta-lactams, quinolones, trimethoprim-sulpha-
methoxazole and vancomycin.
Results: Responses were obtained from 936 physicians including
medical and surgical oncologists, anaesthesiologists and palliative
care/pain management specialist from 26 countries. Most respon-
dents (>90%) practiced in urban setting. Most responses were
received from Brazil (n ¼ 345; 37%), Mexico (n ¼ 129; 14%),
Argentina (n ¼ 108; 12%), and Cuba (n ¼ 59; 6%). The mean
response from Argentina, Brazil, and Mexico generally rated the
availability of all antimicrobial classes as ‘Good’. Respondents
from Mexico, however, despite belonging to the same GNP
(gross national product group III, $ < 7000) as Brazil, reported
availability of vancomycin signiﬁcantly lower than respondents
from Brazil (P < 0.000). Physicians from Cuba (GNP group IV,
$ < 5000), in addition, rated all classes of antimicrobials as signif-
icantly lower compared with responses from the other three
countries, with the exception of trimethoprim-sulphamethoxazole
(P < 0.0001).
Conclusions: In Cuba, reduced availability of all major groups of
antimicrobials for the treatment of patients with advanced cancer
is a concern. This study provides important information in
reassessing and re-establishing future guidelines for regional and
global healthcare support stratagies.
O56 Household survey of residual antibiotics and beliefs
about antibiotics
C. McNulty, P. Boyle, P. Clappison, A. Fiacco, P.G. Davey
Gloucester, St Andrews, Leeds, London, Dundee, UK
Objectives: To measure the extent to which entirely or partially
unused prescribed antibiotics are retained in UK households and
to elicit the reasons for such retention. To assess the public’s
awareness of antibiotic resistance and the content of publicity
campaigns.
Methods: We added additional questions to the Omnibus survey,
conducted monthly throughout Great Britain for 8 months each
year by the Ofﬁce of National Statistics. Our surveys were car-
ried out in February/March and June/July 2003. Adults aged
16 years or over living in private households were approached
by letter for face-to-face interview based on a stratiﬁed probabil-
ity sample of the population. Interviewers had no control over
who was interviewed - they had to interview at the preselected
address and select one adult for interview according to a preset
method. Unlike quota samples this method avoids the bias intro-
duced when interviewers select only people who are easy to per-
suade to take part in the survey. The area in which each house
was located was ranked by the ACORN geo-demographic classi-
ﬁcation.
Results: A total of 7319 households were identiﬁed and 7120
(97%) took part in the survey. Of these 1316 (18%) had 1659 anti-
biotics in the house. Of the 7120 households, 365 (5%) held anti-
biotics that were partially unused from a previous prescription,
219 (3%) held antibiotics that were authorised by a doctor to be
kept for a future infection, 727 (10%) held antibiotics that were
currently in use and ﬁve were unsure. There was no relationship
between geo-demographic area and residual antibiotics: 5%, 95%
CI 4–6% least-deprived; 5%, CI 4–6% most-deprived. However,
people in the least-deprived areas were less likely to believe that
antibiotics work against most coughs or colds (27%, CI 25–28%
vs. 35%, CI 34–37%), more likely to believe that bacteria on their
skin or in their gut are good for their health (64%, CI 62–66% vs.
53%, 51–55%) and more likely to believe that antibiotic resistance
is a threat to them or their family (84%, CI 83–85% vs. 80%, CI
78–81%).
Conclusions: Few households retain prescribed antibiotics for
future use. Although a majority of people believe that antibiotic
resistance is a threat to them or their family a substantial minority
still believe that antibiotics work against most colds or coughs
and there is a signiﬁcant relationship between geo-demographic
classiﬁcation and educational need.
Novel molecular methods for bacteriological diagnosis
O57 A FISH assay with peptide nucleic acid probes for
direct identiﬁcation of blood cultures: evaluation in the routine
setting
M. Sogaard, H. Stender, H.C. Schønheyder
Aalborg, DK; Woburn, USA
Objective: Rapid identiﬁcation of blood isolates is a key to the
management of bacteraemia. The Gram stain is crucial, but a deﬁ-
nite diagnosis must await subculture and supplementary tests.
Identiﬁcation within 3.5 h has recently become feasible by use of
peptide nucleic acid (PNA) probes for ﬂuorescence-in situ-hybri-
dization (FISH). We have evaluated this technique for identiﬁca-
tion of S. aureus (Sau), E. coli (Eco), P. aeruginosa (Pae), and
C. albicans (Cal).
Methods: The evaluation was conducted May–November 2003.
BacT/Alert (bioMe´rieux) was used for blood cultures (BCs) and
a set with two aerobic and one anaerobic bottle was recom-
mended for adults. PNA probes were provided by AdvanDx
(Woburn, MA, USA), and PNA-FISH assays were carried out
with ﬂame-ﬁxed slides. The Gram stain report determined which
probes were used (the Sau probe for Gram-positive cocci in clus-
ters, Eco and Pae probes for Gram-negative rods, and the Cal
probe for yeasts). The observer was blinded to conventional
identiﬁcation. Positive and negative predictive values (PPN and
PNV, respectively) were calculated for monomicrobial cultures
and numbers of patients with homologous and heterologous iso-
lates are given in [ ].
Results: Among app. 9000 BC sets 1241 produced growth. Based
on Gram stain results 789 BCs from 534 patients entered the eva-
luation. Diagnoses provided (or rejected) by PNA-FISH were in
agreement with conventional diagnoses for the following groups
of bacteraemic patients: S. aureus (60) vs. coagulase-negative sta-
phylococci (127), E. coli (197) vs. other Gram-negative rods (145),
and C. albicans (9) vs. non-C. albicans (10). Thus, PPV was 100%
and NPV 100% for the Sau, Eco, and Cal probes. PNA-FISH with
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the Pae probe was positive in 18 of 19 patients with P. aeruginosa;
weak to moderate staining was seen in four patients with other
aerobic bacteria, and 316 patients with a broad range of Gram-
negative rods were negative. The PPV for the Pae probe was 82%
and NPV 99.7%.
Conclusion: PNA-FISH is speedy and the diagnosis of P. aerugi-
nosa is imperative in order to provide coverage for this patho-
gen. PNA-FISH was found to be highly reliable in the routine
setting for diagnosis of four important blood-borne pathogens.
For all four pathogens the NPV was > 99% and the slightly
lower PPV for P. aeruginosa should not limit the clinical utility of
PNA-FISH.
O58 Polymerase chain reaction for the diagnosis of
osteoarticular infections due to Kingella or other fastidious
organisms in paediatric patients
C. Ploton, I. Verdier, P. Taylor, Y. Benito, F. Vandenesch,
J. Berard, A.M. Freydiere
Lyon, F
Introduction: Despite the improvement of bacteriological methods,
synovial ﬂuid and bone biopsy specimens remain negative in a
substantial fraction of patients with clinical osteoarticular infec-
tions. This work evaluated the potential usefulness of a molecular
approach in the diagnosis of osteoarticular infections due to fasti-
dious organisms in paediatric patients.
Patients and Methods: From January 2001 to March 2003, osteoarti-
cular specimens from 182 paediatric patients (age range:
1 month—17 years, median: 3 years and 7 months) were inocu-
lated onto conventional media in our microbiological laboratory.
Moreover, all the liquid specimens were inoculated into Bact/
Alert FAN blood culture bottles. On clinical arguments of infec-
tion, 77 culture-negative specimens were tested by an universal
16S rDNA PCR method followed by direct sequencing of DNA to
identify microbial pathogens.
Results: A positive culture was obtained for 49 specimens
(26.9%) including 22 Staphylococcus aureus (44.8%), eight beta
haemolytic Streptococcus (16.3%), eight Kingella kingae (16.3%),
four Streptococcus pneumoniae (8.2%) and seven miscellaneous
organisms (16.3%). A positive PCR result was obtained for 15
of the 77 culture-negative specimens tested (19.5%). For 12
PCR-positive specimens, the sequencing allowed the identiﬁca-
tion of organisms of the Neisseriaceae family (including the dif-
ferent genus Kingella spp., Eikenella spp., Simonsiella spp. and
Alyssiella spp.) of which two Kingella kingae and one Eikenella
corrodens strains were fully identiﬁed at the species level. For
three PCR-positive specimens, the sequencing was not possible
due to unsufﬁcient amount of DNA. Both patients either with
culture-positive Kingella specimens (n ¼ 8) or PCR-positive spe-
cimens (n ¼ 12) had similar pathologies (15 arthritis, three ostei-
tis and two spondylodiscitis) and corresponded to a young
patient population (age range: 8 months—4 years, median
1.5 year) encompassing 13 boys and seven girls.
Discussion: While fastidious bacilli such as Kingella kingae were
considered as an exceptional cause of osteoarticular infections,
recent improvement of culture methods have demonstrated
that these organisms were more common than previously
recognised. In this study, compared with the culture, PCR
increased the recovery rate of fastidious Bacillus from 16.3 to
46.9%.
Conclusion: PCR is a powerful tool since it contributed to the diag-
nosis and managment in 15 of 77 culture-negative osteoarticular
infections.
O59 Improved diagnosis of listeriosis by real-time
TaqMan-based PCR
N. Murphy, K. Grant, C. Ohai, J. McLauchlin
London, UK
Objectives: The food-borne pathogen Listeria monocytogenes is cap-
able of causing severe and fatal infections in certain high-risk
patient groups including meningitis, encephalitis, septicaemia and
gastrointestinal symptoms. The organism is very widely distribu-
ted in nature with consumption of contaminated foods being the
major route of transmission. A deﬁnitive diagnosis of listeriosis
depends upon culturing the organism from the blood or cerebral
spinal ﬂuid (CSF). However, low numbers of the bacterium may be
present in both samples and problems with culturing this bacter-
ium after commencement of antimicrobial therapy are well recog-
nised. The aim of this study was to develop a sensitive, real time
PCR assay to rapidly conﬁm the identify of isolates, and to detect
L. monocytogenes speciﬁc nucleic acid in patient’s CSF or serum.
Methods: Real time TaqMan-based PCR assay (both nested and
un-nested) to speciﬁcally amplify a fragment of the L. monocyto-
genes hly gene was established.
Results: The assay proved very useful for the rapid conﬁrmation of
L. monocytogenes colonies growing in vitro and was speciﬁc for this
bacterium. Since April 2002 more than a 1000 isolates of
L. monocytogenes from food and clinical samples have been identi-
ﬁed as L. monocytogenes using this assay. Following its successful
introduction the assay was then assessed for detecting L. monocyto-
genes in clinical samples from patients with clinical symptoms of
listeriosis. The sensitivity of the assay was further improved by
performing a 25 cycle PCR assay prior to the real time assay.
Although this step increases the time to get results it signiﬁcantly
improves sensitivity. Of 26 DNA samples extracted from either
serum or CSF only three were positive for L. monocytogenes by the
single round TaqMan PCR assay. Four DNA samples gave equi-
vocal results and 19 were negative. Whereas, by the nested
TaqMan-based PCR assay, 15 samples were positive for
L. monocytogenes, zero gave equivocal results and 11 were negative.
Conclusions: These results show that the assays are useful for
rapid conﬁrmation of cultures growing in vitro, and may also be
applicable for detection in enrichment broths. The nested assay
will provide an additional tool for the establishing of a noncul-
tural diagnosis of listeriosis, especially in patients with suspected
neurological infections.
O60 Evaluation of diagnostic methods for Mycoplasma
pneumoniae and Chlamydia pneumoniae using serology, PCR
and the BD ProbeTec ET System
B.E.B. Claesson, H. Enroth, S. Elowson, M. Hellgren-Leonardsson
Sko¨vde, S
Objective: To evaluate diagnostic methods including the BD Pro-
beTec ET System (ProbeTec), conventional PCR and serology for
M. pneumoniae and C. pneumoniae in outpatients with persistent
cough.
Methods: A total of 193 patients from 12 Swedish primary care
centres were included. The mean duration of cough was 24 days.
Mean age was 45 years (range 8–90). Acute and convalescent serum
samples were obtained from 170 of the 193 (88%) patients. IgG, IgA
and IgM antibodies towards C. pneumoniae were detected by EIA
(ThermoLabsystems). A positive result was deﬁned as seroconver-
sion for IgA or IgG or IgM. Serology for M. pneumoniae was
performed with the particle agglutination test kit of Anti-
M. pneumoniae antibody (Fujirebio). A positive result was deﬁned as
a fourfold rise in titre. Sampling from the posterior pharyngeal wall
was performed with two separate swabs, one for ProbeTec and one
for the Rapidcycler PCR (Idaho Technology). Primers from the 16S
rRNA gene were used for PCR ampliﬁcation of C. pneumoniae DNA
according to Gaydos et al. (1992). For PCR detection of M. pneumo-
niae DNA, primers for the P1 adhesin gene were used. The BD Pro-
beTec ET System M. pneumoniae (MP Assay) and Chlamydiaceae
family (CF assay) are based on real-time homogenous strand displa-
cement ampliﬁcation and detection technology. The sensitivity and
speciﬁcity of the CF and MP assays were calculated using a com-
bined reference of both PCR and serology. True positives were
deﬁned as positive by both reference methods. True negatives were
deﬁned as negative by both methods.
Results: Of the 193 patients, three were not tested with the CF or
MP assays. Results of the remaining 190 patients are listed in the
table below by PCR, serology and ProbeTec Assay.
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Conclusion: There was a very good correlation between the mole-
cular and serologic tests. The CF Assay and MP Assay are suita-
ble for the rapid diagnosis of atypical pneumonia.
O61 Application of different nucleic acid ampliﬁcation
techniques for the detection of M. pneumoniae, C. pneumoniae
and Legionella spp. in respiratory specimens
K. Loens, T. Beck, K. Dirven, D. Ursi, H. Wouters, H. Goossens,
M. Leven
Wilrijk, B
Introduction: The advantage of nucleic acid ampliﬁcation techni-
ques (NAAT) is their extreme sensitivity and speciﬁcity when
compared with traditional techniques. Multiplex formats might
solve the practical shortcoming of detecting only the infectious
agent that is searched for. Real-time assays enable a one-tube
assay that is suitable for high-throughput applications, reducing
the assay time and limiting potential contamination between sam-
ples. A comparison between different NAAT is needed.
Objectives: To compare the sensitivity and speciﬁcity of real-time
(RT) mono- and multiplex nucleic acid sequence-based ampliﬁca-
tion (NASBA), and mono-PCR for the detection of M. pneumoniae,
C. pneumoniae and Legionella spp. in respiratory specimens from
hospitalised and outpatients with community-acquired pneumo-
nia (CAP).
Methods: A total of 244 respiratory specimens were collected from
142 patients with CAP (116 throat swabs, 112 sputa and 16 other
respiratory specimens). NASBA was done by using the NucliSens
Basic Kit (bioMe´rieux), PCR was done as described earlier. PCR
detects L. pneumophila whereas NASBA was designed to detect
Legionella spp. All samples with discordant results were reana-
lysed. Deﬁnition of the expanded gold standard used to calculate
the sensitivities of the tests applied: true positive if positive by at
least two NAAT.
Results: The sensitivities of the different techniques, compared
with an expanded gold standard, were 77.8, 100, and 100% for
detection of M. pneumoniae; and 50, 100, and 50 for detection of
L. pneumophila by PCR, RT mono-NASBA, and RT multiplex
NASBA respectively. If positive by any method, the sensitivities
were 63.2, 92.1, and 71.1 for detection of M. pneumoniae; 57.1,
71.4 and 28.6 for detection of L. pneumophila by PCR, RT mono-
NASBA, and RT multiplex NASBA, respectively. Two samples
were found to be C. pneumoniae positive only by RT mono
NASBA which is an insufﬁcient number to calculate the sensitiv-
ity of the tests applied.
Conclusions: Mono RT NASBA is more sensitive than mono
PCR. When the former is compared with RT multiplex NASBA,
the mono NASBA is the most sensitive test. This conﬁrms
results presented earlier by using spiked clinical specimens. The
RT multiplex NASBA could become a fast, and user-friendly
diagnostic tool for the detection of these organisms in respira-
tory specimens although it seems to be less sensitive. Further
comparison on larger numbers of clinical specimens is neces-
sary.
O62 Consensus real-time PCR assay for Bordetella pertussis
including an internal process control provides, speciﬁc
diagnosis, rapid turnaround time, high diagnostic yield and
enhanced surveillance
N.K. Fry, O. Tzivra, J. Duncan, N. Doshi, T.G. Harrison
London, UK
Objectives: (i) To transfer existing block-based PCR detection of
Bordetella pertussis to a real-time platform; (ii) to offer this as a
diagnostic test for B. pertussis by the Respiratory and Systemic
Infection Laboratory, Health Protection Agency, London, as part
of a range of reference and enhanced surveillance tests useful in
the investigation of individual cases and outbreaks of pertussis
infection.
Methods: A consensus PCR approach was used; LightCycler
(Roche) assays for two gene targets were developed using
hybridisation probes for conﬁrmation of products: (i) pertussis
toxin promoter (B. pertussis-speciﬁc) together with an internal
process control (IPC) and (ii) insertion element IS481 (which
occurs in B. pertussis and B. holmesii). This service is offered
free of charge for testing nasopharyngeal aspirates from chil-
dren, age 6 months or below, with respiratory illness compati-
ble with pertussis, admitted to paediatric intensive care units or
paediatric wards. Real-time assays were introduced in October
2001, with an ofﬁcial launch date in 2002. The QiaAmp DNA
Mini Kit (Qiagen) was used for extraction and samples were
tested at three dilutions, neat, 1:10 and 1:100 (in nuclease-free
water). Samples were considered to be positive for B. pertussis
if both targets were detected.
Results: From October 2001 to October 2003, 346 patient samples
were received for B. pertussis detection. Of these 269 (78%) had no
genomic evidence of B. pertussis infection (i.e., negative for both
targets), 51 (15%) had evidence of recent B. pertussis infection (i.e.,
positive for both targets), 49 (14%) samples showed some inhibi-
tion resulting in a reduced sensitivity of the assays, ﬁve (1%)
were total inhibitory, 16 (5%) were scored as equivocal (i.e. posi-
tive for only one target).
Conclusion: Successful transfer of assays to a real-time platform
was achieved resulting in a more rapid turnaround time. Typi-
cally, a same-day service for samples received before 10 AM was
achieved. Inclusion of an IPC prevented the reporting of false-
negative results. Although the IS481 assay is not B. pertussis-speci-
ﬁc, it is more sensitive that the toxin-promoter assay. Thus, a con-
sensus PCR approach provided speciﬁcity and increased
conﬁdence in the results. Together with serological results and
culture isolation, real-time PCR is a valuable tool for the enhanced
epidemiological surveillance and diagnosis of pertussis and
allows a rapid turnaround time.
O63 MRSA screening by RT-PCR directly from the swab
within the same day
N. Lehn, H.J. Linde, W. Schneider-Brachert, P. Kaiser, U. Reischl
Regensburg, D
Objectives: More than 50% of all patients with MRSA of the
Regensburg University Hospital are already positive on admis-
sion. Isolation of patients results in higher workload, costs and
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results of MRSA screening by real time PCR in patients with high
or low risk for MRSA carriage.
Methods: MRSA screening by RT-PCR directly from the swab was
compared with culture and Pbp2a antigen detection from over-
night culture. All patients admitted to any ICU of the Regensburg
University hospital and at low or high risk to be colonised with
MRSA were included into the study. One swab for culture and
PCR each from both nares were taken. MRSA was cultured on
sheep blood agar and mannitol salt agar and identiﬁed by Slidex
Staph and Slidex MRSA kit (Biomerieux, Nu¨rtingen). DNA was
extracted automatically by the MagNA Pure instrument with the
MagNA Pure Microbiology Kit, Mgrade, detection and differentia-
tion of S. aureus and CNS was performed with the LightCycler
(LC) Staphylococcus Kit Mgrade, mecA by the LC MRSA Detection
Kit (Roche, Mannheim).
Results: A total of 38 of 456 (8.3%) of all patients enrolled were at
high risk for MRSA-carriage and isolated. More than 50% of all
patients were on antibiotics. Main reasons for MRSA screening
were multimorbidity (60%) and prior hospitalisation (18%). A
total of 450 of 456 patients could be evaluated for the comparison
of tests. In culture and PCR MRSA was positive in 31 of 450
(6.8%) and 29 of 450 patients respectively (sensitivity 94%). When
using culture as gold standard sensitivity was 83% (70 of 490).
Only two of 450 samples were false negative in PCR (0.4%). In 63
of 450 patients no deﬁnitive result was obtained by PCR due to
simultaneous presence of S. aureus, CNS and mecA.
Conclusion: Control of sampling and extraction is very important
when performing PCR directly from swabs. In 351 of 450
patients isolation could be stopped due to negative results in
PCR for patients at high risk. All proofed positive patients could
be isolated. In 14% of all tested patients (PCR indeterminates)
isolation for another 2 days until the results of conventional test-
ing was obtained was recommended for patients at high
risk. In 86% of all patients with RT-PCR MRSA could be
proofed or excluded within 2 h test time instead of 1–3 days by
culture.
O64 Evaluation of Multiplex PCR Assay to discriminate
Staphylococcus aureus from coagulase-negative staphylococci
and determine methicillin resistance from culture
S.A.H. Awad, J.P. Burnie, M. Upton
Manchester, UK
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) are
the major pathogens in nosocomial and community-acquired
infections. Molecular methods for the identiﬁcation of MRSA
have shown the need for rapid and dependable methods for the
diagnosis of MRSA infectious diseases. In the present study, a
multiplex PCR assay was established and evaluated to detect
MRSA cells in culture. The new assay targeted both the mecA
gene and a 442 base pair DNA fragment (Sa442) within a single
PCR.
Methods: Strain representing EMRSA types 1–17 were examined
for mecA and Sa442. In addition, 63 strains of MRSA collected
from Manchester Royal Inﬁrmary (MRI) were tested. A total of 25
isolates of a number of different species, including Methicillin-
sensitive Staphylococcus aureus (MSSA), Methicillin resistant Sta-
phylococcus epidermidis (MRSE), Methicillin-sensitive Staphylococcus
epidermidis (MSSE), Streptococcus pyogenes and Escherichia coli from
MRI and an in-house culture collection, were tested to determine
the speciﬁcity of the assay.
Results: Sa442 primers were found to be speciﬁc for Staphylococcus
aureus, although one of 80 isolates (speciﬁcity 98.75%) known to
be Staphylococcus aureus was negative for Sa442. At the same time,
two of 80 (speciﬁcity 97.5%) isolates were negative for the mecA
gene. These two isolates were phenotypically methicillin resis-
tant. Serial dilutions were done to determine the sensitivity of
this method. This method was able to detect as few as
5  102 cells per millilitre.
Conclusion: This multiplex PCR assay represents a rapid and accu-
rate method with potential for direct detection of MRSA from
clinical specimens.
O65 Direct detection of vancomycin-resistant enterococci
from rectal swabs using automated DNA extraction and rapid
real-time PCR: a pilot study
B.M. Willey, P. Akhavan, N. Kreisworth, A. McGeer, T. Mazzulli,
P. Ng, A. Sarabia, C. Bechard, B. Boekelman, M. Skulnick
Toronto, CAN
Objectives: Conventional vancomycin-resistant enterococci (VRE)
culture from rectal swabs (RS) can take 5–7 days, decreasing this
turn-around-time (TATI is a goal of most laboratories. This study
compared direct PCR of VRE in RS to standard and broth enrich-
ment culture methods.
Methods: Each of 209 RS (80 from known VRE carriers in Toronto
hospitals; 129 from surveillance in a single hospital) were inocu-
lated using the routine protocol onto mEnterococcus vancomycin
6 mg/L agar (EV). Each RS was then rolled in 300 lL sdH2O for
PCR. The RS were then inculated into BHI broth. The BHI was
subcultured after 6 h incubation onto Columbia Nalidixic Acid
Vancomycin 6 mg/L agar (CNAV). Two vancomycin discs were
placed in the main inoculum area on the CNAV. EV were exam-
ined daily for 3 days and the CNAV 2 days for PYR + Gram +
colonies around the discs. Identiﬁcation of suspect colonies was
performed using broth microdilution and conventional biochem-
icals. DNA was automatically extracted from the samples after
FastPrep disruption and stabilised in STAR buffer using the Total
Nucleic Acid Isolation Kit on the MagNa Pure (Roche). PCR for
vanA, B,B2/3 genes was by LightCycler (Roche) using the VRE
LC Detection Kit (Roche).
Results: A total of 87/209 RS were VRE+ (86 E. faecium, one E. fae-
calis; 78 vanA, three vanB, three vanB2/3, three vanA+vanB2/
3)by at least one culture method. 64/87 were VRE+ by all three
methods. A total of 15/87 did not grow on EV without enrich-
ment (13 vanA, one vanB2/3, one vanA/vanB2/3) and one vanA
VRE was detected on EV only. Four of 87 vanA VRE were not
detected on CNAV due to overgrowth of Proteus. ‡87 VRE were
not detected by PCR. Sensitivities for EV, CNAV and PCR
were 85.3, 95.6 and 93.5%, respectively. A total of 122/209 RS
were VRE negative:115 were negative by all three methods and
initially generated nonrepeatable low-positive readings with melt-
ing peaks suggestive of ﬁve vanA and two VanB2/3 products.
Negative by culture, these seven may represent very low concen-
trations of VRE but as they were negative on repeat PCR, they
were considered false positives, reducing the speciﬁcity of PCR to
94.6%. The TAT for PCR, CNAV and EV averaged 6 h, 2–3 days
and 4–7 days, respectively.
Conclusions: Direct PCR demonstrated a comparable sensitivity to
broth enrichmnet culture while reducing the TAT to within 1 day.
Further study is required to assess the impact of VRE PCR testing
on a hospital’s budget.
O66 Development of DNA microarrays for detection of
macrolide-resistance genes
M. Cassone, M.M. D’Andrea, F. Iannelli, M.R. Oggioni,
G.M. Rossolini, G. Pozzi
Siena, I
Objective: Purpose of this study was the development of a micro-
array-based assay to detect genes encoding resistance to macro-
lides and related drugs. Such genes are known to cluster within
genetic elements; for this reason a complete macolide resistance
microarray should be useful as a tool for reliable and fast epide-
miological screening.
Methods: A database of resistance genes was constructed by retriev-
ing nonredundant sequences from GenBank. Probes, 40–60 nucleo-
tides in size, were synthesised with a C6-aminolinker and spotted
on epoxy-modiﬁed glass. The ﬁnal DNA chip was printed using an
Afﬁmetrix GMS 417 robotic spotter, and included a triplicate set of
probes, and positive hybridisation controls. Genomic DNA was
labelled with Cy3 or Cy5 by random priming. Hybridization sig-
nals were then detected using an Affymetrix 418 laser scanner and
images were analysed by the GenePix Pro (version 5.0) software.
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Results: A total of 109 oligonucleotide probes were designed for
recognition of 64 macrolide resistance genes. The DNA chip was
tested using 15 control strains from seven different bacterial
species (Staphylococcus aureus, Enterococcus faecalis and Enterococcus
faecium, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococ-
cus gordonii and Escherichia coli), known to harbour 20 different
genes for resistance to macrolides and related drugs. Expected
results were obtained with control strains.
Conclusions: We developed a DNA microarray to be used to
screen for the presence of macrolide resistance genes in bacteria.
Work funded in part by grants from the University of Siena
(PAR 2001).
Helicobacters-update 2004 (Symposium arranged with EHSG)
S80 Sensing H. pylori in the stomach
R. Ferrero
Paris, F
Helicobacter pylori strains that harbour a pathogenicity island, the
‘cagPAI’, induce NF-kappaB activation and IL-8 synthesis in gas-
tric epithelial cell lines. The mechanism involved in this process
is unknown. Though H. pylori is an extracellular bacterium, sur-
face-expressed pathogen recognition molecules (TLR2, TLR4 and
TLR5) do not appear to play a signiﬁcant role in epithelial cell
responses to this pathogen. H. pylori cagPAI was shown to
encode a type IV secretion apparatus, capable of mediating the
translocation of effector molecules into host cells. Thus, we
speculated that an intracellular molecule may be involved in host
sensing of this bacterium. It was recently reported that Nod1/
CARD4, a cytosolic molecule with homology to plant resistance
proteins, mediated epithelial cell responses to the invasive
bacterium, Shigella ﬂexneri. These responses were dependent on
the recognition of a disaccharide-tripeptide motif present in
Gram-negative bacterial peptidoglycan. We showed that H. pylori
bacteria induced NF-kappaB activation in Nod1-expressing
HEK293 cells via a cagPAI-dependent mechanism. Moreover, this
response could be abrogated by co-transfection of cells with a
Nod1 dominant negative construct, indicating a prime role for
Nod1 in epithelial cell signalling to this bacterium. Nod1 was
shown to respond to H. pylori peptidoglycan that was presented
within epithelial cells. We therefore determined the ability of
H. pylori bacteria to deliver this molecule into host cells. H. pylori
mutants possessing a nonfunctional cagPAI secretion apparatus
delivered signiﬁcantly reduced levels of 3H-labelled peptidogly-
can into epithelial cells. This represents the ﬁrst example in
which a bacterial type IV secretion apparatus has been demon-
strated to be engaged in the delivery of a nonprotein effector
into host cells. Finally, Nod1-deﬁcient mice were shown to be
more susceptible to infection by cagPAI-positive H. pylori, when
compared with wild-type animals, thus identifying Nod1 as an
important factor in innate immune responses to H. pylori infec-
tion. We suggest that this novel paradigm of pathogen recogni-
tion may be applicable to other noninvasive Gram-negative
bacteria that cause severe mucosal inﬂammation in animal hosts.
Issues in smallpox
S87 Europe needs to be prepared
G. Gouvras
Luxembourg, LUX
This paper outlines the urgent measures that were taken from
October 2001 onwards by the European Union following the ter-
rorist attacks in the US. It highlights the key elements of the cur-
rent EU programme of medium and long-term action on
chemical, biological and radio-nuclear threats and describes the
health security programme which is being implemented since
December 2001 and its results. The health security programme
forms a key component of the EU action on terrorism. It is now
being embedded in a wider effort on emergency preparedness
and response that became necessary as a result of the lessons
learnt from the SARS epidemic. A Health Security Committee
was established in November 2001, a programme of co-operation
in the EU on preparedness and response to biological and chemi-
cal agent attacks (health security) was drawn up in December
2001 and a Task force on health security was set up with EU
experts in May 2002 The programme aims to ensure an EU-wide
capability for the timely detection and identiﬁcation of biological
and chemical agents in laboratories, the rapid and reliable deter-
mination and diagnosis of relevant human disease cases, the
availability of medicines, co-ordination of emergency plans and
the drafting and dissemination of rules and guidance on facing-
up to attacks from the health point of view. The implementation
of the European Union’s programme on health security helped to
drive action on bioterrorism forward. The future EU Centre for
Disease Prevention and Control, proposed by the Commission in
July 2003, will be a key player in providing advice to the Mem-
ber States and the EU institutions, and in implementing surveil-
lance and response actions in the area of health security.
Infections of intravascular devices
S91 Intra-arterial device-related infections
L. Baddour
Rochester, USA
Objectives: To review clinical aspects of intra-arterial device-
related infections and to outline the diagnosis, treatment and pre-
vention of these infections.
Methods: A review of published literature was performed to for-
mulate a summary of intra-arterial device-related infections for
oral presentation. Devices and procedures included in this report
are peripheral vascular stents and stent-grafts, prosthetic vascular
grafts, including those used for haemodialysis, intra-aortic balloon
pumps, angioplasty/angioplasty-related bacteraemia, coronary
artery stents and carotid patches. The aspects addressed for each
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device include epidemiology, microbiology, predisposing risk fac-
tors, diagnosis, treatment and prevention.
Results: Risk of infection is variable depending upon the device
or procedure. Even for devices that are rarely complicated by
infection, it is crucial that a review be done because of the num-
ber of devices that are annually implanted on a global basis.
Unique clinical ﬁndings assist in the diagnosis of infection.
Treatment options usually mandate device removal. This often
creates a treatment conundrum among patients who are deemed
not appropriate surgical candidates for removal of the infected
device. Moreover, continued use of the device is necessary to
sustain limb or life such that reimplantation of a new device is
needed when the infected device is removed. Prevention of
infection is a key area of continued investigation. Prevention
methods include the use of antimicrobial prophylaxis, alterations
in the design and make-up of the devices, implementation of
sound infection control practices and immunization.
Conclusions: A understanding of intra-arterial device-related infec-
tions is critical because of the ever-increasing number of these
devices being placed, the growing number of different types of
devices becoming available, and the potential limb- and life-threa-
tening nature of these infections.
Methicillin-resistant Staphylococcus aureus – MRSA
O92 Methicillin-resistant Staphylococcus aureus (MRSA)
reported through the European Antimicrobial Resistance
Surveillance System (EARSS), 1999–2002: variation over time
and place
E.W. Tiemersma, S.L.A.M. Bronzwaer, O. Lyytika¨inen,
J.E. Degener, P. Schrijnemakers, N. Bruinsma, J.C.M. Monen,
W. Witte, H. Grundmann and EARSS participants
Objectives: We explored the variation in proportions of methicil-
lin-resistant S. aureus (MRSA) between and within countries and
temporal trends using the antimicrobial susceptibility results of
S. aureus isolates from blood cultures. From 1999 to 2002, data of
28 countries were reported to the European Antimicrobial Resis-
tance Surveillance System (EARSS).
Methods: Participating laboratories performed routine antimicro-
bial susceptibility tests for S. aureus. Reduced susceptibility to oxa-
cillin was conﬁrmed by quantitative or molecular methods. Data
were collected at national level and forwarded to EARSS at the
Dutch National Institute of Public Health for further analysis. We
analysed data from 495 hospitals that reported results of more
than 20 isolates. Time trends were analysed by Poisson regression
modelling for 312 hospitals providing data for at least three con-
secutive years.
Results: EARSS received susceptibility results of 53 264 S. aureus
blood isolates, of which 50 759 (95%) were included in the current
analysis. The prevalence of MRSA differed largely and varied about
100-fold in Europe. A low proportion (<1%) was found in northern
Europe and high proportions (>40%) were reported from southern
Europe, Ireland, and the UK. Between 1999 and 2002, MRSA pro-
portions signiﬁcantly increased in Germany (from 9 to 19%), the
Netherlands (from 0.4 to 1%), UK (from 31 to 45%), Ireland (from
39 to 45%), and Belgium (from 22 to 27%) and decreased in Slove-
nia (from 22 to 15%). Within countries, MRSA prevalence varied
between hospitals with highest variance in Germany and in other
countries with an MRSA prevalence of between 5 and 18%.
Conclusion: MRSA proportions vary substantially between countries
and hospitals. Our ﬁndings should increase the alertness in coun-
tries with increasing MRSA rates. Hospitals with low MRSA preva-
lence in these countries should maintain their efforts to keep this
prevalence low. The occurence of low-prevalence hospitals should
also encourage infection control personnel in high-prevalence hos-
pitals to take appropriate measures to contain the MRSA epidemic.
O93 Community-acquired Methicillin-resistant
Staphylococcus aureus: role of home nursing care in a French
prospective study
F.-X. Lescure, G. Locher, M. Eveillard, M. Biendo, S. Van Agt,
G. Le Loup, Y. Douadi, O. Ganry, F. Eb, J.L. Schmit
Amiens, F
Background: Until recently, Methicillin resistant Staphylococcus aur-
eus (MRSA) was regarded as a multi-resistant pathogen associated
exclusively with nosocomial infections. For 10 years, authors have
evoked an epidemiological ‘drift’ of MRSA towards the commu-
nity. The question is where exactly MRSA acquisition takes place.
The aim of the survey was to research the risk factors in relation
to community acquisition of MRSA, concentrating primarily on
medical or paramedical care in community.
Methods: A case-control study with prospective recruitment
included consecutively 198 cases and 198 controls between the 1st
of April 2002 and the 31st of July 2003 in a french teaching hospi-
tal. All patients were, at the time of admission, infected with Sta-
phylococcus aureus. Cases were infected with MRSA, controls were
infected with MSSA.
Findings: Multivariate analysis showed a strong and highly signiﬁ-
cant independent association between MRSA infection at admis-
sion and prior home nursing care (OR ¼ 3.7, P < 0.0001). The
other independent risk factors were prior hospitalisation in a sur-
gical ward (OR ¼ 3.8, P ¼ 0.0003), transfer from another institu-
tion (OR ¼ 2.3, P ¼ 0.008) and age >65 years (OR ¼ 1.6, P ¼ 0.04).
In addition, there was a dose-effect relation for prior home nur-
sing care and a positive interaction-effect with prior hospitalisa-
tion in a surgical ward (OR ¼ 3.1, P ¼ 0.02).
Implications: These results evoke the possibility of true community
MRSA acquisitions by home nursing care. The MRSA reservoir are
probably MRSA carriers discharged from hospital. A potential vec-
tor are domiciliary nurses who, not daily confronted with nosoco-
mial infections and often ignoring the patient status in relation to
MRSA, do not apply appropriate hygiene measures.
O94 Carriage of Staphylococcus aureus in family units
M.V. Boost, M.M. O’Donoghue, F.P. Choy, C. Lo
Kowloon, HK
Objectives: Although numerous studies have investigated preva-
lence of nasal carriage of Staphylococcus aureus, and several case
studies have documented spread within a family, there have been
no studies of patterns of carriage in families and risk factors
affecting spread in the family. This study aimed to examine
family carriage of S. aureus.
Methods: One hundred families of students were invited to partici-
pate and given an information sheet and consent form. Students
were instructed to collect specimens by swabbing the septum adja-
cent to the nasal ostium. Swabs in transport media were returned
to the laboratory within 14 h for culture and isolation of S. aureus.
Participants provided demographic details and information on
contacts with health care, recent antibiotic use and hospitalisation.
Isolates of S. aureus were screened for methicillin resistance and
tested for sensitivity to eight antibiotics. Relatedness of strains was
determined by pulsed-ﬁeld gel electrophoresis (PFGE).
Results: A total of 92 families with 352 individuals participated in
the study. Specimens were collected from 332 subjects (94%). The
number of family members varied from two to eight (mean 3.8).
Seventy-three (22%) subjects from 49 families carried S. aureus
and there was no signiﬁcant difference in carriage rates between
males and females. Carriage rates were higher in larger families
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(greater than three members) (P  0.001), and in subjects who
had contact with a nursing home (42.8%). Logistic regression indi-
cated that in subjects aged ‡51 years use of antibiotics in the last
4 weeks reduced risk of carriage, whilst long-term treatment
increased risk. Methicillin-resistant strains were isolated from
three subjects. One subject, who worked in a hospital and had
been recently hospitalised, carried a multiply-resistant strain. The
other two strains, one isolated from a nursing home employee,
were resistant only to beta-lactams. Carriage of MRSA was signiﬁ-
cantly associated with occupation in health care. PFGE revealed
multiple carriers of an identical strain within a family in 10 cases.
Different strains were observed in eight families with multiple
carriers.
Conclusion: Carriage of S. aureus and MRSA were 22 and 0.9%,
respectively. Carriage rates were higher in large families and in
elderly subjects on long term treatment. PFGE revealed transmis-
sion within the family unit. Carriage of MRSA in this community
remains low and carriers failed to transmit these strains to other
family members.
O95 A group of related EMRSA15 isolates carrying the
Panton-Valentine leukocidin gene
G.F.S. Edwards, D. Morrison, K. Girvan, B. Cosgrove, C. Gemmell
Glasgow, UK
Objectives: To follow-up the discovery of an EMRSA15 isolate car-
rying the PVL gene, commonly associated with community-
acquired MRSA, by searching the Scottish MRSA Reference
Laboratory (SMRL) collection of MRSA isolates. Unlike many hos-
pital strains, EMRSA15 usually carries few additional resistances
and has the type IV SCCmec element but isolates have not, to our
knowledge, been previously reported to carry the PVL gene.
Methods: A clinical microbiologist had drawn to our attention an
MRSA isolate from a 6-month-old child who had suffered recur-
rent infections suggestive of a PVL-producing strain but who was
otherwise healthy. This MRSA was shown by PCR to have the PVL
gene, the mecA gene and the type-IV SCCmec element; phenotypi-
cally it appeared to be an EMRSA15 with an unusual antibiogram.
The PFGE-banding pattern of the isolate varied from the common-
est EMRSA15 pattern at only one band locus; the change was indi-
cative of an insertion event. We searched the SMRL database for
phenotypically and genotypically related isolates, tested them by
PCR and further characterised isolates with the PVL gene.
Results: Less than 0.1% of the approximately 30 000 EMRSA15
isolates in our database had the same antibiogram as the index
isolate; 21 of these were tested for the PVL gene and 20 were
positive. By PFGE, all the PVL-positive isolates had patterns
typical of EMRSA15; all had the apparent insertion seen in the
index isolate but there was some other variation between the
patterns. Most of the PVL-positive isolates had the same,
uncommon, phage pattern though three were untypable. The
earliest isolate had been received in 1998 and the sending
laboratories were from several different geographical regions of
Scotland. PCR testing for other toxin genes on ﬁve of the iso-
lates has shown that they also carry the enterotoxin C gene,
like most other EMRSA15 isolates that we have tested. We have
also examined about 60 EMRSA15 isolates identiﬁed from our
database as similar to the index isolate, but not identical, and
all were PVL-negative by PCR; none of the individual recogni-
sable characteristics (susceptibility markers, phage type, PFGE
insertion) alone are markers for the PVL gene.
Conclusions: We have shown that a phenotypically identiﬁable
group of EMRSA15 isolates carrying the PVL gene has been circu-
lating in Scotland for at least 5 years.
O96 Increased community-onset MRSA disease prevalence
due to MRSA clones colonising the nares of healthy individuals
in the community
B.A. Diep, H. Carleton, E. Pan, G. Sensabaugh, F. Perdreau-
Remington
Berkeley, San Francisco, USA
Background: The number of MRSA clinical isolates originating
from inpatients and outpatients populations has increased more
than 3.5-fold between 1996 and 2002 in the San Francisco Commu-
nity Health Network(CHN) and has been associated with the
spread of speciﬁc clones.
Objective: A molecular epidemiologic study was undertaken to
investigate the underlying causes for this increased MRSA preva-
lence and a possible association with nasal colonisation.
Methods: The study aimed at assessing temporal changes in MRSA
prevalence between two population-based samplings of (i) 833
homeless and marginally housed adults in 1999–2000 and (ii) 308
homeless and runaway youths in 2002. Genotyping by multilocus
sequence typing, multilocus restriction fragment typing, pulsed-
ﬁeld gel electrophoresis, and staphylococcal chromosomal cassette
mec(SCCmec) was undertaken to proﬁle clonal distribution. The
nasal MRSA genotypes were compared with concurrent genotypes
recovered from community-onset (CO) MRSA diseases (deﬁned as
ﬁrst culture from clinical sites of patients within 72 h of hospital
admission or from an outpatient facility).
Results: MRSA prevalence increased among community nasal car-
riage, from 2.76% (1.76–4.11, 95% CI) in 1999–2000 to 6.17%
(3.75–9.47) in 2002. Over 95% of the nasal MRSA isolates were
SCCmec type IV. There was a signiﬁcant difference in genotype
distribution between the time periods. Three genotypes, desig-
nated as P, S and Z (ST-59, ST-8 and ST-30)were associated with
80.6% of CO-MRSA disease between 1998 and 2002, these clones
were also spreading asymptomatically in the two populations.
The P clone was dominant in both 1999–2000 (21.7% of nasal
MRSA isolates) and 2002 (42.1%). Concurrent to its spread in the
community, the P clone surged in 1999–2002 to account for 20.8%
of CO-MRSA disease. That S clone was not found in the commu-
nity in 1999–2000 matched with its absence among clinical isolates
until September 2000. In 2002, S clone accounted for 42.1% of
nasal MRSA isolates, corresponding to its surge in prevalence
among disease-causing isolates in 2001–2002. The Z clone was
widespread among CO-MRSA diseases in 1999, however, only
one Z nasal isolate was found.This lack of spreading through
asymptomatic nasal carriage in the community by Z clone
explains its drop in prevalence in disease in 2001–2002.
Conclusion: Nasal colonisation by certain MRSA clones is correlated
with widepread MRSA disease originating from the community.
Non-molecular diagnostic methods
O97 External quality assessment for microbiology –
participant performance with anaerobes
C. Walton
London, UK
Objectives: To assess the results from clinical diagnostic labora-
tories taking part in the UK National Quality Assessment Service
general bacteriology scheme with specimens containing anaerobes,
and to compare performance with repeat specimens.
Methods: Quality assessment of general bacteriology (n ¼ 800; 328
UK, 472 overseas) for the isolation and identiﬁcation of bacterial
pathogens, was performed on anaerobic organisms including Acti-
nomyces israelii, Actinomyces odontolyticus, Bacteriodes fragilis, Clostri-
dium perfringens, Clostridium tetani, Clostridium novyi type A,
Clostridium septicum, Fusobacterium necrophorum, Peptostreptococcus
anaerobius, Porphyromonas endontalis and Prevotella intermedia.
Results: The overall level of performance with specimens contain-
ing anaerobes over the last 10 years was 76% of participants’
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reporting the correct result; which compares with 93% for all
identiﬁcation specimens in the general bacteriology scheme over
the same period. Participants’ performance with Clostridium spe-
cies was on average a 78% success rate within a range of 65% for
a C. tetani to >90% for specimens containing C. perfringens, C. sep-
ticum and C. novyi. Performance data for other anaerobes varied
considerably and showed a 97% success rate for a specimen con-
taining Peptostreptococcus anaerobius, 52% for a Prevotella intermedia
and 56% for a Fusobacterium necrophorum. Analysis of results for
anaerobes distributed more than once showed that with Bacter-
oides fragilis performance was consistent with success rates of 84
and 80% over two specimens. In contrast, over ﬁve specimens of
Actinomyces israelii the success rate was 86, 86, 59, 60 and 81%,
respectively.
Conclusions: These data provide an interesting insight into over-
all performance with anaerobes. The level of performance seen
with some anaerobes such as Clostridium species was generally
better than with others, such as Prevotella or Bacteroides
species. Performance over time with repeat specimens was
variable, and no signiﬁcant improvement was seen with any
anaerobe. Although the level of identiﬁcation of anaerobes
required to inﬂuence patient management is the subject of
debate among microbiologists, the failure to isolate anaerobes
should be of concern, and fully investigated by the laboratories
concerned.
O98 Microbial approach in diagnosis of infection in
orthopaedic implants
E. Bebrova, J. Pilnacek
Kladno, CZ
Objective: Orthopaedic device-related infections are rare, but they
carry a high morbidity for patients and are costly. Replacement of
total joint prosthesis is the traditional choice in management ther-
apy of aseptic and septic loosing of implants. Factors inﬂuencing
success are a high-level of experience of the orthopaedic surgeon,
the isolation of pathogens and suspectibility pattern for postopera-
tive therapy. Standard culture techniques can often be moderately
sensitive, because bacteria colonising the surface of implants grow
predominantly in adherent bioﬁlms. We aimed to improve the
isolation of bacteria from hip prostheses removed by using sonica-
tion.
Methods: From March 2001 to September 2003 we retrieved 109
hip prostheses from patients at revision operations for aseptic
loosening 61· or septic loosening 48· of implants. The femoral
and acetabular components after sonication and tissue contact
with the implants after homogenisation in Ringer solution were
cultured aerobically and anaerobically. The routine specimen,
swab and aspirate of joint ﬂuid, were cultured aerobically and
anaerobically simultaneously. The organisms isolated were identi-
ﬁed by biochemical API BioMerieux system and sensitivity to
antibiotics was tested by standard laboratory methods.
Results: Cultures (49.2%) of the aseptic loosing were positive.
Components were positive in 96.7%. Components and tissue in
53.3%, components, tissue and routine specimen were positive in
20%. Bacterial strains isolated: coagulase-negative staphylococci
in 70.5%, streptococci in 18.2%, Propionibacterium sp. in 11.3%. In
87.5% cultures of septic loosing were positive. Components were
positive in 83.3% of the cultures, components and tissue were
positive in 61.9% and components, tissue and routine specimen
were positive in 40.5%. Bacterial strains isolated: coagulase-nega-
tive staphylococci in 31.3%, streptococci in 37.5%, Staphylococcus
aureus in 14.6%, Propionibacterium sp. in 8.3%, enterobacterie and
Pseudomonas sp. in 8.3%.
Conclusions: We believe that sonication technique may increase
detection of infection of total hip replacement because soni-
cation increases sensitivity of the culture technique by disper-
sing adherent bacteria which were not isolated by the routine
cultures.
O99 Rapid diagnosis of leptospirosis: identiﬁcation and
use of a 25 amino-acid peptide [PP (R)] from the
haemolysin-associated protein Hap1
C. Branger, B. Chatrenet, F. Aviat, I. Suard, A. Aubert,
G. Andre´-Fontaine
Nantes, Nice, F
Leptospirosis is an important infectious disease of humans and
animals worldwide. Diagnosis is often difﬁcult because of symp-
toms ranging from subclinical infection to a severe multi-organ
involvement leading to death in ﬁve to 15% of the cases. Early
and accurate diagnosis of leptospirosis is essential for proper
treatment, which is lifesaving for patient. Up to now, MAT is the
gold standard but is late, laborious and time consuming. There is
an urgent need for development of new diagnostic strategies for
leptospirosis and particularly in the initial phase of the disease.
Objectives: Our previous work determined that the haemolysis-
associated protein Hap1 (as known LipL32), able to induce a pro-
tection against leptospire challenge, is expressed in the early
phase of leptospirosis infection by only pathogenic leptospires.
ELISA against the recombinant protein Hap1 is very sensitive but
not enough speciﬁc. To avoid this lack of speciﬁcity, we identiﬁed
and characterized an antigenic epitope of the Hap1 protein. Then,
we used this peptide as antigen ELISA against a panel of human
sera.
Methods: Based on analysis of hydrophobicity and conformation
of the Hap1 protein, we selected antigenic region and synthesized
three peptides of possible epitopes. The synthetic peptides were
screened and the PP peptide was identiﬁed. Then, sera from
human, vaccinated or not against leptospirosis, postinfectious of
conﬁrmed leptospirosis or Lyme disease were analysed by PP-
ELISA (IgM and IgG) and MAT.
Results: One of the three peptides is recognised by monoclonal
antibody against rHap1 and positive control anti-leptospire sera.
This peptide was used as antigen in ELISA to test more than 150
human sera. The peptide PP, highly conserved part of the protein
Hap1, is early recognising during the ﬁrst step of leptospirosis
infection. The results demonstrated a good agreement between
the PP-ELISA and MAT results in leptospirosis cases.
Conclusion: The results of this study show that PP-ELISA is a very
sensitive and speciﬁc tool for diagnosis of leptospirosis. Contrary
to MAT, this serological test allows differentiating of vaccinal or
postinfectious antibody. These ﬁnding indicate that the peptide
PP may be a useful antigen for rapid serodiagnosis of leptospiro-
sis.
O100 ELISA-based rapid diagnosis of Rift Valley fever
J.T. Paweska, R. Swanepoel
Sandringham, ZA
Objectives: Recent outbreaks of Rift Valley fever (RVF) in humans
and livestock outside the African region resulted in an increased
international demand for laboratory diagnosis of this zoonotic dis-
ease. Disadvantages of the classical methods include health risk to
laboratory personnel and inability to distinguish between diffrent
classes of immunoglobulins. Therefore, our aim was to develop
and validate IgM-capture, IgG-sandwich and antigen-capture
ELISA for rapid and safe diagnosis of RVF.
Methods: In house produced biologicals were gamma-irradiated,
safety tested and freeze-dried before use. Development and vali-
dation of assays followed standard laboratory and statistical pro-
cedures. The virus neutralisation test (VNT) and infectivity assay
in cell cultures were used for the veriﬁcation of infection status
with RVF virus. To determine the diagnostic accuracy of IgM and
IgG ELISA human sera collected during outbreaks of RVF in
Africa, diagnostic submissions, and sera from laboratory person-
nel vaccinated against RVF, were used. Cut-off values for IgM
and IgG ELISA were optimised using various statistical
approaches including the two-graph receiver operating character-
istic analysis. Detection limit for antigen-capture ELISA was initi-
ally estimated by titration of sucrose-gradient puriﬁed RVF virus,
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and then veriﬁed using results from laboratory generated and
experimental specimens, and infected mosquito pools collected in
the ﬁeld during the 2000 RVF outbreak in the Arabian Peninsula.
Results: There was no evidence for excessive variations within
and between runs of the assays. Based on our present data the
speciﬁcity of IgM ELISA was 99.4%; about 80% of VNT-positive
sera collected during active RVF outbreaks tested positive. The
speciﬁcity of IgG ELISA was 99.2% and sensitivity 100%. The
detection limit of antigen-capture ELISA was approximately 2000
TCID50/mL. There was no evidence for cross-reactions with com-
mon African phleboviruses, and the ELISA easily detected RVF
virus isolates from disparate historical and geographical origins.
Conclusions: As safe, robust and highly accurate methods, the ELI-
SAs have the potential to replace the traditional diagnostic assays,
which pose a biohazard and thus have to be limited to high con-
tainment facilities. Potential applications are: early diagnosis of
infection, monitoring of immune responses in vaccines, epidemio-
logical surveillance of humans, livestock and vector populations.
O101 A study to assess the efﬁcacy of a MALDI-TOF-MS
database for the rapid identiﬁcation of Bacillus isolates
C.J. Keys, H.N. Shah, K. Grant, D.J. Dare, M. Lunt,
M.A. McDowall
London, Manchester, UK
The genus Bacillus is immensely complex and is currently under-
going major taxonomic revisions based mainly upon 16S rDNA
sequence analysis. Traditionally species are identiﬁed using mor-
phological and biochemical criteria such as crystal formation on
PEMBA agar and lecithinase production. However, these tests can
be prolonged and may not conclusively allow species-level identi-
ﬁcation.
MALDI-TOF-MS is a rapid novel technique that allows the sur-
face components of bacterial cells to be resolved as a characteristic
mass spectrum. A small amount of growth from a culture plate is
applied to a target plate and mixed with matrix solution. Irradia-
tion of the sample with a nitrogen laser in a mass spectrometer
produces a plume of ions that are determined using time of ﬂight
mass spectrometry.
Using a linear M@LDI instrument, (Waters Corporation, Man-
chester, UK), this technique was applied to National Collection of
Type Culture (NCTC) strains representing Bacillus food pathogens
frequently received for identiﬁcation in the Food Safety Microbiol-
ogy Laboratory (FSML), HPA, London. These included B. subtilis,
B. cereus, B. megaterium, B. sphaericus, B. pumilus and B. lichenfor-
mis. Using cluster analysis MALDI-TOF-MS analysis grouped the
data into species-speciﬁc clusters.
Subsequently a dedicated MALDI-TOF database (Manchester
Metropolitan University, Manchester, UK) consisting of >2000
entries and representing nearly 90 strains of Bacillus was utilised
in combination with database matching software (Waters Cor-
poration, Manchester, UK) to analyse 80 well-characterised clinical
isolates from FSML, HPA, London. All B. subtilis isolates were
correctly identiﬁed and 75 and 79% B. cereus and B. lichenformis
isolates, respectively were successfully identiﬁed with high per-
centage probability matches. Nine isolates of B. pumilus were
incorrectly identiﬁed, but upon close inspection of the data bio-
markers that enabled successful differentiation of B. pumilus from
these organisms was located. In conclusion, these preliminary
ﬁndings suggest that MALDI-TOF-MS will represent a useful tool
for the rapid identiﬁcation of Bacillus isolates.
Pathogenesis of infection
O102 Participation of gut commensal bacteria and mucosal
immunity in pathogenesis of inﬂammatory bowel disease (IBD):
gnotobiotic models of human disease
H. Tlaskalova´-Hogenova´, R. Stepankova, H. Kozakova,
L. Tuckova, D. Sokol, B. Cukrowska, T. Hudcovic, Z. Rehakova,
T. Hrncir, P. Heczko, M. Strus, H. Uhlig, F. Powrie, P. Bland
Prague, CZ; Warsaw, Krakow, PL; Oxford, Bristol, UK
Objectives: Immune system associated with mucosal surfaces cover-
ing the largest area of the body (200–300 m) evolved mechanisms
discriminating between harmless commensal microorganisms and
dangerous pathogens. Numerous inﬂammatory and autoimmune
diseases may occur as a result of changes in mechanisms regulating
mucosal immunity, which leads to impaired barrier function of the
mucosa, increased penetration of components of commensal ﬂora
and/or food into circulation and consequently to abberant immune
responses. The aim of our study was to elucidate the initial events
leading to development of intestinal inﬂammation in animal models
of human IBD (i.e. Crohn’s diseases and ulcerative colitis) reared in
gnotobiotic conditions.
Methods: We analysed the role of commensal bacteria in patho-
genesis of gut inﬂammation using experimental model of colitis
developing spontaneously in colon of conventional SCID mice
(mice with severe combined immunodeﬁciency) reconstituted
with the CD45RBhigh subset of CD4+ T cells isolated from spleen
of normal BALB/c mice. As a recipients, germfree SCID mice,
conventional SCID mice or ex-germfree SCID mice monoasso-
ciated with deﬁned bacterial strains or colonised with bacterial
mixtures were used. Mice were colonised with segmented ﬁla-
mentous bacteria (SFB) alone or with deﬁned bacterial cocktail of
speciﬁc pathogen-free (SPF) mice.
Results: Clinical picture and histopathological evaluation revealed
that 8–12 weeks after transfer of pathogenic CD4+CD45RBhigh
T cell subpopulation into germfree SCID recipients intestinal
inﬂammation did not develop. In contrast, severe forms of intest-
inal inﬂammation were present in conventionally reared SCID
mice and in mice colonised with cocktail of SPF microﬂora plus
segmented ﬁlamentous bacteria (SFB). A monoassociation of SCID
mice with SFB, Escherichia coli, Enterococcus fecalis, Bacteroides dista-
sonis or various cocktails of SPF bacteria did not lead to intestinal
inﬂammation. Signs of impairment in tight junctions (TJ) of
epithelial cell layer in the terminal ileum of colitic mice was docu-
mented by anti ZO-1 antibody.
Conclusion: Our studies suggest that noncultivable segmented ﬁla-
mentous bacteria together with deﬁned mixture of cultivable bac-
teria from SPF mice were effective in triggering intestinal
inﬂammation. Supported by EU project QLRT-CT-1999–0050.
O103 Identiﬁcation and disruption of opuB, a novel bile
tolerance locus linked to the virulence potential of Listeria
monocytogenes
R. Sleator, C. Hill
Cork, IRL
Listeria monocytogenes is the causative agent of listeriosis, a debili-
tating illness accounting for approximately 35% of all deaths
caused by known bacterial foodborne pathogens in the US yearly.
Listeria is capable of withstanding a variety of hostile environmen-
tal conditions, including the many stresses encountered during
the production, preparation and storage of food and postcon-
sumption within the animal host. The ability of Listeria to prolifer-
ate under such adverse conditions is attributed, at least in part, to
the accumulation of compatible solutes (of which betaine, carni-
tine and choline are most effective), and the active extrusion of
harmful compounds such as toxic bile salts produced by the host.
Objective: To mine the listerial genome sequence for potential
membrane transporters, which accumulate beneﬁcial compounds
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or extrude harmful ones, thereby allowing the pathogen to mount
a successful infection.
Methods and results: In silico analysis of the L. monocytogenes gen-
ome revealed a fused two-gene operon designated opuB, exhibit-
ing signiﬁcant sequence similarity to certain members of the
betaine carnitine choline transporter (BCCT) family. Preceded by
consensus sigA and sigB-dependent promoter-binding sites we
demonstrate by reverse transcription PCR analysis that the operon
is transcriptionally up-regulated at elevated osmolarities and
reduced temperatures (stresses known to induce sigB). Further-
more, a signiﬁcant reduction in the level of opuB transcription
was observed in the absence of sigB. In addition, we identiﬁed an
important role for PrfA, the master regulator of virulence poten-
tial in L. monocytogenes, in coordinating opuB expression. Com-
puter-aided structural analysis of the OpuB protein suggests that,
rather than functioning as a compatible solute uptake system,
OpuB is in fact an efﬂux pump, actively extruding bile salts from
inside the cell, a ﬁnding conﬁrmed by radiolabelled bile efﬂux
studies. In addition, functionally inactivating OpuB by chromoso-
mal exchange mutagenesis resulted in an approximately 4 log
decrease in the ability of the bacterium to tolerate bile, a pheno-
type which translates to a signiﬁcant reduction in virulence poten-
tial when administered to a murine model by the oral route.
Conclusion: OpuB, which is coordinately regulated by sigB and
PrfA, represents a novel bile tolerance locus in L. monocytogenes,
which contributes signiﬁcantly to the virulence potential of the
pathogen following infection via the oral route.
O104 The impact of mechanical ventilation on the
treatment with moxiﬂoxacin (MXF) in an animal model of
pneumonia caused by Streptococcus pneumoniae
P. Charles, D. Croisier, M. Etienne, C. Lequeu, L. Piroth,
H. Portier, P. Chavanet
Dijon, F
Objective: Streptococcus pneumoniae is a leading cause of commu-
nity-acquired pneumonia (CAP) worldwide. About 25% of hospi-
talized patients with CAP need intensive care unit management.
In this setting, pneumonia is still associated with a mortality of
30–46% in spite of the availability of effective antibiotic therapy,
especially when mechanical ventilation (MV) is required. Experi-
mental data suggest that MV could reduce lung bacterial clear-
ance. Therefore we studied in which extent MV could inﬂuence
the efﬁcacy of MXF, a new active antibiotic treatment against
S. pneumoniae.
Methods: Prospective experimental study in NZ healthy rabbits
(n ¼ 71). A calibrated inoculum of S. pneumoniae (MIC for penicil-
lin, ciproﬂoxacin and MXF were 4, 0.5 and 0.125 mg/L respec-
tively) was intrabronchially instillated in all the animals. Four
hours later, a human-like treatment of MXF corresponding to the
standard regimen (400 mg i.v. od for 48 h) was initiated in ani-
mals undergoing MV and in air-breathing ones. Either mechani-
cally ventilated or air-breathing untreated rabbits were used as
controls. Survivors were sacriﬁced 48 h after inoculation. Pneumo-
nia assessment was based on histologic (macroscopic score) and
bacteriologic (lung and spleen cultures results) ﬁndings.
Results: Whereas MXF treatment was associated with a substantial
survival improvement in the air-breathing animals (21.6% vs.
100% of survivors, in control and treated animals, respectively),
mortality rate remained high in the presence of MV (12.5% vs.
46.1%). In the presence of MV, pneumonia tended to be more
severe in terms of histologic damage. The lung bacterial burden
was higher in treated animals with MV compared with those
without (5.12.4 vs. 1.61.4 log 10 CFU/g, respectively; P < 0.05).
Pneumonia was bacteraemic in almost all the untreated animals.
No animals was bacteraemic in the air-breathing animals treated
with MXF. In contrast, 23.1% of the treated animals had positive
spleen cultures in the presence of MV. Notably, MXF blood con-
centrations was found to be comparable in both groups.
Conclusions: In our model of S. pneumoniae pneumonia, MV
seemed to worsen lung injury and to promote bacterial growth
and systemic spread of the infection. In such conditions, MXF was
less effective than in air-breathing animals. Taken together, these
results suggest that MV may impair host lung defence, making
less-effective antibiotic therapy.
O105 The cylA/B genes of the Streptococcus agalactiae
haemolysin genecluster encode a multidrug resistance ABC
transporter
B. Gottschalk, G. Bro¨ker, M. Kuhn, S. Martin, B. Spellerberg
Ulm, Aachen, D
Objectives: The Streptococcus agalactiae haemolysin is regarded as
an important virulence factor. Haemolysin production is depen-
dent on the cyl genecluster. This cluster comprises 12 genes and
was identiﬁed in 1999 by our group through the analysis of non-
haemolytic and nonpigmented ISS1 mutants. cylA and cylB
encode the ATP-binding and transmembrane domains of a typical
ABC transporter.
Methods and results: The deduced proteins from cylA and cylB dis-
play signiﬁcant homologies to multidrug resistance (MDR) trans-
porters. Insertion mutants in this locus result in a nonhaemolytic
and nonpigmented phenotype. The function of these genes was
further elucidated by construction of nonpolar deletion mutants
of cylA. These mutants are nonhaemolytic and can be partially
complemented by a plasmid harbouring cylA and cylB. To iden-
tify substrates of the putative transporter the wildtype strain, a
cylA and a cylK deletion mutant were exposed to known sub-
strates of MDR transporters. While the susceptibility of the
mutants to various antibiotics was unchanged, growth of the cylA
deletion mutants was signiﬁcantly impaired in the presence of
0.5 mg/L daunorubicin and 1 mg/L doxorubicin. However, the
growth pattern of the nonhaemolytic cylK deletion mutant was
indistinguishable from the wildtype strain. This indicates that the
observed effect is linked to the transporter activity and not to the
nonhaemolytic phenotype. Further indications for the importance
of the transporter to get haemolysis is supported by the fact that
addition of the multidrug pump inhibitor reserpine to culture
media markedly reduced the haemolytic activity.
Conclusion: To our knowledge this is the ﬁrst report of a Strepto-
coccus agalactiae transporter with the ability to transport sub-
stances such as daunorubicin and doxorubicin. This ﬁnding along
with the reserpine inhibition of haemolytic activity may provide
some insight into the chemical structure of possible natural sub-
strates of cylA/B.
O106 Resorbable hydrogel polymer as an antimicrobial
delivery system in the treatment of Staphylococcus aureus
experimental osteomyelitis
M. Rouse, D. Velasquez, S. Bernatchez, J. Steckelberg, R. Patel
Rochester, St Paul, USA
Purpose: Polymethylmethacrylate bone cement (PMMA) is used
for antimicrobial delivery in treatment of bone infections. Antimi-
crobial release from PMMA is limited and PMMA beads used for
local antibiotic delivery need surgical removal after treatment.
Resorbable vancomycin-loaded hydrogel polymer beads (RPH)
will release most of the vancomycin loaded and can be resorbed
in situ. We determined the release kinetics of vancomycin from
RPH and PMMA beads in a continuous ﬂow chamber and used a
rat model of S. aureus osteomyelitis to compare the activity of
RPH and PMMA delivered vancomycin.
Methods: Vancomycin concentration was measured in the efﬂuent
of a ﬂow chamber containing one 3 mm RPH or PMMA bead con-
taining 7.5% vancomycin. The efﬂuent was sampled every 2 h for
48 h. Results were expressed as the mean peak concentration,
mean AUC 0–48 h and mean per cent of antibiotic released for
RPH or PMMA. Experimental osteomyelitis was established in
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Wistar rats by inoculating a sclerosing agent and 106 S. aureus into
the medullary cavity of the proximal left tibia. 4 weeks after
infecting the rats, treatment by debridement of the infection site
and placement of a bead in the bone defect was initiated. After
3 weeks of treatment, rats were sacriﬁced and the tibia removed
and cultured. The results were expressed as the median
log 10 CFU/g of bone.
Results: In vitro release kinetics of vancomycin from RPH or
PMMA are: RPH peak concentration 62.7 lg/mL, AUC
508 h  lg/mL and 56% of vancomycin loaded into beads was
released. PMMA peak concentration 19.1 lg/mL, AUC
180 h  lg/mL and 11% of vancomycin loaded into beads was
released. In vivo results of treatment in S. aureus experimental
osteomyelitis are listed as median log 10 CFU/g (range 25–75th
percentile). Results of treatment with debridement alone were
6.01 CFU/g (5.1–6.5), bland PMMA 6.4 CFU/g (6.1–6.8), bland
RPH 5.9 CFU/g (4.4–6.3), PMMA delivered vancomycin 3.2 CFU/
g (1.5–4.1) and RPH-delivered vancomycin 4.5 CFU/g (3.9–6.0).
Conclusion: The vancomycin peak concentration, AUC (0–48 h)
and the per cent released into physiological buffer in our continu-
ous ﬂow chamber were greater from RPH than PMMA. In the
treatment of MRSA experimental osteomyelitis, vancomycin
loaded RPH beads are more active (P < 0.05) than debridement
alone, bland RPH or PMMA bead but less active (P ¼ 0.02) than
vancomycin-loaded PMMA beads.
Pan-European infectious disease surveillance: do we get the needed information for public health
action?
S108 Early warning of inﬂuenza epidemics: the EISS
network
W.J. Paget, A. Meijer
Utrecht, NL
The European Inﬂuenza Surveillance Scheme (EISS) was estab-
lished in 1996 and is a pan-European inﬂuenza surveillance net-
work that covers 22 countries and 25 surveillance networks. The
scheme includes 30 National Reference Laboratories, over 11 000
sentinel physicians and covers a total population of 445 million
inhabitants (http://www.eiss.org). EISS is funded by the European
Commission (EC) and aims to integrate all of the European Union
Member States. The aim of the EISS project is to reduce morbidity
and mortality associated with inﬂuenza in Europe. EISS monitors
inﬂuenza by collecting clinical and virological data on a weekly
basis during the inﬂuenza season from two sources: sentinel physi-
cians (clinical and virological data) and virological data from other
sources (e.g. hospitals and nonsentinel physicians). During the
inﬂuenza season, EISS publishes a Weekly Electronic Bulletin on its
website, which provides an epidemiological and virological over-
view of inﬂuenza activity in Europe. EISS acts as an early warn-
ing system for inﬂuenza by collecting and presenting detailed data
on a timely basis to its members and the general public. During the
2002–2003 season, EISS monitored the emergence of the new drift
variant A/Fujian/411/2002 (H3N2) at the end of the season and it
has monitored the spread and impact of this virus during the
2003–2004 season. Members share their data and expertise with the
group and EISS makes public health statements concerning new
viruses or public health threats (e.g. a statement for the EC on the
impact of the A/Fujian-like virus). In the context of the EC’s
Community Inﬂuenza Pandemic Preparedness and Response Plan,
EISS has established a Community Network of National Reference
Laboratories for Human Inﬂuenza in Europe. This initiative will
lead to improved collaborations between laboratories, the use of
standard WHO reagents and the establishment of an accreditation
system for National Reference Laboratories. In connection with
pandemic preparedness activities, EISS is also initiating contacts
with surveillance schemes that monitor inﬂuenza in animals. These
developments should, in turn, enhance the surveillance of inﬂu-
enza in Europe and improve the early warning functions of EISS to
detect inﬂuenza epidemics and a possible pandemic.
S109 The EU-MenNet: understanding the changing
patterns of meningococcal disease
M. Frosch
Wu¨rzburg, D
Meningococcal disease remains a major childhood infection in Eur-
ope, with an appreciable number of cases in other age groups, nota-
bly young adults. There is currently no comprehensive childhood
vaccine against this disease, the severity of which, combined with
its rapid progression and nonspeciﬁc symptoms, results in an unac-
ceptable burden of childhood morbidity and mortality. The devel-
opment of effective vaccines and public health management
policies are confounded by the epidemiology of meningococal dis-
ease, which is itself governed by the complex population biology of
the causative organism, Neisseria meningitidis. In addition to its
intrinsic relevance for European public health, meningococcal dis-
ease is a valuable scientiﬁc model system and a paradigm for pan-
European co-operation among publically funded laboratories. In
2001 the EU-MenNet consortium representing all European refer-
ence laboratories for meningococci has been established to address
the need for harmonized nucleic acid sequence-based detection and
typing technologies and the implementation of the multi-locus
sequence typing (MLST) technology throughout Europe. The mole-
cular strain characterisation data together with integrated epide-
miology information gathered by this consortium provides
substantial added value in terms of understanding the dynamics of
spread of hypervirulent meningococcal clonal complexes, which
are responsible for almost all cases of invasive meningococcal dis-
ease. It will now be possible to develop pan-European recommen-
dations for the management of this important disease and to
compare the impact of different vaccine strategies and help to select
the best vaccination schedules. These technologies will also be
applicable to future meningococcal serogroup B vaccines.
S110 EWGLINET: towards legionella-free travel in Europe
C. Joseph – European Working Group for Legionella Infections
Objectives: To identify, control and prevent outbreaks of Legion-
naires’ disease in European travellers.
Methods: Since 1987, European microbiologists and epidemiolo-
gists have collaborated in EWGLINET – a scheme for the identi-
ﬁcation of travel associated legionella cases, rapid detection of
clusters linked to tourist accommodation and exchange of infor-
mation so that immediate investigations and control measures
can be implemented. Collaborators also contribute to improving
clinical and environmental methods for case and outbreak conﬁr-
mation and to enhancing national surveillance schemes for case
detection. In July 2002 European Guidelines for the Control and
Prevention of Travel Associated Legionnaires’ Disease were
introduced. They aim to standardise procedures for informing
and liaising with hotels, tour operators, public health ofﬁcials
and the general public, and for carrying out investigations when
clusters occur. They were endorsed by the EC in June 2003 and
are now used by the majority of European countries. Sanctions
are applied if the country of infection fails to implement the
required public health response in the time frame set out in the
Guidelines. These sanctions include publishing information about
the cluster and the accommodation site on the EWGLI website.
Clusters are also publicised if public health measures are consid-
ered to be inadequate for control and prevention of further
cases.
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Results: A total of 36 countries now participate in EWGLINET.
Cases reported to the scheme have increased from three in 1987
to 168 in 1995 and 675 in 2002. Highest numbers in 2002 were
linked to Italy (132), France (122), Spain (85), Turkey (81) and
Greece (33). How countries of infection respond to single cases
inﬂuences the number of sites that are associated with further
cases. In Italy, France and Spain, between 18 and 21% of their
total cases were linked to clusters whereas in Greece and Turkey
it was much higher at 36 and 59%, respectively. In total 94
clusters were detected in 2002, 27 of them in Turkey. Dealing with
the clusters has been slow in Turkey, and 78% of implicated sites
were published on the EWGLI website between July 2002 and
October 2003.
Conclusions: Management of clusters in most countries is progres-
sing well through use of the Guidelines. The next challenge is to
apply greater efforts to improve prevention of legionella. This
paper will review how this work is contributing towards the
objective of legionella-free travel in Europe.
The threat posed by Rickettsiales and other arthropod-borne pathogens (Symposium arranged with
ESCAR)
S111 Climate impacts on ticks as vectors
S.E. Randolph
Oxford, UK
Pathogens transmitted by vectors are faced with ecological and epi-
demiological hurdles deﬁned by the quantitative balance between
all the factors that determine the rates of transmission. These
depend to a large extent by the impact of a variety of extrinsic
environmental factors on the vector–host–pathogen triangle. Of the
three types of organisms within this triangle the vector is the most
sensitive to climate. Using the framework of a simple tick popula-
tion model, I shall present ﬁeld data and experimental results that
help to quantify the relationships between climatic conditions
and tick demographic rates and therefore pathogen-transmission
rates. Different rates may change in different directions in response
to climatic variation. For example, tick development rates increase
with increasing temperature, but tick host-seeking activity (and
therefore feeding rates and long-term survival) decreases with
increasing moisture stress. Climate may even inﬂuence the differ-
ential attachment of each tick stage to different host species, parti-
cularly to rodents that are commonly important transmission
hosts. The outcome in terms of pathogen-transmission potential
can only be predicted with a fully functional model. This is espe-
cially true for any pathogen, such as tick-borne encephalitis virus,
that requires certain patterns of tick seasonal dynamics to support
the speciﬁc cellular basis of transmission by ticks via rodents.
Nevertheless, until we have a full biological process-based
model, we can use a statistical approach to predict the likely
impact of forecast climate change on the distribution of vector-
borne diseases.
S112 Prophylaxis for tick-borne diseases
J.A. Oteo
Logron˜o, E
To date ticks are the main arthropod-vectors for human disease
in developed countries. They can transmit a broad number of
tick-borne pathogens (bacterial, virus, protozoa, toxins) with a
high rate of morbidity. Tick-borne diseases prophylaxis can be
made by means of pre-exposition measures or after exposition
ones. Among pre-exposition measures is very important to wear
correct clothes when we go to the possible tick-infected areas
(long trousers inside the socks, boots, shirt with long sleeves,
and a cap or similar). The colour of the clothes is also impor-
tant, so the dark ones attract less ticks than bright ones, but in
the last ones we can see them better and remove them before
they can bite us. The use of repellents like permithrin in clothes
is safe for health although short in time but not very effective
in my experience. Other important measure is the removing of
the parasites of our pets to avoid introducing ticks at home. A
measure to reduce ticks is controlling rodents population and
vegetation at town surrounding areas. Since in Lyme borreliosis
has been demonstrated that the tick must feed on his host dur-
ing 24–48 h, it’s very important to look for ticks when we come
back from tick-infested areas. So if we remove ticks before they
transmit borrelias we can prevent Lyme borreliosis. This mea-
sure is less important for preventing Rickettsiosis or Ehrlichiosis
since these bacteria can be transmitted precociously. After tick-
bite there are two important questions. How must I remove the
tick? Must I take antibiotics for prophylaxis? Ticks must be
removed with forceps. Other removal methods as oil, petrol,
cigarette, etc, should be avoided. In reference to the second
question, only an American study has demonstrated that the
use of a single dose of 200 mg of doxiciclyne is effective for
preventing Lyme borreliosis. In Europe none study has been
conducted for answering this question. By other hand this mea-
sure has not been evaluated for preventing Rickettsiosis and
other tick-borne diseases. Vaccines for preventing tick-borne
encephalitis (Centro-European encephalitis) are safe and are
indicated in endemic areas. Lyme borreliosis vaccines were
used in USA and took out from market because of adverse
effects.
Hepatitis C virus infection: pathogenesis, diagnosis and treatment
S116 Humoral response against hepatitis C virus
R. Burioni, N. Mancini, S. Carletti, M. Perotti, A. Grieco,
E. Belardinelli, M. Mammarella, F. Canducci, M. Clementi
Ancona, Milan, I
Antibodies are often a reliable marker indicating vigorous
response against infectious agents and in several viral diseases
presence of anti-viral antibodies indicates an effective protection.
However, in the case of hepatitis C virus (HCV) in spite of an
intense antibody response there is no protection against a new
infection and often the virus overcomes host defences establishing
a persistent infection. There is a lively debate about whether the
humoral response affords any protection against HCV in the
infected host. Indeed, whereas some studies have shown that a
high titre of anti-HCV antibodies does not prevent reinfection,
several other reports indicate the presence of a protective
response consistently with the demonstration that immunoglobu-
lins may prevent the infection in patients at risk. Finally, descrip-
tion of the dynamics of intra-host evolution have shown that a
crucial phase for disease outcome lies at a time point correspond-
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ing to the production of antibodies by the infected host. These
data suggest an important role for antibodies in the evolution of
HCV infection. An important structure studied as a target of
antibody is HCV E2 envelope glycoprotein (HCV/E2), but unfor-
tunately the assessment of the efﬁcacy of this class of antibodies
has been hampered by the poor growth efﬁciency of HCV in cell
culture, by the fact that the murine response is not consistent with
the human antibody response and by the unavailability of animal
models of this infection beside primates. Cloning of the immune
repertoire of an HCV-infected patient on phage display combina-
torial vectors and generation of human monoclonal antibodies
have demonstrated that activity varies widely for single clones. In
particular efﬁciency in neutralizing HCV/E2 binding to cellular
target and in inhibiting infection of cells by HCV pseudoviruses is
different for each clone. The observation that only some clones
are able to inhibit HCV, can help understand how this virus
escapes the control of the immune system. A better characteriza-
tion of the anti-HCV immune response in terms of biological
activity will help the design of possible vaccine strategies and
their in vitro evaluation. This would be a considerable advance in
an infection lacking an animal model. Molecules demonstrated
in vitro to stimulate selectively the production of neutralizing anti-
body clones will be the best candidates for further in vivo studies.
Multidrug resistance in Acinetobacter, Stenotrophomonas and Pseudomonas: similarities and
differences – interactive session
S124 Epidemiology of multidrug resistance in
Acinetobacter, Stenotrophomonas and Pseudomonas
M. Akova
Turkey, TR
The three well-known nonfermentative organisms, namely Pseudo-
monas aeruginosa, Acinetobacter spp, and Stenotrophomonas maltophi-
lia are common commensals and ubiquitous organisms widely
distributed in nature. In addition to factors involved in their viru-
lences, resistance to a wide variety of antimicrobials makes these
organisms effective opportunistic nosocomial pathogens.
Although resistance patterns may differ in these bacteria, multi-
drug-resistant (MDR) strains are usually not affected by all beta-
lactams including carbapenems, aminoglycosides, and quinolones.
In epidemiological studies, respiratory tract was found the most
frequent site of isolation for all three and patients residing in the
ICU were more frequently infected. P. aeruginosa was reported as
the second most common cause of nosocomial pneumonia by
NNIS system, whereas Acinetobacter was the seventh for this infec-
tion in a large European surveillance study. S. maltophilia has been
increasingly reported as a cause of infection in immunosup-
pressed patients, however its incidence was far less common than
the previous ones. In a recent SENTRY trial the incidence of MDR
P. aeruginosa was reported 4.7% in European centers. The rate
was increased up to 20% in certain Italian, Portuguese and Turk-
ish centers. In general the highest rates were found in centres
from South America and this was closely followed by centers
from Europe. Increasing carbapenem resistance worldwide is a
big concern in both P. aeruginosa and Acinetobacter isolates and is
becoming a disturbing clinical problem. Against MDR P. aerugi-
nosa and Acinetobacter isolates, the most effective agents are poly-
myxins, however resistance to these agents has already been
described in Acinetobacter isolates. Similarly, resistance exists for
the most-effective agents against S. maltophilia, namely trimetho-
prim-sulphamethoxazole (upto 10%), ticarcillin-clavulanate (10–
29%), and quinolones (up to 15%). Epidemic occurences with
these three nonfermentatives possessing MDR capabilities seem to
be increasing. Ongoing surveillance for isolates and their resis-
tance proﬁles is important to guide therapy.
HIV: from research to clinical facts
O127 Complement synthesis and activation in the brain of
SIV-infected monkeys
C. Speth, K. Williams, M. Hagleitner, S. Westmoreland,
M.P. Dierich, H. Maier
Innsbruck, A; Boston, Southborough, USA
Objectives: Complement is one of the most important defence
tools against cerebral infections, but uncontrolled complement
biosynthesis and activation can induce brain inﬂammation and
profound tissue damage. To clarify the role of complement in
AIDS-associated neurological disorders we analysed complement
synthesis in the brains of SIV-infected rhesus macaques.
Methods: Immunohistochemical staining in parafﬁn-embedded tis-
sue sections derived from the brain of SIV-infected rhesus maca-
ques and uninfected control monkeys was performed using
speciﬁc antibodies against the complement factors C1q and C3.
Results: The cerebral synthesis of complement factors C1q and C3
is strongly upregulated in SIV-infected monkeys compared with
the spontaneous synthesis in the brain of uninfected control ani-
mals. Astrocytes, neurons, microglia, and inﬁltrating macrophages
and multinuclear giant cells all contribute to the high amounts of
C1q and C3 present in the SIV-infected brains. Secreted C1q and
C3 are not only present extracellularly in the tissue, but are also
deposited on the membrane of neurons, a prerequisite for forma-
tion of the membrane-driven lytic membrane attack complex.
Conclusion: The low constitutive production of complement in the
normal monkey brain is highly upregulated by infection with SIV,
indicating that enhancement of complement synthesis is an impor-
tant defence mechanism of the brain against invading virions. The
membrane deposition of complement on brain cells, however,
suggest a role of complement and complement-induced lysis of
bystander neurons as a potential mechanism for HIV-induced cell
damage.
O128 HE2000 decreases inﬂammatory cytokines and viral
load in HIV patients and opportunistic infections in late stage
AIDS patients
D. Stickney, C. Reading, A. Garsd, C. Ahlem, N. Onizuka-Handa,
J. Frincke
San Diego, USA
Objectives: HE2000, 16-a-bromoepiandrosterone, is a broad spec-
trum immune therapeutic agent that has demonstrated preclinical
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and clinical activity in HIV/AIDS models and patients. Clinical
studies were conducted to determine the effect of HE2000 on the
incidence of opportunistic infections in late stage AIDS patients.
The capacity of HE2000 to act as a therapeutic vaccine to stimu-
late T-cell HIV-speciﬁc immunity in HIV patients was also exam-
ined.
Methods: Two double-blinded placebo-controlled clinical studies
were conducted in South Africa in treatment naive HIV
patients(CD4 > 200) and AIDS patients (CD4 < 100) at risk for
opportunistic infections. Patients were cyclically treated with
HE2000 once daily for 5 days every 6 weeks.
Results: In the study of HIV patients (baseline mean CD4
cells ¼ 475 for treated and 429 for placebo groups), immune mod-
ulation occurred after two to three cycles of treatment. When com-
pared with placebo, HE2000 normalized inﬂammatory cytokines
(TNF-a and IL1-b), increased circulating dentritic cells, stimulated
gag-speciﬁc T-cell immunity and lowered viral titre 0.6 log
(P ¼ 0.01). In late stage AIDS patients (treated group baseline
mean CD4 ¼ 49.9), a statistical trend (P ¼ 0.10) in eduction of
C-reactive protein levels was noted compared with the placebo
group (baseline mean CD4 ¼ 55). Viral load decreased by 0.55 log
using an area under the curve minus baseline model (AUCMB).
The data is suggestive of an increase in CD4 cells (P ¼ 0.11 NS).
There was a delay in the median time to the ﬁrst emergent tuber-
culosis infection (>406 days) when compared with the placebo
(281 days). A statistically signiﬁcant decrease in the cumulative
incidence of opportunistic infections was observed in the treated
group (P ¼ 0.027).
Conclusions: HE2000 restores HIV-speciﬁc immunity in HIV
patients, which results in a decrease in viral load and it decreases
total cumulative opportunistic infections in late stage AIDS
patients. HE2000 may delay the need for antiretroviral therapy in
the treatment of HIV infection.
O129 Differential effect of HAART on CD4 and CD8
T-cell cytokine production and response to CMV antigens in
HIV+ patients
W. Lynn, T. Akerele, R. Moses, S. Lightman
London, UK
Objectives: To determine the effect of HAART on cytokine produc-
tion and response to CMV antigens in CD4+ and CD8+ T-cells in
HIV+ patients no on anti-retroviral therapy and following initia-
tion of HAART.
Methods: A total of 73 patients with HIV infection were divided
into those stable without HAART and those on HAART. Patients
on HAART were divided further on the basis of their length of
time on HAART (> or <3 months), viral load (> or <50 copies/
mL, CD4 count nadir and whether their CD4 count had increased
to >150 cells/lL on HAART, gender and origin. CD4+ and CD8+
T-lymphocyte cytokine production in response to stimulation with
PMA and ionomycin using single cell ﬂow cytometry was per-
formed. In a further cohort of 104 CMV+/HIV+ patients on
HAART, proliferative and cytokine responses to CMV antigens
were analysed and compared.
Results: CD4+ and CD8+ IFNg expression was increased in HIV+
groups when compared with controls. CD4+ cell IFNg expression
normalized on HAART when CD4 count was >150 cells/lL.
CD4+ IL-2 expression was signiﬁcantly reduced in all HIV
patients when compared with controls and did not signiﬁcantly
improve on HAART. However IL-2 production by CD8 cells was
signiﬁcantly improved in all patients on HAART when compared
with HIV patients on no HAART. This was normalized in patients
following HAART for 3 months or greater, when their CD4 count
exceeded 150 cells/lL or when the HIV viral load was
<50 copies/mL. In response to CMV antigens, all groups showed
a signiﬁcant reduction in CD4+ T-cell function and production of
cytokines, despite an increase in absolute CD4+ T-cell numbers.
By contrast in patients responding to HAART, CMV-speciﬁc
CD8+ T-cells have increased responses to CMV.
Conclusion: These results show that the production of IL-2 by CD8
cells and IFNg by CD4+ cells becomes normalized on successful
HAART and that even at low CD4+ counts CD8+ responses to
CMV are enhanced. This is likely to account for the early clinical
improvement in rate of opportunistic infections and reduced risk
of death in patients on HAART.
O130 DAPY non-nucleoside inhibitors of HIV-1 reverse
transcriptase possess high activity in microbicide assays and
have potential for prevention of sexual transmission of HIV
P.J. Lewi, H.F. Njai, Y. Van Herrewege, L. Kestens, G. Vanham,
K. Andries, M.-P. de Be´thune, J. Van Roey, P.A.J. Janssen
Vosselaar, Antwerp, Mechelen, B
Objectives: Several diaryl-pyrimidine (DAPY) compounds have
nanomolar activity in cell-based assays on wild type and mutant
HIV-1. They bind into the non-nucleoside site of HIV-1 reverse
transcriptase (NNRT). Three DAPY compounds are presently in
clinical studies. In parallel, microbicide assays have been carried
out on DAPYs in order to assess their potential for prevention of
transmission of HIV.
Methods: In a ﬁrst set of experiments, monocyte-derived dendritic
and autologous CD4+ T cells (MO-DC/T) were infected with
HIV-1 Ba-L, washed and treated for 14 days with the test com-
pound, yielding the 50% effective concentration (EC50). In a sec-
ond set, exposure to compound was 24 h. After 24 h, cells were
washed and co-cultured for 14 days without compound, followed
by secondary culture with PHA/IL-2 blasts. In a third set, virus
was immobilized on poly-L-lysine and pretreated with compound
for 1 h in the absence of cells. After washing, MO-DC/T were
added and cultured during 14 days.
Results: EC50s of the DAPYs in the 14-days experiment ranged
between 0.4 and 3 nM. For comparison, EC50s for UC-781 and
PMPA in this test were 53 and 106 nM, respectively. Dapivirine
(TMC120-R147681), the prototype DAPY, showed only a small
increase in EC50 in the 24-h assay and completely protected
against HIV between 10 and 100 nM, whereas 100-fold higher
concentrations were required with UC-781 and PMPA. In the
1-h assay, dapivirine completely inhibited replication between
10 and 100 nM, while UC-781 required 100-fold higher concen-
trations.
Conclusion: NNRTIs of the DAPY-class of compounds are highly
potent inhibitors of HIV-1 replication in microbicide assays
which mimick conditions of sexual transmission of HIV.
DAPYs, such as dapivirine, may possess virucidal activity
against HIV in the absence of target cells. DAPY NNRTIs pre-
sent high potential for development as microbicides in order to
prevent sexual transmission of HIV, using vehicles such as gels
and intravaginal rings.
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O131 Q151M complex is frequent in HIV-1 non-B subtype
isolates of patients living in southern Spain
S. Suarez, M. Alvarez, F. Garcia, M. Martinez, J. Parra,
F.J.R. Garcia, J. Herna´ndez-Quero, M.C. Maroto
Granada, E
Introduction and objective: Certain polymorphisms in the pol gene
of HIV-1 have been found more frequently in non-B HIV-1
subtypes. As this may be important in optimising antirretroviral
therapy we studied the prevalence of pol mutations and related
them to HIV subtype in a cohort of HIV-1 patients living in the
south of Spain.
Patients and methods: We studied 292 HIV-1 patients. Sequencing
of the pol gene was made by Trugene HIV-1 genotyping Kit
(Bayer). Subtyping was performed with the pol sequence using
phylogenetic analysis and reference sequences from B and non-B
strains (Stanford HIV-1 database and ABL networks). SPSS 11.0
package was used for statistical analysis.
Results: Subtyping is expressed for protease/reverse transcriptase
genes. A total of 280 patients harboured B subtypes (B/B) as
studied in the pol gene of HIV-1. The rest were as follows: three
F1/B, two D/B, one CRF02_AG, one G/CRF02_AG, one C (C/C),
one G (G/G); for one patient only the RT sequence was available
and it was classiﬁed as K subtype. For RT gene, Q151M mutation
alone, the mutations of its complex, and K219Q were detected
more frequently in patients infected with non-B subtypes
(P < 0.001); L210W, was detected with a higher prevalence in
patients infected with B subtypes (P < 0.001). For the protease
gene, K20M and M36I were more prevalent when patients were
infected with a non-B subtype. No differences in the antirretro-
viral regimen were observed among patients infected with B and
non-B subtypes.
Conclusions: Multi-nRTI resistance Q151M complex is more fre-
quently detected in patients infected with non-B HIV-1 subtypes.
This is of extremely importance when selecting antiretroviral regi-
mens for patients infected with non-B subtypes, and strengthens
the importance of HIV-1 subtyping information as a part of the
resistance report.
O132 Comparison of two algorithms in the interpretation
of HIV-1 drug resistance genotypic data and a novel phenotypic
assay, virtual phenotype
C. Nogales, C. Serrano, J.C. Palomares, R. Jarana, A. Palacı´n,
C. Almeida, R. Claro, S. Bernal, E. Martı´n-Mazuelos
Seville, E
Objective: The aim of this work was to assess the concordance of
two different genotypic resistance interpretation algorithms and
the recently introduce phenotypic assay, Virtual Phenotype.
Material and methods: A collection of 105 plasma samples with
viral load >1000 HIV-1 RNA copies/mL (Roche Amplicor Monitor
Assay) was included in the study. Viral RNA extracted
(TRUPREPTM Extraction Kit, Visible Genetics) was analysed gen-
otypically using TRUGENE HIV-1 Genotyping Kit assay accord-
ing to the manufacturer’s instructions (Visible Genetics). Sixteen
antiretroviral drugs were analysed. Results were interpreted with
either Visible Genetics version 5 and 6 (VG), RetrogramTM 1.4.
(RG) and Virtual Phenotype (Virco Inc’s) (VP). The algorithms
report different levels of resistance, so to obtain output normalisa-
tion interpretations, no evidence of resistance ‘S’ form VG has
been compared with RG class A, resistant ‘R’ from VG to RG class
D and possible resistance ‘I’ from VG to RG class B and C. To
compare with VP we considered susceptible, resistant and an
intermediate level, when >60%, <40% and the 40–60% of the
strains were within normal susceptible range, respectively . The
three algorithms were compared between them grouped into
three pairs, concordance analysis between the different interpreta-
tion systems was conducted by kappa measurement.
Results: The algorithms assigned 1526 drug resistance interpreta-
tions to 105 sequences. Complete concordance results among the
three algorithms were found in the 59.1% of the samples. 27.8%
were assigned an S, 29.4% an R and 1.9% an I level. The percen-
tage of minor discordances (S/I and R/I) was 32.4% and major
discordances (S/R) were found for 8.39%. In pair-wise compari-
sons, low concordances in the interpretation was observed for
most nucleoside reverse transcriptase inhibitors, mainly tenofovir,
didanosine, zalcitabin and abacavir. Results agreed highly for all
nonnucleoside reverse transcriptase inhibitors and most protease
inhibitors.
Conclusions: (i) There exists a great level of discordance in the
interpretation of genotyping results among algorithms mainly for
nucleoside reverse transcriptase inhibitors. (ii) A consensus for
the interpretation of genotypic data and clinical validation of gen-
otypic results are needed. (iii). Prospective comparative studies
are needed taking into account the broad spectrum of factors that
can affect the clinical outcome.
O133 Surgical site infections in HIV-infected patients from
the MASTER cohort
A. Pan, L. Soavi, L. Signorini, B. Cadeo, S. Casari, F. Cristini,
P.Colombini, S. Lorenzotti, R. Stellini, E. Quiros Roldan, G. Carosi
on behalf of the MASTER Group
Objective: The aim of this study was (i) to evaluate the incidence
of surgical site infection (SSI) in a cohort of HIV-infected patients
(HIV+) and (ii) to identify risk factors associated with SSI in HIV+
patients.
Materials and methods: We carried out a retrospective study
involving HIV+ patients seen at the HIV clinic in Brescia, Italy.
Each patient was asked about surgical interventions performed
since they knew they were HIV+. We recorded data regarding:
(i) surgical intervention: type and duration of intervention, ASA
score, level wound contamination, type and duration of antibio-
tic prophylaxis; (ii) HIV infection: preoperative and postopera-
tive CD4 cell count, plasma HIV-1 viraemia, antiretroviral
treatment (ART), if present; (iii) known factors for SSI: neutro-
phil count, length of preoperative hospitalization, smoking
habit, body-mass index (BMI), diabetes mellitus, presence of an
active infection, treatment with steroids. We also recorded the
risk index category as reported by the National Nosocomial
Infection Surveillance System (NNISS). The SSI rate was com-
pared with that reported from the NNISS, matched for inter-
vention type.
Results: Over a period of 2 months, we interviewed 829 HIV+
patients: 229 (27.6%) reported at least one surgical procedure. A
total of 46 clinical charts (20%) were available for analysis. The
interventions were of general surgery (31%), orthopaedic (24%)
and gynaecological (22%). The number of surgical procedures
increased over the last 5 years, with a signiﬁcant difference
between the period 1985 and 1997 and 1998 and 2003
(P < 0.001). The median age was 40 years (interquartile variation
(IVQ): 35–46) and 72% were males. The CD4 cell count was
323/mm3 (175–727), and HIV viraemia was 67 (IVQ 50–1350)
copies/mcl, 82% of patients were on ART. A SSI was diagnosed
in three (6.5%) of the 46 evaluable patients: in one case superﬁ-
cial and in two cases, deep. The rate of SSI was three times
higher than that reported by the NNIS system for matched inter-
ventions. No statistical differences was identiﬁed between the
patients with and those without SSI, regarding the evaluated
parameters related to SSI risk, probably due to the small number
of patients.
Conclusions: Although the number of intervention analysed is
quite small, this study shows that: (i) there is an increase in
the number of HIV+ patients who undergo surgery; (ii) the
rate of SSI in this group is very high. Speciﬁc systems to
reduce the risk of infection should be searched for HIV-infected
subjects.
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O134 Dyslipidaemia during HIV disease: a comparison of
efavirenz- and nevirapine-based regimens
R. Manfredi, L. Calza, F. Chiodo
Bologna, I
Objective: To assess the serum lipid safety proﬁle of the two avail-
able non-nucleoside reverse transcriptase inhibitors (NNRTI): efa-
virenz (E) and nevirapine (N).
Methods: A cross-sectional study performed on 988 HIV-infected
patients (p) treated with antiretrovirals during >12 months and
naı¨ve to NNRTI,allowed us to identify 234 p given E, and 212 p
who introduced N. After excluding 47 p due to compliance <90%,
208 p who received E were compared with 191 p treated with N,
by a multivariate analysis focusing on adverse events, toxicity,
and related treatment interruptions.
Results: Study groups were comparable as to demographic–epi-
demiologic features, HIV disease stage, mean HIV viraemia and
mean CD4+ lymphocyte count, rate of HCV and/or HBV
co-infection, antiretroviral therapy background, and pre-existing
metabolic disturbances and/or lipodistrophy syndrome (in pre-
treated p). When examining the 121 p naı¨ve to antiretrovirals,
the tolerability index measured during the ﬁrst 3 months of ther-
apy did not differ between the two NNRTI, but clinical features
were substantially different, with predominant hypersensitivity
reactions for N, and CNS disturbances for E (P < 0.0001). When
considering p experienced with antiretrovirals, and p on salvage
regimens, a grade 1–3 liver toxicity occurred in >20% of N-trea-
ted p, vs. three p only in the E group (P < 0.0001). When a
NNRTI substituted a protease inhibitor due to prior dysmetabo-
lism, a drop of triglyceridaemia and/or cholesterolaemia >30%
vs. time of NNRTI introduction, occurred in over 66% of p who
switched towards N, compared with <30% of those who intro-
duced E (P < 0.0001), while in 10 p a frank dyslipidaemia
appeared only after E use.
Conclusion: The two available NNRTI have a comparable activity
and resistance proﬁle, but the remarkably different pattern of
potential adverse events has to be carefully considered, due to the
broad spectrum of short- and long-term toxicity, and the signiﬁ-
cant differences between E and N, in terms of incidence and clini-
cal presentation of untoward events. A long-term observation of p
pretreated with other anti-HIV regimens seems to show a ten-
dency towards a cumulative liver toxicity for N, and stable or
worsening metabolic (and lipid) abnormalities for E. The potential
pathogenetic pathways of the remarkably different toxicity pat-
terns of these two compounds belonging to the same therapeutic
class, warrants enlarged investigation.
O135 Comparison between basal parameters in hepatitis
due to HCV alone and HCV-HIV co-infected patients.
A different spectrum of the same disease
J. Guardiola, J. Cadafalch, J. Enriquez, L. Matas, A. Mauri,
H. Corominas, N. Margall, I. Dı´az, E. Coma, M. Gurgui,
P. Domingo
Barcelona, E
Objective: Hepatitis C virus (HCV) is currently the most impor-
tant cause of chronic liver disease and liver-related death. HCV–
HIV co-infection is the most frequently diagnosed associated
pathology in the natural history of HIV-infected patients in the
ﬁrst world, even more than opportunistic infection. Quantitative
determination of HCV RNA viral load and HCV viral genotype
in baseline sera are standarised methods for evaluation of HVC-
infected patients. Plasma HCV viraemia and HCV genotype are
considered predictive for response to treatment. The aim of this
study was to evaluate and compare the levels of basal HCV
RNA in HCV mono-infected patients and HCV–HIV co-infected
patients, and the genotype distribution in both groups of
patients.
Methods: A longitudinal observational case-control (1:1) study
including the consecutive new and untreated HCV-infected
patients attended in a hepatology service were selected. Similarly,
we analysed the consecutive new and untreated HIV–HCV
co-infected patients visited in the HIV unit. Quantitative serum
HCV RNA and HCV genotype were done in all patients using
PCR techniques by Amplicor Monitor. The genotype was analysed
using hybridisation with speciﬁc probes of the different genotypes
after PCR.
Results: A total of 146 HCV-infected patients were included in
this study, 73 of them were HIV co-infected; 93 (64.3%) were
man. The mean age was 42.78 + 7.8 years (28–77). The mean
RNA VHC viral load was 1.357.467 + 1.737.139 UI/mL
(4.940 + 12.200.000). HCV genotype were 1:86 (59.7%), 2:5
(3.4%), 3:29 (20.1%), 4:24 (16.7%). The mean RNA HCV viral
load was 453.598 UI/mL + 274.121 and 2.248.954 UI/
mL + 2.082.892 for HCV alone and co-infected patients, respec-
tively (P < 0.001). Genotype data were (HCV alone: HCV/HIV)
1:69% vs. 50%, 2:6.9% vs. 0%, 3:15.3% vs. 25.0%, 4:8.3% vs.
25.0%, (P < 0.001). HCV viral load (UI/mL) was 474.936 and
2.519.927 (P < 0.001), 380.400 and 0 (no evaluable), 461.581 and
2.570.772 (P < 0.019), 322.150 and 1.353.463 (P < 0.001) for geno-
type 1, 2, 3 and 4 for HCV alone and co-infected patients,
respectively.
Conclusions: Basal HCV RNA viral load was signiﬁcantly higher
in coinfected. We found stastistical signiﬁcantly differences
between both groups with respect of genotypes. Signiﬁcant differ-
ences were found between both groups of patients when compar-
ing viral load for different genotypes.
O136 Is Legionella a coincidental or opportunistic infection
in HIV-positive patients?
M.L. Pedro-Botet, A. Garcı´a Cruz, O. Sarroca, N. Sopena,
M. Garcı´a Nu´n˜ez, S. Ragull, C. Rey-Joly, M. Sabria`
Badalona, E
Objectives: Bacterial pneumonia is, at present, the most prevalent
and severe HIV-associated bacterial infection. The microorgan-
isms most frequently involved in community-acquired pneumo-
nia (CAP) are S. pneumoniae and H. inﬂuenzae, especially since
the initiation of HAART and successful prophylaxis against
P. carinii. Legionella is currently the second cause of CAP in
general population but its incidence is, unexpectedly, not high
in this subset of patients. From 1983 to 2003, 18 cases of
Legionnaires’ diseases (LD) in HIV patients were prospectively
attended in our centre. Clinical and immunological data were
analysed.
Methods: Data related to HIV and Legionella infection were pro-
spectivelly collected.
Results: All the cases were caused by L. pneumophila. L. pneumo-
phila sg one urinary antigen (LUA) was positive in 13 (72.2%), 6
(33.3%) seroconverted and 1 (5.5%) had a positive broncoalveo-
lar lavage culture. Most of the patients (77.8%) were males with
a mean age of 38.4 years (25–62). LD was hospital-acquired in
ﬁve (27.8%). Three (18.8%) were on TMP/SMX prophylaxis. Ele-
ven (64.7%) were on HAART. The mean CD4 count was 348.1
(6–889). Seven (53.8%) had an undetectable viral load. Fifteen
(83.3%) received appropriate antibiotic treatment (macrolides or
ﬂuoroquinolones) following admission. Thirteen (72.2%) were
smokers and 5 (27.7%) had neoplasms. Fifteen (93.8%) had
cough and nine (56.3%) expectoration. Five (31.3%) had chest
pain and 12 (75%) dyspnea. Extrarespiratory symptoms were
present in 10 (62.5%). Thirteen (76.5%) had an increase in AST,
nine (56.3%) hyponatraemia and eight (50%) an increase in CK.
Coinfection with other microorganisms could not be demon-
strated in any of the patients. Fifteen (83.3%) developed respira-
tory failure, nine (50%) had bilateral x-ray inﬁltrates and the
mortality was 22.2%.
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Conclusions: Legionnaires’ disease in HIV-infected patients may be
considered an opportunistic infection because of the high rate of
respiratory failure, bilateral inﬁltrates and mortality observed
despite adequate antibiotic treatment.
Community-acquired infections: alert to unusual epidemics and update on S. pneumonia
O137 Prevalence, phenotypes, genotypes and molecular
epidemiology of macrolide-resistant clinical isolates of
Streptococcus pneumoniae in Norway, 2001–2002
P. Littauer, M. Sangvik, B. Haldorsen, K. Dahl, G. Simonsen,
D. Caugant, A. Høiby, A. Sundsfjord
Tromsø, Oslo, N
Background: We have limited knowledge regarding the prevalence
and molecular epidemiology of macrolide resistant Streptococcus
pneumoniae in Norway.
Objectives: (i) Examine the prevalence of macrolide resistance in
clinical S. pneumoniae-isolates in Norway. (ii) Characterize macro-
lide-resistant S. pneumoniae strains with regard to resistance phe-
notype and genotype and serotype and multilocus sequence
typing (MLST).
Methods: A total of 1708 isolates of S. pneumoniae isolates from
blood cultures (invasive), respiratory tract and wound specimens
(noninvasive), were collected in Norway in two periods in 2001–
2002 by 24 participating laboratories within the NORM surveil-
lance programme for antimicrobial resistance in human patho-
gens. Strains were examined for their susceptibility to
erythromycin by E-test. Reduced susceptibility (MIC > 1 mg/L)
was detected in 55 (3.2%) S. pneumoniae isolates. Further analyses
included by E-tests analysis against azithromycin, chlorampheni-
col, ciproﬂoxacin, clindamycin, erythromycin, penicillin G, tetra-
cycline, trimethroprim-sulpha and double-disk-diffusion
(erythromycin and clindamycin) and serotyping and MLST. Geno-
typic analyses were performed by erm- and mef-speciﬁc PCRs.
Results: A total of 35 (64%) S. pneumoniae isolates demonstrated M
phenotype resistance, and all harboured mef(A) gene. The remain-
ing 19 (35%) isolates constitutively expressed MLSB resistance
and all but one carried the erm(B) gene. One strain (ML) was
reproducible negative in erm and mef PCR analyses, and will be
further investigated. Reduced susceptibility to penicillin was
found in 14 (26%) isolates. These strains were also resistant to tet-
racycline and erm(B) positive. Serotypes 14, 6 and 19F accounted
for 45, 23 and 15% of the strains, respectively. Serotype 14, con-
ﬁrmed as sequence type (ST) nine by MLST, dominated among
the invasive strains (67%). Among the noninvasive isolates, sero-
type 19F was the most common (31%), of which two strains were
ST230.
Conclusions: (i) The prevalence of macrolide resistance among clin-
ical S. pneumoniae isolates in Norway is still low. (ii) The M-type
of resistance was the most prevalent (64%). (iii) Co-resistance to
penicillin and tetracycline was common and linked to MLSB resis-
tance-erm(B). (iv) A clonal spread of serotype 14 possessing
mef(A), characterized by MLST as ST9, was detected in invasive
strains.
O138 Trends in resistance of Streptococcus pneumoniae in
Europe: an EARSS study
N. Bruinsma, K. Kristinsson, W. Hryniewicz, J.E. Degener,
E. Tiemersma, P. Schrijnemakers, J. Monen, H. Grundmann and
EARSS participants
Objectives: Streptococcus pneumoniae (SPN) is an important cause of
otitis media and invasive infections. Of particular concern is the
high incidence of pneumococcal infections with antibiotic-resistant
strains. The present study describes resistance trends for penicillin
and erythromycin among invasive SPN isolates and forecasts
future trends in Europe.
Methods: The European Antimicrobial Resistance Surveillance Sys-
tem (EARSS) has collected routine antimicrobial susceptibility test
(AST) results of primary invasive SPN isolates from blood or cere-
brospinal ﬂuid (CSF) since 1999. The proportion of resistance is
described as the per cent of SPN isolates only resistant (nonsus-
ceptible) to penicillin, only resistant to erythromycin, or resistant
to both. To observe and predict changes of resistance over time a
multinomial logistic regression model was used. Seven European
countries (BE, DE, FI, IE, IT, SE and UK) that reported more than
100 isolates per year for the period 1999–2002 were included (total
number of SPN isolates ¼ 10.989).
Results: Overall, the highest proportion of resistance was
observed for the strains only resistant to erythromycin, which
increased from 14.6% in 1999 to 16.8% in 2002 (rate of
increase ¼ 1.059/year) and is predicted to increase further to
20.4% by 2006. The proportion of strains co-resistant to erythro-
mycin and penicillin increased from 5.4% in 1999 to 6.6% in
2002, and is predicted to increase to 8.9% by 2006 (rate of
increase ¼ 1.076/year). A decrease of 4.8 to 4.4% over time
(1999–2002) was observed for the proportion strains only nonsus-
ceptible to penicillin, and is predicted to be 3.6% by 2006 (rate
of decrease ¼ 0.947/year).
Conclusions: Erythromycin resistance in SPN has exceeded penicil-
lin resistance and is predicted to increase even further in the
future, with or without combined resistance to penicillin. The
increase of co-resistant SPN strains and the decrease of strains
only resistant to penicillin, indicates a shift of only penicillin
resistance to co-resistance with erythromycin. This increasing
trend of erythromycin resistance emphasises (i) the need for pru-
dent use of macrolides, (ii) the need to encourage the use of high
doses of b-lactam antibiotics, especially when isolates are suscep-
tible or intermediately resistant to penicillins and (iii) the impor-
tance to introduce vaccination to prevent pneumococcal
infections.
O139 Changing patterns of pneumococcal (SP) carriage
after an intervention programme
M. Roussel Delvallez, H. Carsenti Dellamonica, C. Laurens,
B. Dunais, C. Pradier, P. Toubol, P. Bruno, P. Dellamonica
Lille, Nice, F
Background: Naso-pharyngeal SP carriage was studied among chil-
dren attending day-care centres (DCC) during Winters 1999 and
2002 in Northern (N) and South-eastern France (AM). An inter-
vention programme to promote judicious antibiotic use started in
AM in 2000. Trends in serotype distribution and penicillin-resis-
tance (PDSP) were compared.
Methods: NP aspirates were obtained from a random sample of
children attending DCC in 1999 and 2002 in N and AM. SP sero-
types (6B, 9V, 14, 19A, 19F, 23F and NT) and penicillin suscept-
ibility were determined. The intervention programme included
peer-conducted academic detailing visits to all AM general practi-
tioners and paediatricians and parent information.
Results: In 1999 SP serotype distribution and carriage rates, and
PDSP/SP for each serotype were comparable in both areas. In
2002, SP carriage was higher (P ¼ 0.01) and PDSP/SP was lower
(P < 104) in AM. Only three children in N and 14 in AM had
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received pneumococcal conjugate vaccine. Changes in serotype
distribution are shown:
Conclusion: In 2002, resistance rates increased in N and not in
AM; 23F strains were more often susceptible in AM. Proportion
of PDSP among 6B strains increased in N, as did 19F strains in
both areas. Differences observed between N and AM are
encouraging and in favour of pursuing the intervention pro-
gramme.
O140 Increasing prevalence of multiresistant S. pneumoniae
in Europe over a 10-year period: Alexander Project
R. Mera, L. Miller, J. Daniels
Collegeville, USA
Objective: To contrast S. pneumoniae resistance rates to single or
multiple antibiotics over a 10-year period in a global resistance
surveillance study, the Alexander Project.
Methods: Isolates were collected from centres in France, Germany,
Spain, Italy and the UK annually during the period 1992–2001.
MICs and resistance to erythromycin (ERY-R), penicillin (PEN-R),
doxycycline (DOX-R) and cotrimoxazole (COT-R) were deter-
mined each year according to NCCLS methodology.
Results: ERY resistance in the period 1992–2001 followed a pattern
of high and low resistance countries, where France, Italy and
Spain had resistance rates that increased steadily from the low
teens in 1992 to 56, 36 and 26% in 2001 respectively; and Ger-
many and the UK maintained low levels of macrolide resistance,
increasing slowly to a level of 7.5 and 11.5% in 2001. The pattern
remains the same regarding COT-R, since it increased from below
10% in 1992 in France, Spain and Italy to 29, 46 and 26% in 2001,
respectively. Germany and the UK had COT-R rates that peaked
in 1998 and then declined to reach 5.4 and 6.9% in 2001. Resis-
tance to PEN has a similar pattern, being in 2001 <5% in the UK,
Italy and Germany, and 36 and 30% in France and Spain. In 1992
there was no joint ERY-COT resistance in the UK, Germany and
Italy; levels for France and Spain were 1.8 and 7.8%, respectively.
By 2001 joint ERY-COT resistance had increased to 25, 19 and
12% in France, Spain and Italy while remaining under 3% in Ger-
many and the UK. In the case of France, COT-R resistance repre-
sented 7% of all ERY-R isolates in 1992, while in 2001 that ﬁgure
was 6.3 times higher or 44%. Joint PEN-ERY resistance in 2001
had signiﬁcant levels only in France and Spain, 33 and 17%. The
only country that had triple resistance ERY-COT-DOX in 1992
was Spain (6.7%), with France and Spain having levels above 3%
in 2001 (14.4 and 17%). Of all ERY-R isolates in Spain, 64% were
triple resistant in 2001. Interestingly the levels of joint PEN-ERY-
COT-DOX-R were almost the same in France and Spain as those
of triple resistance (14.4 and 16%).
Conclusions: Multidrug-resistant pneumococci are an increasingly
common ﬁnding in Europe. Three out of four ERY-R isolates are
also resistant to PEN, COT and DOX in Spain. The rate of growth
of multidrug resistance is higher than that of single antibiotic
resistance and is increasing by approximately 3% per year.
O141 Comparison of the clonality of penicillin and
macrolide non-susceptible pneumococci
O. Dobay, F. Rozgonyi, S. Amyes
Edinburgh, UK; Budapest, HUN
Objectives: Streptococcus pneumoniae is still the most important
respiratory pathogen. The penicillin resistance is mainly caused
by alterations of penicillin-binding proteins, often a consequence
of mosaic gene formation. However, the main resistance
mechanism for the macrolides is either chemical modiﬁcation or
active efﬂux pump. The genes causing these are usually located
on mobile genetic elements. We examined how these differences
inﬂuence the clonality of the isolates and the spread of resis-
tance.
Methods: Of an original cohort of 304 Hungarian pneumococcal
isolates, collected in 2000–2002, we examined the 112 penicillin
nonsusceptible (PNS) and the 82 macrolide nonsusceptible (MNS)
strains in the study (n ¼ 154). The identity of the strains was con-
ﬁrmed by optochin sensitivity and by the presence of the lytA
gene. Serotyping was done with the agglutination antisera by
Mast. PFGE was performed with ApaI enzyme and the patterns
analysed by the Bionumerics programme.
Results: Isolates of serotypes 9 and 23 very genetically closely
related, both belonging to only a single PFGE type. This means
that the resistance is spreading among these strains from one gen-
eration to the other, originated from a common ancestor some
time ago. These were only PNS (second column). We could prove
that these strains are closely related to the internationally wide-
spread clones Spain9V-3 and Spain23F-1, respectively, both being
macrolide sensitive clones.However, the isolates of serotypes 6
and 19 showed a much bigger genetic diversity (<85% identity).
This is possibly because these strains are predominantly macro-
lide resistant, where the resistance is transferred horizontally by
acquiring the resistance genes erm or mef, largely on transposons,
to strains that have different genetic background. Interestingly the
isolates of serotype 14 were also very clonal, although they
usually have high-level macrolide resistance with erm(B).
Conclusion: Penicillin-resistance in penumococci is spread clonally,
whereas macrolide-resistance is much more diverse.
O142 Twenty-ﬁve years of tularaemia in Norway,
1978–2002
A. Broch Brantsaeter, K. Nygard
Oslo, N
Objectives: Tularaemia is a zoonotic disease caused by Franci-
sella tularensis, a small aerobic, Gram-negative coccoid bacter-
Serotype distribution (%) and colonality of the strains
Serotype PNSMS PSMNS PNSMS All PNS All MNS
6 26 55 45 33 50
9 32 – – 21 –
14 8 7 20 13 13
19 3 26 23 10 24
23 25 – – 16 –
Total no. 72 42 40 112 82
Clonal Not clonal Clonal
N AM
1999 2002 P 1999 2002 P
N 250 % 240 % 290 % 294 %
SP isoloates 117 48.8 117 48.8 ns 161 54.0 174 59.2 ns
PDSP/SP 84 71.8 100 85.5 0.01 102 63.4 112 64.4 ns
Serotypes
19A 10 8.5 8 6.8 ns 2 1.2 10 5.7 0.02
23F 30 25.6 32 27.4 ns 50 31.1 29 16.7 0.002
PDSP/SP
6B 18/33 54.5 23/25 92.0 0.001 17/33 51.5 26/35 74.3 0.051
19F 6/10 60.0 16/16 100.0 0.01 7/9 36.8 18/26 69.2 0.03
23F 29/30 96.7 31/32 96.9 ns 49/50 98.0 24/29 82.8 0.02
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ium. F. tularensis biovar palearctica found in Europe generally
causes milder disease than the North American variant, F
tularensis biovar tularensis. Tularaemia was ﬁrst described in
Norway in 1929 and has been a mandatory notiﬁable disease
since 1975. The neighbouring countries of Sweden and Finland
have reported large outbreaks of tularaemia, with mosquito
bites as probable mode of transmission. The objective of this
study was to describe the epidemiology of tularaemia in
Norway.
Methods: The electronic register of the Norwegian surveillance
system for communicable diseases was used to identify and ana-
lyse reported cases of tularaemia from 1978–2002.
Results: A total of 155 cases were reported from 18 of the 19
counties with peaks at 3–4 years intervals. The geographical
distribution was uneven with 111 cases (72%) being infected
in four adjoining counties (Sør-Trøndelag, Nord-Trøndelag,
Nordland and Troms) in Middle and Northern Norway, com-
prising only 17% of the country’s population. Ninety-ﬁve
patients (61%) were male. Mean age was 37.6 years, (range
0–79). Disease occurred in all calendar months with no clear
seasonal pattern. More detailed information was available for
the period 1994–2002: A probable source of infection could be
determined in 32 of 50 cases based on individual records and
outbreak settings. In 24 cases (75%) infection was due to con-
taminated drinking water, six (19%) were due to insect or
tick-bite and two (6%) were due to direct contact with a
rodent. Sufﬁcient clinical detail was reported in 34 cases to
determine the clinical manifestation of tularaemia. Pharyngeal
tularaemia accounted for 24 (71%), ulceroglandular/glandular
tularaemia for nine (26%) and ocular tularaemia for one case
(3%). Forty-ﬁve cases were diagnosed by serological tests, two
cases by serology and culture, one case by culture alone and
two cases by PCR.
Conclusions: Tularaemia is endemic in Norway with outbreaks
occurring at intervals of several years, often in years with high
rodent populations. Contaminated drinking water appears to be
the dominating mode of transmission, explaining why orophar-
yngeal tularaemia is the most common disease manifestation. In
contrast to Sweden and Finland, only a few cases could be
attributed to insect or tick-bite. Most cases were diagnosed by
serological tests.
O143 Cluster of tetanus cases associated with injecting
drug misuse in England
N.J. Beeching, J.M. White, S. Hahne´, R.C. George, M.M. Brett,
N.S. Crowcroft
Liverpool, London, UK
Objectives: To present the clinical features and management of a
patient with severe tetanus, and the epidemiological investigation
of a recent cluster of cases of tetanus in injecting drug users (IDU)
in England.
Methods and Results: A 40-year-old male IDU was admitted to an
orthopaedic ward in Liverpool in November 2003 with an acute
injection-related abscess in his forearm. Within 24 h, he developed
muscle stiffness in the affected arm, difﬁculty swallowing then
trismus with risus sardonicus, opisthotonus, blepharospasm and
respiratory spasms (video to be shown). He had no recent tetanus
immunizations and had recently changed his heroin supplier. A
clinical diagnosis of tetanus was made and he was treated with
i.v. penicillin, metronidazole and anti-tetanus serum before surgi-
cal debridement of the abscess which yielded staphylococci but
not Clostridium tetani. He required assisted ventilation for 21 days,
complicated by dramatic ﬂuctuations of pulse and blood pressure,
but eventually recovered.
This was the second of nine cases of tetanus in IDU reported in
England in 2003, the ﬁrst in July and the remainder in October–
December. The cluster was initially identiﬁed by astute microbiolo-
gists and clinicians liaising with their public health colleagues. Six
of nine were female with median (range) ages 32 years (20–47).
Seven patients required ventilation and one died. Only two could
remember any recent tetanus immunization and at least four had
pretreatment serum tetanus antitoxin levels below the minimum
protective level (<0.1 IU/mL). It is presumed that one or more con-
taminated batches of heroin were the vehicles of infection.
Conclusions: (i) Tetanus associated with drug injection has been
recognised since the late 1800s and still had a high mortality in
New York in the 1960s and 1970s. Mortality is lower with modern
intensive care. (ii) Tetanus should be considered in patients who
are ‘stiff’ and/or who cannot swallow. (iii) Health prevention
measures for IDU should include checking that tetanus immunisa-
tions are complete.
O144 The impact of antibiotic therapy on cognitive and
emotional changes among neurobrucellosis patients
S. Eren, G. Bayam, A. Celikbas, O. Ergonul, B. Pazvantoglu,
N. Baykam, B. Dokuzoguz, N. Dilbaz
Ankara, TR
Objective: The aim of this study is to determine the cognitive and
emotional changes in patients with neurobrucellosis and the
impact of the antibiotic therapy on these changes .
Methods: Patients, who had been hospitalised between 2002 and
2003 in the Infectious Diseases and Clinical Microbiology Depart-
ment of Ankara Numune Education and Research Hospital, were
evaluated prospectively.
Neurobrucellosis was diagnosed by the following criteria; (i)
symptoms or clinical ﬁndings compatible with neurobrucellosis,
including headache, confusion, mental and emotional changes, (ii)
isolation of Brucella spp. from CSF and/or demonstration of anti-
bodies to Brucella >1/4 in the CSF and/or (iii) the presence of
lymphocytosis, increased protein and decreased glucose levels in
the CSF and (iv) clinical improvement with appropriate treatment.
The study was performed in collaboration with psychiatry depart-
ment of the hospital. Two psychiatrists interviewed the patients,
and performed Hamilton Rating Scale for Depression (HAM) and
Mini-Mental State Examination (MMSE) to the neurobrucellosis
patients at the admission day before the therapy and at the end of
ﬁrst and second weeks of the therapy. The score between 7–14 in
HAM with 17 items is accepted as mild depression and scores
<25 in MMSE is accepted as decreased cognitive functions. No
anti-depressive and no anti-psychotic drugs were given to the
patients. Paired t-test was performed to compare the test results
in different periods (STATA 8.0, USA).
Results: Twenty-nine neurobrucellosis cases were included, the
mean age was 41 years, 41% were female. The most common pro-
fessions were farmers (46%), housewives (25%), workers (7%). At
the day of admission before therapy, the mean of MMSE was 21.6
(14–29), 1 week after therapy it was 22.7, and 2 weeks after ther-
apy it was 24.3. The change at the end of 1 and 2 weeks were sta-
tistically signiﬁcant (P ¼ 0.024 and O < 0.001, respectively). At the
day of admission before therapy, the mean of HAM was 9.9
(3–25), 1 week after therapy it was 7.8, and 2 weeks after therapy
Figure 1.
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it was ﬁve. The change at the end of 1 and 2 weeks were statisti-
cally signiﬁcant (P ¼ 0.014 and O < 0.001, respectively).
Conclusion: The cognitive and emotional disturbances could be
seen among neurobrucellosis patients. These disorders improve
by antibiotic therapy, without any anti-depressive or anti-psycho-
tic therapy.
O145 A cluster of community-acquired bacteraemias in an
intravenous drug-using population due to a novel clonal strain
of methicillin-resistant Staphylococcus aureus
C. Jukka, S. Al-Abri, J. Anson, J. Corkill, J. Curnow, N.J. Beeching
Liverpool, UK
Background: Staphylococcus aureus is a common cause of bacterae-
mia in intravenous drug users (IVDU), with about 40 admissions
yearly to our hospital. Isolates from these patients are usually sus-
ceptible to methicillin (MSSA) but we noticed a recent increase in
bacteraemias attributable to methicillin-resistant organisms
(MRSA).
Objectives: To investigate the microbiology and epidemiology of a
cluster of MRSA bacteraemias in the local IVDU population.
Methods: Sensitivity testing of S. aureus isolates was performed to
BSAC recommendations. MRSA isolates were typed by pulsed-
ﬁeld gel electrophoresis (PFGE) and molecular work was carried
out to determine the staphylococcal chromosomal cassette type
(SCCmec) and presence of speciﬁc pathogenicity factors. A case
note review was performed to ascertain epidemiological differ-
ences between IVDU with MRSA and those with MSSA.
Results: From January 2001 to June 2003, 21 patients had MRSA
bacteraemia with a strain possessing a novel antibiogram (resistant
to erythromycin and fusidic acid, susceptible to ciproﬂoxacin). The
‘new strain’ MRSA was clonal on PFGE and the SCCmec was
typed as group 1. In 2001, 2002 and the ﬁrst half of 2003 there were
two, nine and 10 patients, respectively. Nineteen of 21 patients
with ‘new strain MRSA’ were IVDU. During this period 90 other
IVDU were admitted with MSSA bacteraemia. The mean age
(32 years) was the same in both cohorts of IVDUs, but there were
relatively more males (17/19) in the MRSA than in the MSSA
cohort (73/91). The source of MRSA sepsis was often groin or
lower limb infections and many of the patients were poly-drug
misusers.
Conclusions: (i) MRSA bacteraemia in IVDU is a new phenomenon
in Liverpool. (ii) The ‘new strain MRSA’ is clonal and distinct from
nosocomial MRSA prevalent in our region. (iii) Initial review sug-
gests no epidemiological differences between IVDU with MRSA
and those with MSSA and this is being investigated further.
O146 Clinical and microbiological features of Nocardia
infection during a period of 7 years
J. Mun˜oz, N. Gutie´rrez, B. Mirelis, B. Mothe, S. Serradell,
L. Arago´n, R. Paredes, I. Dı´az, F. Sanchez, M. Espan˜ol,
P. Domingo, M. Gurguı´, P. Coll
Barcelona, E
Objectives: Recent application of modern taxonomic procedures,
including molecular characterisation, has expanded our knowl-
edge of the genus Nocardia. Nocardia species can vary in their anti-
microbial susceptibility patterns. We present the identiﬁcation and
susceptibility pattern of Nocardia isolated in our hospital during a
7-year period and its correlation with clinical presentation and
outcome.
Methods: Twenty-ﬁve patients with Nocardia infection were diag-
nosed in a University Hospital in Barcelona, Spain, from 1997 to
2003. Different Nocardia species were identiﬁed by 16S rRNA
sequencing. Sensitivity to cotrimoxazol, imipenem, cefotaxime,
amikacin and linezolid were determined by E-test. Age, comorbid-
ity parameters, and spectrum of disease of Nocardia infection were
collected. Outcome measures were: days of hospital stay, re-
admission, intensive care unit admission, crude and attributable
mortality. Statistical analyses were performed with a Chi-square
test (SPSS statistics package).
Results: The mean age was 69 years (SD ¼ 12.63). Seventeen
patients (68%) were male and 17 over 65 years. Charlson comor-
bidity index was 2.9 (range 1–7). Eighteen patients (72%) had
chronic obstructive pulmonary disease (COPD). Seven patients
(25%) had cellular immunosupression (HIV infection, chronic cor-
ticotherapy, immunosupressive drugs and haemathologic neopla-
sias). Twenty-three of the 25 patients (92%) had pulmonary
infection, three skin involvement, and one cerebral nocardiosis.
Nine isolates (36%) were N. farcinica, six (24%) N. abscessus, ﬁve
(20%) N. cyriacigeorgica, two N. otitidiscaviarum, one N. veterana,
one N. nova and one N. asteroides sensu stricto. Crude mortality
was 56% (14 patients), and attributable mortality was 36% (nine
patients). Nocardia farcinica had higher mortality (88.9%) than
others, followed by N. abscessus (80%) (P ¼ 0.032). All isolates
were sensitive to cotrimoxazol, amikacin and linezolid.
Conclusions: Nocardia infection usually affects patients with active
comorbidity, mainly COPD. There were no differences in comor-
bidity and clinical spectrum among species of Nocardia. Nocardia
farcinica is the most common species found in our study. N. farci-
nica and N. abscessus were associated with higher case-fatality
rates. Cotrimoxazol, amikacin and linezolid showed excellent sen-
sitivity in vitro.
Resistance surveillance: Local hotspots, global strategies: a focus on common RTI pathogens
(Symposium arranged by GlaxoSmithKline)
S155 Introduction: resistance, surveillance and beyond
P. Appelbaum
Hershey, PA, USA
Antimicrobial resistance is an increasing problem worldwide.
Understanding the changes in resistance over time, and how
these changes might be linked to antimicrobial usage in particu-
lar countries is one of the critical elements in combating resis-
tance. Similarly, understanding the underlying mechanisms by
which pathogens express resistance is crucial. Surveillance data
can highlight hotspots of resistance and can help to predict
future growth in the prevalence of resistance by consideration
of resistance data together with antibiotic usage and other rele-
vant factors in speciﬁc geographical areas. Assessing the factors
that lead to resistance, and the impact of resistance on the indi-
vidual patient and the community is necessary if antimicrobial
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resistance is to be adequately addressed. Additionally, compar-
ing countries with a high prevalence of resistance with those
that have a lower prevalence of resistance may contribute to
understanding the factors driving resistance, and highlighting
those efforts which help to prevent the development and
spread of resistant organisms. Strategies to overcome resistance
are needed if antimicrobials are to retain their usefulness in the
clinical environment.




Introduction: Resistance of microorganisms to antimicrobials is an
inevitable and worldwide phenomenon. Despite the availability
of reliable global surveillance data, it is very well understood
that antimicrobial resistance has substantial geographical varia-
tions, thus dictating the need to perform regional surveillance
studies. Striking differences are becoming evident in Europe,
with countries such as Spain and France reporting extremely
high penicillin-, erythromycin- and multi-drug resistance in
Streptococcus pneumoniae, and others (UK, Germany, Russia) tradi-
tionally being considered areas with low prevalence. In the fol-
lowing presentations, an update on the resistance of respiratory
tract pathogens in various regions will be reviewed in detail,
with a special focus on S. pneumoniae and the clinical implica-
tions of these data.
Russia: This presentation provides an update on the current
state of antimicrobial resistance of community-acquired patho-
gens in Russia based on the results of multicentre studies,
organised under the auspices of the Institute of Antimicrobial
Chemotherapy (IAC) and the Center for Monitoring of Antimi-
crobial Resistance of Ministry of Health of Russia (CMARR).
NCCLS methodology was used for all studies. Among 581 clin-
ical strains of S. pneumoniae isolated in 2001–2003 from 25 cen-
tres, 10.2% were nonsusceptible to penicillin (with only 1.9%
with high-level resistance) and none were found to be nonsus-
ceptible to aminopenicillins (amoxicillin, amoxicillin/clavulanate)
or third-generation cephalosporins. With regard to macrolides,
8.6–9.0% of strains were resistant to different 14- or 15-
membered macrolides while 16-membered representatives (mid-
ecamycin) and lincosamides (clindamycin) were more active
(4.0 and 3.3% resistance, respectively). However, regional ana-
lysis indicated that nonsusceptibility to erythromycin, azithro-
mycin, midecamycin and clindamycin was signiﬁcantly higher
(P < 0.05) in Central Russia compared with Siberia and Ural.
The highest nonsusceptibility rate detected was against tetracy-
cline and co-trimoxazole (27.5 and 31.5%, respectively) with no
geographical variations. There were 2.1% of strains with
decreased susceptibility to ciproﬂoxacin (MIC > 4 mg/L). No
resistance was found to respiratory ﬂuoroquinolones (levoﬂoxa-
cin and moxiﬂoxacin). A recent study of nasopharyngeal pneu-
mococci in 4135 children under 7 years old from 91 organised
communities in 19 cities of European and Asian Russia showed
the higher resistance in such strains on comparison with clini-
cal isolates with orphanages being ‘hotspots’ of resistance.
These data suggest that residential institutions, namely orpha-
nages, could be reservoirs for the development and further
spread of resistant isolates. This hypothesis should be con-
ﬁrmed in further studies, potentially involving long-term care
facilities. Ampicillin resistance among Haemophilus inﬂuenzae
was 4.9%, with no resistance to amoxicillin/clavulanate (PeHA-
Sus-I, phase ‘A’ study). Moraxella catarrhalis seems to be of low
epidemiological importance in Russia, being isolated only in
rare cases from patients with otitis media and acute exacerba-
tions of chronic bronchitis, with all strains being b-lactamase
producers and retaining susceptibility to b-lactam/b-lactamase-
inhibitors.
S157 Surveillance hotspots: the highs and lows of regional
resistance. Central and Eastern Europe
P. Appelbaum
Hershey, PA, USA
Antimicrobial resistance is recognised as a global problem, with
certain geographic regions particularly affected. Recent surveil-
lance studies have reported the regional prevalence of penicillin-
resistant Streptococcus pneumoniae (PRSP, penicillin MICs 2 mg/
L) to be between 7.8 and 16.6%, depending on the study cited, for
the Central and Eastern European region. However, these values
can vary considerably between countries, from as low as 1.8% in
the Czech Republic (Alexander Project, 1998–2000) to 37.0% in the
Slovak Republic. Empiric prescribing is further complicated by
the fact that many PRSP isolates are also resistant to other classes
of drugs, particularly macrolides. Macrolide resistance has been
reported in >35% of S. pneumoniae isolates from some Central and
Eastern European countries, and as many as 34.5% of PRSP iden-
tiﬁed in the Alexander Project in Central and Eastern Europe were
also resistant to erythromycin. Quinolone resistance among S.
pneumoniae remains rare, but has begun to emerge in this region,
particularly in Croatia and Hungary. b-Lactamase production is
the primary mechanism of resistance in the respiratory pathogens
Haemophilus inﬂuenzae and Moraxella catarrhalis. Among H. inﬂuen-
zae from Central and Eastern Europe in the Alexander Project, the
prevalence of b-lactamase-positive isolates ranged from 5.5 to
8.3%. Among M. catarrhalis, 91.5% of isolates from this region
were b-lactamase producers. Resistance among these common
respiratory pathogens continues to be of concern, but countries
with a low prevalence of resistance provide opportunities to
examine the differences between these countries and those with a
higher prevalence of resistance to evaluate the factors driving
resistance. Continued surveillance is needed to monitor the activ-
ity of available antimicrobials, and those in development, in order
to help guide effective prescribing.
S158 Surveillance hot spots: the highs and lows of regional
resistance. Europe North and South
J. Garau
Barcelona, E
Antimicrobial resistance among respiratory pathogens, including
Streptococcus pneumoniae (SP), can vary greatly between regions
and countries. In the Alexander Project (2001), the regional preva-
lence of penicillin-resistant SP (PRSP, penicillin MICs 2 mg/L)
in Southern Europe (France, Greece, Italy, Portugal and Spain)
was 21.0%, ranging between 4.9% (Italy) and 46.0% (France), and
of macrolide-resistant SP (erythromycin MICs 1 mg/L) was
29.8%, ranging from 8.0% (Portugal) to 56.4% (France). PRSP pre-
valence in Northern Europe (Belgium, Germany, the Netherlands,
Switzerland and the UK) was between 1.1% (UK) and 9.4% (Swit-
zerland), and was 5.5% overall. The regional prevalence of macro-
lide-resistant SP was 17.7%, ranging from 7.5% (Germany) to
33.2% (Belgium). High rates of penicillin-macrolide co-resistance
were also reported in both Northern and Southern Europe, with
67.7% and 62.6% of PRSP in these regions, respectively, resistant
to erythromycin. The PROTEKT study (2002) showed similar
overall rates of PRSP and macrolide-resistant SP in these regions.
In Southern Europe, the PRSP prevalence ranged from 5.6%
(Italy) to 47.7% (France), and the prevalence of macrolide-resistant
SP from 12.9% (Portugal) to 60.7% (France), while in Northern
Europe, PRSP prevalence was between 0 (Netherlands) and 8.7%
(Switzerland), and macrolide-resistant SP between 11.9 (Nether-
lands) and 32.1% (Belgium). The PRSP prevalence reported by the
EARSS network (2002, invasive isolates only) was generally lower
than that seen in the other studies. Macrolide nonsusceptibility
among SP isolates collected by EARSS ranged from 0 (Portugal) to
58.0% (France). The prevalence of PRSP in Scandinavian countries
was low (all studies), but in recent years the prevalence of macro-
lide-nonsusceptible SP approximately doubled in Finland [EARSS:
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6.0% (1999) to 14.0% (2002)] and Sweden [PROTEKT: 4.7%
(2000)–9.3% (2002)]. The prevalence of b-lactamase-positive Hae-
mophilus inﬂuenzae was greater in Southern than in Northern Eur-
ope, and >90% of Moraxella catarrhalis isolates were b-lactamase-
positive (all studies). The differences in the prevalence of resistant
strains of SP identiﬁed in the countries of northern and southern
Europe indicate that factors driving resistance, such as prescribing
practices and infection control, also vary considerably in these
countries. The rapid increase in the prevalence of macrolide-resis-
tant SP in at least two Scandinavian countries is of concern.
S159 Surveillance hotspots: the highs and lows of regional
resistance. USA and global
M. Jacobs
Cleveland, OH, USA
Antimicrobial resistance among respiratory pathogens, particu-
larly Streptococcus pneumoniae, is now prevalent in many parts of
the world, including the USA. One-quarter to one-third of S. pneu-
moniae isolated in surveillance studies in the USA in 2001–2002
were penicillin resistant (penicillin MICs  2 mg/L). Globally,
around 20% of S. pneumoniae isolates collected in 2001–2002 were
penicillin resistant. Regional variations in the prevalence of peni-
cillin-resistant S. pneumoniae exist both within the USA and glob-
ally. Within the USA, the prevalence of penicillin-resistant
S. pneumoniae ranged from 14 (northwest region) to 30% (south-
central region) in the Alexander Project in 2001. Globally, regions
such as the Far East and Central/Eastern Europe are known to
have particularly high rates of penicillin resistance among S. pneu-
moniae isolates. Macrolide resistance (erythromycin MICs  1 mg/
L) now exceeds penicillin resistance among isolates of S. pneumo-
niae in the USA and globally. In 2001, for example, the Alexander
Project reported the prevalence of macrolide-resistant S. pneumo-
niae to be 28% in the USA and 30% worldwide. Of great concern
as well is that 75% of penicillin-resistant S. pneumoniae are also
resistant to macrolides, both in the USA and worldwide.
Although quinolone-resistant S. pneumoniae have been reported,
mainly in Hong Kong, Canada, Spain, Hungary and Croatia, the
global prevalence of these strains remains <2%. Among Haemophi-
lus inﬂuenzae, b-lactamase production has been identiﬁed in one-
quarter of isolates from the USA in 2001. Globally, the prevalence
of b-lactamase-positive H. inﬂuenzae is lower – around 15% in
2001–2002. Empirical prescribing is further complicated in infec-
tions where H. inﬂuenzae is common, as virtually all strains of this
organism are intrinsically resistant to macrolides and azalides via
an efﬂux mechanism; this presents an additional problem as most
isolates of H. inﬂuenzae are categorized as susceptible by NCCLS
criteria. Quinolone resistance in H. inﬂuenzae has been described,
but is currently very rare (<0.5%). More than 90.0% of Moraxella
catarrhalis isolates worldwide are b-lactamase-positive. These
levels of resistance, and the high prevalence of multiply resistant
organisms, demonstrate that new antimicrobials active against
resistant strains are needed. An increased awareness of resistance
and strategies to prevent its further development and spread are
needed in the USA and on a global scale.
S160 Factors behind the resistance
J. Garau
Barcelona, E
The prevalence of resistance to common antimicrobials among
respiratory pathogens continues to increase and is beginning to
emerge in previously unaffected areas. The differences seen
between regions in the prevalence of resistance suggest that dif-
ferent factors are at work in different areas to drive resistance.
This is exempliﬁed by surveillance data from across European
regions. Known factors in the development of resistance include
inappropriate choice or inadequate dosing of antibacterials,
unnecessary prescribing, and poor patient compliance, along
with the spread of resistant clones. Macrolide resistance among
Streptococcus pneumoniae is a growing concern, as this now
exceeds penicillin resistance in many areas. The introduction of
long-acting macrolides may be a factor driving this increase in
resistance and needs further examination. Quinolone resistance,
although infrequent, represents a considerable clinical challenge,
as these agents are often reserved for patients with more severe
disease or those who have failed previous antimicrobial therapy.
The primary resistance mechanism in Haemophilus inﬂuenzae is
b-lactamase production, which inactivates unprotected b-lactam
antibacterials. Recent research has demonstrated that most
strains of H. inﬂuenzae also have an innate macrolide-efﬂux
mechanism. There is an increasing body of data showing the
clinical relevance and consequences of these resistances. Resis-
tance is no longer a local or homogenous phenomenon, such
that within a region ‘hotspots’ of resistance can occur, and this
is particularly evident across Europe. Areas of low resistance
also exist, and these, when evaluated with data on prescribing
practices and other factors, can provide information on effective
resistance control. An awareness of resistance patterns, and how
they are changing over time, together with appropriate prescrib-
ing and infection control methods are needed to address antimi-
crobial resistance. Novel antimicrobials and new formulations of
existing agents, capable of eradicating resistant pathogens, also
have a key role to play in the containment of resistance.




The prevalence of antimicrobial resistance among common
respiratory pathogens continues to increase. Surveillance is a key
component in the effort to document this and provide informa-
tion on which agents have the best activity. To be of most value,
surveillance needs to be able to provide up-to-date information
on local susceptibility patterns. National and international sur-
veillance is also critical for monitoring the ongoing development
and spread of resistance, and to help predict its future spread.
Ongoing surveillance in regions where resistance does not cur-
rently occur will allow a better understanding of the factors
associated with the emergence of resistance when it develops.
While local clinical laboratories can provide surveillance data on
a local level, more comprehensive surveillance studies require
greater resources and standardised methods of collection, analy-
sis and quality control. Alone, surveillance describes the current
state of resistance, but should be combined with other data,
such as prescribing statistics and patient demographics, to evalu-
ate associations between resistance, drug prescribing and disease
risk factors. Academic institutions, government organisations
and the pharmaceutical industry can all contribute in this area.
Comparisons of resistance data for different geographical
regions, and analysis of those data in light of resistance-driving
factors can provide information towards establishing optimal
practice guidelines. Susceptibility data should be interpreted
according to pharmacokinetic/pharmacodynamic parameters, as
many interpretative breakpoints in current use in the USA are
not valid, particularly for H. inﬂuenzae. Global data also provide
a basis for phenotypic analysis and tracking of genotypic clones.
Long-term storage of isolates allows retesting against new anti-
microbials in development to assess their potential clinical uti-
lity. Surveillance data can help guide prescribing by indicating
areas in which certain antimicrobials are at risk of losing their
clinical efﬁcacy by revealing the most commonly isolated patho-
gens in that region and their susceptibility patterns. By increas-
ing physician awareness about the prevalence and spread of
resistance, surveillance can reinforce the message of the need for
appropriate prescribing. Resistance is inevitable in this era of
antimicrobial use, and surveillance will continue to play an
important role in monitoring its development and adapting to
these ﬁndings.
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Catastrophes after crossing species barriers: lessons from SARS, influenza…




Probably the most tragic examples of virus infections that have
caused the deaths of many millions of people in the past cen-
tury were the inﬂuenza and AIDS pandemics. These events
occurred as a direct result of the introduction of animal
viruses into the human population. Similarly, mass mortalities
among aquatic and terrestrial mammals were caused by the
introduction of viruses into species in which they had not pre-
viously been present. It seems paradoxical that at a time when
we have managed to control or even eradicate major human
virus infections like polio and smallpox we are increasingly
confronted with new or newly emerging virus infections of
humans and animals. A complex mix of social, technological
and ecological changes, and the ability of certain viruses to
adapt rapidly to a changing environment, seems to be at the
basis of this phenomenon. Extensive diagnostic and surveil-
lance networks, and novel vaccine- and antiviral development
strategies should provide us with the safeguards to limit its
impact.
Global pandemics: how well is the global village prepared to deal with emerging infectious
diseases
K170 WHO global response to SARS
G. Rodier
Geneva, CH
Background: On 15 March 2003, the World Health Organization
(WHO) issued an emergency alert to a severe respiratory disease,
of undetermined cause, that was rapidly spreading along the
routes of international air travel. The coordinated global response
that followed marked the ﬁrst time that information about a
newly emerging disease was gathered, in real time, by electroni-
cally interlinked networks of experts, and made available to the
world at large as the outbreak unfolded.
Method: The response to SARS relied on new mechanisms for
detecting unusual disease events and limiting their harm. To
expedite outbreak detection, the Global Public Health Intelli-
gence Network (GPHIN), developed and maintained by Health
Canada, was set up for the real-time systematic gathering of
disease intelligence while WHO made use of its unique and
long-standing international experience in infectious diseases con-
trol to support global alert and response operations. The Global
Outbreak Alert and Response Network (GOARN), currently
uniting 120 partners, was established as a ‘strike force’ of spe-
cialized staff and technical expertise on stand by for emergency
investigations and on-the-spot assistance. A system of electronic
communications was extended to all 141 WHO country ofﬁces.
The network of collaborating centres was expanded. New pro-
cedures for outbreak veriﬁcation and standardized protocols for
all phases of outbreak response were developed. SARS tested
the simultaneous performance of these mechanisms under emer-
gency conditions.
Result: The response to SARS tested an assumption of fundamen-
tal importance to public health: all these safeguards, working at
their best, might be able to prevent a new disease from establish-
ing endemicity, and thus spare the world untold suffering and
expense. From the outset, this was the goal pursued by WHO in
coordinating the activities of many partners.
Conclusion: The containment of SARS within 4 months following
its recognition as an international threat provides some reassur-
ance that international partnership taking advantage of the WHO
global framework makes the world better prepared to defend
itself against new diseases.
The changing faces of S. aureus




Methicillin-resistant Staphylococcus aureus (MRSA) strains have
been considered during two to three decades as the typical bacter-
ial population present in hospital settings and as a major cause of
hospital-acquired (HA) infections. Community-acquired MRSA
(CA-MRSA) emerged worldwide at the end of the last century.
There is a confusion in the literature between healthcare related
MRSA infections which occurred in patients with a past history of
hospitalization and are due HA-MRSA strains, and true CA-
MRSA infections due to strains that are not present in the hospital
settings. Demographic characteristics of HA-MRSA infections
differed from those of CA-MRSA, the former occurring mainly in
elderly whereas the later occurring in young people. HA-MRSA
infections are facilitated by the presence of skin effraction after
surgery or intravenous indwelling catheter, whereas CA-MRSA
infections are mainly primary-skin infections occurring in patients
with no initial skin effraction. The Panton–Valentine leucocidin
present in CA-MRSA strains all over the world represents, by its
necrotic activity, one of the virulence factors possibly associated
with cutaneous tissue destruction. These PVL-positive CA-
MRSA strains are easily transmissible within families, but also on
a larger scale, in communities with high level of promiscuity (in
prisons, schools, sport teams, etc.). The simple skin to skin contact
seems to represent the way of transmission. The skin infection
often appears initially as an insect bite. The same clone of CA-
MRSA strains have been detected in several European countries
demonstrating its extended spread in the community. It has
invaded France, Switzerland, Belgium, Germany but also the Nor-
dic European countries. Several different CA-MRSA clones are
spreading in US and in Australia and New Zealand. Despite a dif-
ferent genetic background, a frequently common trait of these
clones is the presence of the PVL genes and the small-sized
SCCmec type IV cassette. More recently other CA-MRSA clones
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containing other virulence genes such as those encoding the exfo-
liatin or the toxic shock toxin are also emerging.
In some area of the world, CA-MRSA already account for >70%
of the S. aureus isolated in the community, showing that S. aureus
strains could progressively all become resistant to methicillin. The
ultimate issue is to set up and implement the adequate prevention
measures to reduce or limit the spreading of these strains.
S174 MRSA incidence and control in European hospitals
P. Urba´sˇkova´
Prague, CZ
Infections caused by methicillin-resistant Staphylococcus aureus
(MRSA) have been reported in European hospitals for more than
40 years, with increasing frequency in the last decade. Multiple
factors have been involved in the emergence of MRSA, one of the
most important being their capability of adapting to hostile envir-
onments and of spreading rapidly. MRSA have currently been the
worldwide major cause of hospital-acquired infections that are
difﬁcult to treat and control because of emerging resistance to
almost all antimicrobial agents. The recently published reports on
the incidence of hospital infections caused by vancomycin-resis-
tant MRSA and community infections caused by MRSA in indivi-
duals without risk factors give evidence for changes in
epidemiology of MRSA.
Antimicrobial resistance in European countries has been moni-
tored since 1999 within a vast internationally accepted initiative
EARSS (European Surveillance Antimicrobial Resistance System).
Analysis of comparable and validated data from more than 1000
hospitals of 28 European countries revealed substantial and per-
manent differences in the MRSA prevalence among countries and
hospitals. This can be explained by differences in antibiotic con-
sumption, antibiotic prescription patterns and implementation of
and compliance with infection-control measures. The identiﬁcation
of localities with endemic long-term high incidence of MRSA
would be of relevance for analysis of the mechanisms involved in
transmission of resistant clones, their persistence in the population
and resistance development. The ﬁndings would be used as back-
ground information for implementation of an effective strategy for
reduction and prevention of MRSA infections in Europe.
S175 Small colony variants of S. aureus – clinical
signiﬁcance and detection challenges
B. Kahl
Munster, D
SCVs represent a subpopulation of S. aureus with small, nonpig-
mented, nonhaemolytic colonies on Columbia blood agar plates
compared with the growth of normal S. aureus. SCVs of S. aureus
have been recognised since decades. Over the past 7 years, a clini-
cal syndrome has been deﬁned as typiﬁed by persistent, recurrent
and antibiotic-resistant staphylococcal infections. SCVs have been
isolated from diseases such as osteomyelitis, arthritis, abscesses
and from airway secretions of CF patients. SCVs produce greatly
reduced amounts of alpha-toxin, thereby allowing SCVs to persist
intracellular in in vitro systems. Most clinical SCVs were impaired
in their electron transport or thymidine synthesis. Due to the unu-
sual colony morphology, slow growth and possible atypical
appearance in Gram staining, S. aureus SCVs are easily missed or
misdiagnosed in the routine laboratory resulting in major report-
ing errors with regard to their presence and susceptibility.
Diarrhoeal diseases (Joint symposium arranged with the IDSA)
S177 Shiga toxin-producing Escherichia coli
H. Karch
Munster, D
Shiga toxin (Stx)-producing Escherichia coli (STEC) cause a broad
spectrum of diseases in humans ranging from mild diarrhoea
through haemorrhagic colitis to haemolytic uraemic syndrome
(HUS). The most important STEC serotype implicated worldwide
is O157:H7. However, several so called non-O157 STEC serotypes
have emerged. After a mean incubation period of 3 days, patients
develop watery diarrhoea accompanied with cramping abdominal
pain. During next days, bloody diarrhoea may occur. One week
after the onset of diarrhea, in about 15% of patients under
10 years STEC infection results in a systemic complication, the
HUS. Long-term sequelae such as proteinuria, hypertension,
reduced renal function, or neurological residuals occur in about
one-third of the patients who recover from HUS. Stx are consid-
ered the major virulence factors of STEC involved in the patho-
genesis of this extraintestinal manifestation. The toxins cross the
intestinal barrier and bind to endothelial cells of the target organs.
They injure the host cells by inhibition of protein synthesis, stimu-
lation of prothrombotic messages or induction of apoptosis. HUS
is a net effect of a variety of interacting factors, including host fac-
tors (such as age), exogeneous factors (infectious dose, administra-
tion of antibiotics) and virulence characteristics (Stx type, the
presence of intimin, serine proteases) of the infecting STEC strain.
All known STEC virulence determinants are located on mobile
genetic elements and this has an important impact on the evolu-
tion of these pathogens. Domestic animals, especially cattle, are
the major reservoirs of STEC. The principal ways of STEC trans-
mission include contaminated food, contaminated water, person
to person transmission and direct contact with animals. Most of
STEC strains cannot be identiﬁed using conventional culture pro-
cedures. Detection of stx genes and/or Stx using polymerase
chain reaction and enzyme-immunoassay represents an effective,
serotype independent method for screening of STEC. The recent
progress in understanding the pathogenesis and epidemiology of
STEC infections forms a basis for the development of future stra-
tegies to prevent STEC infections in humans.
New technologies for microbiological diagnostics (Joint symposium arranged with ICAAC)




Microorganisms attach to surfaces and form bioﬁlms. Bioﬁlm for-
mation has been implicated in the pathogenesis of a wide range
of human infections, especially those associated with devices such
as orthopaedic hardware, pacemakers, prosthetic heart valves,
and intravascular catheters. Bioﬁlm cells are associated with an
extracellular polymeric substance matrix, and exhibit reduced
growth rates, in the context of altered-regulation and/or the pre-
sence of speciﬁc genes. Most bioﬁlm studies have focussed on the
underlying pathophysiology of bioﬁlm formation and the implica-
tions of the bioﬁlm phenotype on therapeutics. In contrast, little
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attention has been directed towards the microbiological diagnosis
of device-related bioﬁlm-associated infections.
Topics to be explored during this session include new
approaches to the removal of bacteria from medical devices for
the purpose of diagnosing infection and the use of genetic mar-
kers of bioﬁlm formation for the diagnosis of bioﬁlm-associated
infections.
Molecular epidemiology and management of nosocomial outbreaks
O184 Czech epidemic strain of Burkholderia cenocepacia
does not belong to ET12 lineage
S. Vosahlikova, H. Reitzova, O. Cinek, P. Drevinek
Prague, CZ
Objectives: Patient-to-patient transmissible strains of Burkholderia
cepacia complex account for the infection spread among patients
with cystic ﬁbrosis (CF). Epidemic outbreaks in Canada and the
UK were caused by highly virulent ET12 clone that is character-
ized by cbIA-encoded cable pili. In the Czech CF population, an
epidemic strain within B. cenocepacia (former genomovar III of
B. cepacia complex) had been also identiﬁed. Although molecular
typing data indicated sufﬁcient genetic distinction between the
Czech epidemic strain and ET12, the only tool to prove the ET12
occurrence or absence in the Czech CF population is based on the
detection of cbIA gene.
Methods: We examined 81 isolates from 65 Czech CF patients who
had been previously demonstrated to share the same epidemic
strain using RAPD and PFGE typing. All the isolates were sub-
jected to PCR detecting cbIA gene. Simultaneously, we used PCR
targeting 16S rDNA region as an internal control of successful
ampliﬁcation. PCR products were visualised on the 2% agarose
gel stained with ethidium bromide.
Results: All 81 examined isolates were cbIA-negative, while a posi-
tive signal was seen in ET12 reference strains used as a positive
control.
Conclusions: The epidemic B. cenocepacia strain present in the Czech
CF population does not possess the nucleotide sequence encoding
cable pili unique for ET12 strain. Thus, the Czech CF population is
not confronted with highly virulent variant of transmissible strains,
i.e. ET12. To ﬁnd out the origin of the B. cenocepacia infection
epidemic in the Czech CF patients, comparisons with other
previously described transmissible strains abroad are being perfor-
med. Supported by Ministry of Health (grant 6568-3) and Minis-
try of Education (grant 111300003), Czech Rep.
O185 Genetic diversity of penicillin-nonsusceptible
clinical strains of Streptococcus pneumoniae isolated in Russia:
results of a nationwide study
R.S. Kozlov, I.S. Palagin, M.V. Edelstein, L.S. Stratchounski
Smolensk, RUS
Objectives: Antibiotic resistance in respiratory pathogens such as
Streptococcus pneumoniae, is a global issue in many countries,
including Russia. The purpose of the current study was to charac-
terise the genetic diversity of penicillin-nonsusceptible S. pneumo-
niae (PNS SP) isolated from children and adult patients in
different regions of Russia.
Methods: Seventy-four (17 from PeHASus-I, phase ‘A’ and 57 from
PeHASus-I, phase ‘B’) penicillin-nonsusceptible SP isolates (MIC
range 0.12–4 mg/L) obtained from patients of 1 month to 87 years
in 19 Russian hospitals situated in 16 cities (Novosibirsk, Ufa,
Irkutsk, Tomsk, Yaroslavl, Kazan, Krasnodar, Moscow, Stavropol,
Ekaterinburg, Yakutsk, Ryazan, Tyumen, Novokuznetsk, St Peters-
burg, Kovrov) located in the areas of Western, Southern, Central
Russia, Siberia, Ural and Far East during 2001–2002 underwent
molecular typing by BOX-PCR with primer BOX-A
(ATACTCTTCGAAAATCTCTTCAAAC) and RAPD-PCR with
primer M13 (GAGGGTGGCGGTTCT). Cluster analysis of genetic
ﬁngerprints was performed by UPGMA algorithm with Pearson
coefﬁcient using the GelCompar software (AppliedMaths).
Results: The combined analysis of BOX- and RAPD-PCR patterns
revealed 61 unique genetic types of which 10 clonal groups com-
prised from two to four isolates each, and the other 52 included
single isolates. Clonal dissemination of PNS SP was mainly
observed in the hospitals of Moscow and Novosibirsk. Thus, nine
isolates from the Moscow City Clinical Hospital no. 23 produced
very similar ﬁngerprints differing from each other by three bands
at most. Single case of clonal relatedness between the isolates
from geographically distinct centers (Moscow and Novokuznetsk)
was also found. However, the multiplicity of genetic types indi-
cated that resistance to penicillin was acquired by numerous
strains.
Conclusions: Combination of BOX- and RAPD-PCR is a useful tool
for monitoring of circulating pneumococcal population. PNS SP
isolated from Russian hospitals mostly represent genetically
diverse population of strains. The same clone was found to be
spread between faraway situated cities (Moscow and Novokuz-
netsk).
O186 Relationships between virulence factors of
methicillin-resistant Staphylococcus aureus and clonal types
V. Chini, G. Dimitracopoulos, I. Spiliopoulou
Patras, GR
Objectives: Staphylococcus aureus is associated with an increasing
number of hospital infections, including endocarditis, deep-seated
abscesses, bacteraemias and toxemic syndromes, as toxic shock
syndrome (TSS). Methicillin-resistant S. aureus (MRSA) is a major
nosocomial pathogen found throughout the world and in the Uni-
versity Hospital of Patras. We have investigated the presence of
genes encoding the toxic shock syndrome toxin (TSST-1) and the
Panton–Valentine leucocidin (PVL) among MRSA in relation to
clonal types.
Methods: The MIC of oxacillin was determined by the agar dilu-
tion method in Mueller–Hinton agar supplemented with 2%
NaCl, according to the guidelines of NCCLS. PBP2a production
was investigated by a Latex agglutination test (bioMerieux) in all
S. aureus with MIC > 0.5 mg/L. PCR ampliﬁcation with speciﬁc
primers was used for the detection of mecA gene and thus 60
MRSA collected from different patients were characterised during
2002. The lukS and lukF (encoding PVL components S and F) and
tst (which encodes the TSST-1) genes were detected by PCR. Clo-
nal types were determined by PFGE of chromosomal DNA SmaI
digests.
Results: Luk gene was detected 36 MRSA (60%), mainly from
severe skin infections. It was present in 100% of abscesses strains,
82% of skin lesions strains and 50% of wound infections strains.
Tst gene appeared in eight strains (13%) from wound infections
(5), skin lesions (1), urinary tract infection (1) and bacteraemias
(1). PFGE classiﬁed the 60 MRSA into three clonal types. Type A
included 11 strains (18%), type B 13 strains (22) and 36 isolates
(60%) belonged to type C. All the MRSA of type C carried the luk
gene, which was not detected in any strain of the other two types.
The tst gene was detected in eight (73%) strains of type A only.
Strains of clonal type B did not carry the genes tested.
Conclusions: The presence of luk gene in all PFGE type C strains
is indicative of clonal dissemination, associated with necrotic
lesions among hospitalized and outpatients. The tst gene is to a
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less extent associated with another MRSA clone independently of
the underlying disease.
O187 DNA ﬁngerprinting of mycobacteria using
automated repetitive sequenced-based PCR
M. Lising, T. Bittner, K. Reece, D. Walton, K. Shah, M. Healy
Houston, USA
Objective: DNA ﬁngerprinting of mycobacterial pathogens, includ-
ing Mycobacterium tuberculosis (Mtb), Mycobacterium avium complex
(MAC), and nontuberculous mycobacteria (NTM), has numerous
applications in clinical microbiology and molecular epidemiology.
Current genotypic methods used to type Mtb, MAC and NTM
strains include RFLP, PFGE, Spoligotyping, and MIRU-based typ-
ing. Additionally, identiﬁcation of mycobacteria other than tuber-
culosis (MOTT) is challenging and may include sequencing or
traditional biochemical testing. These methods are either time con-
suming, laborious, expensive, or highly restricted with regard to
applicability. This study reports the use of a simple, rapid and
cost-effective rep-PCR technology for typing isolates of most
mycobacterial species using the DiversiLab System.
Method: Fingerprints from 25 different ATCC Mycobacterium spe-
cies were stored in a library. Twenty-ﬁve clinical isolates were
gathered from two geographical regions and were grown on Low-
enstein–Jensen media. DNA from each culture was extracted
using the UltraCleanTM Microbial DNA Isolation Kit. Seventy-ﬁve
nanograms of each sample DNA was used to generate rep-PCR-
based ﬁngerprints using the DiversiLab Mycobacterium Kit, micro-
ﬂuidic chips, and the Agilent 2100 analyser. Sample analyses and
data archiving were carried out using the DiversiLab System.
Result: Dendrogram and gel-like images of rep-PCR proﬁles for
all 25 different ATCC Mycobacterium species and all MOTT clinical
isolates were obtained using DiversiLab System. The rep-PCR
clustering identiﬁed MOTT strains and showed excellent concor-
dance with similar ATCC species and biochemical characteriza-
tion. Similarly, different isolates of rapidly growing mycobacteria
and slow-growing NTM were ﬁngerprinted using the DiversiLab
Mycobacterium Kit.
Conclusion: Rep-PCR has distinctive advantages for mycobacterial
typing such as ease of use, requirement of relatively small
amounts of DNA, the potential for typing strains not typeable by
RFLP due to low IS6110 copy number, and the ability to type
other mycobacterial species. Based on this pilot study, the Diversi-
Lab System shows considerable promise as a tool for identiﬁcation
and typing of MOTT.
O188 Molecular epidemiological analysis of
Mycobacterium tuberculosis isolates reported in England in 1998
A. Gibson, K. Gopaul, J. Anderson, F. LeBrun, R. Pitman, Z. Fang,
J. Watson, F. Drobniewski
London, UK
Background: The resurgence of tuberculosis (TB) since the mid-
1980s has revised public health concern in the UK.
Design: All culture-conﬁrmed cases of TB reported in England
from 1st January to 31st December 1998 were identiﬁed. All iso-
lates were typed using RFLP. spoligotyping was used as a second-
ary typing method for low copy number (LCN) isolates.
Epidemiological information was gathered from the UK Mycobac-
terial Resistance Network (Mycobnet) and the 1998 National TB
survey in England and Wales. Additional information was col-
lected for ‘clustered’ cases and a set of control cases to assess risk
factors for clustering.
Objectives: (i) to analyse the distribution of MTB in England and
Wales in 1998; (ii) to examine the occurrence of clusters of indis-
tinguishable isolates and to identify risk factors associated with
clustering.
Results: A total of 3396 culture conﬁrmed cases of MTB were iden-
tiﬁed of which 2265 produced IS6110 RFLP ﬁngerprints; 1808
(80%) isolates were high copy number (HCN), i.e. those with ﬁve
or more copies of IS6110 and 457 (20%) were LCN. The majority
of strains (64%) had between seven and 14 bands. There were 152
HCN clusters (two or more isolates) comprising 372 isolates. The
degree of recent transmission in cases with HCN ﬁngerprints was
determined to be 12%. LCN isolates were spoligotyped producing
42 LCN clusters made up of 213 isolates. Analysis of the HCN
isolates showed the following risk factors for clustering: having
known previous treatment (OR 3.85, 95% CI 2.21–6.71), having
pulmonary or respiratory disease (OR 1.70, 95% CI 1.16–2.48) and
showing resistance to at least one antimicrobial drug (OR 1.71,
95% CI 1.15–2.54). In a case-control study, homelessness was
shown to be a risk factor for clustering (OR 5.57, 95% CI
1.26–24.7).
Conclusions: Molecular techniques have greatly enhanced our
understanding of the transmission dynamics of TB disease. Com-
bined with epidemiological methods they provide a tool for an
efﬁcient surveillance system for the control of tuberculosis.
O189 Use of statistical process control for early detection
of hospital-acquired outbreak of alarm bacteria
M. Walberg, P. Jenum
Rud, N
Objective: Plotting cumulative retrospective data (c-chart) is one
method of registering nosocomial infection outbreaks. However,
plotting data in statistical process control (g-chart) increases sensi-
tivity signiﬁcantly of outbreak identiﬁcation compared with
c-chart.
Methods: Laboratory data include information about nosocomial
infections. In our examples we included unique data for P. aerugi-
nosa and Pseudomonas sp. from Rikshospitalet and Sykehuset
Asker og Brum (SAB) and S. aureus data from SAB. The data
were plotted retrospectively (c chart, quarterly observations) and
by means of statistical process control (SPC) in g chart (rate, i.e.
‘number of days between new patients with S. aureus or P. aerugi-
nosa’).
Results: Quarterly Pseudomonas numbers (c chart) increased signiﬁ-
cantly for both hospitals in the ﬁrst quarter of 2002 compared
with previous quarters. This increase was because of a national
outbreak of Pseudomonas associated with a commercial mouth
swab. The identiﬁcation of this Pseudomonas outbreak was delayed
when data was plotted in c chart. By plotting data as rate vs.
observation number (g chart), analysis by SPC would have identi-
ﬁed this national Pseudomonas outbreak in SAB about 6 weeks ear-
lier (P < 0.05) than the warning given to Norwegian hospitals by
the National Institute of Health. As a consequence hereof, S. aur-
eus and Pseudomonas data for SAB are now plotted routinely in
Excel as rate of new patients with these bacteria vs. observation
number and compared with average rate (last 30 observations).
On a given observation below average rate, information is given
to the ward as well as the laboratory. This routine has made it
possible to (i) alarm wards early of possible outbreaks and (ii)
keep isolates for later ﬁngerprinting analysis.
Conclusion: Our two examples show that statistical process control
is a valuable tool for early identiﬁcation of outbreaks with hospi-
tal acquired bacteria like S. aureus and Pseudomonas. Future hospi-
tal infection control will beneﬁt signiﬁcantly by use of SPC.
O190 Failure of classical surveillance strategy to detect a
large hospital-wide outbreak of a multidrug-resistant
Enterobacter cloacae
M.A. Leverstein-van Hall, H.E.M. Blok, A. Paauw, E.M. Mascini,
J. Verhoef, A.C. Fluit
Utrecht, NL
Objectives: To identify the determinants causing the failure of a
classical surveillance strategy (CSS) to detect a large outbreak of a
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multidrug resistant (MDR) Enterobacter cloacae (EC). CSS refers to
a strategy based on the recognition of an increased incidence of a
species with a particular antibiogram at certain wards in a limited
time period.
Methods: A hospital-wide increase in the number of MDR clinical
EC isolates was detected in December 2002. Records were
reviewed for the period from January 2001 to Dec 2002 (period I)
to identify patients with cultures positive for EC during their stay
in the hospital. From January to September 2003 (period II) EC
isolates were prospectively stored. Genotyping by PFGE was done
on all available EC isolates.
Results: A total of 466 patients were identiﬁed for being EC cul-
ture positive. From period I, 105 tobramycin-resistant (TR)EC (60
patients) and 27 tobramycin susceptible (TS)EC (24 patients), and
from period II, 58 TREC (48 patients) and 49 TSEC (47 patients)
were available. PFGE showed that 53 patients in period I and 34
patients in period II carried a TREC that belonged to one clone
that was subject to evolution. The susceptibility patterns for eight
non-beta-lactam antimicrobials were analysed for all 239 geno-
typed isolates. The clonal strain expressed 37 different antibio-
grams (including 2 tobramycin S variants) of which 1/4 were
shared by ECs of other genotypes. The clonal strain was isolated
from a large variety of clinical sites, including 30% normally ster-
ile sites (eg BC, CSF). During period I cases were detected on nine
different divisions (three ICUs and 18 wards). Patients were fre-
quently transferred between wards (median 3) and divisions
(median 2) and long laps in time were seen between cases (mean
2 weeks; range 0–18).
Conclusions: The determinants causing the failure of a CSS to
detect this outbreak were: (1) the low incidence, (2) the long time
interval between cases, (3) the hospital-wide occurrence of new
cases, (4) the large variety of clinical sites from which the clone
was isolated, and (5) the high variability of the antibiogram. These
results illustrate the limitations of the CSS and stress the need of
molecular typing facilities and (data mining) surveillance systems
that integrate laboratory and hospital information systems to iden-
tify patterns indicative for the occurrence of hospital infections.
O191 Investigation of the association between the MRSA
colonisation pressure and the occurrence of nosocomial MRSA
infections in 75 German intensive care units
P. Gastmeier, C. Geffers, M. Behnke, D. Sohr, H. Ru¨den
Hannover, Berlin, D
Objectives: To investigate the association between the MRSA colo-
nisation pressure and the nosocomial MRSA infection rate in 75
German intensive care units (ICUs).
Methods: 75 ICUs participating in the German Nosocomial Infec-
tion Surveillance System (KISS) recorded not only the number of
nosocomial infections and patient days; they also determined the
number of all MRSA cases representing the MRSA colonization
pressure in the individual ICUs (i.e. the number of colonized as
well as infected patients, nosocomial cases as well as patients with
MRSA on admission to the ICU) for the ﬁrst half year of 2003.
Thus it was possible to associate the MRSA case rate with the
nosocomial MRSA infection rate for the individual ICU. The med-
ian line of the nosocomial MRSA infection rate and the MRSA
case rate divide the ICUs into four quadrants and differentiate
between ICUs regarding the spread of MRSA.
Results: A total of 398 MRSA cases and 120 854 patient days were
observed during the study period. 229 MRSA cases were already
present upon patient admission to the ICU, the remaining 169
cases were considered nosocomial (i.e. not known at the time of
admission nor detected during the ﬁrst 48 h in the ICU). In all, 95
nosocomial infections were identiﬁed (¼ 24% of all MRSA cases).
The median MRSA cases rate was 2.3, the 75th percentile 4.0 per
1000 patient days. The median nosocomial MRSA infection rate
was 0.6 per 1000 patient days, its 75th percentile being 1.1 per
1000 patient days. The association between the MRSA case rate
and the nosocomial MRSA infection rate for each of the 75 ICUs
is shown in Figure 1.
Conclusions: The distribution of ICUs in Figure 1 allows one to
distinguish ICUs with a low nosocomial MRSA infection rate
despite having a high MRSA case rate (upper left quadrant) from
those with a low nosocomial MRSA infection rate in spite of a
high MRSA case rate (lower right quadrant). Comparison of the
infection control measures within these two types of ICUs may
contribute to stopping the spread of MRSA inside ICUs.
O192 Pseudo-outbreak of Stenotrophomonas maltophilia
bacteraemia related to non-sterile blood collection vials
J. Sampaio, S. Sinto, C. Oplustil, J. Amarante, M. Biancalana,
S. Leao, C. Kiffer, C. Mendes
Sao Paulo, BR
Objective: Disclose the source of a pseudo-outbreak of Stenotropho-
monas maltophilia bacteraemia.
Methods: From September 2001 to June 2003, 24 blood cultures
collected from patients at a Brazilian pediatric emergency unit
(PEU) were positive for S. maltophilia. There was not a clinical-
laboratory correlation in any cases and the occurrences were
restricted to the speciﬁc hospital unit. Patient ages varied from 1
to 10 years. Epidemiological investigation included: culture of
items used at PEU, extensive data and procedure review, and
clonality evaluation of isolates. Cultures of pediatric blood collec-
tion vials and various environmental samples were done on
sheep blood agar and tryptic soya broth. Clonality was evaluated
through enterobacterial repetitive intergenic consensus sequences
polymorphism (ERIC-PCR) method and with pulsed-ﬁeld gel
electrophoresis (PFGE) of genomic DNA restriction fragments
obtained with SpeI.
Results: Genomic DNA restriction patterns of the ﬁrst 13 isolates
were indistinguishable, which led to an intensive surveillance
with no source disclosure at ﬁrst. As part of data and procedure
review, it was detected that blood samples for erythrocyte sedi-
mentation rate (ESR) and for blood cultures were collected during
the same venous punction in all events. Cultures of the sodium
citrate solution from speciﬁc batches of ESR collecting vials were
positive for S.maltophilia. Analysis of ERIC-PCR and PFGE geno-
mic DNA restriction patterns from clinical isolates and ESR vials
showed that they belonged to the same clone.
Conclusion: Utilization of a non-sterile ESR collecting vial asso-
ciated with an order inversion of vials during sampling caused
the pseudo-outbreak. Traditional epidemiological methods asso-
ciated with molecular epidemiology techniques were fundamental
for establishing the precise cause of the pseudo-outbreak.
Figure 1.
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O193 Compliance with hand disinfection in intensive care
units (ICU): the Hawthorne effect
T. Eckmanns, F. Schwab, R. Wettstein, M. Behnke, P. Gastmeier,
H. Ru¨den
Berlin, Hannover, D
Objectives: Hand disinfection (HD) is believed to be the most
important means of preventing nosocomial infections. The
Hawthorne Effect refers to the tendency of people who are being
observed in a research contest to behave differently from the way
they otherwise would. When collecting data, on compliance with
hand HD the situation ought to be avoided where the personnel
observed behave differently from when not observed. An investi-
gation was carried out into what inﬂuence the Hawthorne Effect
has on HD compliance in health care personnel.
Methods: Medical personnel in ﬁve ICUs were monitored in two
periods regarding compliance with HD where there were poten-
tial opportunities for HD. In the ﬁrst period the personnel had no
knowledge of being observed, as the person monitoring them was
present in the ICUs anyway because of other duties. The second
observation period was announced to the ICUs in advance with
detailed information about what the observer would monitor.
Observations were done for 2 h during the morning shifts over
10 days in both periods in all the ICUs. Potential confounders of
HD compliance included: occupational groups (nurses, doctors,
other health care workers), ICUs, nurse-to-patient ratio at the
times of observation. Differences in proportions were compared
by chi-square tests.
Results: Data were collected from 2808 situational opportunities for
HD, of which 937 were in period one and 1871 in period two. Of the
staff categories nurses had contributed 57% of all the opportunities,
doctors 18% and other health care workers 25%. Altogether in the
ﬁrst period the compliance was 29% and in the second period 45%.
Nurses had a compliance of 30 and 58% and doctors a compliance
of 25 and 47%. The differences between ﬁrst and second periods
were signiﬁcant P < 0.001. Other health care workers had a compli-
ance of 29 and 21%. This difference was not signiﬁcant.
Conclusion: In the ﬁrst period substantially fewer HD procedures
were observed with the observer working covertly. Nurses and
doctors had a signiﬁcantly higher compliance in the second period
with the observer working overtly. The less variable compliance in
the group of other health care workers is explicable as they are not
regular workers at the ICU and were not informed about the obser-
vation. The Hawthorne Effect has a marked inﬂuence on the HD
compliance. HD compliance may be lower as we thought because
of results from studies which did not regard the effect.
Communicable infections: surveillance systems and public health issues
O194 Assessing cases for SARS in the Netherlands
A. Timen, G.J.J. van Doornum, M. Schutten, M.A.E. Conyn-van
Spaendonck, J.W.M. van der Meer, A.D.M.E. Osterhaus,
J.E. van Steenbergen
Utrecht, Rotterdam, Bilthoven, Nijmegen, NL
Objectives: To evaluate the assessment of cases presented under
suspicion of SARS and to estimate the impact of various case deﬁ-
nitions.
Methods: Descriptive study of the cases submitted between 17
March and 7 July. A two sources capture-recapture method was
used. The ﬁrst source consisted of cases reported by clinicians
and general practitioners to community health services. Public
health physicians submitted the cases for further assessment to
the National Co-ordination Centre for Communicable Diseases
(LCI). The other source consisted of the data base from the Refer-
ence Laboratory for SARS (Virology Dept, Erasmus MC) where
clinical specimens were received. The ﬁrst assessment by clini-
cian/public health physician was compared with the assessment
on the basis of the ruling case deﬁnition at that moment and with
a retrospective reassessment using the latest Dutch case deﬁnition
(i.e. WHO-case deﬁnition, 1 May 2003).
Results: In the Netherlands ﬁve case-deﬁnitions were issued,
reﬂecting the dilemmas with respect to speciﬁcity versus sensitivity
within risk assessment. Seventy-two patients were submitted for
SARS assessment of which 51 to the LCI, 37 to the reference labora-
tory; 16 patients were identiﬁed in both data bases. The three major
criteria for SARS (respiratory disease, fever > 38C and travel
related risk) were met in 25 cases (34%). Using the most sensitive
case deﬁnition (i.e. WHO; revised 1 May 2003) 21 cases would have
required reporting for SARS-assessment as suspect cases and two
patients as probable cases. Using the more speciﬁc case deﬁnitions,
only nine cases would have met the criteria for reporting and SARS
assessment, whereas, despite the case deﬁnitions, 52 cases were
presented as serious suspect by clinician or public health physician.
Risk ratios for being a suspect case were calculated comparing the
presentation by the physician versus the ﬁrst assessment and the
reassessment. The reference laboratory performed serological test-
ing for antibodies against SARS-CoV, as well as virus culture and
PCR. None of the patients tested positive for the SARS-CoV.
Conclusions: Even when using case deﬁnitions with a high speciﬁ-
city over-reporting of cases takes place. Over-reporting of cases
should be taken into account when estimating and planning epi-
demic control resources. The non-cases would require a thorough
assessment and case management as well. A centralised assess-
ment centre is recommended.
O195 The current health and economic burden of varicella
in Germany
P. Wutzler, S. Wagenpfeil, T. Hammerschmidt, H. Bisanz,
K. Banz, A. Neiss
Jena, Munich, D; Basle, CH
Objectives: In the absence of any vaccination strategy, nearly every
person will suffer from varicella resulting in an estimated 739 000
cases each year in Germany. Varicella can lead to severe compli-
cations and even death. Up to now the German vaccination strat-
egy has targeted risk groups only. The aim of this study is to
estimate the health and economic burden of varicella under this
vaccination strategy.
Methods: The validated simulation model Economic Varicella Vac-
cInation Tool for Analysis (EVITA) (Banz et al. 2003) in which
vaccination strategies can be deﬁned by targeted age-group and
coverage rate was used to estimate the burden of varicella under
the risk group vaccination strategy over a period of 30 years.
Input data for the model came from a representative epidemiolo-
gical survey of 1334 varicella cases collecting data on the course
of disease (complications, hospitalisation) and economic data
(Wagenpfeil et al. 2004) and a representative seroprevalence sur-
vey analysing sera from 4602 persons (Wutzler et al. 2002). Based
on the number of varicella vaccine doses sold in the German mar-
ket, a coverage rate of 10% in the risk group of adolescents aged
12–15 years has been assumed.
Results: Under the vaccination strategy, 721 400 varicella cases
occur on average each year in Germany. Thereof, 38 700 cases
result in complications which are distributed among bacterial
superinfections (45.1%), pneumonia/bronchitis (18.6%), otitis
media (16.1%), acute neurological disorders (2.6%) and others
(17.6%). 5500 complications lead to hospitalisations because of
bacterial superinfections (6.1%), pneumonia (69.1%), acute neuro-
logical disorders (8.0%) and others (16.8%). Overall, 21 deaths are
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caused by varicella p.a. Varicella and varicella vaccination leads
to overall costs of 166.9 million p.a. to society (78.2% work loss
costs, 20.5% treatment costs, 1.3% vaccination costs). Thereof,
72.7 million are paid by sickness funds (50.4% work loss costs,
46.5% treatment costs, 3.1% vaccination costs).
Conclusions: Varicella causes a high medical burden of disease
which cannot be inﬂuenced signiﬁcantly by the risk group vacci-
nation strategy. Varicella causes also a considerable economic bur-
den to society and health care payers while vaccination costs are
very low. The high disease burden speaks for the introduction of
more effective universal vaccination strategies, e.g. targeting at
young children.
O196 StAKoB – The German working group of centres for
the management of highly contagious diseases as part of a
preparedness network responding to biological hazards
T. Gru¨newald, R. Fock, K. Fleischer, G.D. Burchard, R. Kurth,
B.R. Ruf – German working group of centers for the management
of highly contagious diseases (StAKoB)
Objective: Bioterrorism (BT) attacks and biological warfare (BW)
are nowadays recognised as potential threats, which may encoun-
ter any country of the world. Pathogens implicated in such events
are similar to those, which are eventually imported by single per-
sons. To increase readiness for the treatment of highly contagious
diseases Germany has implemented eight centres of competence
throughout the country. In 2003 these centres launched the Ger-
man working group of centers for the management of highly con-
tagious diseases (StAKoB).
Methods: The usefulness of StAKoB and its centres for the prepa-
redness in the case of BT attacks and ﬁtting into existing scenario
planning is evaluated.
Results: Recommendations for the management of single or a
few cases suffering from highly contagious disease are available
in many countries as so in Germany. Statements regarding mass
treatment by providing adequate care for a large number of
victims in classiﬁed containments apart from inﬂuenza pan-
demic plans and smallpox vaccination programmes are usually
not given. StAKoB group members have developed recommen-
dations for the post-exposure prophylaxis, mass treatment and
containment of considerable quantities of patients. Additionally,
training courses for non-medical and medical ﬁrst responders
were installed as well as arrangements for mass quarantine.
Harmonizing individual center approaches resulting in generally
accepted procedures facilitated the use of personal protection
materials as well as the exchange of personnel from each
centre.
Conclusions: StAKoB activities and its members are adding favour-
ably to federal preparedness plans.
O197 Evidence of shiga-like toxin (stx1, stx2), intimin
(eaeA), and haemolysin (hlyA) positive E. coli in private and
public drinking water supplies in Upper Austria – an emerging
issue of public health?
M. Halabi, D. Orth, K. Grif, M. Wiesholzer-Pittl, J. Schoeberl,
M.Kainz, F. Allerberger, R. Wuerzner
Ried im Innkreis, Innsbruck, Vienna, A
Objective: To evaluate the presence of shiga-like toxin (stx1 and
stx2), intimin (eaeA), and haemolysin (hlyA) genes in E. coli iso-
lates from private and public drinking water supplies in Upper
Austria and to assess a possible public health risk. It is well
known that consumption of food or potable water containing
shiga-like toxin producing E. coli isolates can lead to haemorrha-
gic diarrhoea and even to haemolytic uremic syndrome. Out-
breaks associated with public water supplies are well documented
(Olsen et al. 2002; Bopp et al. 2003).
Methods: Samples were taken from 255 private and public drink-
ing water supplies in the western part of Upper Austria. This
region is mainly supplied by wellwater and springwater. The
samples were part of the routine surveillance programme accord-
ing to the regulation concerning water intended for human use of
the Austrian Health Authorities based upon the guideline 98/93
of the European Union. Of the 255 samples 102 were drawn from
drilling wells, 86 from dug wells, 54 from springs and 13 from
water supplies not otherwise speciﬁed. The samples were taken
according to standardised procedures. Hundred millilitres of each
water sample was processed by membrane ﬁltration. Endo-Agar
was used to screen and isolation was performed on Chromogenic-
Agar to yield colonies. Presence of E. coli genes was assessed by
PCR according to published methods.
Results: 11 EaeA containing samples were found in all sorts of
water supplies; the 3 HlyA positive E. coli were from one drilling
well and two springs. Most importantly three shigatoxin 2-con-
taining samples (one of which with additional stx1 gene) were
discovered in one drilling well, one dug well and one spring.
Conclusion: The evidence of shiga-like toxin (stx1 and stx2), inti-
min (eaeA), and hemolysin (hlyA) genes in E. coli isolates of 17 of
255 public and private water supplies in Upper Austria is not
unexpected and underlines the importance of regular assessments.
True EHEC strains, carrying both shigatoxin (stx1 or stx 2) and
virulence genes (eaeA or hlyA), however, were not found. Efforts
should be continued to guarantee the supply of the public and
the private with potable water according to the guideline 98/93 of
the European Union.
Literature:
Bopp et al. J Clin Microbiol 2003;41:174–180.
Olsen et al. Emerg Inf Dis 2002;8:370–375.
O198 Bacterial meningitis in Denmark. Discrepancy
between laboratory registered and notiﬁed cases
C.N. Meyer, H.C. Schønheyder, I.S. Samuelsson, M. Galle,
J.M. Bangsborg, X. Nielsen, N. Høiby
Hellerup, Aalborg, Copenhagen, Herlev, DK
Objectives: Treatment recommendations for bacterial meningitis
(BM) are to a large extent based on notiﬁed cases, but notiﬁcation
rates have been reported to be incomplete. We wished to deter-
mine the variation in notiﬁcation rates among cases of veriﬁed
BM with positive microbiology.
Methods: Cases of BM was identiﬁed in the laboratory information
systems of 12 of 15 existing Danish departments of clinical micro-
biology (dpt.cm) in the year 2002 (population served 4 520 000).
Cases were included if positive cultures of cerebrospinal ﬂuid
were accompanied by clinical and biochemical ﬁndings compati-
ble with BM and contamination was effectively ruled out. Patients
with positive blood cultures and a diagnosis of BM resting on
clinical and biochemical ﬁndings were also included. Four dpt.cm
supplied data on CSF culture-negative and blood-culture positive
cases. Neuro-surgical cases and mycobacterioses were excluded.
The National Notiﬁcation System for Infectious Diseases supplied
relevant data. Capture–recapture methods were not performed
because of population differences.
Results: A total of 196 culture positive cases of BM were identiﬁed
in a population of 4 520 000. S. pneumoniae constituted 88 cases
(45%), N. meningitidis 35 cases (18%), S. aureus 14 cases (7%),
E. coli eight cases (4%), L. monocytogenes six cases (3%), E. faecalis
four cases (2%), streptococci 23 cases (12%), H. inﬂuenzae two
cases (1%), miscellaneous bacteria 16 cases (8%). Of these 196
cases, 78 cases (40%) were not notiﬁed. The notiﬁcation rate for
S. pneumoniae was 88% (77 of 88), for N. meningitidis was 97%
(34 of 35), for S. aureus 7% (one of 14), for E. coli 0% (0 of eight),
for Listeria 83% (ﬁve of six), for E. faecalis 0% (0 of four), for
streptococci 13% (three of 23), for H. inﬂuenzae 50% (one of two),
and for misc. bacteria was 25% (four of 16).
Conclusion: Notiﬁcation rates among cases of BM varies according
to bacterial aetiology. If recommendations for empirical treatment
is based on notiﬁcation data only, there is a risk of insufﬁcient initial
antibiotic treatment for underreported bacterial agents.
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O199 Results from the ﬁrst 6 months of enhanced
surveillance of severe Streptococcus pyogenes disease in England
and Wales
T. Lamagni, S. Neal, A. Efstratiou
London, UK
Objectives: Analyses from the ﬁrst 6 months of enhanced sur-
veillance of severe S. pyogenes infections in England and Wales,
part of the EU FP-5 funded ‘strep-EURO’ programme, were
undertaken to determine the burden, clinical presentation and
risk factors for disease, and microbiological characteristics of
strains.
Methods: Two sources were used to identify cases: routine surveil-
lance of microbiologically-conﬁrmed S. pyogenes infection reported
to the Communicable Disease Surveillance Centre; isolate referral
to the national Streptococcus & Diphtheria Reference Unit. Recon-
ciled data from both systems were analysed and described.
Results: A total of 1055 conﬁrmed cases of severe S. pyogenes dis-
ease were received between 1 January and 30 June 2003, a 6-
monthly incidence of 2.01/100 000 population. Of these, 51%
were in men, 10% in children (<15 years) and 31% in young
adults (15–44 years). Eighty-nine per cent (942) had positive blood
cultures, with 10% (105) diagnosed from other sterile sites. In
eight cases, sterile site isolates were not reported, but because of
their severe and characteristic disease presentation met the case
deﬁnition. Serotyping results indicated M3 to be the most com-
mon type. Analysis of survey questionnaires entered to date indi-
cated that 93% (433 of 455) of cases presented with bacteraemia,
8% (35) with streptococcal toxic shock syndrome, 9% (39) with
septic arthritis, 6% (27) with pneumonia, 5% (21) with necrotising
fasciitis, 3% (12) with puerperal sepsis and 1% (6) with meningi-
tis. Twenty-one per cent of cases were admitted to intensive care
units. Of cases whose outcome was reported (86%), over one-ﬁfth
(22%; 88 of 393) had died within 7 days of the microbiological
diagnosis. Only in 2% of these was the infection not thought to
have contributed to the patient’s death, the majority (80%) being
directly attributed to the S. pyogenes infection. In 22% (97 of 436)
of cases, no predisposing risk factors were identiﬁed. Of the
remainder, injecting drug use was the most common (21%; 91 of
436).
Conclusion: Preliminary results from enhanced surveillance sug-
gest the incidence of severe S. pyogenes disease in England and
Wales to be considerably higher than previously estimated. Inject-
ing drug use appears to have become a major risk factor for
severe S. pyogenes disease. Early results afﬁrm the high and rapid
mortality associated with these diseases, one-ﬁfth of cases having
died within 7 days of initial diagnosis.
O200 Streptococcus pyogenes isolates resistant to
ciproﬂoxacin in Spain: clonal diversity and appearance of
ciproﬂoxacin-resistant epidemic clones
S. Albertı´, G. Corte´s, C. Garcı´a-Rey, C. Rubio, F. Baquero,
J.A.Garcı´a-Rodrı´guez, E. Bouza, L. Aguilar – Spanish Surveillance
Group for Respiratory Pathogens
Objectives: The increasing use of ﬂuoroquinolones for the treat-
ment of bacterial respiratory infections has led to the emergence
of S. pyogenes isolates with resistance to this class of antibiotics. In
this study, we determined the mechanisms of ciproﬂoxacin resis-
tance and the emm-types associated to ciproﬂoxacin resistance in
Spain.
Methods: S. pyogenes pharyngeal isolates belonged to the SAUCE
(standing for Susceptibility to the Antimicrobials Used Com-
monly in ‘Espan˜a’ and is the Spanish word for the willow
tree) national surveillance collection (1998–99). Sequence analy-
sis of speciﬁc PCR products was used to deduce emm-types,
and to detect mutational alterations in the QRDRs of gyrA and
parC. Sequencing was done with the Big Dye terminator mix
and autosequenator (Applied Biosystems). DNA sequences were
subjected to homology searches against the bacterial DNA data-
base. MICs to ciproﬂoxacin were determined with and without
reserpine following standard procedures. Genetic diversity of
the S. pyogenes ciproﬂoxacin resistant isolates was studied by
pulse ﬁeld gel electrophoresis of genomic DNA restricted with
SﬁI.
Results: All the ciproﬂoxacin resistant S. pyogenes belonging to
the SAUCE collection were analysed (n ¼ 27). We found point
mutations at Ser79 and/or at Asp91 of parC that were replaced
in all the strains by Ala and Asn, respectively. By contrast, we
did not identify mutations in the gyrA gene in any isolate. In
addition, MIC of ciproﬂoxacin for these isolates (4–8 lg/mL)
was not inﬂuenced by the presence of reserpine. 66.6 % of the
resistant isolates were M type 6 and the rest expressed different
M types. PFGE analysis revealed that 50% of the M type 6 had
an identical restriction pattern. By contrast we identiﬁed up to
12 different PFGE patterns among the rest of the ciproﬂoxacin
resistant strains.
Conclusions: Reduced susceptibility of S. pyogenes to ciproﬂoxacin
in Spain is essentially caused by point mutations of parC present
mainly in a single M type 6 clone.
O201 External quality assesment of antibiotic
susceptibility testing by laboratories participating in the
European Antimicrobial Resistance Surveillance System in 2003
P. Schrijnemakers, C. Walton, N. Bruinsma, G. Kahlmeter,
J.E. Degener, J.W. Mouton, G. Cornaglia, P. Courvalin,
H. Grundmann – EARSS participants
Objectives: The goal of this exercise was to assess if laboratories
participating to European Antimicrobial Resistance Surveillance
System (EARSS) correctly detect resistance mechanisms that are
clinically and epidemiologically relevant and to compare suscept-
ibility test results across countries and guidelines.
Methods: A panel selected six strains: (1) S. aureus U2A166 suscep-
tible to relevant antibiotics, (2) MRSA U2A1786 heteroresistant to
methicillin and known from outbreaks, (3) S. pneumoniae U2A961
resistant to erythromycin, (4) S. pneumoniae U2A1787 intermedi-
ately resistant to penicillin, (5) E. coli U2A1789 producing ESBL
(SHV5) 6) E. gallinarum U2A604 with VanC type resistance. The
strains were distributed by UK-NEQAS (United Kingdom
National External Quality Assessment Service) to 740 laboratories
which were asked to report clinical categories (S, I, R). Results
were analysed and considered ‘concordant’ if the reported cate-
gorisation agreed with the designated interpretation of the refer-
ence laboratories.
Results: 673 (90%) Laboratories from 26 countries returned reports
in time. For the S. aureus U2A166 the concordance was >95% for
oxacillin, cefoxitin, gentamicin, vancomycin, teicoplanin and peni-
cillinG. For the MRSA the concordance was low for oxacillin
(80%) and cefoxitin (76%), whereas concordance was >94% for
gentamicin, vancomycin, teicoplanin and penicillin G. Erythromy-
cin resistance and clindamycin susceptibility of S. pneumoniae
U2A961 was correctly detected by 95% of laboratories. For the
S. pneumoniae U2A1787 the concordance for penicillinG inter-
mediate resistance was only 76%. For the E. coli the concordance
was high for detection of ESBL production (94%), and for genta-
micin (99%) and ciproﬂoxacin (99%). The Enterococcus was identi-
ﬁed as E. gallinarum by 50% of laboratories, but more
importantly, 90% of laboratories reported the reduced susceptibil-
ity to vancomycin and the susceptibility to teicoplanin, which is
typical for this type of resistance.
Conclusions: Participating laboratories were capable of detecting
most resistance phenotypes. However, 20% of laboratories missed
detection of an MRSA that caused epidemics in Europe. This
resistance was difﬁcult to detect as the resistance phenotype was
heterogeneously expressed. Moreover, 11% of laboratories failed
to detect the reduced susceptibility to penicillin in S. pneumoniae.
The results illustrate that there is room for improvement in Eur-
opean routine susceptibility testing.
34 Abstracts
O202 Bacteriologic diagnostics and antibiotic management
in German intensive care units: data from project SARI
(Surveillance of Antibiotic Use and Bacterial Resistance in
German Intensive Care Units)
E. Meyer, W. Ebner, A. Heininger, F. Daschner
Freiburg, Tubingen, D
Objective: To evaluate bacteriologic diagnostics and antibiotic
management in intensive care units (ICUs) in Germany.
Methods: A questionnaire was sent to each of the 38 (3/2003) ICUs
participating in project SARI, which was initiated in February
2002. Of these ICUs, 29 returned the questionnaire for analysis.
The questionnaire contained questions on the following: imple-
mentation of guidelines concerning antibiotic treatment in ICUs,
diagnostic procedures and empiric choice of antibiotics given for
pneumonia, bloodstream infections, surgical site infections and
other community acquired and nosocomial infections in ICUs.
Results: 19 ICUs use written guidelines on antibiotic management.
Only 14 of 29 ICUs collect quantitative specimens for ventilator asso-
ciated pneumonia, although recommended by national guidelines.
Empiric antibiotic treatment differs considerably in ICUs, even for
common infections. 29 ICUs use nine different ﬁrst line treatment
options for late onset ventilator-associated pneumonia. Only six
ICUs favour a reasonable combination therapy to target P. aeruginosa
and Acinetobacter sp. as important underlying pathogens. Resistance
rates for P. aeruginosa (testing in accordance with DIN) are high in
SARI-ICUs: 18.3% for ciproﬂoxacin, 26.1% for imipenem and 24.3%
for piperacillin/tazobactam (cumulative data from 2/2000–6/2003).
Regarding empiric central line associated blood stream infection, 26
ICUs use a total of 12 ﬁrst line treatment options. 18 ICUs (69%) use
glycopeptides alone or in combination, in spite of the fact that MRSA
rates are low (<10%) in their ICU (n ¼ 5).
Conclusion: Although national guidelines are available, consider-
able differences still exist in microbiologic diagnostics and empiric
antibiotic treatment in ICUs in Germany. Guidelines for ICUs
have proved to be a useful instrument for quality management
and for the improvement of empiric antibiotic treatment and
microbiologic diagnostics. However, discrepancies exist between
the recommendations given by guidelines and actual medical
practice in the ICU setting.
O203 Outpatient systemic antibiotic use in 2002 in Europe
M. Ferech, M. Elseviers, K. Dirven, R. Vander Stichele,
H. Goossens the ESAC Project Group
Objectives: ESAC, European Surveillance of Antimicrobial Con-
sumption, granted by DG/SANCO of the European Commission,
is an international network of surveillance systems, aiming to col-
lect comparable and reliable data on antibiotic consumption in
Europe. Thirty-two countries joined the ESAC project, including
all 15 EU countries, 12 of the 13 applicant countries (not Cyprus),
two of the three EFTA-EEA countries (not Liechtenstein), Croatia,
Russia and Switzerland. Twenty-six of the 32 participating coun-
tries were able to deliver ambulatory care data for 2002.
Methods: Outpatient antibiotic use for 2002 was collected, using
the ATC/DD method. Data were expressed as DDD per 1000
inhabitants per day (DID). Detailed information on the sources of
antibiotic use data can be found at the ESAC website (http://
www.ua.ac.be/ESAC).
Results: Antibiotic use varied with a factor of 3.6 between the coun-
tries with the highest and lowest consumption (32.2 DID in France
and 9.0 DID in the Netherlands). Penicillin (J01C)(PEN) use var-
ied with a factor of 4.7 between France (16.3 DID) and the Nether-
lands (3.5 DID). We observed that in three countries (Norway,
Sweden and Denmark) the narrow spectrum PEN (J01CE) still
represented more than 60% of the PEN, whereas in seven coun-
tries (Belgium, France, Italy, Latvia, Luxemburg, Portugal and
Spain) these drugs represented <2% of the PEN. Cephalosporin
(CEP) (J01DA) use varied with a factor of 256.2 between Greece
(6.7 DID) and Denmark (0.03 DID). In France and Italy, the high
CEP use was because of the markedly high use of third generation
CEP, representing about one-third of CEP use in these countries,
i.e. of the injectable (ceftriaxone in Italy) and oral (ceftibuten and
ceﬁxime in Italy; cefpodoxime and ceﬁxime in France) CEP. Total
use of the macrolides (J01FA), lincosamides (J01FF) and streptogra-
mins (J01FG) varied with a factor of 26.9 between Greece (7.8 DID)
and Latvia (0.3 DID). Quinolone (J01M) use varied with a factor of
21.2 between Italy (3.76 DID) and Denmark (0.17 DID). Sulphona-
mides and trimethoprim (J01E) use varied with a factor of 19.5
between Iceland (2.0 DID) and Latvia (0.1 DID).
Conclusion: Diverging patterns in antibiotic consumption were
observed which need to be confronted with the nature and inten-
sity of health policy measures.
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O204 Proﬁle of antibody responses against SARS-
coronavirus recombinant proteins and their potential use as
diagnostic markers
Y.-J. Tan, P.-Y. Goh, S.G. Lim, W. Hong
Singapore, SGP
Objectives: A new coronavirus, SARS-CoV, has been identiﬁed to
be the aetiological agent of severe acute respiratory syndrome
(SARS). Given the highly contagious and acute nature of the dis-
ease, there is an urgent need to develop diagnostic assays that can
detect SARS-CoV infection. The aim of this study is to determine
which of the viral proteins encoded by the SARS-CoV genome
may be exploited as diagnostic antigens for the development of
serological assays.
Methods: In this study, several proteins encoded by the SARS-CoV
were expressed in mammalian and bacterial cells and tested for
their immuno-reactivity with sera from SARS-CoV-infected
patients using Western blot analysis. The bacterially expressed
proteins were also used to develop a SARS ELISA Test and a 15-
min immunochromatographic device, SARS Rapid Test. In addi-
tion, an immunoﬂuorescence method ulitizing mammalian cells
stably expressing the heavily glycosylated spike (S) protein, is
used to test for antibodies against S.
Results: A total of 83 sera, including six from convalescent
patients, 63 from probable patients who were discharged from the
hospital and seven pairs from two different time-points of infec-
tion, were analysed by Western blot analysis. All of them showed
immuno-reactivity towards the nucleocapsid (N) protein of SARS-
CoV. Sera from some of the patients also showed immuno-reactiv-
ity to a protein that is unique to SARS-CoV, U274. The results
obtained using the SARS ELISA Test and the SARS Rapid Test
were consistent with that obtained using Western blot analysis. In
addition, all the convalescent sera showed immuo-reactivity
against the spike (S) protein. However, samples from the acute
phase (2–9 days after onset of illness) did not react with S, sug-
gesting that antibodies to N may appear earlier than antibodies to
S or this could be due to the difference in the sensitivities of the
two methods. The immuno-reactivities to these recombinant viral
proteins are highly speciﬁc as sera from 100 healthy donors did
not react with any of these proteins.
Conclusion: The recombinant N and U274 proteins may be used
as antigens for the development of serological assays for SARS-
CoV. For detecting of anti-S antibodies in patient’s serum by
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immunoﬂourescence, the stable cell-line expressing S would be
safer to use than SARS-CoV infected Vero cells, which are cur-
rently being used in serological assays.
O205 Recombinant N and M protein-based ELISA for
detection of antibodies to SARS-Coronavirus
A. Carattoli, P. Di Bonito, F. Grasso, C. Giorgi, F. Blasi,
A. Cassone
Rome, Milan, I
Objectives: A new Coronavirus (SARS-CoV) is considered the
aetiological agent of the Severe Acute Respiratory Syndrome
(SARS). Molecular, virologic and serologic tests have been devel-
oped for its identiﬁcation, the latter currently based on puriﬁed
virus or infected cells. In this study we report the development
of an in-house ELISA based on recombinant SARS CoV proteins,
the nucleoprotein N and the membrane protein M.
Methods: The coding region of N and M were cloned and
expressed in Escherichia coli. Moreover the NH2-terminus, central-
portion and COOH-terminus of the N protein, and the cytoplas-
mic tail of the M protein, were also cloned and expressed. The
puriﬁed proteins were used as coating antigens in an in-house
ELISA. Six reference sera from SARS patients with different
immunoﬂuorescence and virus-neutralisation titres and 93 sera
from healthy or no SARS patients with low tract respiratory infec-
tions were tested.
Results: High-titres of IgGs were detected in all sera from SARS
patients, whereas no reaction was detected in the 93 control sera.
The most discriminative and reproducible ELISA results were
obtained with the cytoplasmic tail of the M protein (M2), as anti-
gen. Moreover in this condition the six positive sera examined,
showed almost the same values of O.D. at each dilution tested.
Conclusions: While the low number of SARS sera examined would
preclude a sound assessment of sensitivity of the ELISA methods
we generated, the speciﬁcity of the assay appears to be rather
high considering the elevated number of negative sera tested.
Overall, our results strongly suggest the effectiveness of recombi-
nant antigen-based in house ELISA for serological diagnosis of
SARS, in particular when the novel M2 antigen is used.
O206 Plague returns to Algeria after an absence of 50 years
E. Bertherat, E. Carniel, A. Chaieb, J.-B. Duchemin, E. Tikhomirov,
S.Bekhoucha, L. Ben Abdallah, F. Razik
Geneva, CH; Paris, F; Niamey, NE; Oran, DZ
Background: Throughout the last century, imported cases of plague
regularly occurred in Algeria. To date, no natural focus of plague
had been described in this country. The last human cases were
reported in Oran in 1950. On 23 June 2003 the Algerian authorities
reported 10 cases of bubonic plague to the World Health Organi-
zation (WHO) and sought technical support to respond to this
outbreak.
Methods: A team of ﬁve experts from WHO assessed the situation
and supported the national authorities in containing the outbreak.
Strains were isolated from human specimens and typed by the
Institut Pasteur, Paris, France.
Results: On 5 June 2003, a child from a village 25 km south of
Oran, died suddenly with a severe infectious syndrome. During
the following weeks a total of 11 conﬁrmed and seven suspected
cases of plague were reported from the same area. On 20 June,
the bacteriological analysis performed at the University Hospital
in Oran conﬁrmed the diagnosis of plague. The last case was
reported on 17 July. All the cases were bubonic plague, with two
cases having evolved into the septicemic form. No human-to-
human transmission was observed. Only one death, the ﬁrst case,
occurred. The outbreak was controlled by a variety of means: hos-
pitalization and treatment of patients; chemoprophylaxis of the
contact cases; vector control and improvement of general hygiene.
Molecular typing of the isolates indicated that they belonged to
the most common Y. pestis type (biovar Orientalis, ribotype B)
and that all ﬁve strains were clonal.
Conclusion: The ﬁrst observations are compatible with the hypoth-
esis of the reactivation of an autochtonous focus in the region of
Oran, but in-depth ﬁeld investigations will be necessary to con-
ﬁrm this hypothesis. The return of plague to Algeria 50 years after
its last occurrence, near an international harbour, emphasizes the
need to maintain thorough epidemiological surveillance at the
international level.
O207 Corynebacterium ulcerans diphtheria in France; a dog
as the culprit
M.-F. Lartigue, X. Monnet, P.A.D. Grimont, J.-J. Benet,
P. Nordmann
Le Kremlin-Biceˆtre, Paris, Maisons-Alfort, F
A 47-year-old woman with typical laryngeal diphtheria was
admitted to Biceˆtre hospital (France) for severe dyspnoea. Throat
swab grown on Loefﬂer’s medium and blood agar gave of a
gram-positive catalase positive-rod identiﬁed as Corynebacterium
ulcerans by positive urease reaction, API Coryne system and
sequencing of 16 sRNA gene. Disk diffusion test showed that this
isolate was susceptible to most antibiotics including beta-lactams
and macrolides. A PCR test was positive for the gene of
diphtheria-like toxin that is usually quite invariable in Corynebac-
terium diphteriae. Sequencing identiﬁed a gene that encoded a
toxin that had twenty-ﬁve amino acid substitutions as compared
with diphtheria toxin. The patient was treated with amoxicillin-
clavulanic acid (before identiﬁcation of C. ulcerans) for 5 days,
then penicillin G adapted to renal function for nine days and one
dose of diphtheria antitoxin (40 000 U). She recovered without
complication. She was immunocompromised (prednisone 6 mg/
day, tacrolimus 12 mg/day, and mycophenolate nofetil 1 g/day)
as she had underwent kidney graft and a retrospective analysis
did not evidence detectable diphtheria antibodies in her serum.
Carriers of C. ulcerans in the immediate vicinity of the patient
(family, patients and health care workers, n ¼ 88) using a novel
selective medium settled for this purpose [Columbia colistin-nali-
dixic acid (CNA) agar plates with 5% sheep blood plus fosfomycin
125 mg/L] were not identiﬁed. However, the exact same
C. ulcerans isolate was found from throat, nostrils and labial ulcera-
tion of the companion dog of this patient. This dog had chronic
cutaneous ulcerations, sneezing and rhinorrhea for years. Failure
of an amoxicillin-containing treatment (2 g/day for 15 days) for
eliminating the bacteria from the dog lead to his killing.
Although the main natural reservoir of C. ulcerans is cattle and cat-
tle environment, this is the ﬁrst report that suggests transmission
from a dog to human of a coryneform bacteria as a source of
diphtheria. In addition it raises the growing question of pets as a
reservoir of zoonotic infection in immunocompromised patients.
O208 Group B Streptococcus necrotising fasciitis: an
emerging disease?
C.-H. Wong, Y.-S. Wang, A. Kurup, K.-C. Tan
Singapore, SGP
Objective: We report our recent observation of ﬁve cases of Group
B Streptococcus (GBS) necrotizing fasciitis in our patients.
Methods: The patients were all female, age ranged from 38 to
66 years. Four patients had poorly controlled diabetes mellitus
as the predisposing condition. Four cases involved the lower
limbs and one involved the hand. GBS was the only organism
isolated in the tissue culture in all cases and in the blood culture
in one patient. The GBS isolated had identical antibiogram with
all being susceptible to penicillin. One patient fulﬁlled the deﬁni-
tion of streptococcal toxic shock syndrome. Two patients had
previous soft tissue infections where GBS were isolated prior to
the necrotizing fasciitis episodes. All ﬁve patients survived with
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appropriate antimicrobial use and early aggressive surgical de´b-
ridement.
Results: Single-organism necrotizing fasciitis caused by GBS is
extremely rare. To date, only over 10 cases were reported in the
English literature. Together with the ﬁve cases we observed, it is
clear that group B Streptococcus is capable of causing necrotizing
fasciitis. While the virulence factors that enable GBS to cause
necrotizing fasciitis have not been established, this report high-
lights the emergence of this clinical entity.
Conclusion: The medical literature has focused on GBS as a disease
of pregnancy and neonatal period. While, the emergence of inva-
sive GBS in adults has recently been high-lighted, awareness
should be raised on the spectrum of soft-tissue infections caused
by GBS, in particular the danger of progression to necrotizing fas-
ciitis. This emerging phenomenon afﬂicts particularly diabetics.
Awareness of this disease should heighten the index of suspicion
when treating susceptible patients with GBS soft-tissue infections.
Our small case series add to the limited available literature under-
scoring the potential for GBS to cause necrotizing fasciitis. Early
recognition, aggressive surgical de´bridement and high dose intra-
venous penicillin therapy are the cornerstones in the management
of this deadly disease.
O209 An emerging infection in Turkey: Crimean Congo
haemorrhagic fever
B. Esen, A. Gozalan, J. Fitzner, I. Marendat, S. Kilic, A. Peker
Ozkan, H. Zeller
Ankara, TR; Lyon, F
Objective: To describe the epidemiology and clinical features of an
outbreak detected for 2 years in Turkey.
Method: During springs summers 2002–03, clusters of cases with
similar symptoms and laboratory ﬁndings have been detected in
Middle Black Sea and Northern part of Mid Anatolia. The
patients, families, and the doctors have been interviewed with a
questionnaire. Although, Q fever was considered as the clinical
diagnosis in 2002, according to the clinical and epidemiological
ﬁndings next year, a viral aetiology was suspected. Laboratory
tests included Q fever detection by IFA and CCHF investigation
by ELISA (IgG/IgM)/ RT-PCR on the S segment of the viral gen-
ome and sequence analysis. The presence of CCHF IgM antibo-
dies and/or detection of viral genome by RT-PCR indicated an
acute CCHF case.
Results: In 2002, seven of 19 cases (36.8%) were positive for Q
fever by IFA. From April to September 2003, a total of 155
serum samples were received from 128 patients from 15 pro-
vinces in which 45.3% from the same province. All the speci-
mens for suspected cases tested for Q fever were negative.
Acute CCHF infection was recorded in 86 patients (67.2%): 82
cases with presence of CCHF IgM antibodies (in association with
positive RT-PCR in 18 cases) and four cases with positive
RT-PCR positive. Therefore CCHF IgM and IgG antibodies were
reported in 49 of 116 patients (42.2%). Retrospective analysis on
specimens from the year 2002 indicated that 17 of 26 (65.4%)
patients were CCHF cases. Frequent clinical symptoms in con-
ﬁrmed cases included were fever 86.4% (57 of 66) arthralgia/
myalgia 77.5% (31 of 40), nausea 77.3% (51 of 66) and vomiting
68.2% (45 of 66). Haemorrhagic features were unfrequently
recorded: petechial rash 22.7% (15 of 66), epistaxis 22.7% (15 of
66), intestinal bleeding 9.1% (six of 66), haemoptysis 4.9% (two
of 41). Thrombocytopenia 96.8% (61 of 63), leukopenia 90.6% (58
of 64), elevated AST 98.2% (56 of 57) and ALT 94.6% (53 of 56)
levels were the main laboratory ﬁndings. Fatality rate was 8.1%.
Among risk factors, tick contacts have been detected in 72.5%
(29 of 40) of the cases. Intra-familial cluster of cases or nosoco-
mial infections were not reported.
Conclusion: This is the ﬁrst conﬁrmation of the presence of CCHF
virus in Eastern Turkey since 1980 when CCHF serological evi-
dence was reported. The numerous infections in human in 2003
suggest to consider CCHF as a main public health concern in
direct relationships with tick contact.
O210 Changing microbiological proﬁle of infective
endocarditis in Greece during the last 17 years
E. Giannitsioti, I. Skiadas, K. Kanavos, A. Antoniadou,
H. Giamarellou – Hellenic Endocarditis Study Group
Objectives: To evaluate epidemiological trends on microbiology of
infective endocarditis (IE) in Greece during the last 17 years.
Methods: Isolates from blood cultures of IE and their susceptibility
patterns were constantly recorded in all patients with native valve
endocarditis (NVE) and prosthetic valve endocarditis (PVE) via a
data base electronic registry form activated in 15 General hospitals
of Athens.
Results: 150 NVE and 40 PVE were recorded since 2001 by the
Hellenic endocarditis study group. Streptococcus spp predomi-
nated in NVE (36%) and methicillin resistant Staphylococci in
PVE (37.5%). Compared with epidemiological data of 134 IE
registered between 1986 and 1995 mainly in our Department,
Streptococci still predominates NVE but the incidence of entero-
coccal endocarditis raised from 5 to 8% in the 80s and 90s to 18%
in 2001–03. Staphyloccocal NVE declined by 10% between 80s–90s
and 2001–03. Blood culture negative PVE increased to 20%. The
incidence of Gram-negative, fungal, Brucella and ricketsial endo-
carditis has not substantially changed.
Conclusions: Microbiological patttern of IE has changed within
17 years. Enterococci in NVE and methicillin resistant Staphylo-
cocci in PVE have emerged. Knowledge of current microbiological
trends is essential especially for the empirical treatment of culture
negative IE. Further investigation in order to establish correlations
between the observed microbiological data and other epidemiolo-
gical factors is required.
O211 New acute tick-borne rickettsiosis caused by
Rickettsia heilongjiangensis in the Russian Far East
O. Mediannikov, Y. Sidelnikov, L. Ivanov, E. Mokretsova,
P.-E. Fournier, I. Tarasevich, D. Raoult
Moscow, Khabarovsk, RUS; Marseille, F
Objectives: Russian Far East is a geographical, economical and
political unit within the Russian Federation. Since 1932 the cause
of acute tick-borne spotted fever here is thought to be Rickettsia
sibirica and its antigen has been used for serological studies in
clinical laboratories, although seasonal morbidity, age of affected
personals and seropositivity rate (with R. sibirica as antigen) differ
signiﬁcantly from correspondent data from other regions where
multiple strains of R. sibirica have been isolated. The aim of this
study was to identify the cause of an acute febrile tick-transmitted
disease in the Russian Far East by molecular and serological
methods and to describe the clinical picture in these cases.
Methods: We have studied DNA extracted from blood and skin
biopsies of 65 acutely ill tick-bitten patients in the year 2002.
Nested PCR for gltA gene with modiﬁed primers was used to
amplify full-length gene. Both upstream and downstream to the
tandemly repeated region portions of ompA gene and full ompB
have been ampliﬁed in the samples positive for gltA. All ampli-
cons has been sequenced. Patients’ sera were tested with different
rickettsial antigens by IFA.
Results: Ampliﬁed and sequenced four portions of three rickettsial
genes from the samples of 13 patients showed that these genes
belong to Rickettsia heilongjiangensis recently isolated from Derma-
centor sylvarum ticks in the nearby to the Russian Far East region
of China. This rickettsia belonging to subgroup of Rickettsia japo-
nica was previously suggested to be pathogenic for humans on
the base of serological ﬁndings. We tested 11 patients’ sera with
different rickettsial antigens, and conﬁrmed the increasing of IgG
and IgM titres to spotted fever group rickettsiae, including R. hei-
longjiangensis. Clinical and epidemiological data on these patients
shows that this disease is close to other tick-borne rickettsioses.
Conclusion: Ampliﬁcation of three different rickettsial genes and
serological data suggest R. hilongjiangensis as a cause of acute tick-
borne rickettsiosis in the Russian Far East. Previously this disease,
37Clinical Microbiology and Infection, Volume 10, Supplement 3, 2004
probably, has been misinterpreted as Siberian tick typhus. Mole-
cular biology techniques allowed identiﬁcation of the aetiology of
this acute tick-borne disease.
O212 Laribacter hongkongensis in ﬁsh is associated with
gastroenteritis and traveller’s diarrhoea
P.C.Y. Woo, S.K.P. Lau, J.L.L. Teng, T.L. Que, R.W.H. Yung,
W.K. Luk, R.W.M. Lai, W.T. Hui, S.S.Y. Wong, H.H. Yau,
K.Y. Yuen
Hong Kong, HK
Objectives: After its discovery in Hong Kong in 2001, Laribacter
hongkongensis was recovered from six patients with gastroenteritis.
Three patients were from Hong Kong, and three from Switzer-
land. However, the association of L. hongkongensis with gastroen-
teritis is still unproven and the source of L. hongkongensis is
unknown. We conducted a territory-wide, multi-centred, prospec-
tive study to evaluate the association of L. hongkongensis with
community-acquired gastroenteritis and investigate the epidemiol-
ogy, clinical features, outcome, and risk factors of patients that
were culture positive for L. hongkongensis. Targeted food surveil-
lance was performed to identify the potential reservoir of L. hon-
gkongensis.
Methods: Faecal samples from patients with community-acquired
gastroenteritis and controls were cultured for L. hongkongensis. A
case–control study and targeted food surveillance were performed
to identify the potential source of L. hongkongensis. All L. hongkon-
gensis isolates were characterised by pulsed-ﬁeld gel electrophor-
esis (PFGE) and ribotyping.
Results: During a 4-month period, L. hongkongensis was recovered
from 17 of 3788 patients with community-acquired gastroenteritis,
but none of 1894 controls (P < 0.005). Patients that had commu-
nity-acquired gastroenteritis and were culture positive for L. hon-
gkongensis were associated with recent histories of travel (59% vs.
6% in controls, P < 0.001), ﬁsh consumption (94% vs. 56% in con-
trols, P < 0.01), and minced freshwater ﬁsh meat consumption
(29% vs. 3% in controls, P < 0.05). Twenty-seven additional
L. hongkongensis isolates were recovered from intestinal samples in
25% of freshwater ﬁsh (29% of mud carp, 59% of grass carp,
53% of bighead carp and 6% of large-mouth bass) and 15% of
minced freshwater ﬁsh meat from retail markets in Hong Kong.
L. hongkongensis of the same PFGE pattern and ribotype was
recovered from a patient and minced freshwater ﬁsh meat from
the retail market where he had recently purchased minced fresh-
water ﬁsh meat for cooking. This particular combination of PFGE
pattern and ribotype was not seen in any other isolates.
Conclusion: L. hongkongensis is associated with community-
acquired gastroenteritis and traveller’s diarrhoea. Freshwater ﬁsh
is the source of L. hongkongensis.
O213 Diarrhoea in Danish children under 5 years of age: a
case–control study
B. Olesen, J. Neimann, K. Mølbak, B. Bo¨ttiger, S. Ethelberg,
P. Schiellerup, C. Jensen, M. Helms, F. Scheutz, K.E.P. Olsen,
E. Petersen, P. Gerner-Smidt
Hillerød, Copenhagen, DK
Objectives: To clarify the most important aetiologies of infectious
diarrhoea in Danish children under 5 years of age.
Methods: Stools from 424 cases with diarrhoea from all over Den-
mark and 870 healthy age-matched controls were examined for
parasites, Salmonella, Campylobacter, Yersinia, Shigella and Vibrio
spp. using standard methods. Stools were also examined for vero-
cytotoxin-producing E. coli (VTEC), attaching and effacing E. coli
(A/EEC) including enteropathogenic E. coli (EPEC), enterotoxi-
genic E. coli (ETEC), enteroinvasive E. coli (EIEC), and enteroag-
gregative E. coli (EAggEC) by colony hybridisation of virulence
genes and serotyping. Rota-, adeno- and astroviruses were
detected by ELISA and noroviruses by PCR.
Results: Overall, a potential pathogen was found in 57% of cases.
The following pathogens were associated with disease with ﬁg-
ures given for patients and controls, respectively. Rotavirus: 13%
vs. <1%; Salmonella: 5% vs. <1%; noroviruses: 5% vs. 2%, adeno-
virus: 4% vs. <1%; Campylobacter coli/jejuni: 3% vs. <1%; EPEC
3% vs. <1%; VTEC 3% vs. <1%; Yersinia: 2% vs. <1% and Cryp-
tosporidium: 2% vs. 0%. A/EEC (eae positive non-classical EPEC
serotypes) were found with equal frequencies in patients (11%)
and controls (12%). No Shigella, Vibrio or ETEC were isolated.
Conclusions: Rotavirus was the single most common pathogen iso-
lated. Salmonella was the most common bacterial pathogen
detected in diarrhoea both acquired in Denmark and abroad.
VTEC was an important cause (3%) of diarrhoea. A/EEC were
equally common in patients and controls, in contrast to EPEC,
which was associated with diarrhoea.
Macrolides and inflammation modulation in respiratory tract infections (Symposium arranged by
Pliva)
S226 Immunomodulatory effects of macrolides
O. Culic, V. Erakovic, M. Parnham
Zagreb, HR
Macrolides are widely used as antibacterial drugs. In addition to
their antibiotic properties there is a number of reports describing
other potentially useful effects. Anti-inﬂammatory properties can
partially be linked to the unique cellular pharmacokinetics of
macrolides, particularly to their extraordinary uptake by granulo-
cytes and monocytes. 14- and 15-membered macrolide effects will
be discussed at three different levels: in vitro experiments, animal
models, and ﬁnally clinical studies. Considerable evidence, mainly
from in vitro studies suggests that leucocytes and neutrophils in
particular, are important targets for modulatory effects of macro-
lides on host defence responses. Macrolide antibiotics in vitro reg-
ulate different cell functions, e.g., degranulation, oxidative burst,
cytokine/chemokine synthesis/secretion, adhesion, chemotaxis,
apoptosis, and NO production. Molecular mechanisms of anti-
inﬂammatory action seems to be based on inhibition of transcrip-
tion factors activity (nuclear factor kappa B and AP-1). Neverthe-
less, recent microarray-based data on the inﬂuence of
erythromycin and clarithromycin on epithelial cells are not sup-
portive of this hypothesis. Macrolide antibiotics have also been
proven to be effective in animal models of inﬂammation, e.g. car-
rageenin pleurisy, zymosan peritonitis, LPS-induced inﬂammation
and immune complex lung inﬂammation. The most valuable les-
son about macrolide potential for treatment of inﬂammatory dis-
eases has been obtained from the long history of successful
therapeutic use of erythromycin and azithromycin in diffuse pan-
bronchiolitis. Some recent trials are indicative of possibility of
their long-term use in cystic ﬁbrosis and some other (pulmonary)
diseases. Low toxicity and good safety proﬁle of macrolides addi-
tionally favour their long-term use. The consequences of anti-
inﬂammatory effects of macrolides in infection, as compared with
(chronic) inﬂammation that is not caused by bacteria are probably
different which is something that needs to be considered when
developing either new macrolide antibiotics or macrolide anti-
inﬂammatory drugs.
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S227 Biphasic modulation by azithromycin of human
neutrophil function: implications for therapy
M. Parnham, O. Culic, V. Erakovic, I. Glojnaric, I. Cepelak,
K. Barisic, K. Brajsa, Z. Ferencic, R. Galovic, Z. Manojlovic,
V. Munic, R. Novak-Mircetic, V. Pavicic-Beljak, M. Sucic,
M. Veljaca, T. Zanic-Grubisic, S. Grle
Zagreb, HR
Modulatory effects of macrolide antibiotics on leucocyte function
have been observed by a number of investigators. Relatively few
studies have been performed, however, with azithromycin and its
effects on leucocytes in vitro have been confusing. As the ability of
azithromycin to accumulate in leucocytes is much greater than that
of other macrolides, a study was performed to investigate the
effects of a standard 3-day treatment with azithromycin (500 mg/
day, p.o.) on a variety of leucocyte functions and circulating med-
iators in 12 healthy volunteers. Blood was taken 1 h before treat-
ment, 2.5 h, 24 h and 28 days after the last dose. An initial
neutrophil degranulating effect of azithromycin was reﬂected in
rapid decreases in azurophilic granule enzyme activities in cells
and corresponding increases in serum. The oxidative response to a
particulate stimulus was also acutely enhanced. These actions were
associated with high plasma and neutrophil drug concentrations. It
seems likely that this acute stimulation of leukocyte function, also
observed in some in vitro studies, may facilitate anti-bacterial
effects of azithromycin. A continuous fall, in response to azithro-
mycin treatment, in chemokine and interleukin-6 serum concentra-
tions, within the non-pathological range, was accompanied by a
delayed down-regulation of the oxidative burst and an increase in
apoptosis of neutrophils up to 28 days after the last azithromycin
dose. Neutrophils isolated from blood at this time point still con-
tained detectable drug concentrations. This delayed, potentially
anti-inﬂammatory activity may curtail deleterious inﬂammation
during recovery from an infection. In a more recent study, using
the same azithromycin treatment schedule in patients with chronic
obstructive pulmonary disease, reductions in circulating leucocytes
and in acute phase proteins were found that would appear to sup-
port the potential for azithromycin to exert anti-inﬂammatory
effects.
S228 Macrolides and inﬂammation modulation in the
treatment of respiratory tract infections
G. Amsden
Cooperstown, USA
The use of macrolides either as monotherapy or in combination
with other agents for the treatment of hospitalised patients with
community-acquired pneumonia has consistently been associated
with decreased mortality, decreased lengths of hospital stay and
decreased overall costs. As these beneﬁts occur even when macro-
lides are co-administered with other agents with atypical cover-
age, such as ﬂuoroquinolones, it is likely that these beneﬁts are
secondary to a mechanism that is separate from their antibacterial
properties. As they have been demonstrated to have beneﬁcial
immunomodulatory effects in non-infectious chronic inﬂammatory
airway syndromes when dosed chronically, it is possible they
may produce similar beneﬁts when dosed for short periods of
time for respiratory tract infections as well. In fact ex vivo neutro-
phil research of healthy volunteers administered a standard 3-day
course of oral azithromycin have demonstrated a biphasic modu-
latory effect of azithromycin on inﬂammation. First azithromycin
causes an enhancement of neutrophil degranulation and oxygen
burst in response to particulate matter thereby enhancing the
endogenous host defense mechanisms. Once bacteria are no
longer present, azithromycin induces a curtailment of IL-8 pro-
duction and stimulates neutrophil apoptosis so that the body can
clear these apoptotic neutrophils without spilling their pro-inﬂam-
matory substances thereby suppressing any perpetuation of
inﬂammation and minimizing any secondary short- or long-term
morbidity. Additional in vitro and ex vivo data with other macro-
lides further support these ﬁndings as well as the beneﬁts that
they also have to offer. Although additional animal and human
studies are needed to validate these ﬁndings of the short-term
biphasic anti-inﬂammatory beneﬁts of the macrolides, these initial
data provide strong support for a non-antibacterial explanation
behind the mortality and length of stay beneﬁts demonstrated
with macrolide containing regimens for community-acquired
lower respiratory tract infections, including pneumonia.




Because the macrolide class of antimicrobials is active against key
pathogens associated with community respiratory tract infections
(RTIs), agents from this class are frequently included in recom-
mendations for treatment of these common infections: including
community-acquired pneumonia (CAP), sinusitis, and acute
exacerbation of chronic bronchitis. As they are active against the
‘atypical’ pathogens, they are particularly useful to treat CAP-
either as monotherapy for mild infections or as part of combina-
tion therapy with a beta-lactam for serious infections. Whereas
earlier macrolides have little activity against H. inﬂuenzae, clari-
thromycin and azithromycin are more active, with azithromycin
being most active. A prolonged T1/2 with convenient once-daily
dosing, high intra-tissue concentrations, and better tolerance (less
adverse effects) are signiﬁcant advantages of azithromycin com-
pared with earlier macrolides. Despite reports of increasing resis-
tance of S. pneumoniae to the macrolides in vitro, the number of
published clinical failures due to macrolide resistance appears to
be relatively few given the several millions of prescriptions writ-
ten yearly. Possible explanations include the increased accumula-
tion of the newer macrolides, such as azithromycin, into tissue
ﬂuids and macrophages. In addition, the immunomodulating
properties of the macrolides offer beneﬁcial effects concerning the
host response during RTIs. Numerous randomized clinical trials
as well as observational studies have documented the efﬁcacy and
safety of azithromycin in the treatment of RTIs. These studies will
be reviewed. The positioning of the macrolides in various guide-
lines for the management of RTIs differ in part related to the var-
iance in local epidemiology and the clinical relevance of
resistance. Presently, azithromycin is prominently recommended
in North American guidelines for many RTIs.
Toxoplasmosis in the immunocompromised host (Symposium arranged with ESGT)




Toxoplasmosis remains, in the immunocompromised host, a life-
threatening and quite frequent disease. To study this opportunistic
parasitic disease, two groups of immunocompromised hosts
should be deﬁned: AIDS patients with ‘classical’ cerebral toxoplas-
mosis, and patients with disseminated toxoplasmosis (AIDS or
haematological transplant patients). The epidemiology of cerebral
toxoplasmic reactivations in AIDS patients has been largely modi-
ﬁed by the use of HAART, while its diagnosis still relies mainly on
clinical feature, imaging and evolution under treatment. In
non-complicated cases, the use of biological tests (serology) is
39Clinical Microbiology and Infection, Volume 10, Supplement 3, 2004
useful only for the determination of the risk of reactivation, and
the search for the parasite in CSF is not of great help for the physi-
cian. The epidemiology of disseminated toxoplasmosis (different
from clearly deﬁned cerebral toxoplasmosis) is not clearly known.
In fact, data are mainly reported from small series or case report
whatever the kind of immunosuppression; AIDS or transplant
patients. The diagnosis of disseminated toxoplasmosis (reactivation
in the transplant recipient, or transmission through the graft) is
often difﬁcult due to the fact that the clinical signs are not speciﬁc.
Thus, in this case, biological methods are of paramount importance
to make the diagnosis. T. gondii can be detected in all sorts of biolo-
gical ﬂuids and biopsies, and the clinical value of such result must
be discussed. Several biological techniques can be used to make
such a diagnosis. If serological test are not always useful, the diag-
nosis relies on the direct detection of the parasite. This can be done
using in vivo and in vitro cultures (mouse inoculation and cell cul-
tures) and detection of parasitic DNA par PCR. This technique is,
to date, the most accurate to afﬁrm the presence of T. gondii in
blood, CSF, biopsies. However, the facts that no standardised PCR
kits for toxoplasmosis are available, and that the pathophysiology
is, to date, not completely understood, should lead to careful inter-
pretation of the biological results.




Objectives: Toxoplasma gondii is an intracellular protozoan parasite
causing clinical and latent infection in humans. The incidence var-
ies in different geographical locations depending on cultural
habits and climate. Humans are infected orally by oocysts
excreted from the host, the cat, contaminating the surroundings or
by the ingestion of cysts found in undercooked meat from ani-
mals. In immunocompetent individuals, T. gondii causes an
asymptomatic infection or fever and lymphadenopathy. In immu-
nocompromised patients, it may cause life-threatening infection.
Toxoplasmosis after bone marrow transplantation (BMT) is a rare
but serious and life-threatening condition. It is usually caused by
a reactivation of latent infection but can probably also be trans-
mitted by marrow or blood products. As the incidence is low a
centre will not be able to have enough experience to produce
updated guidelines on diagnostics or treatment but there is a need
for networks.
Methods: The ESCMID Study group on Toxoplasmosis (www.Esc
mid.org) and its aims is described. A review of the latest reports
is described together with a detailed description of a fatal case.
Results: The incidence of toxoplasmois in BMT is estimated to be
between 0.3 and 5%. The most frequently involved organs are the
central nervous system, lungs and the heart. The infection is dis-
seminated or isolated organs as the brain or the lungs are
affected. Postmortem diagnosis is reported to 53% and mortality
attributed to the infection was 66%.
Conclusions: Toxoplasma infection represents a rare but often fatal
complication in BMT recipients. It contributes however to post-
transplant morbidity and mortality in highly endemic areas. A
reduction in incidence and an improvement in outcome is accom-
plished by an increased knowledge which can only be gathered in
a network. We need better knowledge of the clincial signs and
symptoms as well as of treatment and prophylaxis. Also,
improved diagnostics by molecular techniques and quality control
of the assays are essential.
European recommendations for antibiotic resistance surveillance (Joint symposium arranged with
ESGARS)
S237 Recommendations for data analysis and presentation
G. Cornaglia, W. Hryniewicz, V. Jarlier, G. Kahlmeter,
H. Mittermayer, L. Stratchounski, F. Baquero and ESGARS
members
The problem of surveillance of bacterial resistance to antimicrobials
in Europe has been extensively debated in many documents issued
by National Committees and often assuming the value of National
Guidelines. However, a comprehensive document addressing the
whole matter of antimicrobial resistance surveillance from a Eur-
opean perspective, as well as reviewing its present status and draft-
ing future perspectives, is still lacking, thus ESGARS has
committed itself to producing a wide-acceptance document through
a consensus process involving all members of the Study Group.
This document focuses on the detection of bacterial resistance and
its reporting to clinicians, public health ofﬁcers and a wider – and
ever-increasing – audience. Reporting antimicrobial resistance is
considered necessary for selection of empirical therapy based on
local data, for assessing the scale of the resistance problem at local,
national or international level, for monitoring changes in resistance
rates, for detecting the emergence and spread of new resistances,
and for providing a measure of the effectiveness of any interven-
tions aimed at reducing resistance. It is essential that results be
reported as rapidly as possible to as wide an audience as is thought
appropriate, including all those involved in antimicrobial testing,
prescribing, supplying and auditing. A proper comparison of data
between wards, hospitals or geographical areas (at the local,
national and international levels) as well as over time is indispensa-
ble for analysing trends and emerging problems.
Treatment of invasive fungal infections
O244 Safety, tolerance and plasma concentrations of
voriconazole in immunocompromised paediatric patients
H. Kolve, Th. Lehrnbecher, K. Ehlert, M. Paulussen, S. Bielack,
J. Vormoor, T.J. Walsh, A.H. Groll
Munster, Frankfurt, D; Bethesda, USA
Objectives: Voriconazole (VCZ) is a novel triazole with broad anti-
fungal spectrum and documented clinical efﬁcacy. Little is known,
however, about its use in paediatric patients. We therefore ana-
lysed safety, tolerance, and plasma concentrations of VCZ in a
cohort of severely immunocompromised patients requiring VCZ
therapy.
Methods: The cohort included 37 immunocompromised children
and adolescents (2—20 years; mean: 12 years; 12 females and 25
males) with congenital immunodeﬁciencies (9), AIDS (4), haema-
tological malignancies (21; 14 allogeneic blood stem cell transplant
patients), or solid tumours (3) who received VCZ for possible (10)
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and probable/proven (14) invasive fungal infections, as primary
(4) or secondary (6) prophylaxis or as empirical antifungal ther-
apy (3). Following an intravenous loading dose of 2  6mg/kg on
day 1, VCZ was administered intravenously and/or orally at
dosages ranging from 2 to 8 mg/kg BID until occurrence of intol-
erance or maximum efﬁcacy.
Results: The 37 patients received VCZ for a mean duration of
174 days (range, 5–998 days). The mean maintenance dosage was
4.31 mg/kg (95% CI, 4.02–4.61 mg/kg). Grade I or II adverse
events were observed in 19 patients (51%); the most frequent
events included transient increases in hepatic transaminases (19)
and transient visual disturbances (5). Four patients (10%) experi-
enced grade III/IV adverse events [reversible increases in serum
transaminases (2); reversible increases in serum transaminases
and bilirubin (1); increased serum creatinine in a terminally ill
patient] and were permanently (3) or transiently (1) discontinued.
Mean concentrations of voriconazole in plasma at trough ranged
from 0.79 to 3.36 lg/mL without clear dose-dependency
(P ¼ 0.6456, ANOVA). Twelve of the 14 patients (86%) with prob-
able/proven and all 10 patients with possible infections
responded to treatment with VCZ or had stable disease. Twelve
of 13 patients who received VCZ as empirical antifungal therapy
or for primary or secondary prophylaxis completed therapy with-
out breakthrough infections.
Conclusion: Voriconazole displayed acceptable safety and tolerance
and had promising efﬁcacy in treatment and prevention of inva-
sive fungal infections in severely immunocompromised pediatric
patients.
O245 Voriconazole compared with a strategy of
amphotericin B followed by ﬂuconazole for treatment of
candidaemia in non-neutropenic patients
B.J. Kullberg, P. Pappas, M. Ruhnke, C. Viscoli, J.D. Cleary,
E. Rubinstein, L.W.P. Church, J.M. Brown, J.H. Rex, F. Hilton,
I. Oborska, M. Hodges, H.T. Schlamm, J. Sobel
Nijmegen, NL; Birmingham, USA; Berlin, D; Genoa, I; Jackson, USA;
Tel Hashomer, IL
Objectives: Voriconazole (VOR) is an azole antifungal agent with
good in vitro activity against most Candida spp. We conducted a
prospective, randomized, open-label trial comparing voriconazole
to a strategy of amphotericin B followed by ﬂuconazole (AMB/
FLU) for the primary treatment of candidemia in non-neutropenic
patients (pts).
Methods: We enrolled pts with 1 positive blood culture (BC) for
Candida with clinical evidence of infection. Pts were randomly
assigned in a 2:1 ratio to receive either VOR (6 mg/kg IV Q12H
x2 then 3 mg/kg Q12H) or AMB (0.7–1.0 mg/kg/day for 3–
7 days) followed by FLU (400 mg PO QD). All cases were
reviewed by an independent, blinded Data Review Committee
(DRC). The primary analysis of efﬁcacy compared the proportions
of pts surviving with a successful response to treatment, as
assessed by the DRC, at 12 weeks after end of treatment (EOT).
Results: Of the 422 pts enrolled, 370 had 1 BC for Candida within
96 h of entry and were included in the modiﬁed intention-to-treat
(MITT) analysis. Baseline characteristics were similar in the two
treatment groups: the mean APACHE II score was 13.8 for VOR
vs. 14.7 for AMB/FLU; the proportion with non-albicans Candida
was 60.5% for VOR vs. 50.0% for AMB/FLU. BC were still posi-
tive at baseline in 304 of 370 (82.2%), and pre-existing indwelling
catheters were removed within 3 days of study entry in 281 of
324 (86.6%). The median duration of study treatment was 15 days
in both groups: the median duration of AMB was 4 days. In the
primary analysis, the proportion with successful outcomes at
12 weeks was 40.72% for VOR and 40.70% for AMB/FLU (differ-
ence 0.04, 95% CI: 10.55 to 10.63, non-inferiority margin 15%).
In a secondary analysis, which compared the proportions of pts
with successful response at the latest relevant timepoint (EOT
or 2, 6 or 12 weeks after EOT), the efﬁcacy of VOR was 65.11%
compared with 71.33% for AMB/FLU. The median time to nega-
tive BC was 2 days in both groups. The Kaplan–Meier survival
rates at day 98 were 63.3% for VOR and 57.7% for AMB/FLU
(hazard ratio 0.82, 95% CI: 0.58–1.16). The adverse event (AE)
proﬁles were comparable, except for more renal AEs reported in
the AMB/FLU group.
Conclusion: Voriconazole is at least as effective as the strategy of
amphotericin B followed by ﬂuconazole for the primary treatment
of candidaemia, including non-albicans species, in non-neutrope-
nic patients.
O246 Regimens and outcomes of current approaches to
secondary prophylaxis after proven or probable invasive fungal
infections. A multinational case registry
O.A. Cornely, S. Reuter, J. Maertens, D. Arenz, J. Franz,
A.J. Ullmann, R. Martino, A. Bo¨hme, S. Cesaro, X. Schiel,
H. Auner, R. Chopra, A. Gratwohl, W. Jedrzejczak, M. Karthaus,
M.G. Kiehl, W. Kru¨ger, G. Maschmeyer, A. Nosari, G. Silling for
the ID Working Party of the German Society for Hematology and
Oncology
Objectives: Allogeneic bone marrow and stem cell transplantation
after invasive fungal infection (IFI) has become a feasible option
thanks to an expanding arsenal of antifungal agents. Secondary
prophylaxis after IFI is being practiced in a number of centres.
However, a synopsis of regimens used and of their efﬁcacy is
lacking. In this multicentre survey high risk patients with a his-
tory of recent proven or probable IFI were followed up for inci-
dence and type of breakthrough IFI during the subsequent
allogeneic transplantation.
Methods: We are conducting a survey on SP regimens currently in
use in 55 tertiary care centers in 12 countries. Inclusion criteria
are: leukaemia/lymphoma, proven/probable IFI according to
EORTC/BAMSG during the most recent neutropenic episode with
subsequent neutropenia to follow.
Results: Forty-six patients from 19 tertiary care centers in eight
European countries were included: prior proven IFI 21 (45.7%; 17
Aspergillus spp., two other ﬁlamentous, two yeast), prior probable
IFI 25 (54.3%; 23 lung, two liver/spleen involvement), 73.9%
acute myelogenous leukaemia, median age 38.5 years, range 11–
64, 50% female. Patients received secondary prophylaxis with
amphotericin B deoxycholate 6.5%, lipid-based 19.6%, ﬂuconazole
4.3%, itraconazole 41.3%, voriconazole 10.9%, caspofungin 10.9%
or no prophylactic medication 6.5%. Incidence of breakthrough
IFI were 26.1% overall, i.e. 6.5% proven (one Aspergillus spp., one
Fusarium sp.), 8.7% probable (three lung, one liver/spleen), and
10.9% possible (four lung, one liver). Rate of breakthrough IFI by
prophylactic antifungal were 1/3 amphotericin B deoxycholate, 1/
5 lipid-based, 6/19 itraconazole, 1/5 voriconazole, 0/2 ﬂucona-
zole, 2/5 caspofungin, and 0/3 without secondary prophylaxis.
Overall mortality was 32.6%, of these 33.3% were attributed to
IFI.
Conclusion: Incidence of breakthrough secondary IFI and attributa-
ble mortality are high in this population undergoing allogenic
bone marrow or stem cell transplantation. Controlled studies on
secondary prophylaxis are urgently warranted.
O247 Therapy with polyenes and echinocandins in a
model of cerebral aspergillosis
K.V. Clemons, M. Espiritu, R. Parmar, D.A. Stevens
San Jose, USA
Objectives: Central nervous system (CNS) aspergillosis is the most
deadly form of disseminated disease. A recently developed mur-
ine model enabled investigation of efﬁcacy of several agents.
Methods: Mice were immunosuppressed and made neutropenic
with cyclophosphamide, challenged intracerebrally with Aspergillus
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fumigatus conidia, and treated daily for 10 days, beginning 1-day
post-infection, with AmBisome (AmBi) IV or caspofungin (Cas) or
micafungin (Mcf) IP 1, 5, or 10 mg/kg; 1 or 10 mg/kg Abelcet
(ABLC) or maximum tolerated dose of 1 mg/kg amphotericin B
deoxycholate (AmBd) IV. Survivors were killed on day 14 and resi-
dual infection quantitated.
Results: All control mice died. All treatment regimens prolonged
survival, with >60% survival from all regimens except Cas 1 and
5 mg/kg and ABLC 1 mg/kg. Mcf 5 mg/kg was optimal and pro-
duced signiﬁcantly prolonged survival over ABLC. No regimen
cleared >1 mouse of brain infection. AmBi and ABLC were dose-
responsive, whereas the echinocandins were not. Only AmBi
10 mg/kg and ABLC 10 mg/kg signiﬁcantly (P < 0.001) reduced
brain infection. In this model, some dissemination to kidney
occurs. Only 10 mg/kg AmBi (P < 0.001) or ABLC (P < 0.01), and
Mcf 5 mg/kg and AmBd (both P < 0.05) signiﬁcantly reduced
renal CFU, and of 10 mice/group, 4, 1, 0, 1 mice were cleared,
respectively.
Conclusion: These data indicate the ability to give more amphoteri-
cin in lipid preparations produces an advantage in treating CNS
aspergillosis, suggesting a justiﬁcation for ﬁrst-line use for that
indication, and that the echinocandins prolong survival but do
not reduce fungal brain burden.
O248 Posaconazole for Fusarium infections: results of two
clinical studies
I. Raad, R. Hachem, R. Herbrecht, G. Corcoran
Houston, USA; Strasbourg, F; Kenilworth, USA
Objective: Fusarium is a genus of ubiquitous fungi that can cause
life-threatening disseminated infections in severely compromised
hosts. Despite the recent introduction of new antifungal agents,
the treatment of these severe disseminated infections remains par-
ticularly challenging. We describe the experience in the treatment
of these infections with posaconazole, a new oral broad-spectrum
triazole antifungal drug.
Methods: Participants in this analysis were patients who had pro-
ven or probable infections with Fusarium as a primary pathogen
and who were enrolled in two phase 2/3 open-label studies of
invasive fungal infections. All patients were treated with oral
posaconazole suspension 800 mg/day in divided doses. Complete
and partial responses at the end of therapy were considered suc-
cessful outcomes.
Results: Twenty-three patients were included in this analysis; 15
had refractory infections, and eight had non-refractory infections.
The patients ranged in age from 8 to 80 years. Most (70%; 16 of
23) had underlying haematologic malignancies, and seven of 16 of
these patients had undergone haematopoietic stem cell transplan-
tation. At study entry, 40% (nine of 23) of patients were neutrope-
nic and 17% (four of 23) had graft-vs.-host disease. Most (18)
patients were infected with unspeciated Fusarium, four had
F. solani, and one had F. proliferatum. The most common clinical
presentations were disseminated (11), skin (5), respiratory tract
(5), soft tissue (mycetoma; 1), and corneal infection (1). The overall
success rates were 48% (11 of 23) for all infections and 36% (four
of 11) for disseminated infections. Treatment duration ranged
from 1 to 365 days. The success rate was 40% (six of 15) in
patients with refractory infections and 62% (ﬁve of eight) in
patients with non-refractory infections. Posaconazole was well tol-
erated. The most common adverse events noted were nausea and
vomiting.
Conclusions: Oral posaconazole therapy resulted in successful out-
comes in 48% of patients, comparable with the success rates for
other approved salvage therapies and slightly better than the 30%
response rate reported for amphotericin B. This improved success
rate was achieved without many of the potential dose-limiting
toxicities of other antifungal therapies. Posaconazole is clearly
promising as an alternative to therapy with conventional antifun-
gal agents for this often fatal disease.
Sexually transmitted diseases
O249 Performance of the Aptima CTassay for Chlamydia
trachomatis and Aptima GC Assayfor Neisseria gonorrhoeae
using patient- and clinician-collected vaginal swabs
J. Schachter, M. Chernesky, D. Willis, P. Fine, E.W. Hook,
D.H. Martin, D. Fuller, J. Jordan, W. Janda
San Francisco, USA; Hamilton, CAN; Jacksonville, Houston,
Birmingham, New Orleans, Indianapolis, Pittsburgh, Chicago, USA
Objective(s): To assess the performance of Gen-Probe Incorpora-
ted’s APTIMA CT Assay (ACT) for Chlamydia trachomatis (CT)
and APTIMA GC Assay (AGC) for Neisseria gonorrhoeae (GC)
using patient- and clinician-collected vaginal swab (PVS and CVS)
specimens. ACT and AGC target rRNA sequences differ from
those of the commercially available APTIMA Combo 2 Assay
(AC2). The three assays use the same procedures.
Methods: Females are being enrolled at eight geographically
diverse, high and low prevalence sites. First catch urine (FCU),
one PVS, one CVS, and two endocervical swabs were collected
from each subject. ACT and AGC were done on PVS, CVS, FCU,
and one endocervical swab. AC2 was done on the same FCU and
endocervical swab tested by ACT and AGC. The second endocer-
vical swab and FCU were tested using BDProbeTec (Becton Dick-
inson and Company) for CT and GC. Subjects were considered
infected if two FDA-cleared tests on FCU or endocervical swab
were positive.
Results: Of 904 subjects enrolled, results are available for most.
There were 97 CT and 50 GC infected subjects (respective preva-
lences of 12.3 and 6.3%). ACT sensitivities and speciﬁcities were
96.9% (94 of 97) and 97.7% (674 of 690) for PVS and 96.9% (94 of
97) and 96.0% (675 of 703) for CVS. AGC sensitivities and speciﬁ-
cities were 98.0% (49 of 50) and 99.2% (748 of 754) for PVS and
98.0% (50 of 51) and 99.2% (757 of 763) for CVS. ACT vaginal
swab results were in >95% agreement with FCU and endocervical
swab results. With AGC, agreement was >98%. Further testing is
being performed to determine whether the false positives (FP) are
true positives (TP). Previous evaluations of ACT have found that
its exquisite sensitivity results in apparent FPs that are shown to
be TPs by repeat testing.
Conclusions: These interim ﬁndings demonstrate that ACT and
AGC using vaginal swabs are sensitive and speciﬁc for the detec-
tion of CT and GC, respectively.
O250 Molecular techniques in diagnostics of Chlamydiae –
beneﬁts and limits
E. Pavlı´k, A. Pavlı´kova´, J. Kremen, V. Husa´kova´, E. Procha´zkova´-
Francisci
Prague, CZ
Objectives: Chlamydiae are important human bacterial pathogens
with rather difﬁcult diagnostics because of intracellular part of
their growth cycle.
Implementing of molecular techniques provided chance to solve
the problem of routine diagnostics. But is it really so?
Methods: Our study performed on nearly 3500 different patients
samples compares following diagnostic techniques: culture on
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McCoy-cells + microscopy (Iodine and/or Giemsa staining, direct
immunoﬂuorescence microscopy (IF Chlamyset), hybridisation-
protection assay (GeneProbe) and two versions of PCR-tests
(Amplicor and COBAS Amplicor). Additionally, different sample
preparation protocols and two different methods for PCR-inhibi-
tors inactivation were compared. Culture and microscopy were
used as ‘gold-standard’.
Results: IF Chlamyset: Sensitivity 65.41%, Speciﬁcity 91.83%, PPV
79.64%, NPV 84.45%; HPA: Sen 79.55%, Sp 96.71%, PPV 92.41%,
NPV 90.37%; Amplicor v.1.1: Sen. 85.54%, Sp 96.08%, PPV
91.65%, NPV 92.95%; COBAS Amplicor CT/NG: Sen. 97.63%, Sp.
99.21%, PPV 98.27%, NPV 98.92%. Two freeze-thaw cycles inac-
tivated inhibitors in 77% of samples and harmed DNA in 2% of
samples only. With additional cycles dramatically rose damage of
target DNA.
Conclusions: PCR test Amplicor CT/NG provided best results vs.
gold-standard and may serve as new GS. (Culture vs. new GS
Sen.98.27%, Sp. 98.92%, PPV 97.63%, NPV 99.21%.) PCR-inhibi-
tors remain a problem in STD samples. Promising chance for total
removal of inhibitors may be hybridisation capture technique for
sample preparation.
O251 Clinical relevance of PCR tests for detection of
Treponema pallidum subsp. pallidum
J. Kremen, J. Stribrna´, E. Pavlı´k, M. Knappova´, H. Za´koucka´,
V. Kasta´nkova´, Z. Contofalska´
Prague, CZ; Kosice, SK
Objectives: Syphilis remains a very serious sexually transmitted
disease. The increase of incidence in the Czech republic and some
other European countries, one-third of which are recent infections
including vertical mother to fetus transmission, reminds us its
importance. This development returns diagnosis of syphilis back
to a daily practice and requires more speciﬁc, sensitive and objec-
tive methods accessible not only for specialists in venerology, but
also for other clinicians. On the contrary a very reliable and user-
friendly test is needed. Nucleic acid ampliﬁcation methods have
potential for detection treponemas in blood, cerebrospinal ﬂuid,
tissues and lesions.
Methods: Study shows effectivity of tests for different clinical
cases and biological materials. It compares speciﬁcity and sensi-
tivity of different PCR formats (DIG-labelled nucleotides and
anti-DIG ELISA or TaqMan and FRET PCR for LightCycler sys-
tem) for detection of polA(I) and 47kDa genes of Treponema
pallidum subsp. pallidum. Results are correlated to a clinical
stage and standard direct and indirect tests. T.p. strain Nichols
served as positive control, human lymphocytes DNA as nega-
tive control.We used Amplicor STD Specimen Collection Kit
(Roche) for lesions smears, Amplicor Whole Blood Specimen
Preparation Kit (HIV-1QC, Roche) for DNA isolation from
smears, whole blood, CSF specimens. An internal control based
on co-ampliﬁcation of beta-globin or beta-actin gene sequences
was added to avoid false negative results because of polymer-
ase inhibitors.
Results: Different specimens from 100 patients with clinically and
/or serologically veriﬁed diagnosis of syphilis were tested. Detec-
tion and ampliﬁcation systems for polA(I) gene were more effec-
tive than 47 kDa ones. Test sensitivity limit for whole blood was
5  101 T.p.cells/mL (PCR-ELISA format) and 1  101 T.p. cells/
mL (LightCycler systems).
Conclusion: PCR TaqMan or FRET probes used in LightCycler
were more sensitive than the other ones. The internal control is
essential for reliability of test, to avoid false negative results.
Method may facilitate diagnosis of syphilis (congenital, neurosy-
philis, early syphilis) and also help to recognise infectious risk in
a single case. Use in clinical practice demands well experienced
laboratory accustomed with clinical counselling.
Acknowledgements: Project supported by grant IGA NI6751-3/2001
(Ministry of Health, Czech Republic).
O252 Laboratory diagnosis of Trichomonas vaginalis with
culture, ELISA and (real-time) PCR
B. Mulder, M. Homaei, H. Wilke, R. Hendrix
Enschede, NL
Culture of T. vaginalis is actually considered the gold standard in
laboratory diagnosis. Sensitivity of culture might be negatively
inﬂuenced by reduced survival of Trichomonas during transporta-
tion. Diagnosis of Trichomonas by ELISA and PCR techniques do
not require the presence of viable parasites. We investigated
whether these techniques could provide an alternative for labora-
tory diagnosis of T. vaginalis by culture. 171 clinical samples were
cultured and tested by EIA for Trichomonas vaginalis. Culture
showed four positive samples (2.3%) while Trichomonas vaginalis
EIA found 12 positive results (7.0%), indicating a tripling of the
number of positive results. However, comparison with a conven-
tional PCR for T. vaginalis indicated that only ﬁve of the samples
were true positives. All four culture positive samples were con-
ﬁrmed by PCR while only three of 12 positive samples in the EIA
could be conﬁrmed. Using conventional PCR as gold standard,
the positive predictive values of culture and EIA were 100 and
27% respectively. A possible explanation for the low predictive
value of the EIA was found in further examination of eight EIA
positive samples with negative PCR. In seven of eight specimens
Candida albicans was cultured which might have caused false posi-
tive test results because of cross reactivity. The next step was to
investigate whether PCR could be a practical alternative for rou-
tine diagnosis of Trichomonas vaginalis. Conventional PCR was
time consuming and labour intensive. A 1-day protocol was
developed using automated DNA isolation and real-time PCR.
First six culture positive and 39 negative genital swabs showed
identical results in real time PCR. Subsequently, 182 urine sam-
ples, sent in for laboratory examination for Chlamydia, were tested
with this real-time PCR protocol. Only two samples showed a
positive result. We conclude that the tripling of positive results by
EIA compared with culture could not be conﬁrmed with conven-
tional PCR on T. vaginalis. Culture has good sensitivity and high
positive and negative predictive values. EIA has no additional
value compared with culture or PCR. The use of urine as diagnos-
tic specimen for T. vaginalis needs further evaluation. Prevalence
of Trichomonas in our patient population remains low and there-
fore there is a need for reliable sensitive diagnostic tools. Real
time PCR has been made available as a potentially useful alterna-
tive for routine diagnosis of Trichomonas vaginalis.
O253 Efﬁcacy of long-term suppressive therapy with
valacyclovir in recurrent genital herpes
S.V. Sekhin, V.M. Averchenkov, N.A. Petrochenkova,
N.Y. Melekhova, L.S. Stratchounski
Smolensk, RUS
Objectives: Recurrent genital herpes (RGH) has several treatment
options. One of them is chronic suppressive therapy with antiviral
compounds. Present study was performed to assess the efﬁcacy
and safety of long-term valacyclovir for RGH.
Methods: During 1999–2003 in Smolensk 42 patients of both sexes
aged 18–55 years with the history of RGH (duration 1–20 years;
four to nine recurrences/year) were in double-blind manner ran-
domly assigned for valacyclovir 500 mg (22 patients) or placebo
(20 patients) daily for 8 months. Thereafter all of them were given
open-label valacyclovir at the above dose for another 12 months.
Only HSV2+ve / HSV1+/–ve patients (serostatus was determined
with Western-Blot technique) were eligible for the study. During
the double-blind phase every recurrence was treated with valacy-
clovir 500 mg twice daily for 5 days. On the contrary, none of the
patients received episodic treatment but chronic suppressive ther-
apy during open-label phase.
Results: During the double-blind phase statistically signiﬁcant
recurrences frequency reduction in comparison with disease
history was registered in both treatment arms (P < 0.05). How-
ever, while analysing individual cases this was observed in all
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‘valacyclovir’ group patients but only in 75% of ‘placebo’ group.
Similarly, absence of clinical episodes of GH was documented in
68.2 and 40% of patients, respectively. Patients from ‘placebo’
group experienced signiﬁcantly more frequent recurrences than
ones from ‘valacyclovir’ group (P < 0.05). Overall recurrences rate
in former group was 4.8 times higher comparing to active treat-
ment. Further continuation of suppressive therapy up to
20 months has not given any advantages to 8-month treatment in
terms of decreasing GH recurrence rate. The nature and frequency
of adverse events for valacyclovir and placebo were similar.
Conclusion: Daily suppressive therapy with valacyclovir 500 mg is
a highly effective method for prophylaxis of recurrent genital
herpes though it does not eradicate all recurrences. Prolongation
of such therapy from 8 to 20 months does not decrease recurrence
rate any further.
Pharmacokinetics and pharmacodynamics
O254 Plasma and intrapulmonary concentrations of
oritavancin and vancomycin in normal healthy adults
K.A. Rodvold, M.H. Gotfried, J.S. Loutit, S.B. Porter
Chicago, Phoenix, Brisbane, USA
Background: Oritavancin is a semisynthetic glycopeptide with bac-
tericidal activity against Gram-positive pathogens, including resis-
tant pulmonary pathogens such as methicillin-resistant
Staphylococcus aureus and drug-resistant Streptococcus pneumoniae.
Objective: We compared the concentrations of oritavancin and
vancomycin in plasma (P), epithelial lining ﬂuid (ELF) and alveo-
lar macrophages (AM) in adults who underwent bronchoscopy
and bronchoalveolar lavage (BAL).
Methods: Thirty nonsmoking adults (age: 20–54 years; 12 males, 18
females) were randomised to receive intravenous oritavancin
800 mg once-daily for ﬁve doses (n ¼ 20) or vancomycin 1000 mg
q12h for nine doses (n ¼ 10). Serial P drug samples were collected
up to 504 (oritavancin) and 24 h (vancomycin) after the last dose.
Each subject had a single bronchoscopy and BAL following the
last dose at 4, 12, 24 or 168 h (oritavancin) and 4 or 12 h (vanco-
mycin) (ﬁve subjects per sampling time).
Results: Mean  SD concentrations (lg/mL) in P, ELF and AM
are presented in the Table. Both drugs (oritavancin vs. vancomy-
cin) displayed multiexponential decline in P with a mean Cmax
of 183.7 vs. 49.4 lg/mL and AUC0–24 of 2310 vs. 367 lg	h/mL.
Using mean intrapulmonary concentrations, the AUC0–24 in ELF
were 106 vs. 92 lg	h/mL and 3297 vs. 926 lg	h/mL in AM.
Conclusions: Oritavancin is slowly distributed into and out of the
ELF and AM. The ELF concentrations of oritavancin and vanco-
mycin were similar in magnitude. Oritavancin was more concen-
trated in macrophages of the lung compared with vancomycin.
The intrapulmonary concentrations lend support to the potential
effectiveness of oritavancin 800 mg once-daily for the treatment of
susceptible Gram-positive pathogens associated with lower
respiratory tract infections.
O255 Should we routinely monitor b-lactam serum
concentrations during the treatment of endocarditis?
P. Tattevin, O. Tribut, C. Arvieux, M. Dupont, R. Flicoteaux,
G. Le´veiller, Y. Le Tulzo, C. Michelet
Rennes, F
Objectives: Because of pharmacokinetics and pharmacodynamics
concerns, high dosages of b-Lactam (BL) are used for the treat-
ment of endocarditis. Guidelines do not take into account many
factors related to the host, and they have not signiﬁcantly chan-
ged during the last four decades although the population of
patients with endocarditis has dramatically changed with a
mean age of 35 years in 1940 and 60 years in 2000. BL are con-
sidered as drugs with few dose-related side-effects. However,
very high serum concentrations could be toxic on central ner-
vous system, especially in elderly patients. The aim of this
study was to evaluate the range of BL trough serum concentra-
tions obtained when the guidelines on the treatment of endocar-
ditis are applied.
Methods: We performed a retrospective study of all patients with
documented bacterial endocarditis-treated according to the guide-
lines for whom BL trough serum concentrations were measured at
the request of the physician because of tolerance or efﬁcacy con-
cerns in our department from 2000 to 2002. The concentrations
were determined by high-performance liquid chromatography
(HPLC).
Results: Fifteen patients were studied (12 males). Mean age was
62 years (22–79). The bacteria isolated in blood cultures included
organisms of the genera Streptococcus (n ¼ 5), Enterococcus fecalis
(n ¼ 5), Staphylococcus aureus (n ¼ 4) and Klebsiella oxytoca
(n ¼ 1). MIC of the BL used was determined in 10 cases and
was always between 0.05 and 0.4 mg/L. Amoxicillin trough
serum concentrations were determined 11 times, in nine patients.
The mean value was 86.8 mg/L (range: 30–212), and trough con-
centrations were above 1000 times the MIC in ﬁve cases. Cloxa-
cillin trough serum concentrations were determined in three
patients. The mean value was 47.9 mg/L (range: 16.7–104). For
nine patients, BL serum concentrations were measured because
dose-related intolerance was suspected, including renal failure
(n ¼ 8), and/or confusion (n ¼ 3): In seven of these patients, BL
trough serum concentrations were >40 mg/L and led to a reduc-
tion in BL dosage with a subsequent improvement of renal func-
tion and/or mental status.
Conclusion: Following the guidelines for the treatment of endo-
carditis, we observed high and unpredicted values of trough
serum concentrations of BL. The development of HPLC could
offer an opportunity to monitor BL serum concentrations and
would allow individualised rather than standardised treatment
for endocarditis.
O256 Utility of the 750 mg dose of levoﬂoxacin against
Streptococcus pneumoniae as assessed by Monte Carlo
simulation and expectation over a large MIC distribution
G. Drusano, E. Grant
Albany, Raritan, USA
Objectives: Levoﬂoxacin has recently been approved for short
course therapy of community-acquired pneumonia at a dose of
750 mg. Given the results of a recent surveillance study of 4452
strains of Streptococcus pneumoniae (TRUST VII data set), we
wished to determine how well the 750 mg dose attained the tar-
get-free drug AUC/MIC ratio of 30, associated with a good micro-
biological outcome, as described by Ambrose.
Methods: The population pharmacokinetic parameters derived
from a study of 272 patients treated with levoﬂoxacin for
4-h 12-h 24-h 168-h
P Oritavancin 119:6 24:6 75:7 16:3 73:7 28:2 10:4 3:0
ELF Oritavancin 3:1 1:1 3:7 2:5 6:3 1:5 1:7 0:8
AM Oritavancin 121:0 69:1 113:1 49:7 179:4 76:7 557:9 481:6
P Vancomycin 19:8 3:7 5:1 1:7
ELF Vancomycin 5:3 1:5 2:4 0:7
AM Vancomycin 32:0 8:5 45:2 23:3
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community-acquired infections were used to generate a 10 000
subject Monte Carlo simulation. The ADAPT II package of pro-
grammes of D’Argenio and Schumitzky was employed for genera-
tion of this Monte Carlo simulation. Both normal and log-normal
distributions were evaluated. An expectation was taken over the
entire distribution of pneumococcal levoﬂoxacin MICs from
TRUST VII to generate a population target attainment rate
accounting for both pharmacokinetic and MIC variability.
Results: The 4452 strains of S. pneumoniae had levoﬂoxacin MIC
values distributed such that 1% were <0.25 mg/L; 32.3% were at
0.5 mg/L; 64.7% were at 1.0 mg/L; 0.7% were at 2.0 mg/L; 1%
were >2.0 mg/L. The log-normal distribution recreated the para-
meter values and dispersions with greater ﬁdelity and was
employed. The target attainment rate for a free drug AUC/MIC
ratio of 30 was 95.2% at 1.0 mg/L. Other, lower MICs were
>99.9% in target attainment. The population target attainment,
accounting for the variability in pharmacokinetics (10 000 subject
Monte Carlo simulation) and variability in MIC for S. pneumoniae
(4452 strains) was 95.6%.
Conclusion: The 750 mg dose of levoﬂoxacin provides an excellent
population target attainment rate, providing a high probability
(95.6%) of developing a free drug AUC/MIC ratio of 30, concor-
dant with the clinical and microbiological effects seen in clinical
trials.
O257 Use of pharmacodynamics and Monte Carlo
simulations to predict clinical cure of Pseudomonas aeruginosa
infection
S. Valot, M. Etienne, D. Croisier, L. Piroth, H. Portier, P. Chavanet
Dijon, F
Objectives: Pharmacodynamics (PD) indices such as Peak/MIC
(QImax), time above MIC (T > MIC), and AUC24/MIC have been
linked to clinical outcome for numerous antibiotics. The use of
pharmacokinetic (PK) models allows optimising both the dose
and interval of drug at its MIC to obtain the threshold value of
the PD indices. Our objective was to evaluate the frequency with
which the major antibiotics used to treat Pseudomonas aeruginosa
infections attained PD index targets.
Methods: Three hundred and nine strains of P. aeruginosa were col-
lected from patients hospitalised in 2003. MICs were determined
according to CA-SFM standards. Plasma concentrations were cal-
culated using a compartmental PK model based on published PK
data. They were adapted on renal function of each patient. MICs
distribution (susceptible strains) and patient-speciﬁc data includ-
ing calculated creatinine clearance (Cockroft), age, gender and
body weight were used to conduct Monte Carlo simulations of
5000 patients. The evaluated treatments were ceftazidime (CAZ;
1 g tid, 2 g tid, 4 g continuous infusion), imipenem (IMP; 1 g tid),
piperacillin + tazobactam (TZP; 4 g tid), amikacin (AKN; 15 mg/
kg od), and ciproﬂoxacin (CIP; 400 mg IV tid). The forecasts were
focused on a Qimax > 10 for aminoglycosides and ﬂuoroquino-
lones, T > CMI > 70% for beta-lactams, and AUC24/MIC > 125
for all classes of antibiotics.
Results: A 6% of the strains were I/R for AKN, 7% for TZP,
14% for CAZ, 31% for IPM and 27% for CIP. The values of
the PK parameters obtained with the model we used were
identical to those reported in the literature. The frequency with
which the ﬁxed threshold was attained exceeded 95% for beta-
lactams. It was 73% for CIP, and the percentage fell to 41%
with AKN, even when an individualised and adapted adminis-
tration’s interval was used. Frequencies of PD success with anti-
biotics schemes evaluated were <5% when testing P. aeruginosa
I/R strains, except with CAZ 2 g tid (23%) or 4 g continuous
infusion (42%).
Conclusions: When using Monte Carlo simulation modelling, beta-
lactams generate high frequencies of PD success on infections
caused by P. aeruginosa susceptible strains and sometimes by I/R
strains when using CAZ. Similar PD success is not available for
AKN or CIP. These results can explain the high frequency of in
vivo resistant mutants and suggest that higher doses and/or com-
bination therapy may be necessary to achieve optimal PD indices
when using aminoglycosides or ﬂuoroquinolones.
O258 Development of a pharmacokinetic/
pharmacodynamic model to characterise the in vitro activity and
dose–response relationships of daptomycin and linezolid
against vancomycin-resistant enterococci (VRE) using
subpopulation analysis
S. Bajic, B.M. Booker, P. Kelchlin, A. Forrest, P.F. Smith
Buffalo, USA
Background: In vitro and animal PK/PD infection models are pre-
dictive of drug response in patients. Our purpose was to develop
a mathematical PK/PD model for time-kill experiments, account-
ing for bacterial subpopulations, which could be adapted to
in vitro and animal PK/PD infection models to improve transla-
tional PK/PD research between these experimental systems.
Methods: Time-kill experiments were performed according to
NCCLS standards against six clinical bloodstream VRE isolates
with LZD and DAP at concentrations of 0, 0.5, 1, 2, 5 and 10x
MIC. Bacterial counts (CFU/mL) determined at 0, 1, 2, 4, 6 and
24 h. Candidate PK/PD models were ﬁt to the time course of bac-
terial counts (ML, ADAPT II); model discrimination by Akaike’s
Information Criterion. Final PK/PD parameters were determined
by MAP-Bayesian estimation.
Results: DAP demonstrated bactericidal activity against all isolates
(>3 log kill at 24 h), while LZD was bacteriostatic. A mixture
model of three bacterial subpopulations with varying drug sus-
ceptibilities best ﬁt the data for both drugs. The ﬁnal PK/PD
model includes a capacity-limited bacterial growth function (para-
meters Vgmax, CFUm: the maximum bacterial growth rate and
number of bacteria at which growth is half-maximal), and 1st-
order bacterial death rate constant (Kd); and drug may either
enhance bacterial kill or inhibit growth through a Hill-type func-
tion (H, Hill’s constant; SITms, SITmi, SITmr are the relative concen-
trations of drug where drug effect is half-maximal for the most
‘sensitive’, ‘intermediate’, and most ‘resistant’ subpopulations,
respectively). The relative % of the total bacterial inoculum for
each subpopulation (%S, %I, %R) and each organism was deter-
mined by model ﬁtting of the initial conditions. The ﬁt of the
model to the data was excellent, with an overall r2 ¼ 0.96. A sum-
mary of PK/PD parameters (mean, CV%) for all organisms is pre-
sented in the table below.
Conclusions: Daptomycin demonstrated signiﬁcantly greater kill
against clinical isolates of VRE compared with linezolid, and
the model predicted more variability in subpopulations. The
time courses of kill curve experiments for both bactericidal and
bacteriostatic antibiotics were well characterised by a PK/PD
model incorporating bacterial subpopulations of varying drug
susceptibilities. This approach to PK/PD modelling of static in
vitro data of a concentration range over time may aid in trans-













(mg/L) %S (%) %I (%) %R (%)
DAP 2:6 108ð98Þ 8:1 107ð56Þ 0.21(22) 2.0(9.8) 0.37(11) 0.74(7.6) 3.8(16) 3.5(34) 95.2(14) 0.7(116)
LZD 9:6 107ð39Þ 6:7 107ð68Þ 0.16(14) 2.1(4.2) 0.46(17) 1.02(35) 3.7(16) 0.001(24) 99.7(0.001) 0.28(12)
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Group A streptococcal disease in the 21st century
S263 Strep-EURO project: progress report
A. Jasir – Strep-EURO Study Group
To improve understanding of the epidemiology of severe group A
streptococcal (GAS) disease in Europe and achieve an integrated
picture of these infections, Strep-EURO project started September
2002. A European case deﬁnition for severe invasive GAS disease
was agreed upon amongst all Strep-EURO participating countries.
The deﬁnition of the 1993 Working group recommendations for
classiﬁcation of streptococcal infections was used in order to trace
patients with severe invasive infections and to obtain the corre-
sponding GAS isolates. In order to obtain nationwide coverage,
information on the project was given to infectious control units,
relevant hospitals and microbiological laboratories. A clinical
questionnaire containing background identiﬁcation data, possible
predisposing factors, portal of entry of infection, epidemiological
risk factors, source of isolate, clinical condition, complications and
outcome, was used for reporting of each case. Questionnaires
were translated in each respective country. Enhanced surveillance
of GAS invasive disease commenced in all participating countries
from 1 January 2003 for a 2-year period. A total of 1753 invasive
GAS isolates were collected during the ﬁrst 6 months. These
strains were subjected to various investigations. Molecular meth-
ods for typing and clonal identiﬁcation of clinical isolates were
used. Strains were also analysed for antibiotic susceptibility, and
resistance determinants. Furthermore, pathogenic aspects of
severe GAS disease, such as proteolytic activation of the contact
system, and selected virulence factors, such as surface proteins
and superantigens, were investigated. A new Strep-EURO website
was constructed and updated regularly. The website is linked
with other, relevant websites and contains both an ‘intra-net’ site
accessible to those persons participating within the project, and an
‘extra-net’ site for general public. A database for severe GAS
infections was established. Clinical and laboratory information
related to each case will be registered from the questionnaire into
local databases, which have been constructed in a standardised
way in order to be conveniently entered into the main database.
The database ﬁles are available on the Strep-EURO website. Strep-
EURO has now created a European network for epidemiological
analysis and surveillance of severe streptococcal disease in 11 EU
and Associated Countries.
S264 Severe group A streptococcal infections in Europe:
microbiological and epidemiological aspects
A. Efstratiou, M. Monnickendam, T. Lamagni, A. Charlett, S. Neal,
R.C. George on behalf of Strep-EURO Study Group
Streptococcus pyogenes (Lanceﬁeld group A streptococcus, GAS)
causes a wide range of invasive diseases, including bacteraemia,
necrotising fasciitis, streptococcal toxic shock syndrome (STSS)
and pneumonia. In spring 1994, a cluster of cases of necrotising
fasciitis in an area of England attracted global media interest.
Many countries, particularly in Europe, reassessed their surveil-
lance strategies for severe GAS infections. Enhanced surveillance
of invasive GAS disease was carried out in England and Wales
from mid-1994 to mid-1997. The United Kingdom Reference
Laboratory received isolates from 1913 cases. Rates of disease var-
ied with age from 0.84 per 100 000 populations in males and 1.0
in females aged 0–10 years to 7.7 in males and 5.1 in females aged
over 80 years. The median age of all cases was 57 years and of
fatal cases was 71 years. The overall mortality rate was 27%, and
the highest rates occurred in the oldest age groups. Most cases
presented with bacteraemia (76%); other presentations included
STSS (9%), septic arthritis (8%), necrotising fasciitis (6%) and
pneumonia (5%). One-ﬁfth of cases were admitted to intensive
therapy units. The most commonly reported predisposing factors
were skin lesions (38%), a third of which were reported to be due
to trauma, and 11% of cases were reported to be immunocompro-
mised. A total of 13 clusters (two or more linked cases of invasive
GAS infection) were identiﬁed. The predominant GAS serotypes
were M1 (30% of cases and 41% of deaths), M3 (10% and 14%)
and type 28 (10 and 7%). The second period of enhanced surveil-
lance was established under the auspices of the strep-EURO pro-
gramme from January 2002 for 2 years. Preliminary data suggest
that the incidence of severe disease in the UK is considerably
higher than previously reported. In 2002, more than 1500 cases of
invasive GAS disease were reported in the UK; an overall inci-
dence of 2.0 per 100 000 populations. The overall mortality rate
and the distribution of clinical presentations was similar to those
observed in previously. There were differences in the distribution
of serotypes, with the emergence of higher M types.
S265 Multilocus sequence typing of group A streptococci
in invasive infections
P. Kriz, L. Strakova
Prague, CZ
The WHO Collaborating Center for Reference and Research on
Streptococci in Prague participates in the EU project Strep-EURO.
One of the working packages includes implementation of active
surveillance of severe infections caused by group A streptococci
(GAS) and investigation of GAS isolates. All strains isolated
within this surveillance are typed in our laboratory by classical
methods and a sequencing method, emm typing. In addition, we
have decided to use multiloci sequence typing (MLST) for clonal
analysis of GAS isolated in active surveillance in the ﬁrst
6 months of the year 2003. DNA was extracted as described at
emm website (http://www.cdc.gov/ncidod/biotech/strep/proto-
cols.htm). Internal fragments of seven housekeeping genes (gki,
gtr, murI, mutS, recP, xpt, yqiL) were ampliﬁed. Puriﬁcation of
DNA fragments was done using enzyme ExoSAP-IT (Amersham-
Pharmacia). Sequencing on both strands of each gene was per-
formed and ﬁnal trimmed sequences were submitted to the
MLST-strep database (http://spyogenes.mlst.net) to obtain allelic
proﬁle and to assign a sequence type (ST). Our invasive GAS (29
isolates) mostly belonged to emm type 1, followed by emm66,
emm81 and surprisingly emm108. Some of the emm 1 isolates
were identiﬁed as ST 28. At the time of writing this abstract,
MLST was not yet ﬁnished for all isolates? however, we have
found the same correlation between emm types and STs as
described by other authors. We believe that MLST is very useful
for the investigation of clonality of GAS isolates. Further study of
isolates from severe infections, carriers and/or pharyngitis would
allow identiﬁcation of hypervirulent complexes using MLST.
This study was supported by research grant EU Strep-EURO
Contract no. QLRT-2001-01398 and made use of the Multi Locus
Sequence Typing website (http://spyogenes.mlst.net).
S266 Pathogenic aspects on severe group A streptococcal
infections
C. Schale´n – Strep-EURO Study Group
Severe infections caused by group A streptococci (GAS) include a
toxic shock syndrome (TSS) and necrotising fasciitis (NF), both
implying high mortality rates, but also less fulminant disease such
as septicaemia, erysipelas, cellulitis, endometritis and pneumonia.
The majority of GAS infections, like pharyngotonsillitis and
impetigo, however, are superﬁcially located. Virulence properties
speciﬁc for invasive GAS strains have not been identiﬁed but a
variety of new mechanisms of possible role for acute manifesta-
tions have been characterised. As well recognised, massive activa-
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tion of T cells by GAS superantigens, with release of proinﬂam-
matory cytokines, may elicit severe clinical symptoms. Activation
of the contact and complement systems by GAS may be of great
signiﬁcance by induction of shock and tissue damage. Cleavage of
plasminogen by streptokinase to proteolytically active plasmin
may play an important role in soft tissue infections. Out of more
than 150 known M-types, only a minority, such as types 1, 3, 12
and 28, seem to be regularly involved in TSS and NF, indicating a
crucial role in this context of M protein or other type-variable fac-
tors. Together with the hyaluronate capsule, the M proteins are
believed to promote evasion of phagocytosis, allowing for rapid
growth of GAS in fresh human blood. Interactions of M proteins
with plasma proteins are of special interest, as deposition of opso-
nic C3b on the bacterial surface seems to be prevented by the
binding to GAS of complement regulators C4BP and factor H
(FHL-1) and as well ﬁbrinogen. The nonimmune binding of IgA
Fc by GAS, occurring in many strains, may serve to block inges-
tion of the bacteria through phagocytic IgA receptors. Further-
more, direct binding of IgG Fc to the bacteria can interfere with
antibody-mediated opsonisation of GAS, as may also speciﬁc clea-
vage of the IgG molecule by some GAS enzymes. Cleavage of che-
motactic C5a, shown by all GAS strains, is another example of
interference of GAS with host defence systems. In contrast to
increased knowledge about immediate mechanisms, the patho-
genic events leading to the major nonsuppurative complications
of GAS disease, acute rheumatic fever and poststreptococcal glo-
merulonephritis, remain elusive. However, enhanced understand-
ing of virulence mechanisms is now providing a broadened basis
for design of immunoprophylaxis and new therapies against this
important pathogen.
Susceptibility testing and its role in therapy and epidemiology (Symposium arranged with
EUCAST)
S273 Antimicrobial resistance frequencies using EUCAST
epidemiological cut-off values compared with national
breakpoints when applied to the EARSS database
G. Kahlmeter, N. Bruinsma on behalf of EUCAST (ESCMID) and
EARSS (The Netherlands)
Objectives: European Committee on Antimicrobial Susceptibility
Testing (EUCAST) is harmonising European breakpoints and
deﬁning epidemiological cut-off values (JAC 52: 145–148, 2003).
European national breakpoint committees in (BSAC, CA-SFM,
CRG, DIN, NWGA, SRGA) have determined breakpoints for dec-
ades. To complicate the situation further, most European labora-
tories use recommendations from NCCLS (USA), and breakpoints
often differ quite substantially between guidelines. Nevertheless
they are used for both clinical and surveillance purposes. This talk
presents the theoretical impact on resistance rates of using the dif-
ferent guidelines for surveillance.
Methods: Of the total number of routinely collected antibiotic sus-
ceptibility test (AST) results for invasive S. aureus, S. pneumoniae,
and E. coli in the EARSS database (n ¼ 103 472), the available
MICs (n ¼ 18 938) for different drug–bug combinations were rein-
terpreted according to the different national guidelines and the
EUCAST epidemiological cut-off values.
Results: In a number of instances the world is already agreed on
how to differentiate between susceptible and resistant bacteria;
MRSA, penicillin-nonsusceptible S. pneumoniae; vancomycin resis-
tance in Enterococcus species. In other instances, variations may be
substantial but resistance is uncommon or clear-cut with unequi-
vocal changes in MIC. However, in some instances the quantita-
tion of resistance is severely affected by the choice of breakpoint –
the range of resistance frequencies obtained with the breakpoints
from the various committees are given and in parenthesis the rate
obtained with the tentative EUCAST epidemiological cut-off value
(ECOFF); E. coli vs. gentamicin 1.9–14.3% (ECOFF: 5.5%), vs. cefo-
taxime 0.6–2.6% (ECOFF 5%), vs. ciproﬂoxacin 3.9–8.3% (ECOFF
12.7%); S. pneumoniae vs. erythromycin 16–24.1% (ECOFF 24.1%);
S. aureus vs. ciproﬂoxacin 7.2–12.4% (ECOFF 12.4%) and vs. ery-
thromycin 2.9–8.3% (ECOFF 8.3%).
Conclusions: Many breakpoint differences had marginal effects on
epidemiological resistance rate estimates. In other instances the
choice of breakpoint affected the rate substantially. The discrepan-
cies encourage a European harmonisation of breakpoints and the
introduction of common epidemiological cut-off values for the
comparison of resistance rates.
Antibiotic resistance mechanisms
O275 Diversity and evolution of class A chromosomal
beta-lactamase genes in Klebsiella pneumoniae
S. Haeggman, S. Lo¨fdahl, A. Paauw, J. Verhoef, S. Brisse
Solna, S; Netherlands, Utrecht, NL; Paris, F
Objectives: To investigate the diversity of the class A chromosomal
beta-lactamase gene (bla) in Klebsiella pneumoniae, in order to study
the evolution of this gene, and to determine whether bla
co-evolves with housekeeping genes.
Methods: Nucleotide sequencing of bla and the housekeeping
genes gyrA, coding for subunit A of gyrase, and mdh, coding for
malate dehydrogenase, was performed on a panel of 28 K. pneu-
moniae strains. The strains were representatives (i) of three phylo-
genetic groups, KpI, KpII and KpIII, recently identiﬁed, and (ii)
having different chromosomal beta-lactamase variants previously
identiﬁed. Isoelectric focusing of the beta-lactamases was per-
formed on cell-free sonicates. Susceptibility testing was performed
using E-tests.
Results: Three groups of bla sequences were found; two of them
included variants of SHV (pI 7.6) and LEN (pI 7.1), respectively.
One new SHV variant and seven new LEN variants were identi-
ﬁed. The third group, more heterogeneous, included four other
bla variants. These variants formed two subgroups, one with pIs
7.8 and 8.1, and the other with pIs 6.5 and 7.0. Susceptibility to
ampicillin, cefuroxime, cefotaxime, ceftazidime and aztreonam,
and inhibition by clavulanic acid were similar in the three
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groups. The phylogenies based on bla, gyrA and mdh sequences
revealed a parallel evolution for the three genes. The group
comprising SHV-type bla sequences included all strains belong-
ing to the phylogenetic group KpI. The LEN-type bla sequences
were all from KpIII strains. The third group comprised bla
sequences from all KpII strains. The correspondence between bla
sequences and phylogenetic groups was fully conﬁrmed on 34
additional strains in PCR assays that were developed to be spe-
ciﬁc for the three bla groups. Based on the levels of synonymous
substitution, we estimated the time since divergence of the K.
pneumoniae phylogenetic groups to range between 6 and 28 mil-
lion years.
Conclusion: Our results demonstrate a high diversity of the chro-
mosomal class A beta-lactamase gene in K. pneumoniae, and a co-
evolution of this gene and the housekeeping genes gyrA and mdh.
In addition, they show that this beta-lactamase gene was anciently
present in the genome of K. pneumoniae, and that the beta-lacta-
mases SHV and LEN correspond to the native beta-lactamases of
phylogenetic groups KpI and KpIII, respectively.
O276 Resistance to beta-lactam antibiotics in
Staphylococcus aureus
C. Fuda, S. Mobashery
Notre Dame, USA
Objective: Emergence of bacterial strains designated as methicillin-
resistant Staphylococcus aureus (MRSA) from 1960s to the present
has created a state of crisis for nosocominal infections worldwide.
The gene product of mecA is a penicillin-binding protein (PBP)
designated PBP2a. Staphylococcus aureus normally produces four
PBPs, enzymes that are anchored on the bacterial cytoplasmic
membrane, whose functions are the assembly and regulation of the
latter stages of the cell wall biosynthesis. Whereas these four PBPs
are susceptible to modiﬁcation by b-lactam antibiotics, an event
that leads to bacterial death, PBP2a is refractory to the action of all
b-lactam antibiotics. Furthermore, PBP2a is capable of taking over
the functions of the four typical PBPs of S. aureus in the face of the
challenge by b-lactam antibiotics. We studied the basis for resis-
tance of this protein to inhibition by b-lactam antibiotics.
Methods: The mecA gene was cloned and expressed in E. coli, and
PBP2a was puriﬁed to homogeneity for biochemical analyses.
Results: The kinetic parameters for interactions of several b-lactam
antibiotics (penicillins, cephalosporins and a carbapenem) and
PBP2a were evaluated. The enzyme manifests resistance to modi-
ﬁcation by b-lactam antibiotics at the active-site serine residue in
two ways. First, the microscopic rate constant for acylation (k2) is
attenuated by 3–4 orders of magnitude over the corresponding
determinations for penicillin-sensitive PBPs. Secondly, the enzyme
shows elevated dissociation constants (Kd) for the preacylation
complexes with the antibiotics, the formation of which ultimately
would lead to enzyme acylation. The two factors working in con-
cert effectively prevent enzyme modiﬁcation by the antibiotics in
vivo, giving rise to drug resistance. The enzyme undergoes a dra-
matic conformational change in the course of these events in in
vitro experiments, which should be critical for the biological func-
tion of the protein.
Conclusions: The recent emergence of variants of MRSA resistant
to oxazolidinone and glycopeptide antibiotics has created a situa-
tion that certain strains of S. aureus are either treatable only with
a single class of antibiotics or are simply not treatable, which is a
disconcerting situation clinically. These studies provide the ﬁrst
mechanistic details for this critical enzyme, presenting opportu-
nities in antibiotic design.
O277 Analysis of the ﬂexible loop of the SPM-1 metallo-
beta-lactamase in substrate binding and hydrolysis
T. Murphy, J. Spencer, A. Simm, R. Jones, T. Walsh
Bristol, UK; North Liberty, USA
Objectives: Molecular modelling of SPM-1 showed that it has a
very similar structure to IMP-1, differing primarily in the ﬂexible
24 amino acid loop unique to SPM-1. SPM-1 and IMP-1 show very
different kinetics, indicating a hydrolytic role for the loop.
Accordingly, the loop was deleted and substrate binding and
hydrolysis and zinc content were compared with wild-type SPM-1
(wtSPM-1).
Methods: The 24 amino acid loop was deleted from SPM-1 (SPM-
Ldel) by PCR overlapping primer extension techniques and con-
ﬁrmed by sequencing. The PCR product was over-expressed in
Escherichia coli and conﬁrmed by PCR using SPM-1-speciﬁc pri-
mers. RT-PCR was used to verify gene expression. SPM-Ldel was
puriﬁed using an ammonium sulphate precipitation and standard
protein chromatography, and the hydrolytic proﬁle was deter-
mined for, cefuroxime, penicillin G, nitroceﬁn, imipenem and
meropenem. Zinc assays were undertaken using Unicam 919
atomic absorption spectroscopy.
Results: Sequence analysis veriﬁed the deletion and RT-PCR con-
ﬁrmed gene expression. The SPM-Ldel gave kcats of 0.07 s1 and
0.14 s1 for imipenem and meropenem, respectively, compared
with 33 and 63 s1, for the wtSPM-1. Km values decreased from
281 to 61 lM for meropenem and from 37 to 9.5 lM for imipenem.
For cefuroxime, kcat and Km values changed from 37 to 0.6 s
1
and from 4 to 5 lM, respectively. SPM-Ldel weakly hydrolysed
penicillin with a kcat of 3.17 s1 and a Km of 226 compared with
the wtSPM-1 (kcat 108 s1 and Km of 38 lM). Interestingly, the
nitroceﬁn kcat value did not markedly change (0.53 s1 for
wtSPM-1 compared with 0.51 s1 for SPM-Ldel) and the Km
increased from 4 to 23 lM.
Conclusions: Unexpectedly, removal of the loop did not consis-
tently result in weaker substrate binding. The lower kcat values
for SPM-Ldel demonstrate that the loop is integral to the hydroly-
sis of beta-lactams by SPM-1.
O278 Hospital outbreak of an imipenem-resistant VIM-2
encoding Acinetobacter DNA group 14 TU strain in a German
teaching hospital
M. Toleman, H. Seifert, L. Dijkshoorn, R. Reinert, T. Walsh
Bristol, UK; Cologne, D; Leiden, NL; Aachen, D
Objective: To characterise the resistance mechanism of a carbape-
nem-resistant haemolytic Acinetobacter strain which was recovered
from cultures of blood of three patients with bloodstream infec-
tion following coronary angiography. A carbapenem-sensitive
strain was recovered from a fourth patient involved in the same
outbreak.
Methods: Species identiﬁcation of Acinetobacter isolates was per-
formed by ampliﬁed ribosomal DNA restriction analysis
(ARDRA). Strain relatedness was assessed by pulsed-ﬁeld gel
electrophoresis (PFGE). Multi-resistant Acinetobacter strains were
initially analysed with Etest MBL strips and positive strains were
further investigated by PCR using class 1 integron primers
designed to the conserved 5’ and 3’ sequences. Sequencing of
PCR amplicons was undertaken on both strands by the dideoxy-
chain termination method. Sequence analysis was performed
using the Lasergene DNASTAR software package.
Results: All four strains were identiﬁed as unnamed Acinetobacter
DNA group 14 TU. The three carbapenem-resistant isolates exhib-
ited an identical PFGE pattern whereas the carbapenem-sensitive
strain showed a single band shift, the four isolates thus repre-
sented a single clone. The carbapenem-resistant isolates tested
positive for production of a metallo-beta-lactamase (MBL) using
Etest MBL strips with a reduction of MIC from 64 to 3 mg/L in
the presence of EDTA. Crude cell extracts demonstrated moderate
hydrolytic activity against carbapenem antibiotics that was inhib-
ited by EDTA conﬁrming the phenotypic expression of an MBL.
Ampliﬁcation and sequencing identiﬁed a class1 integron contain-
ing two resistance gene cassettes with the blaVIM-2 MBL gene
cassette in the ﬁrst position followed by the aacA4 gene. The
sequence of the integron indicated that it is a class 1 type and
embedded in a Tn21-like mobile genetic element. The combination
of both genetic elements make would make these cassettes highly
mobile although, to date, transfer to other bacteria could not be
demonstrated.
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Conclusions: This is the ﬁrst report of a hospital outbreak caused
by Acinetobacter DNA group 14 and the ﬁrst report of carbapenem
resistance in Acinetobacter species other than A. baumannii. It is
also the ﬁrst report of VIM-2 in Germany and the second report
of a class1 integron containing a MBL gene in this nation (along
with GIM-1). The emergence of these MBL genes in clinical patho-
gens is a serious challenge to current chemotherapy.
O279 Deﬁning the meropenem susceptible population in
Pseudomonas aeruginosa by analysing expression of resistance
genes in clinical isolates with different levels of meropenem
resistance
C. Giske, C. Bore´n, B. Wretlind, G. Kronvall
Stockholm, Va¨xjo¨, S
Objectives: Analysis of meropenem disk-diffusion zone distribu-
tions for Pseudomonas aeruginosa at Karolinska University Hospital
revealed a unimodal pattern without a distinct border between
the susceptible and resistant population, similar to that reported
earlier by the British Society for Antimicrobial Chemotherapy
(BSAC). However, the Swedish Reference Group for antibiotics
has, in contrast to BSAC, chosen to deﬁne also an intermediary
susceptible category. Furthermore, Swedish MIC breakpoint for
meropenem susceptibility is 2 mg/L, compared with the BSAC/
NCCLS breakpoint at 4 mg/L. The rationale for these differences
is that isolates on the border between susceptible and resistant are
believed to consist mainly of OprD-negative mutants that have
slight increases of meropenem MIC-values compared with wild-
type bacteria, but are still considered meropenem susceptible. In
this study we examined the expression of meropenem resistance
genes in clinical isolates, to be able to provide molecular evidence
for deﬁning differences between the populations.
Methods: Twenty clinical isolates of P. aeruginosa with different
levels of meropenem resistance were examined with real-time
reverse transcriptase PCR for expression of resistance genes oprD,
mexB and mexD. Strain ATCC 27853 and three other isolates were
meropenem susceptible, four were borderline susceptible, four
were intermediary susceptible, four were borderline resistant and
four were resistant. Three of the meropenem intermediary suscep-
tible isolates were also imipenem resistant. Meropenem MIC was
determined for all isolates.
Results: The meropenem intermediary susceptible group was het-
erogenous regarding gene expression. Two imipenem-resistant
isolates with meropenem MICs of 2 and 4 mg/L had only
decreased expression of oprD. The imipenem susceptible isolate
had a meropenem MIC of 4 mg/L and a signiﬁcant increase of
mexB, while oprD and mexD expression was comparable to the
ATCC strain. The third imipenem-resistant isolate had signiﬁ-
cantly decreased oprD level, as well as signiﬁcant increase in
expression of both efﬂux genes.
Conclusions: Our ﬁndings indicate that the Swedish intermediary
susceptible population, mostly isolates with MICs of 4 mg/L, does
not only consist of OprD-negative mutants, but also of isolates
with overexpression of efﬂux genes. We believe that this should
be taken into consideration when deﬁning the meropenem suscep-
tible population.
O280 Overexpression of Rob increases MIC to norﬂoxacin
by upregulation of the MdfA efﬂux pump in Escherichia coli in
vitro
H.J. Linde, C. Irtenkauf, M. Arnold, N. Lehn
Regensburg, D
Objective: In E. coli various efﬂux pump systems like AcrAB,
AcrEF, EmrAB and MdfA are known to confer resistance to var-
ious classes of antimicrobials. Several transcriptional factors like
MarA, Rob and SoxS are involved in their regulation. Here we
report how overexpression of Rob affected the transcription of the
acrAB, mdfA, emrAB and norE efﬂux pump systems, all known
to confer resistance to ﬂuoroquinolones.
Methods: Rob was overexpressed from the arabinose-inducible
plasmid pCC1 (Epicentre) under control of the lac promoter in
E. coli (pCC1-lacrob). MICs (Etest, Solna, Sveden) to norﬂoxacin
(NFX) and ciproﬂoxacin (CIP) and transcription levels of gapA,
Rob, mdfA, acrAB, acrD, acrE, acrF, emrB, norE, tolC, marA, and
soxS were determined by quantitative RT-PCR (LightCycler)
comparing induced vs. uninduced cultures (arabinose 0.1%).
Results: Compared with uninduced control, maximum induction
of pCC1-lacrob resulted in an increase of: MIC to NFX: threefold
(0.064 vs. 0.023 mg/L), MIC to CIP: no change; transcription of
rob: 250-fold, mdfA 6.9-fold, acrAB 1.7-fold, emrB 0.6-fold, acrE
0.66-fold, acrF 0.69-fold, acrD 0.75-fold, norE 0.99-fold, marA 1.2-
fold, soxS 0.66-fold, tolC 1.3-fold, and gapA 0.98-fold.
Conclusion: MdfA is a recently recognised efﬂux pump system in
E. coli with preference for norﬂoxacin (1,2). We demonstrate that
increased transcription of Rob from plasmid pCC1-lacrob resulted
in increased transcription of mdfA but not acrAB and produces a
correspondent phenotype with increased MIC to NFX but not CIP.
Other efﬂux pump systems were only mildly affected (upregulation
of acrAB, no effect for norE, downregulation of acrEF, emrB). The
ﬁnding adds to the accumulating knowledge concerning the over-
laps and parallels in regulation of efﬂux systems, and highlights
their potential role in development of antimicrobial resistance.
References
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O281 Mechanisms of resistance to co-amoxiclav in clinical
isolates of Escherichia coli
B.G. Elisha, E. Nelson, Y. Ghebremariam, H. Segal
Cape Town, ZA
Objectives: The aim of the study was to characterise the genetic
basis of resistance to co-amoxiclav in clinical isolates of Escherichia
coli.
Methods and Results: Six independent clinical isolates of E. coli, iso-
lated from patients in hospitals in Cape Town (South Africa),
were investigated. Of the six strains, four were isolated from
urine, and one each was obtained from pus and blood. The MICs
of co-amoxiclav (16–128 mg/L) for the strains indicated that they
were resistant to this combination. All of the isolates were suscep-
tible to cefoxitin and the newer oxyiminocephalosporins, suggest-
ing that overproduction of AmpC was not responsible for the zco-
amoxiclav resistance. To detect the presence of blaTEM genes in
the isolates, PCR assays were carried out using primers to amplify
the functional gene. A product of the expected size (1.2-kb) was
obtained from each of the strains. Amplicons were either
sequenced directly, or cloned into a vector prior to sequencing.
Alignment of the nucleotide sequences with corresponding bla-
TEM sequences in the data bank enabled identiﬁcation of the
genes. blaTEM-1B was obtained from ﬁve strains. Of the ﬁve
genes, four were associated with either of the strong promoters,
Pa/b or P4, indicating increased expression of TEM-1. The strain
containing the remaining blaTEM-1B gene, which was adjacent to
the weak P3 promoter, harboured a second gene (blaTEM-30A),
encoding an inhibitor resistant TEM (IRT). This gene was asso-
ciated with the strong Pa/Pb promoter. An identical gene (bla-
TEM-30A) was identiﬁed in the remaining strain. To study the
promoters used in the transcription of blaTEM-30A, primer exten-
sion studies were carried out. The ﬂuorogram of the primer exten-
sion analysis indicated that mRNA transcription was initiated
from three sites. The majority of transcripts emanated from the Pa
component of Pa/Pb, indicating that of the three promoters
upstream of blaTEM-30A, Pa is the most frequently recognised
and therefore the most active promoter.
Conclusion: Resistance to co-amoxiclav in clinical isolates of E. coli
was associated with either increased expression of blaTEM-1B or
the presence of the IRT, blaTEM-30A.
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O282 Loss of function mutations in smeT lead to
multiresistance in Stenotrophomonas maltophilia
V. Gould, M. Avison
Bristol, UK
Objectives: Stenotrophomonas maltophilia is an important, emerging,
Gram-negative, nosocomial pathogen that can cause bacteraemia,
respiratory tract colonisation and other organ-speciﬁc infections.
Isolates are generally highly resistant to beta-lactams, macrolides
and aminoglycosides, and have the potential to mutate to multi-
drug resistance (MDR), including to ﬂuoroquinolones, tetracy-
clines and chloramphenicol. MDR has been linked to the over-
expression of the tripartite efﬂux pump, SmeDEF in S. maltophilia,
whose expression is believed to be controlled by the putative tran-
scriptional repressor, smeT, encoded immediately upstream of
smeDEF. The aim of this project was to conﬁrm that SmeT is a
repressor of SmeDEF expression, and that loss of function muta-
tions in SmeT produce MDR.
Methods: smeT was ampliﬁed by PCR from the S. maltophilia iso-
late N531, and was manipulated using the HaeII restriction
enzyme, T7 DNA polymerase and DNA ligase to result in a
4-bp deletion within the PCR amplicon. The smeT2 mutant
allele was ligated into the gene replacement vector pEXTc and
the recombinant vector was transferred into S. maltophilia N531
by conjugation from Escherichia coli strain S17. A double recom-
bination event, leading to replacement of wild-type smeT with
the mutant smeT2, was selected for using sucrose, and
transconjugants carrying the mutant smeT2 allele were screened
for by PCR followed by haeII digestion (which should be
negative) of the product. MICs were determined by E-test,
using Muller–Hinton agar.
Results: We were successful in introducing a 4-bp deletion within
the smeT gene on the S. maltophilia chromosome, resulting in a
frame-shift, and so loss of function mutation. MICs of a variety of
antibiotics associated with the MDR phenotype were determined:
i.e. tetracycline, chloramphenicol, erythromycin and ciproﬂoxacin.
The wild-type strain had MICs of 1, 2, 6 and 0.38 mg/L, respec-
tively for these drugs; the mutant had MICs of 6, 8, >256 and 32,
respectively.
Conclusions: Loss of function mutations in smeT lead to greatly
increased resistance to a variety of antimicrobials, but particularly
of ﬂuoroquinolones such as ciproﬂoxacin, in S. maltophilia. As
such MDR mutants are frequently encountered, it is likely that
smeT mutation is a common cause.
O283 Evaluation of differential gene expression in
antimicrobial susceptible and resistant clinical isolates of
Klebsiella pneumoniae by DNA microarray analysis
A. Dome´nech-Sa´nchez, Y. Dong, E.W. Triplett, S. Albertı´,
L. Martı´nez-Martı´nez, V.J. Benedı´
Palma de Mallorca, E; Madison, USA; Santander, E
Objectives: To seek for novel genes involved in antimicrobial resis-
tance in K. pneumoniae, we used DNA chip technology to compare
the gene expression proﬁle of two clonally related strains isolated
from the same patient (CSUB10S, porin+ efﬂux–; CSUB10R, porin–
efﬂux+).
Methods: Total RNA from both strains was isolated, reverse
transcribed, labelled with ﬂuorescent nucleotides and hybridised
to DNA microarrays displaying the complete genome of Escheri-
chia coli. After hybridisation the microarrays were scanned and
the intensity of the spots obtained for both samples were nor-
malised and compared. Statistical analyses of ﬁve independent
experiments identify those genes whose expression was signiﬁ-
cantly different between both strains. RT-PCR quantitation was
used to verify the microarray data.
Results: Nineteen genes were upregulated in the resistant isolate
compared with the susceptible isolate. No changes related to the
AcrAB-TolC system were found. ycjV gene, which encodes for a
transporter, was 4-fold up-regulated suggesting that this protein
might contribute to antimicrobial resistance. By contrast, 33 genes
were down-regulated in the resistant isolate, including 11
unknown genes and genes involved in the permeability of the cell
envelope like ompC.
Conclusions: (1) E. coli DNA microarrays are suitable for K. pneu-
moniae gene expression proﬁle analysis. (2) The number of genes
down-regulated in the resistant isolate is higher that the genes
up-regulated when compared with the susceptible strain. (3)
ycjV is a candidate for a novel mechanism of antimicrobial resis-
tance in K. pneumoniae.
O284 Molecular basis for trimethoprim resistance in
clinical urinary isolates
M. Grape, L. Sundstro¨m, G. Kronvall
Stockholm, Uppsala, S
Objectives: To study the molecular basis for increasing resis-
tance to trimethoprim in clinical, Gram-negative isolates. 105
urinary isolates partly selected for trimethoprim resistance were
investigated regarding antibiotic resistance patterns, integron
carriage, resistance gene cassettes and other resistance determi-
nants.
Methods: Disc diffusion antimicrobial susceptibility test for 12
antibiotics and PCR for integrons of classes 1, 2 and 4 were per-
formed on all isolates. Sequence analysis was used to investigate
the cassette regions of 22 integrons and plasmid analysis was per-
formed on selected isolates.
Results: Sixty-nine of the 105 isolates were resistant to trimetho-
prim. 53 isolates were resistant to at least four antibiotics, of
these, 43 carried an integron. In total 65 integrons of classes 1
and 2 were detected in 59 isolates. Only one of the integron-
positive isolates was susceptible to trimethoprim. As many as
10 isolates were resistant to trimethoprim and still negative for
integrons. In the sequence analysis only dfr and aadA gene cas-
settes were detected despite the fact that the isolates were resis-
tant to many more antibiotics than trimethoprim, streptomycin
and spectinomycin. One new trimethoprim resistance gene,
dfr2d, was also found. It appeared as a single gene cassette in a
class 1 integron and it belongs to the unique group dfr2. The
four genes in this group are completely unrelated to the
remaining groups of about 15 dfr-genes, which are all identical
to at least 20%.
Conclusions: Integrons constitute a vehicle for efﬁcient spread of
antibiotic resistance. These elements have the ability to acquire
gene cassettes containing genes mediating resistance to many
antimicrobials. Selective pressure from one antibiotic can co-
select for genes mediating resistance to other antibiotics if they
are assembled as gene cassettes in integrons. However, in this
study, trimethoprim consumption alone seems to be high
enough to select for integrons containing dfr-genes as the only
advantageous gene for the bacteria. Nevertheless, integrons
were shown to be more abundant in multiresistant isolates and
these integrons are possibly carried by plasmids with many
other resistance genes in addition to the integrated gene cas-
settes.
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O285 Analysis of rotavirus strains detected in 2003 in a
Mantua hospital (Italy)
V. Martella, V. Terio, F. Fabozzi, A. Cirani, F. Cariola,
G. Gambaretto, A. Caroli, G. Elia, F. Rossano, A. Pratelli,
C. Buonavoglia
Valenzano, Mantua, Castellana Grotte, Naples, I
Objectives: Rotaviruses are the major etiologic agents of infantile
diarrhoea worldwide and the development of effective vaccines
for rotavirus disease is considered a primary objective of the
WHO. The main rotavirus serotypes G1, G2, G3 and G4 are the
targets for vaccine development. However, unusual rotavirus ser-
otypes, such as G5, G6, G8, G9 and G10 may acquire local rele-
vance. The objective of the present study was to determine the
antigenic speciﬁcities of the rotavirus strains spreading in Man-
tova (Italy), in 2003.
Methods: A total of 134 stool samples were tested for the presence
of rotavirus by an immuno-chromatographic assay during 2003.
Sixteen rotavirus-positive samples (11.9%) were detected from
children between 6 months and 9 years of age (median age of
2.56 years). A 14-point score system was used to summarise the
clinical severity. Rotavirus RNA was analysed by reverse tran-
scription-PCR, PCR genotyping and sequence analysis for deter-
mination of the G (VP7) and P (VP4) speciﬁcity. In order to
evaluate the correlation between serotypes and pathogenicity, a
statistical analysis was performed by the General Linear Model
procedure (SAS 1990).
Results: Eight samples were typed as G1, 4 as G4, 3 as G9 and
one was not typeable. The VP7 genes of G9 strains revealed high
genetic similarity to each other (about 100%) and to G9 strains
identiﬁed recently in southern Italy (99.8%). Analysis of the VP4
gene revealed that all the strains (G1, G4 and G9) belonged to the
P type P1A[8]. The severity of the disease was signiﬁcantly higher
for G9 rotavirus infections. The linear model ﬁtted to pathogeni-
city score values was signiﬁcant (P < 0.0289; R2 ¼ 0.54). Least
square mean was 10.69 (standard error 1.20) for G9 rotaviruses
and 6.32 (standard error 0.67) for the other serotypes.
Conclusions: The rotavirus strains were characterised as P[8], G1,
P[8], G4 and P[8], G9. The VP7 gene of the G9 strains revealed a
high genetic similarity to other Italian G9 strains and to the glob-
ally spreading G9 lineage described recently worldwide. Interest-
ingly, it was possible to ﬁnd a statistically supported correlation
between the rotavirus serotype and the severity of the rotavirus-
associated disease, as the symptoms induced by rotavirus G9
infections were signiﬁcantly more severe. The results described
here emphasises the role of rotavirus G9 as an epidemiologically
important serotype and the need to include the G9 speciﬁcity in
candidate rotavirus vaccines.
O286 Eye lesions associated with congenital toxoplasmosis:
long-term follow-up of 327 children
M. Wallon, C. Binquet, L. Kodjikian, J. Garweg, J. Fleury,
C. Quantin, F. Peyron
Lyon, Dijon, F; Berne, CH
Background: Retinochoroiditis is the most frequent consequence of
congenital toxoplasmosis. Early diagnosis and treatment are
believed to reduce the risk of visual impairment. We report on
the clinical evolution of ocular lesions and ﬁnal visual function in
a prospective cohort of congenitally infected children identiﬁed
through monthly prenatal screening of pregnant women.
Methods: Of 1466 children born from 1453 mothers managed in
our department for an acute maternal infection between 1988 and
2001, 327 born were eligible in our study: they had proven conge-
nital toxoplasmosis and had been followed up for at least
6 months. Data on date of maternal infection, time and type of
therapy, antenatal, neonatal and postnatal work ups, and ocular
status were available for all of them and analysed.
Results: Most mothers had been infected during the second (27%)
or third (67%) trimester. Pyrimethamine and sulphadiazine were
given in utero to 38% of fetuses and after birth to 72% of new-
borns. Fansidar (R) was given for an average duration of 337 days
( 23) in all but two children. After a median follow-up of 6 years
(range: 6 months to 14 years), 71% of children were free of any
lesions, 18% manifested no sequelae except retinochoroiditis and
11% had at least one none ocular sign (cranial calciﬁcation: 31
cases; hydrocephalus: six; microcephalus: one). Seventy-nine chil-
dren (24%) had at least one retinochoroidal lesion, including a
macular lesion in 31. Half of the initial lesions were diagnosed
before 2 years of age and 76% before 5 years. In 23 of them (29%)
at least one new event had been diagnosed up to ten years after
detection of the ﬁrst lesion. At the last examination, 55 children
had lesions in one eye; of 45 children for whom data on ﬁnal
visual acuity were available, 31 (69%) had normal vision. Twenty-
four children had lesions in both eyes; of the 21 for whom data
on ﬁnal visual acuity were available, 11 had normal vision in both
eyes; none had bilateral visual impairment. 13 children had stra-
bismus, four had microphtalmia, two had retinal detachment and
one had cataract, hyalitis and optic nerve atrophy.
Conclusions: Clinicians, parents and elder children with congenital
infection should be informed that late-onset retinal lesions and
relapse can occur many years after birth but that the overall ocu-
lar prognosis of congenital toxoplasmosis is satisfactory when
infection was identiﬁed early and treated accordingly.
O287 Quick resolving of unilateral middle ear effusion in
acute otitis media monitored daily with tympanometry
T. Kontiokari, M. Renko, M. Uhari
Oulu, FIN
Objectives: Although duration of middle ear effusion (MEE) is one
of the most important outcomes in the treatment of acute otitis
media (AOM), little is known about the possibilities to measure it
accurately and to minimise it. The aims of this study were to eval-
uate the duration of MEE in AOM treated by antimicrobials and
to ﬁnd factors inﬂuencing it.
Methods: Daily monitoring with tympanometry was performed by
the parents among 90 children with AOM. They were 3 months to
7 years old (mean 3.1 years) and were randomly allocated to be
treated with either oral amoxicillin (40 mg/kg/days) or cefurox-
ime-axetil (30 mg/kg/days) for 7 days. Daily monitoring was con-
tinued at least for 14 days or until the tympanometry was normal
(curve A or C) in both ears. Clinical control with pneumatic oto-
scopy was carried out every 2 weeks.
Results: The disappearance of MEE took a mean time of 10.2 days
from the diagnosis (median 7.5, range 1–58) among 75 success-
fully monitored patients. In two-thirds (69 %) of them MEE
resolved in 14 days. The median duration of MEE did not differ
signiﬁcantly between the two treatment groups (8.0 vs. 7.0,
P ¼ 0.7). Ten children (13%) ﬁnished the monitoring with MEE
still present, ﬁve of them at 14 days and another ﬁve at
29–43 days. The 23 (31 %) children with MEE lasting longer
than 14 days had statistically signiﬁcantly more often bilateral
AOM at diagnosis and were younger than those recovering faster.
The children who had unilateral AOM cured more rapidly than
those with bilateral AOM (P < 0.0001 in log rank test, Figure 1).
In logistic regression analysis adjusted for age, bilaterality
explained the resolution of MEE at 2 weeks signiﬁcantly (odds
ratio 14.8, 95% conﬁdence interval from 3.7 to 60, P < 0.001). Sea-
son, amount of previous AOM episodes, history of adenoidectomy
or tympanostomy, sex, day care and parental smoking did not
associate signiﬁcantly with the cure rate.
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Conclusion: Unilateral cases of AOM appeared to resolve much
quicker than bilateral ones. This could be taken account when
considering which of the AOM cases should be treated with anti-
microbials and when planning control visits after AOM.
O288 M-serotypes, sensitivity to antibiotics and pyrogenic
exotoxin genes of Streptococcus pyogenes invasive strains
isolated in a Greek paediatric hospital during 1996–2002
G. Chronopoulou, L. Zachariadou, N. Petropoulou, A. Tanna,
A Efstratiou, A. Pangalis
Athens, London, GR
The reemergence of severe group A streptococcal infections
(GAS), following many years of decreased incidence, was
initiated during the late 1980s and is now described in all parts
of the world. These infections, fatal in a signiﬁcant rate, were
caused by particular M-serotypes, especially M1. The aim of this
study was to investigate the distribution of M-serotypes among
GAS strains isolated from invasive infections of children.
Thirty-nine strains isolated from equal number of patients dur-
ing a 7-year period (1996–2002) were tested. Eighteen of thirty-
nine of the children were boys and 21 of 39 girls. Mean age of the
little patients was 3.7 years (range: 1 day to 11 years). Samples
from blood (32), skin lesions (3), pharynx (2), and pus (1) were
cultured on blood agar 5%. The preliminary identiﬁcation with
bacitracin disk 0.05 U (OXOID) was followed by Lanceﬁeld sero-
grouping (TRANSLAB UKkit). The study was accomplished by
serum opacity factor investigation, T-serotyping (anti-T sera from
SEVAC Ltd, Prague), M-serotyping and spe genes (conventional
and molecular techniques, RSIL, HPA, London). Sensitivity to
antibiotics (penicillin, vancomycin, chloramphenicol, rifampicin,
erythromycin, clindamycin), was also tested by disk diffusion
method, double disk test for MLS resistance (Becton Dickinson’s
disks) and MIC ( Etest, AB Biodisk). M1 (30.7%) was the predo-
minant serotype, followed by M12 (17.9%), M4 (12.8%) and M89
(10.2%). Less frequent serotypes were M77 (7.7%) and M28
(5.1%). M6, M22, M73, M84, M90 and T5OF(+) shared the rate of
2.6% each. No strain was found resistant to penicillin, vancomy-
cin, chloramphenicol and rifampicin. Seven of 39 (17.9%) isolates
revealed resistance to macrolides (EryR). 5/7 EryR strains were of
M phenotype (71.4%) whereas 2/7 (28.6%) of iMLS . Three of ﬁve
(60%) of M phenotype strains were serotype M4 and the remain-
ing two, M22 and M84. Strains of iMLS phenotype were M12
and M77. Eighteen of thirty-nine GAS strains were tested for
pyrogenic exotoxin (spe) genes. SpeA was found in seven and speC
in eight strains. As expected, all strains expressed speB gene. All
M1 strains expressed speA gene. M1 was also the only serotype
where speA gene was expressed. In conclusion, it seems possible
that the most frequent GAS serotype causing invasive infections
in children residing in Greece, is M1 (30.7%). Macrolide resistance
rate with equal distribution over the years, was 17.9%, less than
the one found in noninvasive strains (24%). As expected, M1
strains expressed speA gene.
O289 Penicillin for children affected with acute sore throat
with or without group A beta-haemolytic streptococci in
primary care
S. Zwart, M.M. Rovers, R.A. de Melker, A.W. Hoes
Utrecht, NL
Objectives: To assess the effectiveness of penicillin for 3 days and
the treatment for 7 days in resolving symptoms in children with
of sore throat as compared with placebo.
Methods: A randomised double-blind placebo-controlled trial was
performed in 43 family practices in the Netherlands. A total of
156 children, aged 4–15 years, were included. They had sore
throat for <7 days and matched with at least two of the four Cen-
tor criteria – that is, history of fever, absence of cough, swollen
tender anterior cervical lymph nodes, and tonsillar exudate.
Patients were randomly assigned to penicillin for 7 days, penicil-
lin for 3 days followed by placebo for 4 days, and placebo for
7 days. The main outcome measures were duration of symptoms,
mean consumption of analgesics, duration of not attending school,
occurrence of streptococcal sequelae, eradication of the initial
pathogen after 2 weeks, and recurrences of sore throat after
6 months.
Results: Penicillin treatment was not more beneﬁcial than placebo
in resolving symptoms of sore throat, neither in the total group
nor in the 96 children with group A beta-haemolytic streptococci.
In the 7-day penicillin, the 3-day penicillin and the placebo group
1, 2 and 8 children experienced a streptococcal sequela, respec-
tively. These sequelae were an imminent peritonsillar abscess,
impetigo and scarlet fever.
Conclusion: Our study showed no major beneﬁcial effect of peni-
cillin treatment in children with sore throat on average length of
symptoms. Penicillin may, however, reduce streptococcal seque-
lae.
O290 Pertussis incidence in the Netherlands after
introduction of an acellular booster vaccination at 4 years of age
S.C. de Greeff, J.F.P. Schellekens, F.R. Mooi, H.E. de Melker
Bilthoven, NL
Objectives: In 1996–1997 different surveillance sources revealed an
outbreak of pertussis in the Netherlands mostly among vaccinated
children. In the following years the incidence of pertussis
remained higher than in the period before 1996 and in 1999
another peak was observed. The high incidence of pertussis
resulted in the introduction of an acellular booster vaccination for
4-year-olds in the National Vaccination Programme from October
2001 onwards.
Methods: To gain insight into the incidence of pertussis and into
the effect of the introduction of an acellular booster vaccination
for 4-year-olds in the Netherlands, surveillance data based on
notiﬁcations, laboratory data, hospitalisations and deaths were
analysed for 2001 and 2002, and compared with previous years.
Results: The reported incidence (per 100 000/year) in 2001 based
on notiﬁcations (50.2), positive two-point serology (4.4), positive
one-point serology (30.7) and hospital admissions (2.5), was com-
parable with 1999, but was higher than in 2002 (notiﬁcations
Figure 1. Disappearance of MEE after AOM in 75 children treated
with antimicrobials by laterality at diagnosis.
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28.0, positive two-point serology 2.1, positive one-point serology
15.4 and hospitalisations 1.6). Although the total incidence in
2002 was slightly higher than in 2000 (26.6), the incidence in the
age group vaccinated with the acellular booster vaccination had
decreased with 45% compared with 2000. For the older age
groups a slight increase in incidence was observed in 2002 com-
pared with previous years. However, hospitalisations and severe
disease still occurred mainly among young unvaccinated infants.
Conclusions: Pertussis is still endemic in the Netherlands with a
higher incidence compared with the period prior to the epidemic
in 1996–1997 and with a peak in the incidence every 2–3 years
(1996, 1999, 2001). The introduction of an acellular booster-vacci-
nation for 4-year-olds in 2001 has caused a decrease in the inci-
dence of pertussis among the target-population itself. Long-term
surveillance will be necessary to provide insight into the possible
effect among the population at large. However, pertussis is still
most severe among young unvaccinated infants. For the develop-
ment of future vaccination strategies (e.g. boostering of adoles-
cents and/or adults) more insight in the main sources of infection
of young unvaccinated children in the Netherlands is therefore
necessary.
O291 Intensiﬁed surveillance after introduction of
vaccination against meningococcal C disease in the Netherlands
S.C. de Greeff, L. Spanjaard, M. van Deuren, H. Ruijs, J. Dankert,
A. Timen, M. de Vries, L. Schouls, H.E. de Melker
Bilthoven, Amsterdam, Nijmegen, Tiel, Utrecht, NL
Objectives: After introduction in 2002 of routine vaccination for
children aged 14 months and a catch-up campaign for all
1–18 year olds (coverage 94%)in June-November 2002 with the
conjugated meningococcal C vaccine, an intensiﬁed surveillance of
meningococcal disease was implemented in the Netherlands from
January 2003 onwards. The aims of this intensiﬁed surveillance
are to determine the remaining incidence and disease burden of
meningococcal infections, to provide estimates of vaccine-efﬁcacy,
to identify vaccine failures and to gain insight into the role of
early recognition in reducing disease severity.
Methods: A voluntary electronic questionnaire was linked to the
mandatory notiﬁcation system and notiﬁcations were combined
with typing results from isolates of patients with meningococcal
disease, collected by the Netherlands Reference Laboratory for
bacterial meningitis.
Results: Incidence of meningococcal C disease decreased soon
after the vaccination campaign had been carried out. In 2002 215
patients with meningococcal C disease were reported from Janu-
ary till November, while in the same period in 2003 only 37
patients had been reported. The largest decrease was observed
among the vaccinated age groups. Among patients with meningo-
coccal C disease those aged 1–19 years amounted yearly 58–69%
in 2000–2002, while in 2003 this was only 19%. Since the introduc-
tion of meningococcal C conjugate vaccine, no cases of meningo-
coccal C disease have been reported in children previously
vaccinated. Remarkably, the number of patients aged 1–19 years
with serogroup B also decreased (until November: 217 in 2000,
243 in 2001, 199 in 2002 and 137 in 2003). In January–November
2003 for 79% of notiﬁed cases the electronic questionnaire was
completed. Further results will be available by the beginning of
2004. Conclusions: The vaccination campaign has had an
immediate effect on the incidence of meningococcal serogroup C
disease in the Netherlands, especially among vaccinated children.
No vaccine failures have been reported so far. Surveillance of
meningococcal disease remains necessary to evaluate long-term
effects of the vaccination programme and will also give insight in
the role of early recognition in reducing disease severity particu-
larly for meningococcal group B disease for which no vaccine is
available yet.
O292 Vaccination against hepatitis B in newborns of
HBsAg positive mothers
L. Roznovsky, I. Orsagova, I. Lochman, L. Lukacova,
A. Zjevikova, A. Sulakova, L. Pliskova, A. Kloudova, J. Chovancik
Ostrava, Hradec Kralove, CZ
Objectives: Breakthrough infections after immunisation against
hepatitis B, protective titres of anti-HBs antibodies after vaccina-
tion and vanishing of anti-HBs in long-term period were investi-
gated in 576 neonates of HBsAg-positive mothers.
Methods: Combine passive–active immunisation was commenced
in 1988. The number of immunised children gradually increased
and the group included now 576 newborns. All mothers were
HBsAg-positive during pregnancy, 30 of them (5%) were also
HBeAg-positive. The children received hepatitis B immunoglobu-
lin at birth and three 10 lg doses of plasma-derived or recombi-
nant vaccine at interval 0, 1 and 6 months (only 21 children of
HBeAg-positive mothers at interval of 0, 1 and 2 months). The
immunisation schedules were completed in 534 children, serologic
investigations after immunisation were performed in 489 chil-
dren. Blood samples were obtained after completion of immuni-
sation schedule, at 2 years of age, and biennially thereafter.
Samples were tested by ELISA for HBsAg, anti-HBs and anti-HBc.
Results: Only two children became chronic HBsAg carrier, both
suffered from mild, acute hepatitis B in the second year of life.
One of them was infected with variants of HBsAg with substitu-
tions at residues 137 and 139. Asymptomatic infections with pre-
sence of anti-HBc antibodies were observed in ﬁve children since
fourth till eighth year of life. The increase of anti-HBs without
revaccination was observed in 104 children. Anti-HBs antibodies
were tested in 489 children after immunisation, protective titres of
anti-HBs were proved in 471 of them (96%). Vanishing of protec-
tive anti-HBs antibodies were detected in 10, 29 and 37% children
during second, ﬁfth and tenth years of their life.
Conclusion: During 15-years monitoring in 576 children vaccinated
against hepatitis B, were proved chronic HBsAg carrier status in
two children, asymptomatic infections in ﬁve children, protective
anti-HBs titres after immunisation in 96% children and vanishing
of protective anti-HBs in 37% of them.
Grant support: Ministry of Health, Czech Republic, IGA No.
NI6047-3.
O293 Protective effect in monkeys following immunisation
with a live attenuated chimeric ﬂavivirus against tick-borne
encephalitis
N.S. Pripuzova, L.V. Gmil, T.I. Dzhivanyan, A.A. Rumyantsev,
V.A. Lashkevich, G.G. Karganova
Moscow, RUS; Bethesda, USA
The attenuated chimeric virus Tp21/DEN4, containing genes
encoding premembrane (preM) and envelope (E) glycoproteins of
Langat virus in the backbone of Dengue four virus genome, was
constructed by Dr Pletnev (Pletnev et al., 1998). It has been shown
that chimeric virus Tp21/DEN4 has low neurovirulence and no
neuroinvasiveness in immunodeﬁcient mice (SCID). It protects
immunocompetent mice against lethal challenge with a virulent
strain of tick-borne encephalitis virus (TBEV) and is highly immu-
nogenic and effective for protection against Langat virus in
Macaca mulatta monkeys (Pletnev et al. 2001). Protective efﬁcacy
of the chimeric Tp21/DEN4 virus was evaluated in African green
monkeys (Cercophithecus aephiops) against challenge with the
highly virulent TBEV strain Abssetarov. Six of nine monkeys that
received a single dose of 6.7–7.1 lg PFU of chimera developed a
TBEV neutralizing antibody titre of 1:80 (GMT) at 2 weeks after
inoculation, and all monkeys became seropositive after a second
dose of inoculation that was administrated 35 days later. Two
monkeys that received one immunization and three monkeys that
received two immunizations with the chimera were challenged
subcutaneously with 6.7 lg PFU of the highly virulent Absettarov
strain of TBEV 5–6.5 weeks after the last immunisation and were
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sacriﬁced on 35–37 days postchallenge. Control animals (two)
were twice immunised with a commercial inactivated vaccine
against TBEV. A 10-fold increase in NT antibody titre was
observed in all monkeys on the second day postchallenge. Virae-
mia was very low, even in nonimmunized animals, and thus
reduction of virus titres in blood could not be used to evaluate
protective properties of the chimera in this species of monkey.
TBEV challenge virus was not detected in submaxillary, axial
lymph nodes and spleen of the monkeys immunised twice with
the chimera or with inactivated vaccine; however, TBEV was
detected in the organs of nonimmunized animals 3 weeks after
inoculation. Therefore, a single immunization of Tp21/DEN4
chimera that contains structural preM and E proteins of Langat
virus in African green monkeys elicits an immune response
against TBEV. Double immunization with the chimera and the
inactivated vaccine protects monkeys from the persistence of
TBEV in peripheral organs.
O294 HLA polymorphisms and T cell cytokine responses
to processed HLA class II measles virus peptides: the rationale
for a measles peptide vaccine
I.G. Ovsyannikova, K.L. Johnson, R.A. Vierkant, D.C. Muddiman,
G.A. Poland
Rochester, USA
Objectives: Previously we have reported that HLA-DR molecules
contribute the main restriction determinants for antigen-speciﬁc
T-cell recognition of naturally processed measles virus (MV) class
II epitopes derived from MV phosphoprotein (MV-P) and nucleo-
protein (MV-N). We demonstrated a signiﬁcant association of
DRB1*0301 alleles with MV-P speciﬁc IFN-c and IL-4 responses.
In addition, DRB1*1501 and DRB1*1103/*1303 alleles were
associated with MV-N induced IFN-c and IL-4 secretion, respec-
tively. Because of the tight linkage disequilibrium between DR
and DQ and/or DP alleles and the frequent sharing of epitopes
among these HLA class II loci, the importance of non-DR class II
molecules in MV peptide responses should be understood.
Methods: We studied the association between cytokine responses
and DQ and DP alleles among 313 (168 males and 145 females)
children aged 12–18 years who received two doses of MMR-II
vaccine. Genomic DNA was extracted from blood samples and
used for HLA allele typing. PBMC were cultured alone or stimu-
lated with peptides, and cytokines in supernatants were measured
by ELISA. The allelic associations were determined by linear
regression analysis.
Results: Overall mean IFN-c and IL-4 secretion levels for MV-P
and MV-N peptides were 99.3 compared with 13.2 pg/mL, and
0.3 compared with 4.1 pg/mL, respectively. Examination of IFN-c
responses to MV-P peptide indicated that none of the alleles of
the DQ locus were associated with MV-P induced T-cell response.
A marginally signiﬁcant increase in the frequency of the
DQB1*0201 (P ¼ 0.06) and DQB1*0603 (P ¼ 0.10) alleles was
found among subjects who demonstrated high IL-4 levels to
MV-P. DPB1*0201 (P ¼ 0.05) and DPB1*1301 (P ¼ 0.10) alleles pro-
vided suggestive evidence of an association with MV-P induced
IL-4 secretion. DQB1*0602 (P ¼ 0.03) allele provided the evidence
of an association with MV-N induced high IFN-c responses. By
examining the DP alleles individually, we found a signiﬁcant
(P ¼ 0.006) increase in the frequency of the DPB1* 0501 allele
among subjects who produced low MV-N speciﬁc IL-4 responses.
Conclusion: We demonstrated that MV-derived peptides can be
recognised in association with different HLA molecules, including
DR, DQ and DP alleles. We suggest that non-DR class II mole-
cules also restrict cytokine responses to naturally processed MV
peptides. These results should be viewed cautiously due to multi-
ple testing issues. This information is important for the design of
new vaccines.
Tropical and parastic diseases
O295 Post-travel related hospitalisation in Israel
S. Stienlauf, G. Segall, Y. Sidi, E. Schwartz
Tel Hashomer, IL
Objectives: Data regarding travel-related morbidity is still limited.
In this study we evaluated the in-hospital diagnoses of travel-
related diseases in the largest tertiary hospital in Israel.
Methods: Records were reviewed of all patients with a history of
recent travel prior to their admission to The Sheba medical centre
during 1 January 1999 to 30 November 2003. Demographic data,
discharge diagnoses and travel destinations were recorded. In
addition, demographics and destination of healthy travellers pre-
senting to our clinic for pretravel consultation were recorded.
Results: During this period, 205 patients with travel-related infec-
tions were admitted. There were 144 (70%) males and 61 (30%)
females; all were travellers except for 13 who were immigrants or
foreign workers, most from Africa. Altogether 39 different diag-
noses were recorded. A total of 159 patients (78%) were admitted
with febrile diseases. The most common febrile diseases were:
malaria in 54 (26%) patients, dengue fever in 27 (13%) and non-
speciﬁc (unidentiﬁed) febrile disease in 31 (16%) patients. Of the
nonfebrile diseases, New World cutaneous lieshmaniasis (L. brazi-
liensis) was the most common cause of admission (8%). Diarrhoeal
diseases, which are the most common cause of morbidity during
travel, accounted for only 11% of admissions. 99 (49%) had been
to Asia, 69 (39%) to Africa, and 32 (16%) to the Americans.
Although the distribution (statistics) of our healthy traveller popu-
lation show that 70% travel to Asia, 25% to the Americas and
only 5% to Africa. The major health problems of patients return-
ing from Asia were dengue fever (27%), nonspeciﬁc febrile
disease (18%), diarrhoeal diseases (13%), skin disorders (7%) and
malaria (7%). The overwhelming majority of patients who had
returned from Africa had malaria (59%), followed by nonspeciﬁc
febrile disease (13%) and diarrhoeal diseases (10%). Most patients
who were returning from Latin America suffered from lieshma-
niasis (49%), Plasmodium vivax malaria (12%) nonspeciﬁc febrile
disease (9%) and secondary-infected myiasis (9%).
Conclusion: Febrile diseases are the most common cause for post-
travel hospitalization. Among them malaria, dengue fever and
unidentiﬁed febrile disease were the most common. There were a
destination-related diseases and travel to Africa is associated with
higher rate of hospitalisations. Malaria and cutaneous lieshmania-
sis had substantial male predominance, probably due to risk tak-
ing behaviour.
O296 Treatment of uncomplicated imported falciparum
malaria in Italy
N. Saleri, A. Matteelli, M. Gulletta, Z. Bisofﬁ, R. Visona`, G. Gaiera,
G. Gregis, L. Tomasoni, F. De Iaco, F. Castelli – Lombardy Study
Group on International Health (SIRL)
Objectives: We compared a 3-day quinine-sulphadoxine/pyri-
methamine regimen with meﬂoquine in travellers with acute falci-
parum malaria acquired in Africa.
Methods: Multicentre, randomised, oben-label trial. The efﬁcacy
end-points were the early cure rate, the rate of recrudescence dur-
ing the 28 days of follow-up, the time required for parasite clear-
ance, the time to clearance of fever and the time of hospital stay.
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The tolerability end-point for the rate of emergence of adverse
events during the follow-up period of the hospital stay.
Results: A total of 187 patients were enrolled from July 1999 to
February 2003, of whom 93 were randomised to receive meﬂo-
quine (M) and 94 quinine-SP (Q). Immigrants and persons visit-
ing relatives and friends represented 90% of all cases. The
early cure rate was similar in the two groups: 98.9% (CI
97–100%) in M arm and 96.8% (93–100%) in Q arm. The
extended follow-up was completed by 135 subjects (72.2%) with
no recrudescences. There were no differences in the parasite
clearance time, but patients in the M group had lower mean
fever clearance time (35.9 h vs. 44.4 h, respectively, P ¼ 0.05)
and lower mean hospital stay time (3.9 days vs. 4.6 days,
respectively, P ¼ 0.007). The overall proportion of reported side-
effects was similar in the two arms, but patients in the M arm
had a signiﬁcantly higher rate of central nervous system (SNC)
disturbances (29.0% vs. 9.6%, P < 0.001).
Conclusion: Early and late cure rate were similar for a 3-day regi-
men of quinine-SP compared with meﬂoquine. Patients treated
with meﬂoquine had a shorter fever clearance time and time of
hospital stay.
O297 Retrospective study of imported malaria diagnosed
in Mallorca, Spain
M. Rotger, C. Lloret, T. Serra, S. Pons, M.A. Vicente, A. de Lucio,
J.L. Perez
Palma de Mallorca, Madrid, E
Objectives: To evaluate the epidemiology, clinical and laboratory
results of imported malaria diagnosed in Mallorca.
Methods: We included all malaria episodes diagnosed from Jan-
uary 1995 through November 2003 at the University Hospital
Son Dureta by a positive blood smear. Species of plasmodia
were identiﬁed by the blood smear and/or seminested multi-
plex PCR. Severe malaria was deﬁned according to WHO cri-
teria.
Results: A total of 79 malaria episodes were identiﬁed. We found
Plasmodium falciparum in 54 episodes (68%), P. vivax in 10 (13%),
P. malariae in two (3%), P. ovale in one (1%), mixed infection in
four (5%), and unspeciﬁed plasmodia in eight (10%). Most (93%)
P. falciparum infections were acquired in Africa, while ﬁve of 10
P. vivax infections where acquired in Latin America. Medical
records were available for 65 episodes (82%); median age was
28 years (range 2–71 years), 66% were males. Eighteen patients
(28%) were travellers and 47 patients (72%) were immigrants, of
whom 22 reported recent travel (<1 year of malaria onset) to their
country of origin. Thirty patients (46%), mostly immigrants, had a
history of previous malaria. Among travellers, only two took che-
moprophylaxis correctly, others took no prophylaxis (n ¼ 15) or
took it incorrectly (n ¼ 8). Most patients (92%) were hospitalised.
The median of duration of symptoms at diagnosis time was docu-
mented for 56 patients and was 3.5 days (range 0–30). The most
common reasons for consultation included fever (86%), headache
(51%) and chills (49%). Interestingly, nine patients (all immi-
grants) reported no symptoms at the time of diagnosis. At presen-
tation, the following physical signs were present: fever (61%),
lymphadenopathy (11%), hepatomegaly (42%), splenomegaly
(44%), jaundice (11%), and haematuria (10%). Thrombocytopenia
(<150  109/L) was reported in 38 (58%) of patients followed by
anaemia (haemoglobin levels below 12 g/dL) in 34 (52%) patients.
Only two patients (3%) had severe malaria and no episode was
fatal.
Conclusions: Most malaria episodes were caused by P. falciparum
and involved immigrants who acquired malaria either before
immigration to Spain or during a visit of their country of ori-
gin. We recommend performing a blood smear examination for
malaria in this high-risk patient group. Enforcing adequate che-
moprophylaxis during a visit of malaria-endemic areas, includ-
ing immigrants, may represent an efﬁcient strategy to prevent
malaria.
O298 Ultrasound guided ﬁne needle aspiration biopsy in
the diagnosis of visceral Leishmaniasis
A. Giorgio, G. de Stefano, V. Scala, G. Liorre, A. Di Sarno,
A. Sullo, P. Sorrentino
Naples, I
Background: We report our experience with US-guided ﬁne needle
aspiration biopsy (FNAB) of the spleen in the diagnosis of visceral
leishmaniasis in patients with negative sternum needle aspiration
(SNAB).
Patients and methods: We reviewed clinical and imaging records of
16 patients (11 male; age range: 11–48 years) affected by visceral
Leishmaniasis. All patients had previously undergone SNAB that
had failed to show Leishmania parasites in all cases. The maximum
spleen diameter was 14–21 cm (mean:17 cm). Blood scores were :
platelets – 60.000 to 120.000 (mean 79.000); Prothrombin activity:
67–100% (mean 87%). We performed US guided spleen FNAB
with a 22G  9 cm length spinal needle.
Results: All the slides from spleen FNAB were positive for Leishma-
nia amastygotes and all the cultures were positive for Leishmania
infantum (sensitivity 100%).
Complications: The procedure was well tolerated in nine patients.
Four patients complained mild to moderate pain in the upper left
abdominal quadrant and showed haemoperitonaeum in the left
subdiaphragmatic space at US (thickness 0.5–2 cm) within a few
minutes from the spleen FNAB. Another patient, 24 h after the
procedure, referred left thoraco-lumbar pain and showed left sub-
diaphragmatic blood collection (thickness 3 cm) without apparent
lesions of the spleen capsule at US. All ﬁve patients only under-
went US daily follow-up for 2–5 days that showed complete reso-
lution of the peritoneal ﬂuid collection. In no case blood
transfusion was required.
Conclusions: US-guided spleen FNAB is an highly sensitive techni-
que in the diagnosis of visceral leishmaniasis (100% in our experi-
ence). However, it can cause haemoperitonaeum also in patients
with slight alteration of coagulation parameters (ﬁve of 16, 31%
in our series), therefore, it should always be performed only in
case of negative result of SNAB.
O299 Short-course liposomal amphotericin B in the
treatment of infantile visceral leishmaniasis: the Italian
experience
A. Cascio, L. di Martino, P. Occorsio, R. Giacchino, S. Catania,
A.R. Gigliotti, C. Aiassa, C. Iaria, S. Giordano, C. Colomba,
V. Frasca Polara, L. Titone, L. Gradoni, M. Gramiccia, S. Antinori
Messina, Naples, Genoa, Rome, Palermo, Milan, I
Objectives: To evaluate in a retrospective analysis the efﬁcacy and
the safety of a short course of liposomal amphotericin B (L-AmB)
in infantile cases of Mediterranean visceral leishmaniasis (VL)
diagnosed over a 10-year period in Italy.
Patients and methods: Patients diagnosed as having VL consecu-
tively admitted from December 1992 to December 2001 at four
main referral childrens’ hospitals of Italy and treated with six
intravenous doses of 3 mg L-AmB/kg given on days 1–5 and 10
(a total dose of 18 mg/kg) were included. Demographic data,
nutritional status, underlying diseases, clinical and laboratory
ﬁndings and therapy outcome were considered.
Results: A total of 164 HIV-negative children (median age
1.6 years, range 4 months–14 years) were enrolled. All the patients
responded clinically to treatment and did not present adverse
events related to drug infusion. Seven patients (4.3%) had a clini-
cal and parasitological relapse 3–15 months after therapy. All
relapses were successfully retreated with 3 mg L-AmB/kg for
10 days consecutively (a total dose of 30 mg/kg).
Conclusion: This study highlights the efﬁcacy (>95%) and safety of
the 6-dose L-AmB regimen and validates it as a ﬁrst-line treat-
ment for Mediterranean visceral leishmaniasis in children.
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O300 An open, randomised controlled trial of penicillin,
doxycycline, and cefotaxime in patients with severe
leptospirosis
Y. Suputtamongkol, K. Niwatayakul, C. Suttinont, K. Losuwanaluk,
R. Limpaiboon, W. Chierakul, V. Wuthiekanun, S. Triengrim,
M. Chenchitikul, N. White
Bangkok, Loei Province, Nakhon Ratchasima Province, Bureerum
Province, Udornthani Province, Nondhaburi, TH
Objective: To compare the efﬁcacy and safety of parenteral
doxycycline, cefotaxime and penicillin in the treatment of severe
leptospirosis.
Methods: Between July 2001 and December 2000, an open label
randomised study in patients with suspected severe leptospirosis
was conducted in 540 patients admitted to four hospitals in North
Eastern Thailand; Udornthani Hospital, Udornthani Province;
Maharaj Nakhon Ratchasima Hospital, Nakhon Ratchasima Pro-
vince, Loei Hospital, Loei Province and Ban Mai Chaiyapod Hos-
pital, Bureerum Province.
Results: A total of 252 (47%) patients had serological or culture
conﬁrmed leptospirosis. Overall mortality was 4.8%. There were
no signiﬁcant different between the antibiotics in mortality, defer-
vescence, or time to resolve laboratory overall, or in the subgroup
of patients with conﬁrmed leptospirosis. Rickettsial infection was
diagnosed in 132 patients, and in these patients doxycycline was
superior to penicillin.
Conclusion: Doxycycline or cefotaxime are satisfactory alternatives
to penicillin for treatment of severe leptospirosis.
O301 A study on some epidemiologic and paediatric
aspects of toxocarosis in Hungary
Z. Sze´na´si, O. Bede, J. Danka, K.N. Horva´th, I. Kucsera, E´. Fok,
E. Orosz
Budapest, Szeged, HUN
Objectives: Toxocarosis is the most frequent human helminthosis
in Hungary. Most of the clinical symptoms are nonspeciﬁc, thus,
its diagnosis depends considerably on laboratory methods, such
as ELISA and Western blot (WB) techniques. The objectives of our
study was to determine the frequency and distribution of Toxocara
seroprevalence in the different regions and the different age
groups of Hungary. Special reference will be given to children in
whom anti-Toxocara antibodies were determined for differential
diagnostic reasons, such as exanthemata and/or asthmatic symp-
toms.
Methods: Sera were obtained from 6985 asymptomatic individuals
representing all age groups of the population of Hungary distrib-
uted to 20 different regions. Sera of 1427 symptomatic children
aged <1–14 years were also obtained from different regions of
Hungary. Seroprevalence of the symptomatic children were com-
pared with 1605 asymptomatic children. Toxocara seroprevalence
was measured with NOVATEC Toxocara ELISA IgG kit. In case of
negative or low-positive values obtained by ELISA, the results
were conﬁrmed by WB method (LDBIO).
Results: The sera of 1977 persons of 6985 asymptomatic indivi-
duals were found to be positive for Toxocara IgG antibody
(28.3%). The lowest prevalence (17.6%) was found in Budapest,
the highest ones were found in Szabolcs-Szatma´r-Bereg (39.4%)
and Hajdu´-Bihar (38.2%) countries. Seropositivity rapidly
increases by age reaching 37.0% at the age of 10–14 years. A sig-
niﬁcantly higher percentage (31%, P ¼ 0.01) of Toxocara seroposi-
tivity was found in children suffering from bronchial asthma
when compared with the 17% seropositivity measured in asymp-
tomatic control groups of children. The borderline anti-Toxocara
IgG ELISA results were found to be positive with WB method.
Conclusions: In Hungary, 28.3% of the population has anti-Toxo-
cara IgG antibodies. The highest positivity (39.4%, 38.2%) were
found in the most under-developed regions of Hungary, the low-
est one (17.6%) was found in the capital. Probably, this reﬂects
the differences in the hygienic conditions. The Toxocara seropreva-
lence rapidly increases by the age. This can be explained by the
frequent contact of children with contaminated soil. A signiﬁ-
cantly higher percentage of Toxocara seropositivity was found in
asthmatic children compared with the asymptomatic children.
The Western blot technique is very useful in conﬁrming the bor-
derline and negative anti- Toxocara IgG values obtained by ELISA
method.
O302 Serological evidence for the occurrence of tick-borne
diseases in northern Mongolia
G. Walder, E. Lkhamsuren, D. Abmed, T. Batmunkh, D. Orth,
M.P. Dierich, R. Wu¨rzner, G. Heinz
Innsbruck, A; Ulaanbaatar, MN; Moscow, RUS; Vienna, A
Objective: The aim of our study was assess the seroprevalence of
antibodies against the TBE virus in patients from northern and
central Mongolia.
Methods: During August 2003, 223 serum samples were drawn
from volunteers of Selenga aimag, 110 serum samples were drawn
from volunteers of Bulgan aimag and central aimag each. They
were screened by a commercially available IgG ELISA (Dade
Behring) and positive samples were subjected to a neutralisation
assay. Samples, which yielded a neutralisation at 1:10 or higher
were rated as positive.
Results: Eleven patients from Selenga (4.7%) and one patient from
Bulgan (0.9%) were found seropositive against TBE virus. No
sample from central aimag was found positive. Neutralisation
titres lay between 1:10 and 1:60. About 20% of the patients
reported a tick bite, which were usually acquired in the northern
part of the country.
Conclusions: Tick-borne encephalitis is likely to exist in the north-
ern parts of Mongolia, where Ixodes scapularis occurs. In the cen-
tral parts of the country, serological ﬁndings do not support the
occurrence of this disease.
O303 The United Kingdom National External Quality
Assessment Scheme for Parasitology: Toxoplasma Subschemes
M. Kettelhut, P. Chiodini, D. Ho-Yen, R. Holliman, V. James,
P. Thomas
London, Inverness, Swansea, UK
Objectives: The Toxoplasma Serology Subschemes are operated
from the department of Clinical Parasitology, Hospital for Tropi-
cal Diseases, London in collaboration with the Toxoplasma Refer-
ence Laboratories in Inverness and Swansea and the Department
of Medical Microbiology, St George’s Hospital, London. The sub-
schemes consist of toxoplasma serology and toxoplasma IgM are
designed to provide information allowing participants to gain an
insight into their performance in the detection of Toxoplasma anti-
bodies and to take individual action to investigate and remedy
any discrepancies. Participation is open to UK and overseas
microbiology laboratories.
Methods: Serum samples for the detection of Toxoplasma IgG antibo-
dies are distributed to 312 laboratories and to 213 laboratories for
the detection of Toxoplasma IgM antibodies. Following analyses of
results, a full report is provided for all participants. This includes
speciﬁc comments on the Toxoplasma-speciﬁc antibody content of
each specimen and, for one specimen, its relevance to the clinical
problem. Serum samples, pre and postdistribution testing of sam-
ples and teaching information are provided by the Toxoplasma
Reference Laboratories in Inverness and Swansea and the Depart-
ment of Medical Microbiology, St Georges Hospital, London.
Results: In general, participants experience very few problems
with an average of 98% of participants obtaining the correct result
for Toxoplasma IgG detection since 1993 and 95% obtaining the
correct results for Toxoplasma IgM detection since 1999.
Conclusion: Although participants experience very few problems,
the Toxoplasma subschemes have highlighted some problems with
the detection of Toxoplasma antibodies. The most common problem
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is failure to detect low positive titres (i.e. dye test 16 IU/mL and
Eiken latex agglutination test of 1:16) by many participants, which
were related to participants deviating from the manufacturer’s
instructions as noted from the range of titres and cut-off titres
reported. These specimens highlighted the importance of adhering
to the manufacturer’s instruction and choosing the correct assay for
the clinical group of interest.
O304 Web-based guidelines for the evaluation of fever in
returning travellers and migrants (http://www.fevertravel.ch):
promotion and appropriateness for the primary care physician
V. D’Acremont, A. Ambresin, B. Burnand, B. Genton
Lausanne, CH
Background: Fever upon return can be caused by diseases that are
rapidly fatal if left untreated. The differential diagnosis is wide.
Physicians often lack the necessary knowledge to appropriately
take care of such patients.
Objectives: To develop, promote and assess practice guidelines for
the ﬁrst evaluation of patients presenting with fever upon return
from a tropical or subtropical country.
Methodology: After a systematic review of the literature, a decision
chart was constructed and extensively discussed with a national
and international panel of experts in travel/tropical medicine,
specialists in infectious diseases and internal medicine as well as
by private practitioners. After publication (J Travel Med 2003; 10
Suppl. 2), a website was created and is now freely available on
the internet for the medical personal who want to use the guide-
lines (http://www.fevertravel.ch). Presentations and tutorials
were run at national and international travel/tropical and internal
medicine meetings to promote the use of the guidelines. At the
same time, a pilot study was conducted at the Medical Outpatient
Clinic to assess the feasibility and safety of the guidelines when
used in the context they have been designed for. Physicians on
call were asked to use the decision chart when caring for travelers
or migrants with fever upon return. Navigation through the deci-
sion chart was recorded. Diagnostic tests performed, treatment
administered, initial and ﬁnal diagnosis and ﬁnal outcome were
collected prospectively. When the proposed attitude was not fol-
lowed, reasons for nonadherence were investigated.
Results: From April to November 2003, 1775 visits were made to
the website, mainly in Europe and the USA. Since study initiation,
53 physician/patient pairs have been included. Results on this
ﬁrst sample show that 51% were fully adherent to our guidelines.
The main reasons for nonadherence were no repetition of malaria
tests (nine of 23), no chest X-ray in case of cough (seven of 13)
and no presumptive treatment for fever + diarrhoea (four of 11),
all in the absence of alternative documented diagnosis.
Conclusion: Although considered very useful by our primary care
physicians, the guidelines will need reﬁnements following inves-
tigation on a larger sample size. Infectious disease specialists
who work in collaboration with primary care or emergency phy-
sicians are welcome to join the study when internet support for
complete recording of the path followed by the user will be
available.
Novel advances in antifugal therapy (Symposium arranged Vicuron)




Serious fungal infections affect patients with compromised
immune systems and are often fatal despite current treatments. A
major concern when treating serious fungal infections is the
agent’s ability to eradicate the fungi responsible for infection
rather than simply inhibit or slow its growth. Most importantly,
empiric therapy requires broad-spectrum agents that can eradicate
a wide range of fungi that cause infection. An entirely new class
of antifungals, the echinocandins, have a novel mode of action.
Three new compounds in this class (caspofungin, anidulafungin,
and micafungin) appear to be potent in vitro against the fungi
most often responsible for serious systemic infections, Candida
and Aspergillus. These compounds are noncompetitive inhibitors
of (1,3)-a-D-glucan synthase, an enzyme involved in the synthesis
of glucan, which is the major component of the cell wall of many
fungi. The echinocandins are different with respect to their phar-
macokinetic and pharmacodynamic properties, however trials
comparing these agents are not currently available. Anidulafungin
is chemically degraded, not metabolised through the cytochrome
P450 system, and not excreted renally. Other members of the
class, caspofungin and micafungin, are also chemically degraded,
but in contrast to anidulafungin, undergo some hepatic metabo-
lism. Chemical degradation may allow for fewer of the drug inter-
actions and side effects seen with the azole class. In general, the
echinocandins have improved antifungal activity and in particu-
lar, anidulafungin is highly effective both in terms of breadth of
spectrum and potency as compared with natural echinocandins.
Anidulafungin is a broad-spectrum agent that has shown potency
in vitro against Candida and Aspergillus. Preclinical studies have
shown that a 5 min exposure to anidulafungin in vitro kills more
than 99% of Candida, including ﬂuconazole-resistant strains. Early
clinical studies have suggested an improved safety proﬁle com-
pared with that of available agents and the lack of drug-to-drug
interactions (1). In addition, no dose modiﬁcations are required
for anidulafungin in patients with any degree of hepatic and or
renal impairment (2). It is important to note that the application
of pharmacodynamic principles to antifungal drug therapy of
Candida infections has provided an understanding of the relation-
ship between drug dosing and treatment outcome, which is simi-
lar to that observed for antibacterial pharmacodynamics. Initial
observations of the pharmacodynamics of triazoles have corre-
lated with the results of clinical trials and have proved useful for
validations of in vitro susceptibility breakpoints (3).
References
1. Krause D, Schranz J, Birmingham W. 41st Annual IDSA, San Diego,
9–12 October 2003.
2. Stogniew W, Pu F, Henkel T, Dowell J. Anidulafungin biotransformation
in humans is by degradation not metabolism. Poster presented at 2003
ECCMID.
3. Andes D. Antimicrob Agents Chemother 2003;47(4):1179–1186.
S310 Emerging epidemiology of fungal infections
F. Menichetti
Pisa, I
Over the past decade, changes have occurred in the patterns of
Candida species and infections and in fungal pathogen dominance.
From 1980 to 1990, Candida albicans was very common, accounting
for 61% of nosocomial fungal infections. C. glabrata accounted for
approximately 8% of such infections that were reported to the
Centers for Disease Control and Prevention in the USA (1). Other
organisms, like Aspergillus, also cause invasive mycoses and are
difﬁcult infections to manage especially since they target immuno-
compromised patients. Data collected from surveillance programs
in the USA during the 1990s demonstrate that C. albicans is still
the primary pathogen. Candida glabrata is now the second leading
cause of candidal bloodstream infections in the USA (2). The use
of low-dose ﬂuconazole may be contributing to the emergence of
nonalbicans Candida species (NAC), most notably C. glabrata and
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C. krusei. A current limitation to ﬂuconazole use is its in vitro
activity against NAC species. NAC species are emerging as a
growing cause of invasive candidiasis in all immunocompromised
patient groups. This knowledge makes the initial antifungal drug
choice critically important. The low minimum inhibitory concen-
trations (MICs) of echinocandins against a broad spectrum of Can-
dida species offer great potential in treating invasive Candida
infections. Recently published guidelines from the Infectious Dis-
ease Society of America (IDSA) review strategies for treatment of
most forms of invasive candidiasis (3). In general, amphotericin B-
based preparations, the azole antifungal agents, and the echino-
candin antifungal agents play a role in treatment, whereby the
proportions of patients to be treated for systemic infections with
polyenes is decreasing continuously.
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S311 Anidulafungin, a new echinocandin and its role in
the management of invasive Candida infections
P. Pappas
Birmingham, USA
Anidulafungin is a novel echinocandin that has demonstrated
potency in vitro and in vivo against medically signiﬁcant fungi,
including Candida and Aspergillus (1). Consistent with its mechan-
ism of action, anidulafungin is fungicidal for Candida spp. and
there is no cross-resistance with older classes of antifungal agents
(e.g. azoles, polyenes) that have different molecular targets. Iso-
lates of Candida that are resistant to azoles or amphotericin B exhi-
bit no cross-resistance to anidulafungin. To date, resistance to
anidulafungin has not been detected in vitro, in animal infection
models, or in the clinic. Pharmacokinetic (PK) studies indicate that
anidulafungin has predictable PK. The half-life in humans and
most animal species is 1 day, which allows for once-daily dosing
in the clinic. PK data also show that anidulafungin dosage adjust-
ments are not required for adult patients on the basis of age,
weight, gender, race/ethnicity, hepatic or renal impairment
(including haemodialysis), or concomitant medications. Clinical
studies of anidulafungin are evaluating its safety and efﬁcacy in
the treatment of patients with oesophageal candidiasis, candide-
mia, and other forms of invasive candidiasis, azole-refractory
mucosal candidiasis, as well as invasive apergillosis. This antifun-
gal has proven to be highly effective in eradicating Candida spp.
in clinical studies of oesophageal candidiasis and invasive candi-
diasis/candidemia. Anidulafungin was well tolerated by patients
in a large comparative phase 3 oesophageal candidiasis study and
a phase 2 invasive candidiasis study. Results of a phase 1 drug–
drug interaction study demonstrate that the combination of anidu-
lafungin and cyclosporin A may be administered safely and may
not require dosage adjustment of either drug (2).
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Medical advances such as newer, aggressive chemotherapy, the
frequent use of bone marrow transplantation, and organ trans-
plantation have given rise to an increased incidence of invasive
aspergillosis (IA) that parallels the increase in immunocompro-
mised patients. The incidence of invasive mould infections follow-
ing hematopoietic stem cell transplantation has tripled (1) with
Aspergillus species the most common pathogen. For decades, the
treatment for IA has been relatively toxic. Amphotericin B is only
moderately effective against IA and causes signiﬁcant nephrotoxi-
city and infusion-related toxicity (2). Voriconazole has recently
been shown to be superior to amphotericin B in primary therapy
of IA (3). However, nearly half of the patients are unresponsive to
voriconazole and further improvement in therapy is needed. Cur-
rently, there are many new antifungals under development or in
clinical trials, including new classes of drugs with novel targets
such as the echinocandins. The activity of echinocandins against
Aspergillus species has been studied for over a decade and its
potential use in aspergillosis has been documented. In particular,
the activity of anidulafungin against Aspergillus spp. has been
demonstrated under a variety of growth conditions. As is the case
for Candida, the apparent MICs of anidulafungin for Aspergillus
vary with the culture medium. In recent studies, potentially useful
synergy between anidulafungin and itraconazole or voriconazole
was observed against Aspergillus isolates (4) and lack of antagon-
ism was seen with amphotericin B (5). The use of newer antifun-
gals and the potential synergistic effect of antifungal
combinations, possibly with cytokine therapy, provides a basis for
improved treatment strategies to combat IA.
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Meningococcal infection: still a challenge in the 21st century




Invasive meningococcal disease (IMD) is still one of the most dan-
gerous infectious diseases, despite early antibiotic treatment and
development of modern intensive care for the patients. The
National Reference Laboratory (NRL) for Meningococcal Infec-
tions in Prague has been dealing with this disease since the 1970s
using a multi-discipline approach to the study of the causative
agent and host factors. The NRL has a collection of 3500 N. menin-
gitidis strains isolated from both patients with IMD and healthy
carriers over a period of more than 30 years. Clonal analysis of
meningococcal populations by multilocus sequence typing (MLST)
identiﬁed hypervirulent complexes which are spread worldwide
and cause severe IMD with a high case fatality rate. The interna-
tional collaborative studies showed differences between meningo-
coccal populations causing IMD and the carriage lineages. The
meningococcal population from carriers was highly diverse and
most nucleotide sequence diversity resulted from the reassortment
of alleles by horizontal genetic exchange (J Clin Microb
2000;38:4492). Hypervirulent complex ST-11 of Neisseria meningiti-
dis C emerged in the Czech Republic in 1993 and caused an
increase in morbidity and case fatality rate of IMD. We developed
a method for MLST directly from clinical specimens (Epidemiol
Infect 2002;128:157) which allows more precise surveillance of
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IMD. Recently, hypervirulent complexes of serogroup B (ST-32
and ST-18) have started to replace ST-11 and to cause a high case
fatality rate of IMD as well. Higher and quicker adhesion to
epithelial cells with lower phagocytosis as revealed in strains iso-
lated from IMD compared with those from healthy carriers
(Microbiologica, 2000;23:185) also conﬁrmed the difference between
these meningococcal populations. Analysis of correlation between
socioeconomic and indoor enviroment factors and risk of IMD
showed strong association of IMD with smoking (Arch Dis Child
2000;83:117). Hypervirulent complex ST-11 which emerged in the
Czech Republic in 1993 caused an increase in antimeningococcal
herd immunity among healthy population against this meningo-
coccal complex (Epidemiol Infect 1999;123:193). However, naturally
occurring antimeningococcal antibodies are not able to stop the
spread of the hypervirulent complex in the population. A strategy
of vaccination targeted to the part of population at highest risk of
IMD was adopted in the country.
Cancer and infection: a two-way road (Joint symposium arranged with IATG-EORTC)
S328 Tuberculosis and stem cell transplantation
H. Akan
Ankara, TR
Tuberculosis (TB), once accepted as a disease that seemed uncur-
able, lost its importance in the last decades of the 20th century.
Tuberculosis is reemeerging in recent years. The main reasons for
this problem are weakened TB control programs, HIV/AIDS and
immigration and drug resistance. According to the reports of the
WHO; one-third of the world’s population has latent TB, 9 million
cases of active TB emerge annually, causing 2–3 million deaths.
Most new cases occur in the most populated nations such as India
and China. Although the incidence of tuberculosis declined in
North America and Western Europe, case rates have increased
over the past 10 years. High rates of TB is inevitable in Stem cell
transplantation (SCT) patients because of impaired cellular immu-
nity, T-cell depletion, GVHD, Corticosteroids, high dose che-
motherapy/TBI and the underlying disease. When compared with
the solid organ transplants, TB rates are not as high as expected
in SCT (0.16–2.29%) maybe due to the facts that duration of
immunosuppression is not very long and most SCT are performed
in developed countries where Mycobacterium infections is low. In
the autologous transplants, TB has the same rate with the popula-
tion. In allogeneic setting most of the cases are diagnosed
+100 days posttransplant and acute GVHD is common (64%).
Extrapulmonary TB is not infrequent (15%) and classical pulmon-
ary manifestations of TB are rare. Nonspesiﬁc pulmonary ﬁndings
are frequent. Mortality is high (18.5%) and most of the cases can
be diagnosed and treated before death (90.7%). Prophylaxis may
bring a reduction in TB cases but there will be toxicity related to
the prophylactic agents. A study by Arslan et al. showed that INH
prophylaxis in SCT patients reduced the rates of TB with an
acceptable toxicity. Prophylaxis can be employed in endemic
regions and has to be reserved only for PPD (+) patients or
patients with a previous history of TB. As a conclusion; TB rates
in SCT are parallel to the TB rates in a given population, endemic
TB countries have highest TB rates, there are some ill deﬁned risk
factors such as previous TB history, positive PPD, GVHD, T-cell
depletion and, corticosteroids. There is no need for prophylaxis in
autologous SCT. There is a satisfactory response to standart anti-
TB therapy, but mortality is still high, early diagnosis improves
response to anti-TB therapy and drug resistant TB is not a pro-
blem at this moment.
Vector-transmitted diseases in the tropics
S330 Epidemiology of imported malaria in Europe
T. Jelinek for TropNetEurop
Malaria continues to cause high morbidity among European tra-
vellers. A thorough recording of epidemiological and clinical
aspects of imported malaria has been shown to be helpful for
detecting new outbreaks and areas of developing drug resis-
tance. Data from national surveillance systems in Europe vary
greatly in terms of quality and reliability. It has been estimated
that coverage rates are at or below 50% of actual cases. In par-
ticular imported malaria through immigrants, many of them
being illegal, are rarely reported. Since there is a general lack of
surveillance data for imported infectious diseases in Europe, the
European Network on Imported Infectious Disease Surveillance
(TropNetEurop), an electronic network of clinical sites related to
imported infectious diseases was founded in February 1999. The
network is designed to effectively detect emerging infections of
potential regional, national or global impact at their point of
entry into the domestic population. From the beginning, malaria
has been one of the major targets within this network of 46
clinical sites throughout 16 European countries. Judging from
the data provided by national systems of disease notiﬁcation,
TropNetEurop covers approximately 12% of all malaria patients
seen in Europe. Reports from immigrants and European patients
with falciparum malaria are continuously analysed for epide-
miological information and clinical features. Data from indivi-
dual European regions are quite diverse, reﬂecting the local
pattern of immigrants and the amount of international travel in
the local population. By far the most infections are being
imported from West Africa, suggesting a high risk for falci-
parum malaria for travel to that region. Data show that Eur-
opeans or other nonimmune travellers suffer more complications
during the clinical course of the disease. Consequently, deaths
occur almost exclusively in this group. Data reported by mem-
ber sites of TropNetEurop can contribute to the understanding
of epidemiology and clinical characteristics of imported falci-
parum malaria.
S331 Filarial infections – a risk for travellers?
C. Hatz
Basle, CH
Filarial infections present with lymphatic (Wuchereria, Brugia),
cutaneous (Onchocerca, Loa, Diroﬁlaria, Drancunculus), ocular
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(Loa, Diroﬁlaria) or pulmonary (Diroﬁlaria) manifestations.
Symptomatic infections usually occur after repeated insect bites,
or exceedingly rarely by ingestion of infested water (Dracuncu-
lus), in endemic areas. Thus, these infections are rarely seen in
travellers. Long-term travellers and expatriates living in infested
areas may be affected, but the most likely persons to be diag-
nosed in industrialised countries with such an infection are
migrants who have been living in their endemic countries of
origin. The low risk for travellers is reﬂected in the scientiﬁc
literature, revealing mainly anecdotal reports among people
returning from endemic areas. However, the possibility of treat-
ing some of these rare, often long-standing infections with
effective drugs such as ivermectin, diethylcarbamazine and
albendazole render the diagnosis important. Finding the para-
site or antibodies against the various worms should be in the
hands of experts who can also advise general practitioners on
their geographical distribution and on their clinical features.
The disease management approach for the returned traveller or
migrant with ﬁlarial infections is often different from the
approach taken for ﬁlarial-infected residents in endemic coun-
tries.
S332 Imported and autochthonous Leishmaniasis
J. Alvar
Madrid, E
The Leishmania genus is constituted by two dozens of human
pathogenic species, causing three major clinical forms: cutaneous,
mucocutaneous and visceral leishmaniasis, with speciﬁc geogra-
phical distribution along 88 endemic countries. All Leishmania spe-
cies share a typical metaxenic cycle but each with given
vertebrate reservoirs, and sand ﬂy vectors, conditioning endemic
or epidemic transmission. A re-emergency of leishmaniasis in dif-
ferent areas of the world is proven due to agriculture and irriga-
tion programmes, urbanisation, deforestation, population
displacements, famine, introduction of infected reservoirs or sand
ﬂy neo-colonisations, human behaviour changes and international
mobility, aspects that are anlysed in this paper. Emphasis is paid
to Mediterranean leishmaniasis updating some epidemiological
features on HIV–Leishmania co-infection and its transmission when
sharing contaminated syringes, blood banks, the capability of
infected dogs (asymptomatic or symptomatic) to transmit the
parasite to sand ﬂies both before and after chemotherapy, and
leishmaniasis imported by (or exported to) international travellers.
The clinical relevance of rapid diagnostics (symposium arranged with ESGMD)
S334 Real-time PCR detection of group B streptococci
(GBS) in less than 1 h: a clinical revolution
M.G. Bergeron
Que´bec City, CAN
Group B streptococci (GBS) are an important cause of neonatal
sepsis and meningitis. Implementation of selective intrapartum
chemoprophylaxis based on either a screening-based approach or
a risk-based approach has led to a substantial decrease in the
morbidity and mortality of GBS disease. Current ‘gold-standard’
detection methods for GBS are selective broth cultures of com-
bined vaginal and anal specimens collected at 35–37 weeks gesta-
tion. Rapid immunological detection assays, including latex
agglutination-based test, are available. These methods are useful
in rapid identiﬁcation of heavily colonised women, but are unable
to detect light GBS colonisation due to poor sensitivity. Recent
development of real-time PCR and ﬂuorescence labelling technol-
ogies has provided new detection platforms for bacterial identiﬁ-
cation. Combining appropriate, simple and very rapid sample
preparation and DNA extraction methods with real time PCR, our
research group in collaboration with Infectio Diagnostic (IDI) Inc.
have developed, fabricated and commercialised the ﬁrst FDA
approved real time PCR assay that can identify in 30–45 min GBS
in pregnant women in labour. Stat microbiology is here! The
application of these assays in the current prevention strategy
recommended by CDC, will simplify the prevention practice and
rationalise antibiotic use. This rapid GBS DNA based theranostic
test as well as others in development will revolutionise clinical
practice by providing the physician with appropriate microbiol-
ogy information that will immediately orient the management of
his patient.




The development and transnational spread of bacterial antibiotic
resistance is an increasing source of concern and can be reduced
if proper and rapid diagnostic tests can be made available for the
aetiologic diagnosis of infections. Particularly in the diagnosis of
lower respiratory tract infections (LRTI), the lack of a clear dis-
tinction between bacterial and viral aetiologies is a permanent
cause of difﬁcult diagnostic and therapeutic decisions. The devel-
opment of more rapid diagnostic methods might allow better tar-
geting of antimicrobial treatments with minimisation of
unnecessary use of these drugs. For the detection of respiratory
viruses conventional culture techniques are still considered as the
gold standard. However results are mostly available too late to
have an impact on patient management. Newer nonampliﬁcation
methods have become available, e.g. enzyme immunoassays, opti-
cal immunoassays, agglutination assays and immunoﬂuorescence.
Advantages and limitations of these assays will be discussed. The
newest developments include appropriate DNA and RNA based
ampliﬁcation techniques (both NASBA and PCR) for the detection
of an extended number of agents responsible for LRTI. To
increase the diagnostic value of the tests, multiplex formats were
developed. Their sensitivity and speciﬁcity compared favourably
with the corresponding mono formats. Real time ampliﬁcation,
the latest technical progress, produces, within a considerable
shorter time, results with a lower risk of false positives due to
cross-contaminations. As results can be obtained within the same
day, patient management with appropriate therapy or reduction
of unnecessary antibiotic therapy in LRTI will be possible. A num-
ber of technical aspects of these ampliﬁcation assays, and their
advantages will be discussed. Indications for the use of these
rapid techniques in different clinical situations will be discussed.
For the clinical implementation of these tests, a compromise must
be found between test sensitivity, turnaround time and cost.
S336 Cost-effectiveness of real-time PCR for respiratory
viruses in patients hospitalised with lower respiratory tract
infection
A.M. van Loon, J.J. Oosterheert, R. Schuurman, G. Nossent,
I.M. Hoepelman, M. Bonten
Utrecht, NL
Objectives: Because of their sensitivity nucleic acid ampliﬁcation
techniques (NATs) are potentially very attractive for early, rapid
diagnosis of lower respiratory tract infections (LRTI). However,
costs of NATs are high and may preclude their implementation in
routine diagnostic practice. We studied the cost-effectiveness of
NATs for rapid diagnosis of LRTI.
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Methods: Between November 2002 and May 2004, nose–throat
samples were taken from immunocompetent patients hospitalised
for antibiotic treatment of LRTI. The samples were evaluated by
virus culture and by real-time PCR’s for Adenoviruses, Corona-
viruses, Inﬂuenzavirus A/B, Parainﬂuenzavirus 1-4, Rhinoviruses,
RS virus and Chlamydia pneumoniae, Legionella pneumophila and
Mycoplasma pneumoniae. Patients were randomised into one of two
arms, in only one of which PCR results were made available
within 24–48 h to allow modiﬁcation of patient management. In
addition, blood and sputum samples were taken for bacterial cul-
tures and serology for respiratory viruses and atypical pathogens.
Results: Sxity-three consecutive patients (34 men, age 63  16)
were included; 29 (34%) had pneumonia (chest X-ray showing
inﬁltrate). Respiratory viruses were detected by culture in eight
patients, by real-time PCR in 19 patients (30%). Most frequently
detected agents were Inﬂuenzavirus A (n ¼ 9) and Coronavirus
(n ¼ 5). In one patient Inﬂuenzavirus A was cultured, but not
detected by real-time PCR. In 14 patients (22%), the virus
detected by real-time PCR was the only aetiologic agent identiﬁed.
In these patients, antibacterial treatment could have been with-
held. An average standard 10-day course of antibiotic treatment
for a for LRTI costs approximately 450 . Thus, real-time PCR can
reduce antibiotic costs by 14  450 ¼ 6300 in 63 patients. In
practice, however, physicians were reluctant to discontinue anti-
biotic treatment after a positive PCR. Conclusion Antibiotic use
may be reduced using real-time PCR to rapidly identify viral
LRTI. To achieve such reduction, physicians should be willing to
discontinue antibiotic treatment in case of positive PCR-results
and negative routine cultures.
The international dimension of epidemiological typing (Symposium arranged with ESGEM)




Objectives: The introduction of multilocus sequence typing (MLST)
schemes for a number of pathogenic bacterial species has made it
possible to draw rapid global comparisons between different
disease-causing strains via the Internet. In order to fully exploit
this resource, it is necessary to visualise the overall clonal struc-
ture of different species from entire MLST datasets of thousands
of strains. Furthermore, a convenient means is required by which
newly generated data can be compared against these datasets.
Methods: The implementation of a new Java tool, eBURST, freely
available on the www.mlst.net.
Results: The approach produces ‘populations snapshots’ showing
all the major clonal lineages present within entire MLST data and
also successfully untangles short-term patterns of descent within
these lineages.
Conclusions: This approach provides a simple and intuitive means
to visualise large MLST datasets and should help to standardise
the nomenclature describing different clones within different
pathogenic populations.
S338 Genetic portraits of methicillin-resistant
Staphylococcus aureus clones in hospitals and in the community
M. Aires de Sousa, H. de Lencastre
Oeiras, P
Objectives: In order to understand the emergence and spread of
multidrug-resistant methicillin-resistant Staphylococcus aureus
(MRSA), international surveillance systems such as the CEM/
NET (Center for Molecular Epidemiology and International Net-
work) initiative have been created. Over 3500 MRSA isolates
collected between 1992 and 2003 in surveillance studies and
outbreak investigations in hospitals located in Europe, Latin
America, the USA, and Asia were characterised in order to cre-
ate an inventory of MRSA clones in different regions of the
world.
Methods: Isolates were initially characterised by pulsed-ﬁeld gel
electrophoresis, ClaI-mecA polymorphisms, and Tn554 insertion
patterns and their identity was later re-analysed by spa typing,
multilocus sequence typing (MLST), and SCCmec (staphylococcal
cassette chromosome mec) typing.
Results: The large majority of the isolates belonged to a limited
number of clones, namely the Iberian (ST247-SCCmecIA), Brazi-
lian/Hungarian (ST239-III), New York/Japan (ST5-II), Paediatric
(ST5-IV), and EMRSA-16 (ST36-II) clones. In contrast to these epi-
demic clones, minor clones (i.e. clones clearly dominant in some
hospitals but not seen in others) and sporadic isolates (i.e. isolates
recovered only from one or a few patients in a single hospital)
were identiﬁed as well. MLST, spa typing, and SCCmec typing
demonstrated extensive diversity among isolates belonging to
minor clones or sporadic MRSA both in the genetic background
and in the structure of the associated SCCmec elements. Never-
theless, the BURST (i.e. based upon related sequence types) algo-
rithm grouped these isolates into restricted clonal complexes and
predicted that most have evolved from pandemic MRSA clones.
In addition, several of the sporadic MRSA resembled community-
acquired MRSA isolates in properties that included a relatively
limited multiresistance pattern, diversity of genetic backgrounds,
faster growth rates, and a frequent association with SCCmec type
IV.
Conclusions: There is evidence of the existence of only a few noso-
comial epidemic MRSA clones spread worldwide. Some of the
MRSA strains described as community-acquired may have origi-
nated in hospitals, while others seemed to have been transfered
from the community to the hospital.
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S339 Review of MDR tuberculosis in Russia
S. Popov, T. Sabgaida, V. Puzanov, S. Borissov, B. Kazenny,
E. Nemzova
Moscow, RUS
Up to 1990 Russia had a recession of the main epidemiological
indicators in tuberculosis. At active revealing the incidence rate
was about 38 per 100 000. 700 TB laboratories gave an appro-
priate picture of drug resistant TB: H: 10–16%; R:6–8%; E: 4–
6%; S: 14–18%. The problem to keep standard treatment regi-
mens from 1992 to 1998, active migration, reduction of number
of laboratories, generated resistant TB pool. The size and their
inﬂuence on an epidemic situation in Russia could not be pre-
dicted. In 1996 the data came to: H: 24.6%; R: 18.7%, E: 19.5%,
S: 34.3%. Since 1978 until 1998 14 million cultures and 1.17 mil-
lion DST was performed. This data was not divided according
to attributes for new cases and previously treated cases and the
MDR estimation was not made. In 1999 the registration form of
MDR was included in the federal annual statistics. The annual
territorial reports on MDR varied from 1.3% (Ivanovo reg.) up
to 47.1 % (North Caucasus) and reﬂected regional problems. To
avoid the further spread of TB the new conception of TB
National Programme was created. This programme includes
detection, treatment, laboratory work, registration, quality con-
trol. For an estimation of resistant TB prevalence and recogni-
tion of approach to MDR treatment a few projects were
developed. These projects were developed since 1998 at partici-
pation of WHO, CDC and other international agencies. The pro-
jects cover six regions with the population of more then
10 million people and include centralisation of TB service, the
personnel training, external quality assessment of drug suscept-
ibility test (DST), use of uniform laboratory and registration
techniques, development of regiment treatments. The DST are
performed by the method of absolute concentration. For an
external quality assessment for region laboratories 50% of resis-
tant and 25% of susceptible strains are quarterly directed for
testing to Federal reference laboratory and independently CDC.
The data was very close. So there is reliable data to estimate
the increase of the MDR prevalence (from 1.4% in 1999 up to
7.7% in 2002 among new cases, Ivanovo region). In 2003 the
project of MDR TB treatment started in Orel region. According
previously data the good results were achieved in 72% of MDR
cases. During the programme the territorial MDR indicators
remained constant among new cases. The adverse effects during
the treatment result in need to develop reliable DST for second
line TB drugs and quality assessment.
S341 Microbial surveillance of diphtheria across Europe
A. Efstratiou, A. De Zoysa, J. White, N.S. Crowcroft on behalf of
DIPNET
Global resurgence of diphtheria during the last 14 years, mainly
within the Newly Independent States (NIS) of the former Soviet
Union and South East Asia, has stimulated renewed interest in
this ‘vaccine preventable disease’. A major goal for many inter-
national has been to improve surveillance for early detection of
emerging and re-emerging diseases by the establishment of
laboratory and disease speciﬁc networks. These epidemics have
major implications for Europe and its associated countries,
where there are many immigrants from the NIS and Eastern
Europe. Monitoring the spread of diphtheria and related infec-
tions caused by toxigenic strains of Corynebacterium diphtheriae
and C. ulcerans has been the basis of several European Commis-
sion funded programmes during 1998–2004. These programmes
along with effective liaison with WHO EURO have established a
network of Diphtheria Reference Centres across Europe and
have improved communication and exchange of information
between countries. Initially, the European Laboratory Working
Group on Diphtheria, ELWGD, was established at the request of
WHO EURO in 1993, in response to the epidemics in the NIS,
which comprised the key microbiologists responsible for
diphtheria in each country. Participation within the ELWGD
grew since 1993, from 10 to 40 countries globally by 2002. The
effective collaboration was signiﬁcantly enhanced by the partici-
pation of the key epidemiologists from each country in 2000, to
establish DIPNET, the Diphtheria Surveillance Network, now
ofﬁcially recognised by the EU as a disease speciﬁc network.
The collaborations have enhanced laboratory diagnostics consid-
erably and have also established a deﬁnitive genotyping scheme
for the identiﬁcation of epidemic and nonepidemic clones. Ribo-
typing was identiﬁed by the ELWGD as the most discriminatory
method for tracking the international dissemination of
diphtheria, particularly useful in the NIS epidemics for identify-
ing the main epidemic genotype, ‘Sankt Petersburg’ and also for
identifying the geographic origin of strains globally. More than
70 ribotypes have been recognised thus far to build and estab-
lish a genotype database. C. diphtheriae appears to be a species
with signiﬁcant genetic diversity with the potential for changes
that could facilitate the appearance of large-scale epidemics, thus
highlighting the importance of monitoring the molecular epide-
miology of strains globally.
Auditing antimicrobial prescriptions in Europe (Symposium arranged with ESGAP)
S342 Audit Project Odense for General Practice
K. Schaefer, A. Munck
Roskilde, Odense, DK
Background: For the past 10 years, Audit Project Odense (APO)
has been performing audits in general practice in the Nordic
countries. Audits on the diagnosis and treatment of respiratory
tract infections (RTIs) have been the most successful.
Objective: The aim of the present study was to maintain, and pos-
sibly improve, a restrictive antibiotic policy for RTIs via audit of
general practitioners (GPs), feed back of results and group discus-
sion.
Methods: In November to December 2001, an audit on diagnosis
and treatment of RTIs was carried out in Denmark, Norway, Swe-
den, Finland and the Faroe Islands. In Denmark, 366 GPs took
part in the project. Audit data were registered by the GPs them-
selves according to the APO method (http://www.Apo-Danmark.dk).
The well-validated standard APO registration chart was used.
These data were supplemented with data from the central pre-
scription register of the County of Roskilde. Data were analysed
at the APO institute and reports were sent to all participating
GPs. Follow-up meetings were arranged, where the results were
compared and discussed with colleagues and local guidelines
could be elaborated. A second registration was carried out 1 year
later.
Results: Important quality problems, i.e. high-level and inap-
propriate consumption of macrolides, diverging use of diagnostic
tools and great variation between GPs on a number of other para-
meters such as the frequency of antibiotic prescribing, the
frequency of macrolide prescribing and the ratio narrow-/broad-
spectrum penicillins, were identiﬁed in all countries. In Denmark,
the frequency of macrolide prescription varied from 11 to 37%
and the ratio narrow-spectrum penicillin/broad-spectrum penicil-
lin use varied from 0.9 to 6.8, depending on the GP. Self-regis-
tered data from the second registration showed no essential
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changes in Denmark. However, central register data showed a
decline in macrolide consumption.
Conclusion: The APO method has proven a useful instrument in
maintaining a rational antibiotic policy among GPs in Denmark
and other Nordic countries. Moreover, our experience shows that
it is possible to improve the prescription habits of GPs using the
APO method. The combination of self-registered data and central
register data seems to represent an ideal basis for discussion.
Indicators, calculated on the basis of register data, can be followed
regularly. Information on APO can be found at: http://
www.Apo-Danmark.dk E-mail: apo@health.sdu.dk, syks@ra.dk.
S343 Antibiotic prescribing in the primary paediatric care
in Central Eastern Europe – common history with different
approaches
V. Jindrak, H. Hupkova, J. Marek, J. Cervenka, V. Vanis,
M. Tavodova, L. Janiga, P. Urbaskova
Prague, CZ; Bratislava, SK; Veseli nad Luznici, CZ; Zvolen, SK
ESAC project shows important differences of antibiotic consump-
tion in ambulatory care in CEE countries. Antibiotic consumption
in the Czech Republic (CZ) and Hungary (HU) is about 20 DID,
in Slovakia (SK) and Poland (PL) is about 25 DID. While the con-
sumption in CZ, HU and SK is stable, there is ongoing increase in
PL. Prevalence of resistance is also different, occurrence of penicil-
lin-resistant pneumococci is high in SK and HU, low rates are in
CZ and PL. Growing resistance of S. pyogenes to macrolides, espe-
cially in primary paediatric care, indicates changes in prescribing.
ESAC consumption data describe current, relatively stable situa-
tion, but the most important changes in antibiotic prescribing
were happened during early 1990s, when the healthcare system
was totally transformed in all of former members of Soviet block.
As example, in CZ, there was observed rapid increase of total
consumption (14–19 DID) including deep changes of its structure
(decrease of penicillins, increase of broad spectrum drugs).
Changes in consumption were followed with growing resistance.
These countries are under strong marketing pressure from the
pharmaceutical industry, without experience on how to overcome
it. It is extremely important to support the implementation of
independent and effective intervention methods for improving
antibiotic prescribing in the region. Project on auditing antibiotic
prescribing in primary paediatric care was established in the late
1990s in the Czech Republic and Slovakia. The same protocol and
methodology was applied for repeated multicentric studies, per-
formed in several regions. Although both countries have common
history in the same state for more than 70 years, and transforma-
tion of healthcare system was very similar, antibiotic prescribing
practices and also resistance rates are extremely different. Antibio-
tic prescribing for acute respiratory illness is twice more frequent
in SK, prescribing for common cold is extremely rare in CZ, while
in SK is common. Audits successfully identiﬁed proportion and
reasons of inappropriate prescriptions, when acute bronchitis is
the most important for antibiotic misuse. Although CZ situation
looks better, the proportion of inadequate prescribing is 50% as a
minimum. The most of repeatedly audited GPs signiﬁcantly
improved their practice during the time. Based on the 5 years of
experiences, there is good opportunity to extend auditing as a
routine tool for interventions.




Several factors are believed responsible in helping facilitate the
low rates of bacterial antibiotic resistance in the Netherlands as
compared with other European countries and the USA. These fac-
tors include, the inﬂuential position of the medical microbiology
and infectious diseases profession, the establishment of elaborate
infection control programs, and cultural inﬂuences (including the
traditional prudent use of antimicrobials). Furthermore, in a
recent survey, the majority of Dutch physicians reported no reluc-
tance to clinical guidelines. Evidence-based guidelines on surgical
prophylaxis have been developed to improve the quality of care
and to reduce inappropriate prescribing in many countries. Var-
ious authors still report frequent overuse. The Dutch Working
Party on Antibiotic Policy (SWAB), issued national guidelines for
surgical prophylaxis in the year 2000, and these have been used
as a framework for the development of local policies. The goal of
these guidelines (besides reducing the incidence of surgical site
infections), was to limit the spectrum of the antibiotics (based
upon microbiology data from the Netherlands), promoting single
dose administration and optimising the timing to within 30 min
preoperative. The Surgical Prophylaxis and Surveillance Study
(Chirurgische Profylaxe en Surveillance, CHIPS) investigated the
implementation of this SWAB guideline in a prospective interven-
tion study involving 13 Dutch hospitals. The intervention consis-
isted of feedback, educational and logistic support. Process
outcome was documented both several months before and after
intervention, by recording the choice, duration, dose and timing
of antibiotic prophylaxis. SSI were monitored as the patient out-
come indicator, with the Dutch national surveillance network
(PREZIES) providing the SSI data. The study succeeded in
increasing the use of ﬁrst generation cephalosporins as a single
dose and in improving the timing of prophylaxis, while maintain-
ing efﬁcacy in terms of preventing SSI. At present, further
national projects are ongoing and are especially targeted towards
the timing of prophylaxis (a factor particularly sensitive to organi-
sational constraints). The guideline program of SWAB, the PRE-
ZIES network, the CHIPS study and the ongoing quality
improvement program are supported by the Dutch government.
In this presentation, quality indicators of process and outcome of
surgical prophylaxis will be compared with international data
from the literature.
S345 Antibiotic prescribing practices and policies in
intensive care units
D.L. Monnet, H. Hanberger
Copenhagen, DK; Linko¨ping, S
Multidrug-resistant microorganisms are commonly found in inten-
sive care units (ICUs), which are now recognised as ‘hot zones’
for antimicrobial resistance in hospitals. However, much less is
known about antibiotic prescribing practices in ICUs. Aggregated
pharmacy data on antimicrobials dispensed to ICUs are generally
used for this purpose. Data from ICU surveillance networks such
as the Swedish IVA-STRAMA and the German SARI, as well as
data from Denmark and from studies in single hospitals, show
that ICU antimicrobial use varied from 490 to 3456 WHO Deﬁned
Daily Dose (DDD)/1000 patient-days. This means that on average
on a given day, most ICU patients receive one antimicrobial, if
not a combination of antimicrobials. This also means that the eco-
logical pressure due to antimicrobials is generally higher in ICUs
than in most hospitals (around 40–80 DDD/100 patient-days or
400–800 DDD/1000 patient-days) and much higher than in ambu-
latory care (around 10–40 DDD/1000 inhabitant-days, depending
on country). When patient-level data are available, one can calcu-
late the proportion of patients exposed to antimicrobials during
ICU stay. From various studies, it can be estimated at 50–80%.
Such patient data also allow the measurement of the number of
daily antimicrobial treatments as in the EC-funded ‘European
Strategy for Antibiotic Prophylaxis’ (ESAP) project. Certain poli-
cies seem to be associated with high/low antimicrobial prescrib-
ing in ICUs. The ESAP project showed that two ICUs that
routinely used selective decontamination of the digestive tract
(SDD) reported 3753 and 4794 daily antimicrobial treatments/
1000-patient days, respectively, which was four to ﬁve times the
median ecological pressure of 928 daily antimicrobial treatments/
1000-patient days observed in 21 other European ICUs that did
not use SDD. Among these, having a list of antimicrobials subject
to restricted use and reporting excellent communication between
senior and junior doctors were independent factors associated
with low use. The EC-funded ‘Antibiotic Resistance Prevention
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And Control’ (ARPAC) project should soon provide more recent
and detailed data on antimicrobial use and policies in European
ICUs. These will form the basis for the implementation of inter-
ventions. However, additional efforts are still needed to better
understand and improve the quality of antimicrobial prescriptions
in ICUs. This may be addressed by repeated audits of prescribing
practices.
Antibiotic resistance: from ESBL to fluoroquinolones
O346 EARSS report on increasing ﬂuoroquinolone
resistance among Escherichia coli in Europe
H. Grundmann, P. Schrijnemakers, N. Bruinsma, E. Tiemersma,
J. Monen, J.E. Degener, G. Cornaglia and EARSS participants
Objectives: We explored proportions and trends of ﬂuoroquino-
lone-resistant E. coli isolated from blood-cultures reported to the
European Antimicrobial Resistance Surveillance System (EARSS)
by participating laboratories.
Methods: Participating laboratories carry out routine antimicrobial
susceptibility testing (AST) for invasive E. coli isolates. Fluoroqui-
nolone resistance in E. coli is deﬁned as a minimum inhibitory
concentration (MIC) of >4 mg/L to either oﬂoxacin or ciproﬂoxa-
cin. Data are collected at the national level and forwarded to
EARSS at the National Institute for Public Health and the Envir-
onment (RIVM) in Bilthoven, The Netherlands.
Results: From January 2001 until October 2003, 24 countries
reported AST results for 38 370 E. coli isolates. A signiﬁcant
increase in resistance to ﬂuoroquinolones, from 8% (666 of 8411
isolates) in 2001 to 10% (479 of 4684 isolates) in 2003 was
observed in laboratories that participated all 3 years. Resistance
ranged from 3% in Ireland (155 isolates) to 21% in Italy (617 iso-
lates). Between 2001 and 2003, resistance increased in 15 of the 24
countries. For eight countries this increase was signiﬁcant (two-
sided P < 0.05). No country showed a signiﬁcant decrease in resis-
tance proportion.
Conclusions: Our data suggest a common trend of expanding
ﬂuoroquinolone resistance in all parts of Europe.
O347 First detection of the transferable quinolone
resistance determinant in clinical Providencia stuartii strains in
Egypt
I. Wiegand, N. Khalaf, M.H.M. Al-Agamy, B. Wiedemann
Bonn D; Cairo, EGY
Objectives: Quinolones are potent antibiotics that target the bac-
terial DNA gyrase and topoisomerase IV. The recently described
plasmid-encoded Qnr protein protects both enzymes from quino-
lone inhibition which leads to low-level resistance and is there-
fore able to facilitate the selection of high-level resistance. The
qnr determinant has been found in E. coli and K. pneumoniae
strains in the USA and in E. coli strains in Shanghai, China.
However, studies including strains from diverse geographical
origins did not result in further ﬁndings. Here we describe the
detection of the qnr resistance determinant in clinical strains iso-
lated in Egypt.
Methods: Strains used in this study were isolated in a burn unit in
a university hospital in Cairo, Egypt between April and October
2001. MIC values were determined using a microdilution method
according to the NCCLS and E-tests. Strains with ciproﬂoxacin
MIC values of 0.25 mg/L or higher were screened for possession
of qnr using primers binding at the 5‘ and 3’ end of the gene.
These included the following species: E. coli (n ¼ 4), K. pneumoniae
(n ¼ 4), E. cloacae (n ¼ 1), S. marcescens (n ¼ 2), P. rettgeri (n ¼ 4),
P. stuartii (n ¼ 4), M. morganii (n ¼ 1) and P. mirabilis (n ¼ 10).
One qnr PCR product was sequenced. Epidemiological relation-
ship was examined using RAPD-PCR methods. Conjugation
experiments were performed using E. coli W3100 RifampicinR as
the recipient.
Results: Screening for qnr revealed the resistance determinant in
four P. stuartii isolates RAPD-PCR indicated that two of the
P. stuartii strains were clonally related. The three unrelated iso-
lates show intermediate quinolone susceptibility and resistance
(Table 1). Sequencing of one PCR product derived from
P. stuartii Ps125 showed 100% identity with the published qnr
sequence found on E. coli plasmids. The qnr determinant of all
strains was transferable to E. coli W3110 RifR. All transconju-
gants had the same susceptibility phenotype and showed ele-
vated quinolone MIC values compared with the recipient
(Table 1).
Conclusion: Until now, qnr has only been found in clinical E. coli
and K. pneumoniae strains. However, it had been shown that plas-
mids carrying the qnr gene have a broad host range. The detec-
tion of transferable quinolone resistance in P. stuartii shows the
extension of the host spectrum of qnr plasmids in the clinical set-
ting. Though qnr genes are still rarely detected, ﬁnding of qnr in
Egypt points to a wide geographic distribution of this resistance
determinant.
O348 Fluoroquinolone consumption and ﬂuoroquinolone
resistance in haematology–oncology patients – ecological
analysis in two university hospitals, 1999–2002
W.V. Kern, K. de With, C. Gonnermann, E. Strehl,
M. Steib-Bauert, S. Reuter, H. Bertz, U. Frank, H. von Baum
Freiburg, Ulm, D
Objectives: The MABUSE (Medical AntiBiotic Use Surveillance &
Evaluation) network, a German cooperative group of infectious
disease specialists, WIdO, the SARI programme and hospital
pharmacists, collects antibiotic consumption data in ambulatory
and hospital care (HC) settings. In a HC antibiotic consumption
study of eight university hospital medical services, we identiﬁed
two services with extremely low and extremely high consumption
of ﬂuoroquinolones in haematology–oncology departments. We
compared ﬂuoroquinolone consumption data in these services
with ﬂuoroquinolone resistance rates among Escherichia coli (EC),
Pseudomonas aeruginosa (PA), and staphylococcal isolates from
patients admitted to the services.
Table 1. MICs (mg/L) of P. stuartii(Ps) strains and their derived
transconjugants(TC)
Antimicrobial







Ciproﬂoxacin 2 0.5 4 0.06 0.004
Norﬂoxacin 2 0.5 16 0.25 <0.016
Levoﬂoxacin n.d n.d n.d 0.064 0.004
Moxiﬂoxacin 16 2 8 0.125 0.03
Gatiﬂoxacin 8 1 8 0.06 <0.016
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Methods: Consumption data were expressed as DDD per 100
patient days (DDD/100) using the WHO/ATC deﬁnition. An
alternative daily dose deﬁnition using local guidelines was used
and expressed as prescribed daily doses per 100 patient days
(PDD/100). In vitro susceptibility to ﬂuoroquinolones (ciproﬂoxa-
cin and/or levoﬂoxacin) of bloodstream isolates of EC and coagu-
lase-negative staphylococci (CNS), and of PA and S. aureus (SA)
clinical isolates from other body sites was performed according to
DIN (Deutsches Institut fu¨r Normung) guidelines and breakpoints
using microbroth dilution or agar diffusion tests.
Results and Conclusions: Hospital A haematology–oncology ser-
vices showed a ﬂuoroquinolone use density of 75 DDD/100
(4-year average, 1999–2002, range, 53.2–92.8) which was signiﬁ-
cantly higher than in hospital B (4-year average, 12 DDD/100;
range, 9–13.2). Applying the alternative PDD deﬁnition, ﬂuoroqui-
nolone use in hospital A was still much higher than in hospital B
(4-year averages, 37.9 vs. 10.7 PDD/100), while total consumption
of antibiotics was similar (81.9 vs. 81.4 PDD/100). Rates of in vitro
resistance to ﬂuoroquinolones were high in hospital A haematol-
ogy–oncology service isolates of EC (range, 64–79%) compared
with rates for hospital B (range, 8–11%), and correlated well with
the consumption data. The correlation between use and resistance
was less clear for trimethoprim-sulphamethoxazole resistance of
EC and for ﬂuoroquinolone resistance of staphylococci and PA.
Fluoroquinolone resistance among coagulase-negative staphylo-
cocci was surprisingly high in both hospital A and B haematol-
ogy–oncology services (ranges, hospital A, 68–97%, hospital B,
70–79%).
O349 Genetic analysis of emerging ﬂuoroquinolone-
resistant Escherichia coli in Indonesia
K. Kuntaman, E.S. Lestari, J. Severin, N.M. Mertaniasih,
M. Purwanta, A. van Belkum, H.A. Verbrugh on behalf of the
Antimicrobial Resistance in Indonesia (AMRIN) Study Group
Objectives: In a recent population-based survey of 4000 people
in two cities in Indonesia (Surabaya and Semarang) ﬂuoroqui-
nolone-resistant Escherichia coli (FQREC) were found to be emer-
ging. FQREC were prevalent in the faecal ﬂora of patients at
times of admission and discharge from hospital, but not among
healthy relatives nor patients visiting primary healthcare cen-
tres. We studied the phylogenetic background and clonal relat-
edness of FQREC and compared them with that of
ﬂuoroquinolone sensitive strains (FQSEC) isolated in the same
population.
Methods: 196 FQREC and 200 FQSEC strains were assigned to one
of four phylogenetic groups (A, B1, D, B2) using multiplex PCR
for the presence of determinant genes chuA, yjaA and TspE4.C2.
Clonality was determined by PCR ﬁngerprinting using ERIC pri-
mers. Mutation rates were assessed using rifampicin-containing
media (Antimicrob Agents Chemother 47, p. 3222).
Results: The distributions of FQREC and FQSEC across the phylo-
genetic groups A (57% vs. 52%), B1 (23% vs. 30%), D (20% vs.
11%) and B2 (1% vs. 7%) differed signiﬁcantly (P ¼ 0.001). The
mutation rates of the strains varied widely, but those of FQREC
strains were generally higher compared with the mutation rates
observed among FQSEC strains (P < 0.0001). Phylogenetic group-
ing of the strains of the two cities was highly similar. Clonal ana-
lysis of 196 FQREC yielded 110 different genotypes. Sharing of
genotypes was observed among strains isolated from patients at
the time of discharge from the same hospital, indicating nosoco-
mial spread of FQREC in each of the two hospitals. The number
of patients sharing the same FQREC genotype varied from 2–8.
Transmission of FQREC was found in departments of Internal
Medicine, General Surgery and Gynaecology.
Conclusions: The emergence of FQREC in Indonesia predomi-
nantly involves the relatively low virulence phylogenetic groups
A and B1, but FQREC has also emerged in higher virulence
groups D and B2. The emergence of FQREC in Indonesia is so far
largely restricted to those groups of patients that require and are
admitted to hospital care where selection and spread of FQREC
can be documented.
O350 Outpatient use of ﬂuoroquinolones in Europe with
focus on respiratory tract infections
H. Goossens, K. Dirven, M. Ferechthe ESAC Project Group
Objectives: We investigated geographical differences, temporal
trends and seasonal ﬂuctuations of the outpatient use of ﬂuoro-
quinolones (FQ) in Europe within the ESAC project, funded by
DG SANCO, using the ATC/DDD method (WHO, version 2003).
We focused on the new FQ, levoﬂoxacin (LEV) and moxiﬂoxacin
(MOX), which were marketed for the treatment of respiratory
tract infections (RTI), particularly due to penicillin and/or macro-
lide resistant Streptococcus pneumoniae.
Methods: We assessed outpatient FQ (J01M ATC group) use from
1997 to 2002 from 24 countries, and use data were expressed in
DDD per 1000 inhabitants per day (DID). Seasonal data were
available from 19 countries.
Results: Total outpatient FQ use in 2002 varied with a factor of
21.2 between countries with the highest and the lowest consump-
tion (3.76 DID in Italy vs. 0.17 DID in Denmark). Norﬂoxacin still
represented the most widely prescribed FQ in 2002 in Croatia
(89.0% of the J01M group), Czech Republic (46.9%), Sweden
(44.4%), Slovenia (46.0%), Latvia (43.6%), Hungary (33.8%) and
France (35.9%). In the 17 other countries, ciproﬂoxacin (CIP) was
the most widely prescribed FQ in 2002, except in Italy and Bel-
gium (LEV most prescribed FQ) and in Slovakia (oﬂoxacin most
prescribed FQ). In all but one country (Portugal, PT) we found no
seasonal variation of CIP, which is consistent with it being admi-
nistered as therapy of adult RTI. Only in Belgium (BE) and PT,
and to a lesser extent in Austria, LEV showed seasonal ﬂuctua-
tions, with peaks during the winter season (peak of 1.64 DID and
0.97 DID in the winter of 2002, in BE and PT, respectively).
Although consumption is lower and only seen from the second
half of 2000 onwards, the same seasonal trend was observed with
MOX, with the highest winter peaks in BE.
Conclusions: A low seasonal ﬂuctuation of the earlier FQ, such as
CIP, may be a good marker of restrained antibiotic prescription.
The introduction of LEV and MOX was very successful in BE and
PT. The Belgian data are surprising because all guidelines clearly
state that these drugs are not ﬁrst-line therapy for adult RTI.
Sounding the alarm about the peril of rising antimicrobial resis-
tance may be inadvertently promoting inappropriate use of these
new FQ, which will inevitably lead to emergence of resistance.
O351 Extended-spectrum beta-lactamases from the
community and hospital environments in Portugal:
dissemination of TEM-24 E. aerogenes European epidemic clone
and emergence of CTX-M enzymes
E. Machado, R. Canto´n, A. Rolla´n, J.C. Sousa, F. Baquero,
T.M. Coque, L. Peixe
Porto, P; Madrid, E
Objectives: To evaluate the prevalence and epidemiology of ESBL-
producing Enterobacteriaceae from the community and hospital
setting in Portugal.
Methods: Twenty-eight raw poultry products, two sewage, 25
swine and 85 healthy volunteers faecal samples (1999–2003) were
cultured in both MacConkey agar and MacConkey broth with or
without ceftazidime (1 mg/L) and cefotaxime (1 mg/L). One col-
ony per morphology was selected for posterior studies. Sixty-three
recent clinical isolates from three hospitals of the area under
study (18 K. pneumoniae, one K. oxytoca, 13 E. coli, four E. aerogenes,
ﬁve E. cloacae, 13 S. marcescens, six P. mirabilis, one M. morganii,
one C. freundii and one P. stuartii) were included. All isolates were
screened for ESBL by the double disk synergy test. ESBLs were
characterised by IEF, PCR for blaTEM, blaSHV, blaCTX-M-9 and
blaCTX-M-10, and sequencing. Susceptibility to non-beta-lactam
antibiotics was performed by the disk diffusion method. Clonality
was searched by PFGE.
Results: ESBL producers were obtained from 10 poultry (12 E. coli
and four K. pneumoniae isolates), two sewage (two E. coli) and
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three healthy volunteers faecal samples (three E. coli), but not in
those from swine samples. Beta-lactamase characterisation
revealed the presence of TEM (pI ¼ 5.4, 5.6, 5.9) and SHV
(pI ¼ 7.6) ESBL-types, both in nonclinical and clinical isolates. A
CTX-M-type enzyme, CTX-M-14, was detected for the ﬁrst time in
our country in an E. coli isolate from a healthy volunteer.
blaTEM-24 was identiﬁed in three E. aerogenes clinical isolates
which by PFGE revealed the same pattern of the E. aerogenes
epidemic clone reported in French, Belgium and Spanish hospi-
tals. Nonsusceptibility rates of ESBL-producing organisms of
clinical and nonclinical origin were as follows: gentamicin
(42–17%), streptomycin (85–75%), sulphonamides (84–92%), tri-
methoprim (83–75%), tetracycline (88–83%), chloramphenicol
(56–33%), nalidixic acid (85–75%) and ciproﬂoxacin (70–47%).
Conclusion: ESBLs were found in Enterobacteriaceae from
Portuguese hospitals, poultry, sewage and healthy volunteers
samples. An european epidemic clone with TEM-24 was
detected in isolates from different hospitals of our country, but
interestingly, the presence of the worldwide-distributed CTX-M
ESBLs was only demonstrated in the community. This might
be related to local differences in the genetic structure of
bacterial populations from hospital and community environ-
ments.
O352 Isolation of extended-spectrum beta-lactamase
producing Enterobacteriaceae from community-based patients in
the United Kingdom
F. M’Zali, J. Dave, S. Ager, M. Denton
Leeds, UK
Objectives: Extended-spectrum beta-lactams are commonly
included in empirical antibiotic regimens for the treatment of
Gram-negative infections. The emergence of extended spectrum
beta-lactamase (ESBL)-producing bacteria poses a serious threat to
the continued use of this family of antibiotics. To date, ESBL-pro-
ducing bacteria have been reported worldwide, mainly in hospital
settings. The aim of this study is to ascertain the level of ESBL-
producing bacteria in clinical samples submitted from patients
outside of hospital.
Methods: Over a 3-month period, we saved all cefradine-resis-
tant Enterobacteriaceae collected from urine samples submitted
to our laboratory for microbiological analysis. Isolates were pro-
visionally identiﬁed by their colonial appearances on CLED
medium and conﬁrmed using the API 20E system. Antibiotic
susceptibility to a range of antibiotics was determined using
Stoke’s disk diffusion method. All the isolates were screened
for ESBL production using the standard Disc Synergy Testing
(DST) and the commercially available MAST DD test. Polymer-
ase chain reaction (PCR) using speciﬁc primers was used to
screen for the presence of blaSHV and blaTEM in the isolates
scoring positive for ESBL production. Nucleotide sequence ana-
lysis was used to determine the identity of the resistance deter-
minants.
Results: Eighty-four isolates from 78 patients were obtained dur-
ing the study period. Forty-two (54%) were community-based
patients. ESBL production was detected in 16 isolates from 10
patients (13%): nine Klebsiella species, ﬁve Enterobacter species,
one Escherichia coli and one Citrobacter freundii. Three of the ESBL+
patients were community-based, only one of whom had recently
been discharged from hospital. PCR showed that eight isolates
harboured blaSHV while two isolates harboured blaTEM. Nucleo-
tide sequence analysis of an internal fragment of the blaSHV
showed the isolates to produce an SHV-2 like ESBL (ﬁve isolates).
Identity of the ESBLs in the remaining isolates has not been deter-
mined yet.
Conclusion: This is the ﬁrst report describing the presence of
extended-spectrum beta-lactamases in UK community-based
patients. This highlights the continuing global emergence of these
clinically important enzymes and the importance of screening for
their presence not only in hospitalised patients, but in the com-
munity as well.
O353 Characterisation of a new integron carrying a
metallo-beta-lactamase and a carbenicillinase from Pseudomonas
aeruginosa
S.M. Quinteira, J.C. Sousa, L. Peixe
VN Famalica˜o, Porto, P
Objectives: An increasing prevalence of carbapenem resistance
mediated by acquired metallo-beta-lactamase genes (blaIMP and
blaVIM), inserted in integrons, is being reported, particularly for
Pseudomonas aeruginosa clinical isolates. Here, we report the
genetic characterisation of a new integron carrying a carbapenem
resistance determinant, blaVIM-2, from a P. aeruginosa clinical iso-
late.
Methods: A clinical imipenem-resistant P. aeruginosa strain was
isolated in a Portuguese hospital from a blood culture. MICs for
beta-lactam antibiotics (including carbapenems) were determined
by the Etest method. IEF was also performed in crude extracts.
Susceptibility to aminoglycosides was assessed by the disk diffu-
sion method. The presence of metallo-beta-lactamases was investi-
gated, using a bioassay and a PCR multiplex for blaVIM and
blaIMP genes. Class 1 integrons were screened with sets of pri-
mers speciﬁc for 5’CS and 3’CS. The obtained amplicon was
cloned in pPCR-ScriptTM Cam SK(+) plasmid vector and
expressed in Epicurian coli XL10-Gold. Characterisation of integron
containing the metallo-enzyme gene was possible through sequen-
cing.
Results: The P. aeruginosa isolate was resistant to most beta-lac-
tams, including imipenem (>32 mg/L), meropenem (>32 mg/L),
ceftazidime (32 mg/L), but remained susceptible to aztreonam
(8 mg/L). The isolate was also resistant to tobramycin, gentami-
cin, amikacin, netilmicin and ciproﬂoxacin. A positive bioassay
was observed, suggesting a metallo-beta-lactamase and prelimin-
ary PCR-based experiments detected the metallo-beta-lactamase
blaVIM-2. Two beta-lactamases of pI 5.3 and 5.7 were observed in
crude extracts by IEF. Sequencing of the cloned PCR amplicon,
containing the gene cassette blaVIM-2, revealed the structure of a
new class 1 integron. In fact, assembly of sequence data, showed
blaVIM-2 and blaP1b, two beta-lactamases that have never been
associated in the same integron before. The integron also carried
two aminoglycoside resistance genes.
Conclusions: To our knowledge, this is the ﬁrst description of an
integron that contains a metallo-beta-lactamase associated to
another beta-lactamase.
O354 Epidemiology and clinical features of bacteraemia
due to extended-spectrum betalactamase-producing Escherichia
coli
J. Rodrı´guez-Bano, M.D. Navarro, L. Romero, M.A. Muniain,
L. Martı´nez-Martı´nez, R. Pe´rez-Cano, E.J. Perea, A. Pascual
Seville, E
Objectives: The rate of bacteraemia because of extended-spectrum
beta-lactamase-producing Escherichia coli (ESBLEC) seems to be
increasing, but speciﬁc information about this infection is scarce
as they are usually described together with episodes caused by
ESBL-producing Klebseilla pneumoniae (ESBLKP). We describe the
clinical features and the epidemiology of a series of bacteraemia
because of ESBLEC.
Methods: We included all episodes of bacteraemia because of
ESBLEC in out centre from January 2001 to June 2003. ESBL pro-
duction and antimicrobial susceptibility were tested by microdilu-
tion following NCCLS guidelines. Relatedness of the isolates was
performed by REP-PCR. ESBL were preliminary characterised by
isoelectric focusing and PCR. The sequencing of the genes encod-
ing the ESBLs is in progress.
Results: Nineteen episodes were included. The distribution of the
episodes showed an increasing trend throughout the study per-
iod, from 3.9% of the episodes of bacteraemia because of E. coli in
2001 to 8% in 2003. The mean age of the patients was 70 years,
74% were male, and all of them had comorbidities. Ten episoded
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were community-acquired (eight could be considered health-care
related) and nine were nosocomially-acquired (none of them were
in the ICU). Three patients were neutropenic, and 14 had recently
received antimicrobials (seven ﬂuorquinolones). The main sources
of bacteraemia were the urinary tract (48%) and the biliary tract
(26%); it was unknown in 16%. Sixteen per cent had severe sepsis
and 5% septic shock. Fifty-three per cent of the isolates were sus-
ceptible to amoxicillin/clavulanic acid, 95% to piperacillin/tazo-
bactam, 100% to imipenem, 32% to ciproﬂoxacin, and 84% to
gentamicin. Empirical antimicrobial treatment was considered
appropriate according to in vitro susceptibility data only in 37%
of the episodes (10 patients received extended spectrum cephalos-
porins). One patient died, and it was related to the infection. Only
the isolated from three patients were clonally related; 84% of the
isolates produced CTX-M type ESBL.
Conclusion: Bacteraemia caused by ESBLEC is an emergent infec-
tion that affects predisposed patients, most of whom had
received antimicrobials. About half of the cases were commu-
nity-acquired, although most of them are health care-associated.
Most of the isolates were not clonally related and produced an
CTX-M type ESBL. These data suggest that the epidemiology of
bacteraemia due to ESBLEC has relevent differences with
ESBLKP.
O355 The ﬁrst report of a metallo-beta-lactamase-
producing Proteus mirabilis clinical isolate from Greece
I. Galani, M. Souli, Z. Chryssouli, D. Katsala, H. Giamarellou
Chaidari, GR
Objectives: Proteus. mirabilis is the second most common cause of
urinary tract infections and also an important cause of nosocomial
infections. Class B metallo-beta-lactamases (MBLs) have recently
been reported in several strains of Gram-negative bacilli but not
yet in P. mirabilis. In 2003, a P. mirabilis strain with a reduced sus-
ceptibility to imipenem was isolated in a tertiary care hospital in
Athens (Greece). The strain demonstrated a positive EDTA-disc
synergy test and it was studied for the presence of a MBL gene.
Methods: Proteus mirabilis was isolated from the cerebrospinal ﬂuid
of a patient suffering from meningitis secondary to craniocerebral
trauma. Susceptibility testing was performed by the disk diffusion
technique and MICs were determined by the broth microdilution
method, according to the NCCLS guidelines (M7-A5, Vol. 20, No. 2,
2000). EDTA-disc synergy test, was used to screen for MBL produc-
tion. Beta-lactamases were detected by isoelectric focusing (IEF)
and the MBL gene was identiﬁed by PCR with the following set of
primers: VIM-F (5’-ATGGTGTTTGGTCGCATATC-3’) and VIM-B
(5’-TGGGCCATTCAGCCAGATC-3’). Sequencing of cloned PCR
products was performed by MWG – The Genomic Company.
Results: The P. mirabilis isolate was resistant to ampicillin, cepha-
lothin and cefuroxime, had reduced susceptibility to ceftazidime
and cefepime (MIC 8 and 4 mg/L, respectively) and was fully
susceptible to aztreonam (0.25 mg/L). MICs of imipenem and
meropenem were 2 and 0.25 mg/L, respectively. EDTA-disc
synergy test was positive suggesting the presence of a MBL. IEF
identiﬁed a beta-lactamase with a pI of approximately 5.4.
Sequencing of the cloned PCR product identiﬁed the blaVIM-1.
Conclusions: To the best of our knowledge, this is the ﬁrst time
that a MBL gene has been detected in P. mirabilis. The spread of
MBLs in Enterobacteriaceae has enormous therapeutic implica-
tions. Routine susceptibility testing cannot be used to predict the
presence of MBLs, and laboratories must be prepared to screen
MBL-producing isolates in order to guide the prompt implemen-
tation of infection control measures and the proper treatment of
the patient.
Hepatitis
O356 HCV core, F, NS3, NS4B and NS5A are the major
immunogenic proteins in humoral immunity in chronic HCV
infection
K. Melen, M. Sillanpa¨a¨, P. Keskinen, M. Lappalainen, I. Julkunen
Helsinki, FIN
Hepatitis C virus (HCV) genome encodes for three structural
(core, E1 and E2) and six nonstructural (NS2, NS3, NS4A, NS4B,
NS5A and NS5B) as well as a recently identiﬁed F protein pro-
duced from an alternative reading frame from the core region. In
order to study humoral immune responses against individual
HCV proteins they were produced by baculovirus of Escherichia
coli expression. The proteins were puriﬁed by preparative SDS-
PAGE and antibody responses against different HCV proteins
were analysed by quantitative Western blotting. The study mate-
rial included serum specimens from 68 individuals chronically
infected with HCV. All serum specimens were HCV RNA posi-
tive, and 21, 20, 23 and four individuals were of HCV genotypes
1, 2, 3 or 4, respectively. The core, F, NS3, NS4B and NS5A were
the major antigenic proteins, and 97, 94, 68, 85 and 53% of the
individuals had antibodies against these proteins, respectively.
Lower rate of antibody positivity was observed also against E1,
E2, NS4A and NS5B (4–28%) proteins, whereas NS2 protein
appeared to be completely nonantigenic. As analysed by Western
blotting the mean antibody levels were 4–30-fold higher against
the core protein (mean titre 1:35 000) as compared with the other
HCV proteins. Clearly detectable antibody levels were also
observed against F (mean titre 1:1500), NS3 (1:4000), NS4B
(1:9000) and NS5A (1:4500) proteins. No signiﬁcant differences in
antibody levels were seen in infections caused by different HCV
genotypes. Follow-up of serum specimens from ﬁve individuals
during a period of 2 years revealed that the antibody speciﬁcity
and their levels remained remarkably constant in each individual.
Our results indicate that baculo/ E. coli-produced HCV proteins
are well suitable for diagnostic purposes and there is a tremen-
dous variability in individual anti-HCV antibody levels and pro-
tein speciﬁcity.
O357 Comparative analysis of intra-hepatic mRNA levels
for IFNs and IFN-related genes in HCV mono-infected and in
HCV/HIV co-infected patients
I. Abbate, G. Cappiello, S. Rosati, G. Tocci, G. Antonucci,
M. Solmone, R. Longo, A. Spano`, M.R. Capobianchi
Rome, I
Objectives: Hepatitis C virus (HCV) infection runs a more rapid
and severe course of liver disease in HIV-1 co-infected patients
and treatment of HCV is at present a major challenge in these
individuals. In a previous work we showed that mRNA levels for
IFNs and for some IFN related genes were altered in HCV mono-
infected subjects, as compared with nonalcoholic steato-hepatitis
(NASH) patients. In this study we analysed mRNA levels for
IFN-alpha, IFN-gamma, IFNAR-1 and PKR in liver biopsies of
HCV/HIV co-infected patients to compare their levels with those
found in HCV-monoinfected subjects.
Methods: To this aim liver biopsies from 20 HIV/HCV co-infected
patients and from 24 HCV-infected patients, similar for demo-
graphic features, HCV viral load and genotypes, as well as for liver
histology, were analysed. Total RNA was extracted from liver
biopsy, and a limiting dilution RT-PCR was performed by using
primers speciﬁc for IFN-alpha, IFN-gamma, IFNAR-1 and PKR.
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Results: In HCV/HIV co-infected patients intra-hepatic IFN-alpha
mRNA levels were up-regulated as compared with HCV monoin-
fected patients, whereas IFN-gamma, IFNAR-1 and PKR were pro-
foundly down regulated, as in all biopsies from co-infected patients
they were under detectable levels. We observed a positive correla-
tion between IFN-alpha mRNA levels and HIV-RNA viral load
(r ¼ 0.526, P ¼ 0.018, in Spearman rank sum test). In co-infected
patients, similar mRNA levels for IFN-alpha were found in patients
with HCV viraemia higher or lower than 500 000 IU/mL, and they
were not related to ALT levels or CD4 cell counts. Furthermore, no
different IFN-alpha mRNA levels were observed in co-infected
patients with absent/mild vs. moderate/severe ﬁbrosis. This is at
variance with monoinfected patients, were IFN-alpha mRNA levels
were higher in patients with lower extent of ﬁbrosis.
Discussion: The presence of up-regulated IFN-alpha mRNA,
together with a parallel absence of mRNA for IFNAR-1 in liver
biopsies of HIV-HCV-co-infected patients indicate that, in spite
of a strong activation of IFN-alpha expression, driven presum-
ably by HIV, there is an impaired ability to respond to IFN-
alpha action, because of the lack of expression of its receptor.
This is also supported by the virtual absence of mRNA for the
main IFN-alpha effector protein (PKR). These results may have
important implications regarding the pathogenesis of the liver
damage and the therapeutic regimens to be used in co-infected
patients.
O358 Sustained response to interferon-ribavirin
combination therapy in chronic hepatitis C predicted by a
model of viral dynamics using both HCV-RNA and alanine
amino transferase
P. Colombatto, L. Civitano, P. Ciccorossi, F. Oliveri, B. Coco,
D. Flichman, R. Sacco, M. Campa, F. Bonino, M.R. Brunetto
Pisa, Milan, I
Objectives: Serum hepatitis C virus (HCV) RNA decreases quickly
in the ﬁrst 48 h of alpha interferon (IFN) therapy (1st phase) and
slowly thereafter (2nd phase). Standard mathematical models
found a correlation between the clearance of infected cells (2nd
phase) and the response to IFN, however do not predict whether
the response will be maintained. Aim of this work was to identify
new parameters that can predict the sustained response early dur-
ing treatment.
Methods: We developed a new model in which the rate of infected
cells clearance is computed by the alanine-aminotransferase (ALT)
decline during the ﬁrst month of therapy and, thereafter, it
diminishes according to the infected cell number. The model com-
putes and ﬁts HCV-RNA and ALT variations with the values
measured during the ﬁrst month of therapy (days: 0, 2, 4 or 5, 7,
14, 21, 28) and calculates the number of infected cells. We ana-
lysed 28 of 31 chronic hepatitis C patients consecutively treated
with IFN alfa 2b 3–5 MU, with or without Ribavirin, for 6 or
12 months depending on HCV genotype.
Results: The percentage of infected hepatocytes computed at base-
line was consistent with that reported by in situ studies and lower
in seven sustained responders (mean: 11.7%, range: 1–24.6%) than
in 14 transient responders (mean: 28.2%, range: 7.4–75.5%) and in
seven nonresponders (mean 41%, range: 8.8–86%) (P ¼ 0.036). At
the end of therapy the computed infected cell number was
<100 cells/mL of extracellular ﬂuid in all sustained responders
(mean 18.4, range: 1.7–48), in three transient responders
(mean: 3500, range: 1.52–17 500) and in none nonresponders
(mean: 28 500, range: 1200–96 000) (P ¼ 0.003). All three transient
responders with <100 cells/mL received IFN alone, two devel-
oped a breakthrough of viral replication during treatment.
Infected cells clearance was faster in patients with HCV genotypes
2 and 3 with an average half-life of 5.4 days (range: 3.8–14.3) vs.
8.7 days (range: 3.7–23.2) in genotype 1 (P ¼ 0.015).
Conclusion: Our data suggest that, besides inhibition of viral repli-
cation, an efﬁcacious clearance of the infected cells, as determined
by ﬁtting both HCV-RNA and ALT decline, is mandatory for sus-
tained response. Accordingly, genotype 2 and 3 infected patients,
who have a higher chance of response, show faster infected cell
clearance. The analysis of infected cells dynamics by the new
model might be useful to tailor duration of combination therapy
in the single patient.
O359 Treatment of acute C hepatitis with pegylated
interferon alpha-2b: preliminary results
G. Cariti, F.G. De Rosa, S. Quaglia, I. Meoli, L. Veronese,
S. Audagnotto, T. De Blasi, O. Bargiacchi, M. Bonasso, R. Raiteri,
G. Di Perri
Turin, I
Objective: Infection caused by hepatitis C virus (HCV) leads to
chronic infection in up to 80% of patients. Treatment with
pegylated interferon signiﬁcantly increased rates of cure com-
pared with standard interferon. Acute C hepatitis may also ben-
eﬁt from interferon treatment. Identiﬁcation of patients at risk
of acute C hepatitis, such as intravenous drug users, sexual
partners of HCV-infected patients and exposed health-care pro-
fessionals may increase the detection rates of acute cases. We
treated patients with acute C hepatitis with Peg-interferon a-2b
for 12 weeks.
Methods: Inclusion criteria were documented seroconversion, posi-
tive HCV-RNA and elevated ALT levels with a known risk factor
in the preceding 6 months. Patients were treated with Peg-inter-
feron alpha-2b (1.5 lg/kg once weekly subcutaneously) for
12 weeks in an open, nonrandomised, prospective cohort study.
ALT and HCV-RNA measurements were made at weeks 4, 12
and 24 weeks after the end of treatment. The primary endpoint
was the sustained viral response (SVR).
Results: Twelve patients completed the treatment. Eight patients
(75%) had HCV genotype 1. At baseline, median HCV-RNA
level was 129 500 copies/mL (range: 3 000–3 100 000); eight
patients were asymptomatic. Treatment was given within
30 days (range: 8–30) of the ALT level peak. At week 4 HCV-
RNA was undetectable in all patients but one, and at week 12
all patients were HCV-RNA negative. Sustained viral response
was achieved in eight of nine patients evaluable (88.8%). The
only patient without SVR was the one positive for HCV-RNA
at week 4.
Conclusions: Pegylated interferon alone administered for
12 weeks is effective in patients with acute C hepatitis. High
rates of SVR were observed even in patients with genotype 1.
Identiﬁcation and treatment of acute C hepatitis may decrease
the rate of chronic liver diseases. Further studies are needed to
conﬁrm the efﬁcacy of a 12-week regimen with PegIFN in acute
C infections.
O360 Mutation analysis of ISDR and V3 domains of
hepatitis C virus NS5A region during interferon therapy with or
without ribavirin
P. Veillon, C. Payan, F. Lunel-Fabiani and the Fontevraud Study
Group
Objectives: The hepatitis C virus (HCV) nonstructural 5A (NS5A)
has been controversially implicated in the resistance of HCV to
Interferon (IFN) therapy in clinical studies. In Japan, mutations in
IFN sensitivity-determining region (ISDR) (aa 2209–2248) in the
NS5A gene were associated with response to IFN therapy in
patients infected with genotype 1b. In contrast, studies from
Europe did not conﬁrm such association. More recently, it has
been suggested that the V3 domain (aa 2353–2379) outside the
putative ISDR may also have amino acids changes that may be
associated with response to IFN. In this study, the relationship
between NS5A mutations in ISDR and V3 domains and virologi-
cal response to therapy was investigated.
Methods: The NS5A gene was sequenced from 35 HCV genotype
1b infected patients, in a prospective clinical trial of IFN therapy
and IFN plus Ribavirin combination therapy at D0, M3 and M6.
Results: In the ISDR domain, we did not observed signiﬁcantly
different variations in amino acids between responders
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(1.52  1.75, n ¼ 21, range 0–6) and nonresponders (1.07  0.83,
n ¼ 14, range 0–3), (P ¼ 0.778), to therapy when tested before the
beginning of treatment. In the V3 domain, we found more muta-
tions in responders (6.48  1.86, n ¼ 21, range 2–11) than in non-
responders (4.71  1.20, n ¼ 14, range 3–8), before the beginning
of treatment (P ¼ 0.001). Few variations were observed during
treatment in nonresponders (1.38  1.51, n ¼ 8, range 0–4) but the
number of substitutions in responders to combination therapy
was more important (6.60  4.51, n ¼ 5, range 1–13), after
3 months of treatment (P ¼ 0.019).
Conclusion: Our results conﬁrm that, in Europe, the sequence of
the ISDR domain of HCV was not predictive for treatment suc-
cess. However, we found that the V3 domain have greater varia-
bility in responders than nonresponders suggesting that this V3
domain needs further investigation.
O361 A nosocomial hepatitis B outbreak in Danish
children
N. Fisker, N.L.T. Carlsen, H.-J. Kolmos, L. Tønning-Sørensen,
A. Høst, P.B. Christensen
Odense, DK
Objectives: To investigate an outbreak of hepatitis B virus (HBV)
infection in a paediatric haematology/oncology ward. The out-
break was disclosed subsequently to the incidental ﬁnding of
HBV infection in a ward patient as the infecting viral strain (the
epi-strain) was found to be identical to a virus isolated from the
same ward 1 year earlier through a phylogenetic survey of conse-
cutive HbsAg-positive samples in the country.
Methods: Patients admitted to the ward since the initial admission
of the ‘source patient’ were screened for HBsAg and anti-HBc and
HBV DNA was isolated and sequenced from infected individuals.
Patients from whom the epi-strain was isolated were categorised
as deﬁnite cases. Hygienic investigations were performed by the
hospital infection control team.
Results: Of 175 patients admitted during the epidemic period, 155
were contacted and 133 were tested. Apart from the source, seven
deﬁnite cases were identiﬁed. All case patients were immunodeﬁ-
cient, had a central venous catheter (P ¼ 0.0007) and their stay at
the ward clustered in time. Based on minute review of hospital
records, transmission most likely took place on at least three occa-
sions. In periods of high bed occupancy rates the ward medica-
tion room was used for blood sampling and intravenous
medication. Following the re-establishment as a ‘clean’ room,
including the replacement of multidose vials with single dose
vials; no new cases were identiﬁed during 15 months of follow-
up. HBV-infected patients remained asymptotic and HbeAg-posi-
tive during follow-up.
Conclusion: Case patients were probably infected through conta-
minated injections possibly via multidose vials accidentally con-
taminated in the medication preparation room. Molecular
epidemiological surveillance of blood-borne viruses may identify
unsuspected transmission routes and thereby reduce nosocomial
transmission.
O362 Flares of hepatitis, circulating hepatitis B core (HBc)-
speciﬁc T cells, and sustained virologic response to antiviral
therapy in chronic hepatitis B patients
P. Carotenuto, O. Pontesilli, A. Artsen, M. van Zonneveld,
H. Janssen, H. Niesters, A. Osterhaus
Rotterdam, NL
Objectives: To test whether HBc-speciﬁc immune response plays a
role in the sustained suppression of hepatitis B virus (HBV) after
interruption of antiviral therapy.
Methods: Peripheral blood lymphocyte proliferation in response
to autologous monocyte-derived dendritic cells pulsed with
recombinant HBcAg was longitudinally assessed in 21 chronic
hepatitis B patients during and after a 1-year course of pegylated
interferon-a, alone or in combination with lamivudine. In vitro
lymphocyte proliferation was measured by bromodeoxyuridine
incorporation after 7-day culture and FACS analysis. Minimum
12 samples per patients were studied employing one single
dendritic cell preparation. Eleven patients presenting HBV-DNA
reduction greater than three logs at the end of a 6-month
therapy-free follow-up (responders) were compared with the
remaining patients who again attained pretherapy HBV-DNA
levels (nonresponders).
Results: HBc-speciﬁc responses, both in CD4 and CD8 circulating
T cells, were transiently detected during therapy and after therapy
discontinuation in the majority of patients. Magnitude and fre-
quency of responses did not signiﬁcantly differ between respon-
ders and nonresponders. After therapy discontinuation, eight
nonresponders presented vigorous HBc-speciﬁc T-cell responses.
In ﬁve of them, signiﬁcant elevations of transaminase levels
occurred in temporal association with the presence of HBc-speciﬁc
T cells in the circulation. In contrast, only one of the nine respon-
ders with detectable HBc-speciﬁc T cells in the circulation showed
elevated transminase levels (P < 0.05 vs. nonresponders).
Conclusions: These data suggest that: (i) chronic hepatitis B
patients are able to mobilize and expand HBc-speciﬁc T cells; (ii)
the release of HBc-speciﬁc T cells is not invariably associated with
ﬂare-ups of hepatitis; (iii) the presence of HBc-speciﬁc T cells in
the circulation in the absence of transaminase elevations is asso-
ciated with prolonged suppression of viral replication.
O363 A new model of HBV infection dynamics shows a
multiphasic decay of viral load and a short half-life of
circulating virus in anti-HBe positive patients treated with
lamivudine
L. Civitano, P. Colombatto, R. Bizzarri, D. Flichman, F. Oliveri,
P. Ciccorossi, B. Coco, R. Sacco, F. Bonino, M.R. Brunetto
Pisa, Milan, I
Objectives: Standard biphasic model of viral dynamic applies only
partially to HBV patients. Our aim was to analyse the dynamics
of HBV infection during Lamivudine (100 mg/die) in anti-Hbe-
positive chronic hepatitis B using a new bio-mathematical model
that can explain multiphasic decay patterns.
Methods: In 11 patients ALT and HBVDNA levels were measured
(Amplicor HBV Monitor) at baseline, hourly in the ﬁrst day, at 1,
2, 4 or 5, 7, 14, 21, 28, 45 and 60 days upon treatment and
monthly thereafter. Experimental data were ﬁt into a model in
which: (i) the effect of the drug on virus production is described
by a block followed by an exponential decline to an asymptotic
value; (ii) the immune clearance of the infected cells is determined
by the decline of alanine aminotranferase (ALT) and HBV-DNA
and diminishes over time due to the negative feedback of the
infected cells reduction; (iii) the number of infected cells at the
beginning of therapy is estimated by the value of their immune
clearance computed in the ﬁrst month and that of ALT at base-
line.
Results: Three phases of HBV-DNA decline were observed in
eight of the nine analysable patients (two patients with minor
ﬂuctuation of ALT/HBV-DNA could not be analysed). During the
1st phase (days 0–2), mainly related to the block of virus produc-
tion (median drug effectiveness value: 0.910, range: 0.320–0.999),
the free virus decay constant was on average 2.38 days-1 (range:
1.70–2.91) with a half-life of circulating viruses of about 7 h
(range: 5.7–9.8). In the 2nd phase (days 2–14) HBV-DNA decline
was slower, with a median virus production decay constant of
0.34 days-1 (range: 0.00–0.75) and a median infected cells decay
constant of 0.05 days-1 (range 0.028–0.12) corresponding to an
infected cells half life of about 14 days (range: 6–25). A 3rd slow-
est phase of viraemia decline (from day 14 on) could be documen-
ted as long as HBV-DNA remained detectable (52 to >360 days)
in seven patients. In this phase virus production per infected cell
reaches its asymptotic value and viraemia decline depends only
from the immune clearance of the infected cells.
Conclusions: HBV dynamics was successfully described in 80% of
patients by this model. The circulating virus half life resulted to
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be three to four times shorter with a narrow range of variability
than reported previously. This ﬁnding could be due to the earlier
and frequent sampling or, less likely, to peculiar features of the
HBeAg defective HBV infection.
O364 Control of hepatitis A outbreaks before and after the
era of routine childhood hepatitis A vaccination
C. Stein-Zamir, I. Volovik, S. Rishpon
Jerusalem, Haifa, IL
Objectives: Hepatitis A (HA) outbreaks occur in well-deﬁned
endemic communities. The World Health Organization recom-
mends routine HA childhood vaccination in countries with inter-
mediate endemicity and vaccinating young children in
communities with recurrent outbreaks. Routine childhood HA
vaccination was implemented in Israel in 1999. We observed two
large HA outbreaks among young children in an endemic com-
munity before and after routine HA vaccination.
Patients/methods: A community-wide (118 cases) outbreak in 1996
was controlled through mass active vaccination of 1133 children
born between 1991 and 1995. Subsequently, children who were
born after 1 January 1998 were routinely vaccinated with two doses
of Havrix Junior vaccine at ages 18 and 24–30 months. After
31 months without HA cases, a second outbreak occurred in 2000.
Results: Altogether, 65 children were diagnosed clinically and con-
ﬁrmed serologically, nine (13.8%) were hospitalised and recov-
ered. The speciﬁc attack rates were 13.6, 5.5, 1.65 and 0.97% for
the 1996, 1997, 1998 and 1999 cohorts, respectively (P < 0.01).
Most cases (90%) occurred in the unvaccinated 1996–1997 cohorts.
Outbreak control measures included enhancing hygiene measures,
catch-up immunisation and modiﬁcation of the HA immunisation
routine by giving the ﬁrst vaccine dose at 12 months. Immunisa-
tion coverage for the ﬁrst dose was 82 and 94% for 1996–1997
and 1998–1999 cohorts. No HA cases were observed since June
2000 and intensive follow-up continues.
Conclusions: (i) With implementation of routine childhood HA
vaccination, it is essential to perform catch-up vaccination of
young children in communities with recurrent outbreaks. (ii) Low-
ering the age of the ﬁrst dose of vaccine to 1 year provides rapid
protection, as no morbidity was reported in the young age group.
O365 20 years hepatitis A sero-epidemiology in Belgium
R. Vranckx
Brussels, B
Objectives: Five epidemiological patterns (very high, high, inter-
mediate, low and very low) become apparent when incidence
rates and age-speciﬁc antibodies to HAV (anti-HAV) prevalence
are examined. This study evaluated, for a 20-year period, the age
distribution of the prevalence of immunity to HAV, and the inci-
dence of acute HAV infections in Belgian populations.
Methods: General population (GP) age-speciﬁc anti-HAV prevalence
in 2000 were compared with the 1979, 1989 and 1994 prevalence.
Results: A clear epidemiological shift showing decreasing preva-
lence in the youngest age groups was found. In 1979 some
50% of the 30–34 years age group population were positive. In
1989 50% of immune individuals was reached in the age group
35–39 years and shifted in 1994 to the age group 40–44 years.
In 2000 50% of immune individuals was only reached after the
age of 45 years. So we can conclude that, over a period of
20 years, prevalence pattern shifted from intermediate to low.
For selected populations different, social status linked, epide-
miological patterns were seen. In emigrants, mostly from Mediter-
ranean origin, we still see an intermediate pattern. Health care
workers, with an over-representation of higher social class, have a
signiﬁcantly lower prevalence than the GP. The incidence of
clinical acute viral hepatitis A was lower in 2000–2001 than in the
periods 1982–1984 and 1991–1992. The average age of the patients
rose signiﬁcantly compared with the two other periods. This
proves that with the decreasing endemicity of HAV, the average
age of exposure and infection has shifted to older age groups.
Conclusion: In Belgium the number of unprotected individuals
younger than 50 years increased in the past 20 years. This number
will still increase in the coming years. Considering the more
severe course of the disease as age increases, vaccination may
become an important strategy to protect susceptible individuals
(i.e. paediatric nurses, catering personnel, travelers).
Epidemiology and management of community-acquired pneumonia
O366 Epidemiology of community-acquired pneumonia in
Belgium
M. Ieven, K. Dirven, K. Loens, D. Ursi, T. Beck, H. Wouters,
H. Goossens
Wilrijk, B
Background: In the diagnosis of pneumonia the lack of a clear dis-
tinction between typical (S. pneumoniae) and atypical (C. pneumo-
niae, M. pneumoniae, L. pneumophila and viral agents) pneumonia is
a permanent cause of difﬁcult diagnostic and therapeutic deci-
sions. There is a lack of information of the prevalence of atypicals
in Belgium.
Methods: During the winter period 2000 and 2001 consecutive
patients with an X-ray documented community-acquired pneumo-
nia (CAP) were included in 10 centres (GPs and hospitals) partici-
pating in a multicentre study. Demographic and clinical data
were collected. Conventional microbiological techniques and PCR
were performed on respiratory samples for the detection of M.
pneumoniae and C. pneumoniae (all except for three, where real-
time was performed). Real-time PCR was performed for the detec-
tion of S. pneumoniae, L. pneumophila, Inﬂuenza A and B, RSV and
para-inﬂuenza 1 and 3 viruses
Results: CAP was documented in 147 patients (44 out-patients and
103 patients needing hospitalisation). An aetiologic agent was
detected by PCR in 67 patients (45.6%). Bacteria were found in
59 of 147 (40.1%) and viruses in 16 of 143 (11.2%) tested patients.
Combined infections (bacterial–bacterial, bacterial–viral or viral–
viral) were found in 13 cases (8.8%). Of the bacterial causes,
S. pneumoniae was found in 46 (31.3%) and the atypical bacterial
agents M. pneumoniae, L. pneumophila and C. pneumoniae in 17
(11.6%) cases (respectively 9.5, 2.0 and 0%). Of these 59 patients,
13 (22.0%) had taken antibiotics prior to consultation (average
8 days before) Of the viral causes, inﬂuenza A and B, RSV and
para-inﬂuenza 1 and 3 were respectively found in 3.5, 0.7, 4.2, 1.4
and 2.8%. Of those 16 patients six (37.5%) had previously
received antibiotics (average: 10 days before).
Conclusion: Atypicals were seldomly found in CAP patients.
Rapid real-time detection methods are helpful in the detection of
a bacteriological agent (particularly in patients with prior antibio-
tic therapy), and in installing appropriate antibiotic treatment.
O367 Value of real-time PCR for the aetiologic diagnosis
in adults hospitalised with lower respiratory tract infections
J.J. Oosterheert, A. van Loon, R. Schuurman, G. Nossent,
A. Hoepelman, M. Bonten
Utrecht, NL
Objectives: Nucleic acid ampliﬁcation techniques are increasingly
implemented in diagnostic settings. However, few hospitals have
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introduced these techniques in the routine setting of diagnosis
and treatment of lower respiratory tract infections in adults.
Methods: To determine the diagnostic value of real-time PCR tech-
niques in a routine setting, we collected nose-throat samples of
immunocompetent patients admitted in our hospital for antibiotic
treatment of lower respiratory tract infections. The samples were
evaluated by virus culture and by real-time PCRs for adeno-
viruses, coronaviruses, enteroviruses, inﬂuenzavirus A/B, parain-
ﬂuenzavirus 1–4, rhinoviruses, RS virus and Chlamydia
pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae. In
addition, blood and sputum samples were taken for culture and
acute and reconvalescent serology samples were evaluated for
respiratory viruses (inﬂuenza virus A/B, para-inﬂuenza virus
1–4, RS-virus, adenovirus) and atypical pathogens (M. pneumoniae,
C. pneumoniae, L. pneumophila).
Results: 63 consecutive patients (34 men, age 63  16) were
included of whom 29 (34%) had pneumonia (chest X-ray showing
inﬁltrate). Respiratory viruses were detected by culture in eight
patients, by real-time PCR in 19 patients. (30%). The most fre-
quently detected agents were inﬂuenza A (n ¼ 9) and coronavirus
(n ¼ 5). Viruses were more frequently detected in patients with-
out pneumonia (15/34; 44%) than in patients with pneumonia
(ﬁve of 29; 17%) (P ¼ 0.02) In one patient inﬂuenza A virus was
cultured, but not detected by real-time PCR. In nine of 20 patients
(45%) with a virusinfection as determined by real time PCR,
respiratory complaints were present for 3 days or less. Added to
sputum and blood cultures, real-time PCR increased the number
of patients in which a causative micro-organism was identiﬁed
from 14 (22%) to 27 (43%).
Conclusion: Viral agents play a substantial role in the aetiology of
hospitalised lower respiratory tract infections. Real-time PCR
increases the number of aetiologic diagnoses in immunocompetent
adults admitted with lower respiratory tract infections with 21%.
O368 Signiﬁcance of bronchoscopy and invasive
techniques in the diagnosis of community-acquired pneumonia
E. Manali, A. Papadopoulos, K. Kanellakopoulou, M. Tsivra,
V. Polychronopoulos, H. Giamarellou
Athens, GR
Objective: The role of ﬁbreoptic bronchoscopy in the diagnosis of
CAP is not well deﬁned.The aim of this study was to evaluate the
diagnostic yield of protected specimen brush (PSB) and bronch-
oalveolar lavage (BAL) cultures in hospitalised patients with CAP
and to compare the results with sputum cultures.
Methods: Ninety-three patients with a presumpive diagnosis of
CAP were enrolled. CAP was deﬁned as symptoms of lower
respiratory tract infection along with new inﬁltrate on chest x-ray
in a patient not hospitalised for the last 2 weeks. All patients
underwent ﬁbreoptic bronchoscopy (FB) with PSB and BAL before
antibiotic treatment. Gram-staining, quantitative cultures of spu-
tum, PSB and BAL and identiﬁcation of microorganisms were per-
formed according to NCCSL. McNemar’s test was used for
statistical analysis.
Results: Of 93 patients, 33.3% had a positive sputum culture,
62.3% had a positive PSB culture and 72% had a positive BAL
culture. S. pneumoniae was the most frequent pathogen (18.2%).
H. inﬂuenzae developed in 8.6% of patients, K. pneumoniae and
P. aeruginosa in 3.22% each, L. pneumoniae, M. catarrhalis, H. parain-
ﬂuenzae, S. aureus and S. mitis in 2.15% each. M. pneumoniae was
isolated in PSB and BAL in 2.15% of patients through antigenic
identiﬁcation techniques. Mixed infections were detected in 11.8%
of patients and 6.4% of patients developed M. tuberculosis. Nontu-
berculous mycobacteria were isolated in three patients and
N. asteroides in one patient. During the work-up an alternative
diagnosis emerged for ﬁve patients. Mortality was 5.37%.
Conclusions: (i) A statistically signiﬁcant difference was found con-
cerning the diagnostic yield of PSB and BAL culture compared
with sputum culture. (P < 0.001) (ii) PSB and BAL contributed to
the early diagnosis of tuberculosis in nonhighly suspected
patients. (iii). Treatment modiﬁcation supervened in 33% of
patients due to bronchoscopic results.
O369 Diversity of Legionella subtypes in cooling towers.
Why only one environmental strain causes the clinical cases
S. Ragull, M. Garcia-Nun˜ez, E. Junyent, M.L. Pedro-Botet,
N. Sopena, A. Dominguez, M. Sabria – Grupo de Estudio de la
Legionelosis
Objectives: Outbreaks of Legionnaires’ disease (LD) are frequently
associated with cooling towers. Although different strains may co-
inhabit a cooling tower, only one strain may be responsible for an
outbreak. In 2002 an outbreak of community-acquired LD was
reported in Mataro´ (Spain) involving 113 patients. All the clinical
isolates (n ¼ 10) exhibited the same chromosomal DNA subtype.
However, two chromosomal DNA subtypes were found in the
cooling tower responsible for the outbreak, one of which matched
the clinical isolates. In order to know why one only environmental
strain caused clinical cases, we decided to study the growth of
both environmental strains in BCYE broth and a cell culture.
Methods: The same quantity of the two strains of Legionella were
cultured in BCYE broth. The broth was maintained at 37C with agi-
tation for 70 h. An aliquot of the coculture was periodically plated
in GVPC agar. Ten colonies were isolated from each. The chromoso-
mal DNA subtype of these colonies was determined by pulsed-ﬁeld
gel electrophoresis (PFGE). Macrophages were also infected with an
identical amount of the two strains of Legionella. At 24, 48 and 72 h
the culture was lysed and plated in GVPC the bacterial suspension.
Ten colonies of each well were analysed by PFGE.
Results: During the ﬁrst hours of growth the proportion of the
two strains was similar in either the microbiological culture and
the cellular experiment. However, over time the proportion of the
strain found to cause the outbreak increased in comparison with
the other. At the end of the experiment almost all the strains iso-
lated presented the chromosomal DNA subtype corresponding to
the strain responsible for the outbreak. Comparing these data in
the growth curve we observed that the outbreak causing strain
clearly predominated in the postexponential phase of growth .
Conclusions: The environmental isolate causing most of the clinical
cases in the Mataro´ outbreak was able to grow and survived better
in two different experimental models compared with another iso-
late found in the same cooling tower system. This better adaptation
to the environmental conditions suggests greater virulence which
may explain both the experimental and clinical data observed.
O370 Current clinical outcomes in hospitalised patients
with community-acquired Legionella pneumonia
A. Mykietiuk, J. Carratala`, N. Ferna´ndez-Sabe´, R. Verdaguer,
J. Dorca, F. Manresa, F. Gudiol
L’Hospitalet de Llobregat, E
Objectives: It has been suggested that urine antigen testing and
ﬂuoroquinolone treatment might have improved outcomes in
patients with community-acquired Legionella pneumonia (LP). The
aim of this study was to analyse current clinical outcomes in
patients with LP; including response to antibiotic therapy, devel-
opment of in-hospital complications, and mortality.
Methods: Prospective observational study of consecutive nonse-
verely immunosuppressed adults hospitalised with community-
acquired pneumonia (CAP) from February 1995 to June 2003 in a
university hospital.
Results: Of 1869 patients hospitalized with CAP, 125 (6.7%) had LP
(urine antigen test 107, fourfold rise in serum antibodies 78, and
positive culture 40). There were 109 males (87.2%); mean age of
56 years (SD 20.9). Sixty-two patients (50%) had comorbid condi-
tions, 57 (46%) presented with multilobar pneumonia, and 59
patients (47%) were classiﬁed in risk classes IV and V, deﬁned by
the Pneumonia Severity Index. A total of 110 patients (88%)
received an appropriate empirical therapy, including a macrolide
(erythromycin or clarithromycin) in 80 (73%) cases, levoﬂoxacin in
29 (26%) cases, and both in one case. Patients receiving levoﬂoxa-
cin had a faster time to defervescence than patients receiving
macrolides (2.5 days vs. 5.8 days, P < 0.001) and to clinical stability
according to predeﬁned criteria (3.7 days vs. 6.6 days, P ¼ 0.006),
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but no differences were found regarding the development of com-
plications (31% vs. 31%, NS) and mortality (<30 days) (3.4% vs.
5.0%, NS). Length of hospital stay was 9.6 days in patients treated
with levoﬂoxacin and 14.4 days in patients receiving macrolides
(P ¼ 0.010). Overall, 39 of 125 patients (31%) with LP had one or
more in-hospital complications; mainly worsening of comorbid
conditions (26 cases), ICU admission (19), respiratory failure
requiring mechanical ventilation (11), renal failure (8), and pleural
empyema (2). Early mortality (<48 h) occurred in four patients
(3.2%) and overall mortality (<30 days) in seven patients (5.6%).
Conclusion: Our data suggest that, in hospitalised patients with
LP, levoﬂoxacin produces a faster clinical response than macro-
lides. LP is still associated with signiﬁcant morbidity, but current
mortality is substantially lower than that traditionally reported.
O371 Outbreak of pneumococcal pneumonia in a
retirement home in France in 2003
Y. Hansmann, A. Doyle, O. Lesens, A. Perrocheau, B. Jaulhac,
V. Murbach, V. Remy, D. Christmann
Strasbourg, Paris, F
Streptococcus pneumonia is the main causative agent of bacterial
pneumonia. However, outbreaks of pneumoccocal disease are
rarely described in France. We describe an outbreak of invasive
pneumococcal pneumonia occurring in a retirement home with 94
residents and 63 staff. In France, national recommendations for
adult pneumococcal vaccination are restricted to speciﬁc medical
conditions.
Methods: The health authorities in Strasbourg were alerted when
four cases of invasive pneumococcal infection were detected, over
the space of a few days, in a retirement home in the town. A ret-
rospective cohort study was carried out among the residents of
the retirement home. All residents were examined for respiratory
symptoms and fever. Conﬁrmed cases had infectious signs and
isolation of S. pneumonia in blood or CSF or presence of urinary
streptococcus antigens. Probable cases had only clinical and radi-
ological signs of pneumonia. We collected information on clinical
signs, co-morbidities, living habits, self-sufﬁciency, and social
activities. A nested case-control study was carried out to identify
risk factors for pneumococcal infection. Previous medical history,
contact with ill residents or visitors and previous vaccination for
pneumococcal diseases were investigated. Active case ﬁnding
among staff also took place. Oropharyngeal samples from all staff
and residents in the week following the epidemic were tested for
the presence of S. pneumoniae.
Results: Between 13 and 17 October 2003, we observed nine con-
ﬁrmed and two probable cases of pneumococcal invasive infection
among the residents (attack rate ¼ 11.7%). No cases were
observed among the staff. Carriage of S. pneumonia was found
only in one nonsymptomatic resident. S. pneumoniae serotype 4
was isolated in ﬁve cases. One case had meningitis. All other
cases had pneumonia and/or bacteraemia. Three of the 11 cases
died. All cases were women with a mean age of 89.3 years. None
of the cases had received the pneumococcal vaccine in the last
5 years while four of them were eligible for pneumococcal vacci-
nation according to the national recommendations. The cases were
distributed over all ﬁve ﬂoors of the building. No common activ-
ity was identiﬁed for all cases. Data from cohort and case-control
studies will be presented.
Conclusion: The low level of vaccination among the cases suggests
that the applicability and pertinence of current vaccination recom-
mendations need to be examined.
O372 Early administration of antibiotics in patients with
community-acquired pneumonia in the emergency room
E. Coma, J. Solis, G. Vidal, C. Ferre´, J. Alba, C. Agusti,
J.M. Guardiola, M. Gurgui, G. Vazquez-Mata for the
S.C.M.U.-A.C.M.E.S. - Pneumocom2 Study Group
Objective: To evaluate the impact of initial choice of antibiotics
and the time door-antibiotics to the clinical outcome for the
patients with community acquired pneumonia (CAP) at the Emer-
gency Departments (ED).
Methods: (i) Design – multicentre prospective study. (ii) Setting –
14 ED of Catalunya (Spain) and Principality of Andorra. (iii) Per-
iod: from 20th January to 1st July 2003. Patients: All patients
>18 years admitted through the ED with a diagnosis of CAP. The
diagnosis of CAP required the following: (i) new inﬁltrate on chest
radiograph; (ii) clinical evidence of pneumonia, with presence of
at least two of the following – temperature  38C, cough, puru-
lent sputum, pleuritic chest pain, dyspnoea, confusion. Patients
were excluded if they had an immunosuppressive illness, hospita-
lisation in the last 14 days or another alternative diagnosis. Data
was collected for demographic information, triage time, previous
or current antibiotic administration, time to antibiotic administra-
tion, intial antibiotic regime and clinical outcome at 30 days. The
study was approved by the Sant Pau Ethic’s Comitte´e.
Results: A total of 1034 patients were entered into the study. One
hundred had an immunosupressive illness or an alternative diagno-
sis and were excluded from the analysis. Two hundred patients
received prior ambulatory antimicrobial treatment. This included:
aminopenicillins (83), macrolides (40), quinolones (31) and oral
cephalosporins (15). Initial empiric antimicrobial treatment after
admission to the ED comprised the following: levoﬂoxacin (343),
amoxicillin–clavulanate(244), third generation cephalosporin +
macrolides(153) and others. The mean time to administration of ﬁrst
dose of antibiotics was 4 h 39 min (SD 3 h). Clinical outcome at
30 days was: complete recovery in 630 (77%), partial recovery in 113
(14%), treatment failure 20 (3%) and 54 (7%) deaths. There were sig-
niﬁcant differences between the mean time to administration of ﬁrst
dose of antibiotics and mortality (<4 h: 45%, 4–8 h: 22%, >8 h: 5%,
unknown: 30%), and mortality was statistically different among the
various antibiotics regimes (cephalosporins 9%, cephalosporins +
macrolide 7%, aminopenicilins 5%, levoﬂoxacin 4%).
Conclusions: (i) The initial choice of antibiotics may inﬂuence the
clinical outcome. (ii) The administration of antibiotics within 4 h
of admission in the ED, as an isolated factor, does not reduce the
mortality in adult patients with CAP. (iii) Future studies using a
multivariate analyses may be undertaken.
O373 Treatment with sequential intravenous/oral
moxiﬂoxacin was associated with faster clinical improvement
and earlier discharge from hospital in CAP patients requiring
initial parenteral therapy compared with standard therapy
T. Welte, T. Bauer for the MOXIRAPID study group
Objectives: To compare the efﬁcacy and safety of sequential intra-
venous (IV)/oral (PO) moxiﬂoxacin (MOX) and high-dose cef-
triaxone with or without erythromycin (CEF) in patients with
community-acquired pneumonia (CAP) requiring parenteral ther-
apy.
Methods: This controlled, multicentre, randomized, prospective,
nonblinded phase-IIIb study was performed in 54 centres in Ger-
many, France, Greece, Lithuania and Poland. Adult patients with
signs and symptoms consistent with bacterial CAP requiring
initial parenteral treatment were randomised to MOX (400 mg
once daily) IV, possibly followed by oral tablets or to ceftriaxone
(2 g IV once daily) with or without erythromycin (1 g IV q6 h or
q8 h), for 7–14 days. The primary efﬁcacy variable was the clinical
response at the test-of-cure visit (TOC) 5–20 days after end of
study therapy.
Results: Of 397 randomised patients 317 (79.8%) were evaluable
for efﬁcacy. Mean age was 58.1 years (range 18–96). 59 of 156
(37.8%) patients in the CEF group had additionally received ery-
thromycin. 81% of MOX-treated patients were switched to oral
drug at a mean of 5.7 days. Clinical cure at TOC was achieved in
138 of 161 patients (85.7%) in the MOX group and in 135 of 156
patients (86.5%) in the CEF group (95% CI, 7.9 to 7.1%). After
3–5 days of therapy only the MOX-treated group had achieved an
at least 50% decrease in the mean serum concentration of C-reac-
tive protein from baseline (CEF group 42%). In patients with
fever (>38.5C) at entry, defervescence occurred signiﬁcantly
earlier in the MOX group than in the CEF group at a mean of
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3.8 days vs. 4.8 days (P ¼ 0.0027). Furthermore, a faster improve-
ment of symptoms in the MOX group was recorded by the
patients in standardised diaries. Due to IV-to-oral switch, overall
IV treatment duration was shorter for MOX than for CEF
(5.4 days vs. 9.5 days). Mean length of stay in hospital (LOS) was
signiﬁcantly shorter in the MOX group than in the CEF group
(9.8 days vs. 11.1 days; P ¼ 0.0005).
Conclusions: In adult patients hospitalized with CAP, sequential
IV/PO MOX was clinically equivalent to high-dose ceftriaxone
with or without erythromycin. However, faster defervescence and
faster symptoms’ improvement was observed in MOX treated
patients. Switch to oral treatment was feasible in most patients
without compromising clinical efﬁcacy. The faster clinical
improvement observed in MOX-treated patients allowed an earlier
discharge from hospital with potential cost savings.
O374 Management of community-acquired lower
respiratory tract infections in the emergency department.
A prospective 2-year observational study in over 170 centres
throughout France
D. Elkharrat, P. Gerbaux, C. Ginzburg, M.C. Grossin, C. Leroux,
N. Peschansky, M. Herad, J. Imperatori and the French LRTI
network RESAU
Prevalence of community-acquired lower respiratory tract infec-
tions (LRTI) is high in emergency departments (ED) worldwide.
Purposes of this survey of 11 days in March 2002 (I) and 8 days
in March 2003 (II) are (i) describe the epidemiology of LRTI seen
in the ED (ii) identify management of patients with acute exacer-
bation of COPD and pneumonia (CAP) and (iii) determine their
short-term outcome in II.
Methods: Consecutive LRTI patients aged 18 years or more were
included. Anthonisen criteria, Fine score and their usefulness for
management were circulated during I and II and antibiotics
guidelines for LRTI issued by Health Care Authorities were
handed during II only.
Results: A total of 137 EDs in I and 114 in II (74 participated in I
and II) included 1603 and 1552 LRTI patients. aged 62.8  19.0
and 61.9  21.1 years, sex ratio 58% M in both I and II. Among
them, 844 and 689 had CAP, 554 and 325 COPD, 205 and 538 mis-
cellaneous. Based on a total of 126 000 visits in I and 98 000 in II,
LRTI accounted for respectively 2.9–3.4% of nontrauma patients.
With a ratio of 2 CAP/1 COPD in both instances. Severity of dis-
ease was based on Fine for CAP (Fine 1, 18 and 19%; 2, 19 and
16%; 3, 24 and 22%; 4, 27 and 31%; 5, 10 and 13%) and for
COPD, on the presence of chronic respiratory insufﬁciency
(COPD+ 40.8% vs. 55%) or not. COPD are older than CAP
patients. (72.1  14.0 years vs. 66.6  20.3 years in I and
71.0  13.8 years vs. 63.5  21.0 years. in II) and more often hos-
pitalised (90% vs. 79.9% in I and 78% vs. 76% in II). However,
more CAP than COPD received antimicrobials (AM) in the ED
(83% vs. 58% and 85% vs. 74%; P < 0.001) and AM combination
was more frequent in CAP than COPD (25% vs. 20% and 25%
vs. 24%). There is a signiﬁcant trend to discharge patients
between I and II for CAP (20% vs. 24%) and COPD (10% vs.
22%; P < 0.001). At day 5 of hospital admission during II (523/
689 CAP and 253/325 COPD), patients were discharged in 14 and
16%, still hospitalised in 75 and 72% and dead in 4 and 3% of
cases. AM prescribed in the ED were conﬁrmed for 72% of
patients hospitalised.
Conclusions: (i) These two surveys conﬁrm that French EDs are
the ﬁrst management site for many LRTI patients; (ii) The trend
to discharge patients of mild to moderate severity has increased
between 2002 and 2003. Management guidelines speciﬁcally
designed for the ED, with emphasis on orally administered AM
and safety, would probably enhance ambulatory treatment of
LRTI patients.
O375 Recently formulated guidelines for empiric therapy
of community-acquired pneumonia increase antibiotic use with
63%
J.J. Oosterheert, M. Bonten, M. Schneider, A. Hoepelman
Utrecht, NL
Objectives: New BTS and IDSA guidelines advocate empirical
treatment with both b-lactams and macrolides for patients
admitted to hospital because of community-acquired pneumonia
(CAP). We evaluated the impact on antibiotic usage of such a
strategy when introduced in the Netherlands.
Methods: Patients admitted with severe CAP (signs and symptoms
of CAP and chest X-ray showing inﬁltrate) but not needing
mechanical ventilation to six hospitals in the Netherlands were
prospectively studied for 28 days. Sputum and blood samples
were cultured, acute and reconvalescent serology samples were
evaluated for atypical pathogens (Mycoplasma pneumoniae, Chlamy-
dia pneumoniae and Legionella pneumophila) and urine samples were
tested for Legionella and pneumococcal antigen. Demographic,
clinical and treatment data were documented. Subsequently, we
evaluated costs and adequacy of treatment assigned, should BTS-
guidelines have been followed. We deﬁned antibiotic usage as the
number of deﬁned daily doses (DDD) of a standard 10 day anti-
biotic course.
Results: A total of 232 consecutive patients (mean Fine 114  28;
age 69  15) were included between July 2000 and May 2003.
Empirical therapy was b-lactam monotherapy in 82.2%, b-lactam
in combination with macrolides, quinolones or aminoglycosides in
9% and quinolone monotherapy in 0.5%. Overall mortality was
8.2%. Antibiotic usage was 2601 DDD. 26 patients (11.2%) had
atypical infection and empirical antibiotic treatment did not cover
atypical infection in 17. Five of these showed a delayed clinical
response, but none (0/5) died or needed mechanical ventilation.
Should BTS guidelines have been followed, b-lactam/macrolide
combination treatment would have been given to 83%, resulting
in antibiotic usage of 4200 DDD, an increase of 63%. In three
patients with atypical infection, initial antibiotic treatment would
not have covered atypical infection.
Conclusion: While this population had a high mean Fine score,
overall mortality remained low with current empiric therapy
recommendations. The clinical beneﬁt of b-lactam/macrolide
empirical treatment for CAP in this population remains to be
determined, but such a strategy certainly increases antibiotic
usage, possibly enhancing development of antibiotic resistance.
Biofilms
S384 Bioﬁlm biology – role of quorum sensing
K. Riedel, L. Eberl
Zurich, CH
The Gram-negative bacteria Pseudomonas aeruginosa and Burkhol-
deria cepacia are opportunistic human pathogens that are respon-
sible for severe nosocomial infections in immunocompromised
patients and are the major pathogen in cystic ﬁbrosis. Both
bacteria utilize quorum-sensing (QS) systems, which rely on
N-acyl-homoserine lactone (AHL) signal molecules, to control
the expression of virulence factors and to regulate bioﬁlm
development. It is shown that the two bacteria are capable of
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unidirectional communication by the aid of AHL molecules and
that this interaction appear to be of profound importance for
the virulence of the mixed consortium. Efﬁcient treatment of
P. aeruginosa or B. cepacia infections is often hampered by the
intrinsic resistance of the organism against a large range of
antibiotics. The design of novel agents that speciﬁcally target
the quorum-sensing systems of the two organisms is reported.
In the presence of respective compounds the two opportunistic
pathogens were greatly attenuated in different animal pathogen-
esis models.
Current problems in clinical mycology (Symposium arranged with EFISG)
S388 Mucormycosis: pathogenesis, diagnosis, management
A.H. Groll
Munster, D
The Zygomycetes constitute a class of organisms that are charac-
terised by the presence of sparsely septated, broad and poly-
morphic hyphae in tissue. They are divided into two orders, the
Mucorales and the Entomophthorales. The majority of cases of
zygomycosis are caused by the Mucorales. While Rhizopus spp.
are the most commonly implicated organisms, an expanding spec-
trum of other Zygomycetes has been reported during the past
decade, including but not limited to Mucor, Rhizomucor, Absidia,
Apophysomyces, Cunninghamella and Cokeromyces. In immuno-
compromised or debilitated hosts, the Mucorales have a high pro-
pensity to invade blood vessels, resulting in a rapidly
deteriorating clinical course refractory to antifungal therapy with
extremely high mortality. Infection may develop at various tissue
sites and may be classiﬁed as rhinocerebral; pulmonary; cuta-
neous; abdominal-pelvic and gastric; and disseminated disease.
Rhinocerebral, pulmonary and disseminated zygomycosis are the
most frequently encountered entities. The clinical and radio-
graphic presentation resembles that of invasive infections by other
ﬁlamentous fungi, in particular, Aspergillus spp. Therefore, the
diagnosis of zygomycosis entirely relies on conventional microbio-
logical, microscopic and histological demonstration of the organ-
ism in specimens from clinically suspected sites, with molecular
detection methods being developed at a rapid pace. Always, a
detailed radiographic evaluation is needed to assess the anatomic
extent of invasive zygomycosis and to guide surgical resection of
infected tissue. The mainstay of therapy of invasive zygomycosis
consists of aggressive surgery of amenable lesions and high
dosages of amphotericin B (1–1.5 mg/kg/day). A valid option is
to use high dosages (5 mg/kg/day and greater) of an amphoteri-
cin B lipid formulation upfront to deliver the largest amount of
drug to the site of infection and to preserve renal function. While
echinocandins are inactive as single agents, antifungal triazoles
have organism-dependent activity that is worthwhile to be
explored further. Early clinical data suggest that the investiga-
tional triazole posaconazole may be useful for treating invasive
zygomycosis. Critical to successful outcome of zygomycosis is the
reversal of immunological or metabolic defects that precipitated
its development.
S389 Fungal bone infections
O. Lortholary
Paris, F
Fungal bone infections are rare. Worldwide ditributed infections
such as those caused by Candida sp., Aspergillus sp. and Cryptococ-
cus neoformans should be separated from those which are endemic
(Histoplasma sp., Blastomyces dermatitidis, Coccidioides immitis, spor-
otrichosis and fungal mycetoma or dematiaceous fungi). Bone
involvement can result from haematogenous dissemination or be
secondary to skin infection followed by a contiguous extension.
Evolution of the disease is most often subacute or chronic and
radiological images are nonspeciﬁc. Diagnosis of fungal bone
infection should be emphasized in some high-risk patients such as
those who are immunocompromised or those who have travelled
and stayed in endemic areas in the presence of subacute bone
infection nonresponding to antibiotics. The diagnosis is obtained
through direct examination or culture of a bone sample in associa-
tion at least for some fungal diseases by the serum detection of
fungal antigen or antibody. At the acute stage, the treatment is
often based on the combination of surgery and antifungals, most
often including amphotericin B or its lipid derivatives. New anti-
fungals and particularly voriconazole recently gave very encoura-
ging results in bone aspergillosis in our hands. In addition,
caspofungin which has been shown to be active against bioﬁlm
producing Candida sp. strains could be promising for the treat-
ment of fungal infected articular prosthetic devices. Systemic
azoles are the long-term therapy of choice of such very difﬁcult to
treat infections.
Antimicrobial susceptibility testing of difficult organisms
S394 Mycoplasmas and chlamydia: requirements for
antibiotic susceptibility testing and results
C. Be´be´ar, B. de Barbeyrac, S. Pereyre, C.M. Be´be´ar
Bordeaux, F
Mycoplasmas and chlamydia are fastidious microorganisms
involved in urogenital and respiratory tract infections. They differ
by their growth requirements, acellular speciﬁc media for myco-
plasmas, cell culture methods for chlamydia. Because of their
intrinsic resistance, only tetracyclines, macrolides and related anti-
biotics, and ﬂuoroquinolones, are useful therapeutic agents. Ac-
quired resistance to these drugs have been reported in clinical
isolates of Mycoplasma hominis and Ureaplasma spp., two genital
mycoplasmas. They concern mainly tetracyclines and at a lower
extent, macrolides and related antibiotics and ﬂuoroquinolones.
Because of these resistances, antibiotic susceptibility testing is use-
ful, mainly when mycoplasmas are isolated from immunosup-
pressed patients. In vitro, strains of M. pneumoniae resistant to
macrolides or to ﬂuoroquinolones have been selected. However,
in vivo, only resistance to macrolides has been reported in a very
small number of isolates. So, susceptibility testing of M. pneumo-
niae is not currently indicated except when new drugs are
proposed. Several techniques can be used for mycoplasmas, broth
or agar dilution, kits adapted to genital mycoplasmas, or even-
tually E-test for M. hominis. Few reports have described antimi-
crobial resistance in chlamydia. Rare cases of therapeutic failures
in Chlamydia trachomatis infections have been attributed to multi-
drug heterotypic resistance, concerning only a small number of
organisms. Homotypic resistance has not been detected in any
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human Chlamydia species. In vitro, strains resistant to ﬂuoroquino-
lones were obtained by serial passages of C. trachomatis, in the
presence of oﬂoxacin and sparﬂoxacin. Furthermore, naturally-
occuring antibiotic resistance has not been reported in C. pneumo-
niae. Considering these results, Chlamydia susceptibility testing,
useful for new drugs, could be also interesting to explain some
therapeutic failures in C. trachomatis infections. Conditions for sus-
ceptibility testing for Chlamydia must take into account the cell-
line utilized, the time between infection and addition of antimi-
crobial, the inoculum used, the effects of multiple passage and the
technology used to investigate antibiotic activity (immunoﬂuores-
cence staining, ﬂow cytometry, molecular-based test). Finally,
whatever the organisms, mycoplasmas or chlamydia, the major
drawback in evaluating the antibiotic susceptibility is the lack of
standardised methodology.
Tick-borne diseases
S396 Epidemiology and ecology of tick-borne encephalitis
M. Labuda
Bratislava, SK
Tick-borne encephalitis is caused by tick-borne encephalitis virus
(TBEV; Flaviviridae, genus Flavivirus) which is distributed in an
endemic pattern over a wide territory of Europe and northern Asia
within the range of the main ixodid tick vectors, Ixodes ricinus (Eur-
opean subtype) and I. persulcatus (Siberian and far eastern sub-
types). TBEV, as an arbovirus, relies on two different types of hosts
for its transmission cycles: ticks which act as both virus vectors and
long-term reservoir hosts, and vertebrates that amplify the virus
infection by acting as a source of virus for feeding ticks. Reciprocal
speciﬁc interactions between TBEV and tick vector, TBEV and ver-
tebrate host, and, between tick vector and vertebrate host in the
appropriate environment of the speciﬁc geographical area create in
a concerted manner unique conditions for virus to perpetuate its
transmission cycles and survive. TBEV survival is based on the
intimate ecological association with I. ricinus, or alternatively, I. per-
sulcatus ticks having three developmental stages (larvae, nymphs
and adults) overlaping in their activity and feeding strategy with a
preference for certain selected vertebrate hosts. The role of verte-
brate species as amplifying hosts is highly speciﬁc with only a few
species efﬁciently supporting TBEV transmission. Among tested
species Apodemus ﬂavicollis ﬁeld mice were the most efﬁcient ampli-
fying hosts of TBEV. Coincident aggregated distribution of I. ricinus
larvae and nymphs was highest on A. ﬂavicollis as observed in wes-
tern Slovakia. This speciﬁc feature consistently increased the num-
ber of infectible larvae feeding alongside potentially infected
nymphs and was characteristic for tested natural foci of infec-
tion. Human infections occur via an infected tick bite, or, alterna-
tively and less frequently, via drinking of row goat or sheep milk.
Exposed groups such as forest workers are in TBEV endemic areas
at high risk of infection and should be preferentially vaccinated.




Tick-borne encephalitis (TBE) is the most important arbovirus in
Europe with approximately 3000 reported cases annually, the Bal-
tic States included. The acute infections can present as a subclini-
cal infection or an unspeciﬁc fever. These patients are never
diagnosed as TBE in clinical practise. But as much as one fourth of
the infected will develop a second stage of disease with central
nervous system (CNS) involvement. The clinical spectrum includes
meningitis or meningoencephalitis with or without myelitic invol-
vement. The lethality in Europe (western TBE-virus) are 0.5%. The
patients have a protracted acute and convalescent phase compared
with other viral aetiologies (e.g. enterovirus). The risk for perma-
nent sequelae are high, up to 40%. The most common reported
complaints included in this postencephalitic syndrom are different
cognitive and neuropsychiatric symptoms, headache, dysphasia,
ataxia and hearing disturbances. Approximately 5% of the patients
develop permanent pareses (shoulder girdle, hemi- or tetrapare-
sis). The acute clinical manifestations and the described postence-
phalitic syndrome will be reviewed in this lecture.




Tick-borne encephalitis (TBE) virus transmitted by ticks remains a
serious health problem in Central and Eastern Europe. TBE virus is
a member of the ﬂavivirus family. The biology of the main vector
ticks, I. ricinus and I. persulcatus, is explained as far as it is medically
relevant. Since no speciﬁc therapy of TBE exists, vaccination against
the TBE virus has been established for many years in TBE virus
endemic countries. Two commercially available vaccines are used
in Europe: new versions of Encepur, Chiron Behring, Germany; and
FSME-IMMUN, Baxter, Austria. The conventional vaccination sche-
dule consists of three doses at day 0, month 1–3 and 9–12 after the
second dose. In 1971, the development of an inactivated vaccine
was initiated by Prof. Ch. Kunz. Various versions of this ﬁrst TBE
vaccine (FSME-IMMUN) have been approved since 1976. In 1999
the preservative thiomersal was removed. In the year 2000 a new
TBE vaccine (TicoVac) was introduced which was free of thiomersal
and human serum albumin. This led to an increased reporting rate
of high fever and cases of febrile convulsions in infants and small
children. Human albumin was subsequently reintroduced into the
vaccine formulation in 2001 and there was a dramatic reduction of
adverse event reports with this amended formulation (FSME-
IMMUN new) compared with TicoVac. A paediatric formulation is
presented at half the antigen dose in a 0.25 mL volume (FSME-
IMMUN Junior). The ﬁrst licensed TBE vaccine speciﬁcally for chil-
dren (Encepur K), was licensed in 1994 in Germany with a reduced
antigen content from the adult preparation. Although very rare, a
number of children had symptoms of allergic reactions, probably to
the polygeline content. Therefore, an improved TBE vaccine was
developed: Encepur Adults (0.5 mL), licensed for use in persons
older than 12 years, containing 1.5 lg inactivated TBEV antigen
(strain K 23) with 1 mg aluminium hydroxide. Encepur children
(0.25 mL) contains 0.75 lg inactivated TBEV antigen with 0.5 mg
aluminium hydroxide. These vaccines are also licensed for rapid
immunization to be applied at days 0, 7 and 21. The cloning of the
TBE virus genome has provided the basis for detailed studies on
the molecular basis of virulence and evaluation of new vaccine con-
cepts. This includes vaccines consisting of recombinant subviral
particles, DNA vaccines and conventional attenuated vaccines.
S399 Containment of TBE: the Austrian experience
C. Kunz
Vienna, A
In the prevaccination era, Austria had the highest recorded mor-
bidity of tick-borne encephalitis (TBE) in Europe. This prompted
us in 1971 to develop an inactivated vaccine in a co-operative
research project with J. Keppie from the Microbiological
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Research Establishment, Porton Down, England. Immuno (now
Baxter) fortunately decided to take over the industrial produc-
tion of the candidate vaccine (FSME Immun), which became
commercially available in Austria in the spring of 1976. More
than 25 years of experience with vaccination in Austria, where
more than 38 million doses of the Austrian vaccine have been
used, has demonstrated, that FSME Immun is both well tolerated
and highly immunogenic. The rate of protection under ﬁeld con-
ditions after completing the whole series of three vaccinations
exceeds 98%. Initially our attempts were mainly directed
towards achieving a high vaccination coverage in the high risk
population. However, by 1979, a year with a record incidence of
cases, it became apparent that, as in most other countries, TBE
had become a disease that is predominantly acquired during lei-
sure activities. Subsequently a mass vaccination was started in
1981 which since then each year lasts for 5–6 months in the ﬁrst
part of the year. Due to this measure, the vaccination coverage
of the Austrian population of 8 million increased from 6% in
1980 to about 87% in 2002. After the onset of the vaccination
campaign, beginning in 1984 (vaccination coverage of the Aus-
trian population about 40%), a more or less steady decline of
the disease could be observed, from 677 cases in 1979 to an
average of 59 annual cases in the years 1999–2003. In particular,
vaccination programmes for children at mandatory school age in
endemic areas had a substantial impact on the incidence of TBE.
Whereas in 1971–1981 almost 19% of the patients were 7–
14 years of age, in the years 1990–2000 the percentage in this
age group had fallen to 2.3%. It is noteworthy that in some Eur-
opean countries an increase of TBE has been observed in recent
years. For example, in our northern neighbour, the Czech
Republic, a marked increase of disease has been recorded in the
early nineties. In that country, even in high risk areas such as
southern Bohemia, only about 10% of the population has been
vaccinated. This level of vaccination coverage will not sufﬁce to
substantially lower the incidence of TBE as the Austrian experi-
ence has shown.
In vitro studies of antimicrobial agents, ﬁtness and virulence factors of bacteria
O400 Sensititre YeastOneTM Colorimetric Antifungal Plate
for testing voriconazole against isolates of Candida species: a
comparison with the NCCLS M27-A2 microdilution reference
method
A. Espinel-Ingroff, S. Killian, C. Knapp, N. Holliday
Richmond, Westlake, USA
Objectives: The purpose of this study was to extend the evaluation
of the commercial Sensititre YeastOne Colorimetric Antifungal
Plate for susceptibility testing of Candida spp. to the new triazole
voriconazole. The available National Committee for Clinical
Laboratory Standards (NCCLS) microdilution method for the anti-
fungal susceptibility testing of Candida spp. and Cryptococcus neo-
formans (M27-A2 document) may not be the most efﬁcient and
convenient procedure for use in the clinical laboratory. It has been
demonstrated that the Sensititre YeastOne plate provides compar-
able MICs to those obtained by the NCCLS method for testing
yeasts and has been recently cleared by the FDA for testing ﬂuco-
nazole.
Methods: We compared MIC values obtained simultaneously by
Sensititre YeastOne Colorimetric Antifungal Panel and NCCLS
M27-2A broth microdilution methods after 24- and 48-h of incuba-
tion for voriconazole and reference agent, ﬂuconazole. The 102
selected clinical isolates evaluated included 25 Candida albicans, six
C. glabrata, 22 C. krusei, 21 C. lusitaniae, 19 C. parapsilosis, ﬁve C. tropi-
calis and other four less common Candida spp. Colorimetric MICs of
both antifugal agents were the ﬁrst blue (no growth) or purple well.
Results: Two comparisons of MIC pairs were evaluated to obtain
percentages of agreement (2 dilution range): 24-h colorimetric
vs. 24- and 48-h NCCLS MICs. The agreement between the meth-
ods for voriconazole MICs was 97% when colorimetric MICs were
compared with 24-h NCCLS MICs; the agreement was lower
(90%) when 24-h colorimetric values were compared with 48-h
NCCLS MICs. The agreement for ﬂuconazole was excellent with
both NCCLS incubation times MICs (98–99%). Although MICs for
10 of the 20 C. lusitaniae isolates could not be obtained at 24-h
(lack of colour change) by the YeasOne plate; the comparison of
48-h MICs was excellent for both agents.
Conclusion: These data suggest the potential value of the YeastOne
plate for use in the clinical laboratory to test the susceptibilities of
clinical Candida spp. isolates to voriconazole.
O401 Susceptibility of Aspergillus fumigatus to
voriconazole by ﬂow cytometry
R. Arau´jo, A. Gonc¸alves Rodrigues, C. Pina-Vaz
Porto, P
The reference method for susceptibility testing of moulds NCCLS
M38-A is cumbersome and time-consuming. Flow cytometry (FC)
has proved to be a valuable alternative for susceptibility testing of
Candida spp (1) and it would be of interest to evaluate its role in
susceptibility testing of moulds.
Objective: To study the antifungal activity of Vor on clinical iso-
lates of A. fumigatus, using FC with the probes FUN-1 (a marker
of metabolic integrity) and propidium iodide (PI) (a marker of cell
death by cell membrane lesion).
Methods: Two clinical strains of A. fumigatus were employed. MIC
values were determined according the NCCLS M38-A protocol.
Conidial suspensions (2  106 conidia ⁄mL) were incubated at
37C with different concentrations of Vor (MIC, 2  MIC,
4  MIC, MIC/2, MIC/4), for 8 h. Conidia were washed (to pre-
vent interference between antifungal agents and the probe),
suspended in PBS with 2% glucose and stained with 5 lg/mL of
FUN-1 or 1 lg/mL of PI, for 30 min. Heat-treated conidia (90C,
for 30 min) were used as the control for cell death. The conidial
cells were analysed by FC (Beckman-Coulter Corp., Hialeah, FL,
USA): the morphology (scattergram) and the intensity of ﬂuores-
cence of the stained cells (FL2 (green) for FUN-1and FL3 (red) for
PI) were determined.
Results: It was possible to establish a MIC for Vor after 4 h by FC.
At this time, virtually all conidia were metabolically impaired, as
shown by FUN-1 staining. Similar cytometric results were seen
with 2  MIC and 4  MIC. Dead conidia were detected with PI
staining after 5 h, at MIC concentration.
Conclusions: FC can be used to determine the susceptibility of
A. fumigatus to Vor. FC is a rapid and reliable alternative to the
standard NCCLS M-38A method. Moreover, FC provides key
information regarding the mechanism of antifungal activity of Vor
and allows the analysis of a large amount of conidia.
References
1. Pina-Vaz C, Sansonetty F, Rodrigues AG et al. (2001) Cytometric
approach for rapid evaluation of susceptibility of Candida strains to
antifungal. Clinical Microbiology and Infection 11: 609–618.
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O402 In vitro activity of novispirins-antimicrobial peptides
with broad spectrum activity
P.-H. Mygind, C.-P. Sonksen, D. Raventos, O. Taboureau,
B. Weber, J. Lin, S. Otani, D.-S. Yaver, H.-H. Kristensen
Bagsvaerd, DK; Davis, USA
Objectives: Antimicrobial peptides (AMPs) are ubiquitous in nat-
ure where they establish a ﬁrst line of defence against invading
pathogens or competing microorganism. A series of small a-heli-
cal peptides (NZ1000) are being investigated for potential
therapeutic use and have antimicrobial activity against both
Gram-positive and Gram-negative bacteria. A lead peptide from
this series novispirin (NZ1001) has been tested in several topical
and systemic animal models. In addition, several variants of
NZ1001 have been generated. We report here the antimicrobial
activity of novispirin and its variants.
Methods: Antimicrobial activity and spectrum of the puriﬁed com-
pounds were assessed by determining the minimum inhibitory
and bactericidal concentrations using the NCCLS guidelines with
the addition of 0.01% BSA. Kinetics of bactericidal activity was
characterized by time kill experiments at several concentrations.
Results: Puriﬁed novispirin showed potent bactercidal activity
against both Gram-positive and Gram-negative bacteria including
drug-resistant strains with MICs and MBCs as low as 0.25 lg/mL
against Shigella dysenteriae. In general, the novispirins are more
potent against Gram-negative organisms with MICs and MBCs of
0.25–8 lg/ml. In addition, novispirins do not show any cross
resistance with traditional antibiotics when tested against drug-
resistant strains including several clinical isolates. Analysis of the
killing kinetics against Escherichia coli revealed that novispirins
eliminate >99.9% of the bacteria in <30 min while against Staphy-
lococcus carnosus the same level killing is observed after 3 h. Sev-
eral antibiotics including vancomycin, tetracycline, penicillin,
erythromycin and gentamicin were also included in the time kill
studies and the novispirins display a more rapid killing than the
control antibiotics.
Conclusion: Novispirin and its variants demonstrate potent cidal
activity against both Gram-positive and Gram-negative bacteria
including several drug-resistant strains. In addition, novispirins
kill bacteria faster than traditional antibiotics.
O403 Study of the impact of macrolides against
Pseudomonas aeruginosa cystic ﬁbrosis isolates grown as bioﬁlm
A. Dubouix, L. Vaugien, C. Andrieu, S. Barthet, J. Grimoud,
C. Roques, N. Marty
Toulouse, F
Pseudomonas aeruginosa lung infection is the most important factor
of mortality and morbidity among cystic ﬁbrosis patients. While
planktonic model is generally associated with inital steps of the
pathology, bacteria grown as bioﬁlm are pathognomonic of the
chronic phase of infection. This last is responsible for deleterious
effects but little is known about antibiotic susceptibility.
Objective: To know the impact of macrolides against P. aeruginosa
strains grown both as planktonic and bioﬁlm models.
Methods: Azithromycine and clarithromycine alone or associated
with ceftazidime, tobramycine, doxycycline and sulfamethoxazole
were tested against six cystic ﬁbrosis clinical isolates (four smooth
and two mucoid strains) and bactericidal kinetics were evaluated
in a planktonic model. Bioﬁlm formation in presence of four sub-
inhibitory concentrations of the macrolides mentioned above was
then followed-up.
Results: In planktonic model, tobramycine and ceftazidime could
be fully bactericidal for concentrations as low as 2 mg/L after 2 h
of incubation. When combined with ceftazidime, macrolides led to
a prolonged bactericidal effect up to 24 h. Interestingly, doxycy-
cline led to a signiﬁcant reduction of the inoculum after 6 h for
75% of the strains tested. Furthermore, the combination macro-
lide-doxycycline enhanced this reduction. When bioﬁlm formation
was followed-up, a reduction of adhesion could be observed and
interestingly, a signiﬁcant impairment of colonisation resulting in
a delayed bioﬁlm structure could be noted when azithromycine
was used. This effect was concentration-dependent and was maxi-
mal between 0 and 20 h (three log reduction vs. control).
Conclusion: These results indicate that macrolides, essentially
used in cystic ﬁbrosis therapeutics for their anti-inﬂammatory
properties could enhance the bactericidal effects of other antibio-
tics in the initial steps of colonisation. Furthermore azithromy-
cine seems to interfere not only with bacterial adhesion but also
with factors involved in the initial phases of bioﬁlm formation.
Further tests including macrolides associated with other antibio-
tics are actually performed and should provide new therapeuti-
cal approach.
O404 Comparison of the mutant prevention concentration
of gatiﬂoxacin, garenoxacin, gemiﬂoxacin, levoﬂoxacin and
moxiﬂoxacin against clinical isolates of Streptococcus
pneumoniae collected prior to (1994–1997) and after 1997 (1997–
2003)
J. Blondeau, K. Metzler, P. Hedlin, G. Hansen, K. Drlica
Saskatoon, CAN; Newark, USA
Objectives: SP is an important human pathogen and antimicrobial
resistance has compromised the use of many agents. Gatiﬂoxacin
(GA), garenoxacin (GAR), gemiﬂoxacin (GM) and moxiﬂoxacin
(M) have enhanced in vitro activity against Streptococcus pneumo-
niae (SP) [compared with levoﬂoacin (L)]. The mutant prevention
concentration (MPC) deﬁnes the drug concentration threshold that
prevents the growth of ﬁrst-step mutants. New quinolones (Q)
were previously shown to be less like to select for resistance than
L by MPC and we speculated that use of less-active agents would
elevate minimal inhibitory concentrations (MIC), MPCs or both.
We tested SP isolates collected prior to (1994–1996) and after 1997
(1997–2003) by MIC and MPC.
Methods: MIC testing was by microbroth dilution in Todd–Hewitt
broth and in accordance with NCCLS guidelines. For MPC testing
approximately 10(10)cells were applied to blood agar plates con-
taining drug, incubated at 35–37C in 5% CO2 and screened for
growth at 24 and 48 h. MPC was the lowest drug concentration
with no growth.
Results: Over >400 isolates were tested (1994–1996, 106; 1997 to
present, >300). MIC distributions for SP remained unchanged dur-
ing both time periods. MPC90 (mg/L) values remained
unchanged during both periods respectively except for GAR
(0.125 vs. 0.25) and GM (0.25 vs. 0.5). 2.5% of isolates from 1994–
1996 had MICs to L 2 mg/L compared with 6% from 1997 to
present. MPC90 values to L were 4 mg/L and <1% of isolates
from 1994 to 1996 had L MPCs 8 mg/L when compared with
7% of isolates from 1997 to present. Rank order of potency based
on MPC90 values (lg/mL) was GR 0.25 > GM 0.5 >M 1 > GA
2 > L 4.
Conclusion: The percentage of organism with MICs and MPCs to L
was higher but not for other compounds for isolates collected from
1997 onward. The MPC concept predicts that the use of less-active
compounds for SP may increase the likelihood of resistant SP. L
was the least active agent on this study. Preferential use of Qs more
active against SP may slow the rate of resistance emergence.
O405 Virulence factors of ciproﬂoxacin-resistant
Escherichia coli in intensive care units
D. Jonas, F. Garcia, D. Hartung, F. Daschner
Freiburg, D; San Jose´, CR
Objectives: Extraintestinal-pathogenic strains (ExPEC) of patients
in intensive care units (ICU) belong disproportionately to the
virulence-associated group B2, in contrast to ciproﬂoxacin-resis-
tant isolates (FQREC). A recent scrutiny of nine FQREC strains in
regard of 35 VF has revealed a lower frequency of particular VF.
Hence a lower virulence-potential of FQREC was concluded
(J. Infect. Dis. 186: 1852). The aim of this study was to investigate
by use of a larger number of ExPEC whether the FQREC of the
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four phylogenetic groups are distinct from ciproﬂoxacin-suscepti-
ble isolates (FQSEC) in regard of occurrence and distribution of
VF and whether this is only related to the various frequencies of
the different virulent groups.
Methods: In order to examine a large and comparable number
of both FQREC and FQSEC isolates from the same groups, 137
isolates were selected from a collection of E. coli of known
group assignation originating from 28 ICU. PCR was used to
determine the presence of seven VF: the siderophores aerobactin
(iutA) and yersiniabactin (fyuA), the capsule synthesis-gene
locus (kpsMTII), the invasiveness factor (ibeA), the serum-resis-
tance factor (traT), the adhesins (papA, papG) and the iron-
regulated gene homologue adhesin (iha). The numbers of
detected VF in one isolate were added up to give an aggre-
gated VF score.
Results: Comparison of both resistance types showed that FQREC
revealed a larger number of VF than FQSEC with regard to the
groups A (2.41 vs. 1.69), B2 (4.56 vs. 3.65) and D (4.00 vs. 3.07)
and with the exception of group B1 (1.07 vs. 2.00). The frequencies
of particular VF signiﬁcantly differed between FQREC vs. FQSEC
in the groups B1 (fyuA: 7.1% vs. 57.1%), B2 (papG: 11.1% vs.
64.7%; traT: 88.9% vs. 35.3%) and D (papA: 60% vs. 20%; papG:
56% vs. 13.3%; fyuA: 84% vs. 46.7%; traT: 44.0% vs. 80%; iha:
60% vs. 20%).
Conclusions: Analysis of FQREC and FQSEC, taking into consid-
eration the phylogenetic groups, did not give any indication of a
lowered virulence potential in resistant E. coli with the exception
of group B1 strains. Contrarily, FQREC tend toward a larger num-
ber of VF than FQSEC. Furthermore, the comparison of both resis-
tance types within the same phylogenetic group revealed an
accumulation of particular VF in FQREC. This investigation con-
tradicts a recently published assumption of a lowered virulence
potential in ciproﬂoxacin-resistant E. coli.
O406 In vitro and in vivo ﬁtness cost of antibiotic
resistance in Escherichia coli
V.I. Enne, A.A. Delsol, G.R. Davis, J.M. Roe, P.M. Bennett
Bristol, UK
Objectives: Little is known of the ﬁtness cost that antibiotic resis-
tance exerts on wild-type bacteria, especially in their natural
environments. We therefore examined the ﬁtness costs that four
antibiotic resistance-encoding genetic elements (AbR element)
exerted on a wild-type E. coli isolate.
Methods: A rifampin-resistant (RifR) derivative of E. coli 345-2, a
recent porcine isolate, was selected as the study organism based
on its ability to compete successfully in vitro and in vivo. Plas-
mid R46, transposons Tn3 and Tn7 and a K43R RpsL substitu-
tion were separately introduced into 345-2 RifR using methods
mirroring those that may occur in the wild. The insertion sites
of Tn3 and Tn7 were identiﬁed using PCR and DNA sequen-
cing. The ﬁtness cost of each AbR element was assessed in vitro
by pairwise growth competition in Davis minimal medium
against the isogenic 345-2 RifR parent and in vivo by monitoring
the number of CFU/g of faeces regularly for 21 days following
inoculation of six 7-week-old organic piglets with 109 CFU. The
organism was recovered by plating onto MacConkey agar con-
taining rifampicin and retention of the AbR elements was moni-
tored by replicating onto agar containg the appropriate
antibiotics. Each derivative of 345-2 RifR carrying an AbR ele-
ment was grown in laboratory culture without antibiotics for 200
generations in an attempt to eliminate any ﬁtness costs asso-
ciated with carriage of AbR elements and the experiments to
assess ﬁtness were repeated.
Results: Tn3 had inserted into a cryptic DNA sequence of
unknown location. Tn7 had inserted downstream of glmS, as
expected. R46 and RpsL K43R were found to impose ﬁtness costs
on E. coli 345-2 RifR in vitro but did not compromise survival
in vivo; on the contrary the strain carrying R46 that had been
grown for 200 generations in vitro appeared to survive better in
vivo (Table 1) than the AbR-free parent. Acqusition of Tn7 had no
impact on the ﬁtness of E. coli 345-2 RifR in vitro or in vivo
(Table 1). Acquisition of Tn3 improved ﬁtness of E. coli 345-2 RifR
in vitro and in vivo (Table 1).
Conclusions: The ﬁtness impact exerted upon E. coli 345-2 RifR
by carriage of AbR elements is variable depending on the ele-
ment. Costs tended to be lower in vivo than in vitro. In most
cases in vitro passage for 200 generations did not affect ﬁtness. It
is unknown whether the ﬁtness gain brought about by Tn3
acquisition was a function of the insertion site or the transposon
itself.
O407 Fitness cost of sul2-coding plasmids in Escherichia
coli
V.I. Enne, P.M. Bennett, D.M. Livermore, L.M.C. Hall
Bristol, London, UK
Objectives: Following national advice to prescribe trimethoprim
instead of trimethoprim-sulphamethoxazole there has been a 97%
reduction in sulphonamide use in the UK since 1991. Neverthe-
less, the prevalence of resistance among clinical E. coli isolates
remains at approximately 40–45%. Linkage of sulphonamide
resistance to other resistances is thought important for this main-
tenance, but it also implies that sulphonamide resistance exerts lit-
tle ﬁtness cost. We therefore examined ﬁtness costs of three
plasmids carrying the commoner sulphonamide resistance deter-
minant, sul2.
Methods: The per-generation ﬁtness costs of three sul2 plasmids
were determined by pairwise growth competition against iso-
genic plasmid-free bacteria in Davis minimal medium. The
sequence of plasmid p9123 was determined by primer walking.
Results: Two of three sul2 plasmids imposed ﬁtness costs,
whereas p9123 improved the ﬁtness of both its original clinical
host and E. coli JM109 (Table 1) by approximately 4%. Sequen-
cing revealed that p9123 carried the remnants of a transposon-
like structure containing the sul2, strA and strB genes. Outside
this structure p9123 encoded four putative open reading frames
of unknown function.












None NA NA 50(10–110) NA
R46 plasmid 3.3  1.7 3.8  1.6 20(0–60)c 1270(0–4900)
RpsL K43R 2.2  0.9 3.6  0.9 120(10–510) 40(10–50)
Tn3 +6.0  2.6 +3.4  1.3 380(10–500) 4430(80–5130)
Tn7 +1.2  1.2 +0.8  4.4 20(0–40) 110(0–420)
aPer generation ﬁtness impact on E.coli 345-2 RifR(%)
bMean CFU/g of faeces (range) on day 21 post-inoculation
cvalue for day 17 as no isolates were recovered on day 21. NA(not applicable)












p9123 6.2 Su +4.3  1.9 +4.1  2.8
p9938 6.7 Su Tm 18.2  15.4 9.0  1.5
p9118 >66 Su S A NA 4.7 3.1
A(ampicillin), C(chloramphenicol), T(tetracycline), S(streptomycin) Tm(trimetho-
prim), NA(not applicable as plasmid could not be cured)
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Conclusions: The ﬁtness advantage conferred on their hosts by
some sul2 plasmids such as p9123 may have contributed to the
maintenance of sulphonamide resistance in the UK in the
absence of clinical selection pressure. The mechanism by which
p9123 confers a ﬁtness advantage on its host is unknown. Other
sul2-coding plasmids remain prevalent despite their ﬁtness
costs, probably due to co-selection by other agents. These data
suggest that once antibiotic resistance has been established on
mobile genetic elements, it may be difﬁcult to eliminate.
O408 High prevalence and combinations of antimicrobial
resistance traits in commensal bacteria from a very remote rural
community of Alto Amazonas (Peru)
A. Mantella, H. Rodriguez Ferrucci, C. Fernandez Neyra,
M. Benedetti, L. Pallecchi, M. Strohmeyer, F. Bartalesi,
C. Kristiansson, T. Falkenberg, E. Gotuzzo, A. Bartoloni,
G.M. Rossolini, F. Paradisi
Florence, I; Yurimaguas, PE; Siena, I; Stockholm, S; Lima, PE
Objectives: Several aspects concerning the impact of antimicrobial
usage in the emergence and spread of resistance remain poorly
understood and are difﬁcult to investigate due to the almost uni-
versal use of antimicrobial agents for several decades, and to the
lack of representative bacterial collections from the preantibiotic
era. The purpose of this work was to investigate antimicrobial
susceptibility of the commensal Escherichia coli of the population
of a very remote rural community of Peruvian Amazonas, where
the use of antimicrobials has been minimal.
Methods: The studied community (113 subjects) was selected as
one of the most isolate of the Alto Amazonas Province. Antimicro-
bial susceptibility of the commensal E. coli was investigated by
means of a rapid screening method in which faecal swabs were
plated onto McConkey Agar and antimicrobial disks (ampicillin-
AMP, ceftriaxone-CRO, tetracycline-TE, chloramphenicol-C, tri-
methoprim-sulphamethoxazole-SXT, quinolones and aminoglyco-
sides) were applied onto the seeded plate. Resistant isolates
showing an E. coli-like colony morphology were collected, identi-
ﬁed, and the susceptibility pattern was then conﬁrmed by stan-
dard disk-diffusion method. A simple questionnaire was used to
investigate antimicrobial usage (last 12 months) and to collect
demographic information.
Results: A total of 93 healthy subjects (42 males, 51 females; age
range 0–59 years, median 9) was enrolled. Five of them (5%)
reported previous antimicrobial use. Eighty-three of 93 (89%) sub-
jects carried commensal E. coli resistant to at least one antimicro-
bial agent. The highest resistance rates were observed for TE
(82%), AMP (68%), SXT (65%), and C (44%). The majority (85%)
yielding antibiotic-resistant E. coli harboured multidrug–resistance
(MDR) strains. The most frequent MDR phenotype included
AMP, TE, and SXT. No resistance was detected against ceftriax-
one, amikacin, nalidixic acid and ciproﬂoxacin.
Conclusion: The high resistance rates unexpectedly detected in this
isolate community suggest that, in some cases, the spread and
maintenance of resistant strains and resistance determinants could
be not directly related to antimicrobial consumption. The notable
diversity of resistance traits and of their combination patterns,
underscore a considerable complexity of the resistant bacterial
ecosystem and of their resistance-associated metagenome.
ANTRES project, supported by EU INCO-DEV grant (ICA4-CT-
2001-10014).
O409 Bacterial ﬁtness of drug-resistant Pseudomonas
aeruginosa
S. Frank, U. Frank, F. Daschner
Freiburg, D
Study objective: To investigate the properties of drug-resistant
Pseudomonas aeruginosa mutants regarding bacterial ﬁtness,
i.e. their survival in the environment.
Materials and methods: Development of resistance against cefepime,
imipenem, meropenem and gatiﬂoxacin was investigated in clini-
cal isolates of P. aeruginosa n ¼ 10) in up to 30 serial passages on
microtitre plates containing concentrations from three steps below
to at least four steps above the MIC of the respective antibiotic.
Antimicrobial resistance was deﬁned as a four-step (16-fold)
increase in the MIC with stability after 10 serial passages on anti-
biotic-free media. Environmental behaviour of the drug-resistant
mutants selected in vitro was compared with the isogenic parental
strains The survival of the bacteria was tested in (i) sterile tap
water and (ii) on a dry surface (patapar cellulose) at room tem-
perature (22C). Survival of P. aeruginosa in water was analysed
once daily for a study period of 2 weeks, whereas survival on the
dry surface was investigated 2, 4, 6, and 8 h after inoculation.
Tests in water were performed in duplicate, tests on the dry sur-
face in triplicate.
Results: Of all the P. aeruginosa mutants tested in water (n ¼ 40),
ﬁve (12.5%) showed signiﬁcantly improved survival in tap water
when compared with their isogenic parental strain, whereas 10
(25%) mutants showed signiﬁcantly impaired growth (P < 0.05);
the remaining 25 (50%) mutants did not show any differences in
growth kinetics. Improved growth kinetics were observed among
cefepime and gatiﬂoxacin-resistant mutants. Impaired bacterial ﬁt-
ness was noted in half (50%) of the meropenem-resistant and a
third (30%) of the imipenem-resistant mutants. On a dry surface,
four P. aeruginosa mutants (10 %) showed improved growth, only
one mutant (2.5%) showed impaired ﬁtness. There was no differ-
ence in growth kinetics among the remaining 35 mutants
(87.5 %).
Conclusions: Impaired bacterial ﬁtness in multidrug-resistant
P. aeruginosa is not a rare phenomenon. However, bacterial ﬁt-
ness can vary according to environmental conditions. In our in
vitro study, bacterial ﬁtness was particularly impaired among
carbapenem-resistant strains, whereas in some cases, an increase
in bacterial ﬁtness occurred in cefepime and gatiﬂoxacin-resistant
mutants. The importance of these ﬁndings deserves further
study.
Mycobacterial infections: diagnosis and epidemiology
O410 Increased expression of adhesion molecules on
peripheral blood monocytes in patients with severe pulmonary
tuberculosis
M. Ioanas, A. Riecks, M. Pletz, H. Lode, T. Schaberg
Berlin, D; Atlanta, USA; Rotenburg, D
Objectives: The aim of the present study was to determine
whether the expression of monocyte adhesion molecules (MAM)
on peripheral blood monocytes from patients with active pulmon-
ary tuberculosis (TB) is increased compared with healthy volun-
teers or to other respiratory infections (ORI).
Methods: Blood samples were obtained from 88 patients with
active pulmonary TB at admission, and also after 4 and 8 weeks
in severe cases (n ¼ 53). A group of healthy volunteers (n ¼ 53)
and an ORI group ORI (n ¼ 34) were also investigated. Blood was
incubated with FITC-labelled monoclonal antibodies against
CD11a, CD11b, CD11c, CD35, CD54, CD49a, CD58. Fluorescence
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intensity was measured by ﬂow-cytometry. Serum levels of
ICAM-1, VCAM-1 and IL-8 were measured by an enzyme linked
immunoassay.
Results: No differences in the expression of MAM could be
observed when comparing patients with mild to moderate TB vs.
ORI patients or healthy volunteers. In contrast, severe TB patients
presented a signiﬁcantly higher expression of all MAM
(P < 0.0001, except for CD49a) when compared with healthy
volunteers, and higher levels of CD11a, CD11c, CD35, CD54,
CD58, ICAM-1 and VCAM-1 when compared with ORI patients
(P < 0.04). No decrease was noted in MAM levels from severe TB
patients during the follow-up period.
Conclusion: Severe pulmonary TB is associated with an increased
expression of the monocyte adhesion molecules compared with
healthy volunteers or to patients with other respiratory infections.
These levels are maintained over 8 weeks, reﬂecting a persistent
process of recruitment of monocytes into the lung tissue despite
antituberculotic therapy.
O411 The diagnostic potential of the QuantiFERON-RD1
test in patients with active tuberculosis
P. Ravn, M. Munk, A˚.B. Andersen, B. Lundgren, J. Lundgren,
L.N. Nielsen, A.K. Jensen, P. Andersen, K. Weldingh
Copenhagen, Hvidovre, DK
Objectives: The QuantiFERON(QFN) test may have the potential
to replace the tuberculin skin test and it has been launched for
immuno-diagnosis of latent tuberculosis infection (LTBI) in low
risk population. The aim of this study was to evaluate potential of
the QFN test improved by the two M. tuberculosis speciﬁc antigens
(CFP-10 and ESAT-6) for the diagnosis of active TB.
Methods: We have measured IFN-c responses to the M. tuberculo-
sis-speciﬁc RD1 coded antigens, CFP-10 and ESAT-6 in a whole
blood assay (QFN-RD1) and compared the sensitivity with con-
ventional microscopy and culture (M/C). Prospectively, 82
patients with high risk of TB were enrolled; 51 of these suffered
from active TB and 31 patients did not have TB. Twenty-three
patients with unrelated diseases and 39 healthy persons were
included as controls. Whole blood samples from all donors were
analysed using the QFN-RD1 without knowing the ﬁnal diagnosis
of the patient. ROC curves analysis based on data from 39 healthy
donors was used to select the cut-off.
Results: The QFN-RD1 was positive in 82% (42/51) of the TB
patients and was negative in all 39 healthy individuals. Under
these conditions sensitivity was 82% and speciﬁcity was 100%.
More patients were diagnosed by the QFN-RD1 (82%) than by
M/C 62% (32/51, P ¼ 0.043) and a high percentage 89% (17/19)
of smear-negative TB patients were QFN-RD1 positive. Interest-
ingly, 92% (12/13) of the patients with extra-pulmonary TB were
QFN-RD1 positive, whereas only 39% (5/13) were positive by M/
C (P < 0.02). Among patients with no TB suspicion, the propor-
tion of QFN-RD1 responders was low 17% (four of 23) whereas
40% (10/25) of the patients with a strong clinical suspicion of TB
had a positive response. The majority of the latter patients had
one or more risk factors (born in high endemic country, alcohol
misuse, or IVDU), and we suggest that these QFN-RD1 positive
patients without active TB had a LTBI.
Conclusion: The sensitivity of the QFN-RD1 was high especially in
cases extra-pulmonary TB, and the QFN-RD1 may serve as an
additional diagnostic tool especially in situations where material
is not readily available for M/C. None of the healthy unexposed
individuals responded indicating high speciﬁcity, but 40% of the
patients with high risk of TB responded, which strongly suggests
LTBI. The impact of latent TB on speciﬁcity in different settings
remains to be determined and we suggest that all QFN-RD1-
positive individuals should be follow clinically.
O412 The role of a new immune diagnostic test based on
ESAT-6 epitopes in the evaluation of subjects with a clinical
suspicion of active tuberculosis
D. Goletti, S. Carrara, D. Vincenti, F. Palmieri, A. Rianda,
M. Bocchino, C. Saltini, N. Petrosillo, M. Amicosante, E. Girardi
Rome, I
Background: Mycobacterium tuberculosis ESAT-6 puriﬁed protein
and its peptides are currently being evaluated as antigens for the
immune diagnosis of TB. We set up an ELISPOT assay for IFN-c
whose novelty consists on two multiepitopic peptides from ESAT-
6 protein, selected by computational analysis, that allows the dis-
crimination between latent and active TB and the monitoring of
the efﬁcacy of anti-TB therapy (Vincenti et al., Mol. Med. 2003;
Carrara et al., Clin. Infec. Dis.).
Objective and methods: Aim of this study was to assess the perfor-
mance of the ELISPOT assay based on our selected ESAT-6 pep-
tides in the diagnosis of TB. In 12 months, a total of 120 HIV-
negative patients and 61 HIV-positive patients with symptoms
and signs consistent with active pulmonary or extra-pulmonary
TB were prospectively enrolled. In vitro IFN-c response to ESAT-6
intact protein and its selected peptides, PPD, recall antigens and
mitogens was evaluated in PBMC by ELISPOT assay.
Results: Of the HIV-negative patients enrolled, 67 (56%) were
diagnosed with TB and in 53 of them the diagnosis was microbio-
logically conﬁrmed (culture from biological ﬂuids and/or PCR
from biopsies specimens). Among the HIV-positive patients, 32
(52%) were diagnosed with microbiologically conﬁrmed TB.
In vitro anergy (unresponsiveness to mitogen) was present in 10%
of HIV-negative patients vs. 25% of those with HIV disease. The
analysis was performed among the nonanergic patients. In parti-
cular, among the HIV-negative patients, 44/62 with TB and four
of 49 without TB had a positive response to ESAT-6 selected pep-
tides. Thus, the sensitivity of our assay in this group is 71%, spe-
ciﬁcity is 91%, positive and negative predictive values are 92%
and 71%, respectively. Among HIV-positive patients, 17/23 with
TB and one of 23 without TB had a positive response to ESAT-6
selected peptides. Thus, sensitivity of our assay in this group is
70%, speciﬁcity is 93%, positive and negative predictive values
are 95 and 73%, respectively. In contrast, in both groups of
patients with or without HIV-disease, an in vitro response to PPD
and the intact ESAT-6 protein did not allow a discrimination
between subjects with active TB compared with those without.
Conclusions: This immune diagnostic assay, although with a still
sub-optimal sensitivity, has a high positive predictive value for
active TB, providing rapid (2 days) and speciﬁc diagnostic infor-
mation in patients with or without HIV disease.
O413 Evaluation of a new automated, rapid, colorimetric
culture system using solid medium for laboratory diagnosis of
tuberculosis and determination of antituberculosis drug
susceptibility
O. Baylan, O. Kisa, A. Albay, L. Doganci
Ankara, TR
Objective: To evaluate the performance of Dio-TK Culture System
(CS), a new colorimetric, automated and rapid CS.
Methods: Results of Dio-TK CS were compared with routinely
used Lo¨wenstein Jensen (LJ) medium and BACTEC 460 TB CS.
Results: In this study, 449 specimens, mostly sputum samples
obtained from 348 patients were evaluated. Mycobacteria isolated
from 31 (6.9%), 23 (5.1%), 18 (4.0%) and 21 (4.7%) of the speci-
mens in BACTEC 12B, LJ, Dio-TK Medium and Dio-TK SLC
(selective), respectively. The mean time to detection of growth of
13 isolates by BACTEC 12B, Dio-TK Medium, Dio-TK SLC and LJ
medium were 8.9, 15.1, 17.0 and 26.1 days, respectively. Contami-
nation ratios for BACTEC 12B, Dio-TK Medium, Dio-TK SLC and
LJ media were 1.3% (n: 6), 3.8% (n: 17), 1.6% (n: 7) and 2.4%
(n: 11), respectively.
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Conclusion: Dio-TK CS may be a practical and rapid CS for daily
use. However, the manufacturer should improve the CS to mini-
mize the effects of manipulation errors. Comparative studies with
a larger number of isolates are needed to standardise drug con-
centrations used in antituberculosis drug-susceptibility testing.
O414 Quality assurance in molecular diagnosis of
tuberculosis
A. Flountzi, D. Houhoula, A. Priftis, N.J. Legakis, L. Zerva
Athens, GR
Objectives: The analysis of laboratory data and their correlation
with clinical information constitutes an important quality assur-
ance exercise. We retrospectively analysed all data on molecular
diagnosis of tuberculosis recorded in a laboratory, which started
functioning as a diagnostic center since April 2000.
Methods: Laboratory data (specimen type, volume and number/
patient; PCR results) obtained from April 2000 to October 2003
were analysed, while clinical and other laboratory ﬁndings were
recorded for patients submitting specimens during the last
13 months, and for all patients with PCR(+) specimens. Two diag-
nostic PCR methods were applied, a screening and a conﬁrmatory
assay.
Results: During a 42-month period, 508 samples from 291 patients
originating from 35 hospitals were examined. Sputum (n ¼ 92,
18%), urine (n ¼ 65, 13%) and CSF (n ¼ 55, 11%) were the most
frequent samples, while 174 (34%) originated from the lower
respiratory tract. Mean volume for CSF samples was 1.8 mL, for
pleural ﬂuid 24.5 mL and for peritoneal ﬂuid 45.8 mL. Of 39
patients submitting sputum samples, 24 demonstrated three con-
secutive samples (62%) and four patients two samples (10%),
while three consecutive urine samples were submitted from 18 of
a total 28 patients (64%). Ten patients revealed at least 1 PCR(+)
sample: eight demonstrated positive cultures, one was culture-
negative and for one, cultures were not performed. PCR testing
was negative for seven patients for whom tuberculosis diagnosis
was established either by histology or clinical criteria but not cul-
tures (three pleural ﬂuids, two cutaneous biopsies, two biopsies in
parafﬁn). During the last 13 months, 123 specimens from 91
patients were examined. Mycobacterial cultures were submitted
for 57 patients (62%), were not submitted for 19 (21%), while cul-
ture status was unknown for 15 (17%). Speciﬁcity and PPV for
PCR were 100%, NPV 91% and sensitivity ranged from 100%
(lower respiratory tract specimens) to 0% (tissue in parafﬁn and
pleural ﬂuid).
Conclusions: Better communication between laboratory and clini-
cians will improve specimen quality in terms of adequate number
and volume of specimens and ascertain that they are all cultured.
The high frequency of extrapulmonary samples reﬂects the neces-
sity to rapidly rule out/in extrapulmonary tuberculosis, for
which, the sensitivity of molecular diagnosis is compromised. The
application of quality assurance methods can only improve
patient care.
O415 Molecular characterisation of Mycobacterium
tuberculosis strains from Southern Ukraine: evidence of drug
resistance rates and Beijing strains prevalence
V. Nykolayevskyy, T. Brown, Y. Bazhora, A. Asmolov,
N. Levitskaya, F. Drobniewski
Odessa, UKR; London, UK
High rates of TB and HIV incidence were observed recently in
Ukraine, particularly in the Southern region.
Objective: Detection of rifampicin, isoniazid, multidrug resistance
rates and Beijing strain prevalence in TB isolates from Odessa and
Nikolaev oblasts (southern Ukraine) in 2003 using a macroarray
technique and spoligotyping.
Materials and methods: In total, 110 Mycobacterium tuberculosis
strains isolated from patients of TB hospitals in Odessa and Niko-
laev oblasts (both chronic and new cases) were available for
study. The macroarray method is based on ampliﬁcation of rpoB,
katG and inhA genes fragments with three pairs of biotin-labelled
primers followed by reverse hybridisation of PCR products with a
set of oligonucleotide probes immobilized on nylon membranes.
DNA extracts were prepared by heating cell suspensions followed
by chloroform deproteinisation. Streptavidin-alkaline phosphatase
colour development system was used for results visualisation.
Spoligotyping was done using standard protocols.
Results and discussion: In total, 32.7% of isolates possessed muta-
tions consistent with rifampicin resistance, 41.8% consistent with
isoniazid resistance and 29.1% possessed mutations both in rpoB
and katG (or inhA), i.e. were considered to be multidrug resistant
(MDR). In strains isolated from the patients who had never
received TB treatment MDR rates did not exceed 16%. Analysis
of occurrence of different types of mutations consistent with drug
resistance development demonstrated that in the majority of cases
rifampicin resistance was due to mutations in codon 531 (54.8%
of all resistant isolates) and in codon 526 (25.8%) of rpoB gene.
76.0% of isoniazid resistant isolates possessed mutations in codon
315 of katG gene, and other 24.0% both in katG and inhA genes.
Spoligotype patterns were obtained for all strains, 30 (27.3%) of
which produced a typical Beijing family proﬁle (hybridisation
with ﬁnal nine probes). According to these results, M. tuberculo-
sis drug resistance rates for the southern Ukraine are lower than
in north-western and central Russia, but still much higher than in
the majority of European countries. A relatively low prevalence of
Beijing family strains and a wide range of mutations associated
with drug resistance demonstrate genetic diversity of M. tuberculo-
sis strains circulating in southern Ukraine although this may not
reﬂect epidemiological situation in the Ukraine as a whole.
O416 Repetitive element typing of M. tuberculosis from
the Caribbean and African population in the UK reveals
unsuspected transmission
J.M. Greig, J.T. Evans, E.G. Smith, J.A. Innes, P.M. Hawkey
Birmingham, UK
Objectives: Tuberculosis case rates are increasing worldwide. In
Birmingham in recent years, case numbers have risen in common
with other metropolitan areas in the UK. Different molecular typ-
ing methods are being developed and have been used to examine
strains from clusters, and broader population studies. VNTR and
MIRU are PCR-based methods that give an easily reproducible,
numerical output. The combination of the two methods has been
shown to be highly discriminatory and useful for outbreak inves-
tigation. Spoligotyping is a reproducible PCR-based method with
simple binary output. Plans are under development to introduce
real time molecular typing into routine clinical practice. Will this
add information to that collected by routine contact tracing and
which method will give the most useful results?
Methods: DNA was extracted from M. tuberculosis cultured from
101 patients in Birmingham with tuberculosis, from two distinct
ethnic groups, during the years 1999–2002. The DNA was ana-
lysed by VNTR and spoligotyping. Those strains with identical
VNTR proﬁles were further analysed by MIRU typing.
Results: Spoligotyping identiﬁed 11 clusters with 59 clustered iso-
lates. African and Caribbean isolates were mainly separated in
different spoligotyping clusters. MIRU typing reduced the number
of clusters to seven, with 38 clustered isolates. The larger spoligo-
typing and VNTR clusters were sub-divided by MIRU typing and
three MIRU clusters were split by spoligotyping, with the loss of
a single spacer. There was a group of 15 Caribbean patients with
identical MIRU proﬁles, not previously identiﬁed as epidemiologi-
cally linked by traditional contact tracing. This may explain the
on-going excess rates of tuberculosis within this community.
Most of the Caribbean population were born in the UK and
thought to have acquired their infection locally. 67% of VNTR
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types were clustered, the Harlem clade, 32333, being most com-
monly represented. The newly identiﬁed X clade, 32 433, was seen
in seven patients, ﬁve of whom were born in the Caribbean. In
contrast, most of the African populations were recent arrivals in
the UK and had disease as a result of re-activation of latent infec-
tion rather than from local spread. Only 27% of VNTR types were
clustered.
Conclusion: A combination of VNTR and MIRU typing is more
discriminatory than spoligotyping and can identify unsuspected
community transmission of tuberculosis and aid work to control
spread of disease.
O417 Clinical and social proﬁle of TB patients in civilian
and penitentiary sectors in Samara, Russia
Y. Balabanova, M. Ruddy, C. Graham, I. Fedorin, S. Kuznetsov,
A. Melentyev, S. Zakharova, N. Malomanova, E. Elizarova,
V. Nikolayevskyy, F. Drobniewski
London, UK; Samara, RUS; Odessa, UKR
Background: The epidemics of tuberculosis (TB) and HIV are conti-
nuing in the Russian Federation particularly within the prison
system.
Design: Cross-sectional study of TB patients with and without
HIV co-infection in the prison and civilian sectors of Samara, Rus-
sia Federation.
Objectives: Describe the demographic, clinical, social and HIV sta-
tus of civilian and penitentiary TB patients.
Results: Individuals (3408) with TB were enrolled including 1345
prisoners. The majority of civilians were male (74.7%); 20.8%
had been in prison before. Many had advanced disease:
approximately 30–40% of patients had two or more zones and/
or cavities on CXR; 89.9% had been BCG vaccinated. For all
TB cases HIV co-infection was seen in 4.7, 2.4 and 7.5%,
respectively; hepatitis B/C co-infection in 18.2, 14.1, and 24.3%;
previous gonorrhoea was seen in 4.7, 3.6 and 6.4%. Two-thirds
(66.1%; 84/127) of the HIV-positive patients were IVDU. Over-
all 726/3400 (21.4%) admitted to recreational drug use typically
opiates (84.8%) by injection (87.8%). Male civilians compared
with male prisoners with TB were less likely to be HIV-positive
(OR ¼ 0.07), co-infected with hepatitis B/C (OR ¼ 0.59), use
drugs (OR ¼ 0.04), have had previous gonorrhoea (OR ¼ 0.68),
syphilis (OR ¼ 0.3), to smoke (OR ¼ 0.11) or drink alcohol
(0.53). In the multivariate analysis, civilians were more likely to
have COPD (OR ¼ 28.75), localised disease on CXR (OR ¼ 2.03),
thoracic surgery (OR ¼ 8.41), signiﬁcantly less likely to have a
productive cough (OR ¼ 0.53), chest pain (OR ¼ 0.33), be BCG
vaccinated (OR ¼ 0.09), have had syphilis (OR ¼ 0.25) or herpes
(OR ¼ 0.03). They were also more likely to smoke (OR ¼ 0.25)
and to use recreational drugs (OR ¼ 0.04). Prisoners with HIV
and TB were more likely to have been treated for TB before
(OR ¼ 1.44), be on post-treatment anti-relapse therapy
(OR ¼ 2.61), and have jaundice (OR ¼ 6.38) and concurrent
hepatitis B/C (OR ¼ 2.13) than those who were HIV negati-
ve. Multivariate analysis showed that HIV-positive individuals
were more likely to have been treated (OR ¼ 2.17), to have
chest pain (OR ¼ 2.01), jaundice (OR ¼ 8.48) and gonorrhoea
previously (OR ¼ 2.25) but were less likely to report weight
loss (OR ¼ 0.47), shortness of breath (OR ¼ 0.42).
Conclusion: Major risk factors for the spread of HIV and drug
resistant TB exist particularly in the prison sector and there are
important social and gender differences underlying the epidemiol-
ogy of HIV and TB.
O418 Clinical presentation and outcome of HIV-associated
tuberculosis in the HAART era in Rome
N. Petrosillo, A. Rianda, D. Goletti, E. Girardi, P. De Mori,
E. Busi Rizzi, R. Urso, M. De Marco, R. Maddaluno, F. Palmieri
for ‘‘Tuberculosis-I.N.M.I. L.Spallanzani Study Group’’
Objectives: To assess changes in clinical presentation and outcome
of pulmonary tuberculosis (TB) diagnosed in HIV-infected
patients in the time period preceding and following the wide-
spread introduction in clinical practice of highly active antiretro-
viral therapy (HAART) in Italy.
Methods: We reviewed clinical charts of 221 HIV-infected
patients with culture-conﬁrmed pulmonary TB hospitalised at
National Institute for Infectious Diseases ‘‘L. Spallanzani’’, Rome
from January 1987 to December 2002. A total of 121 patients
diagnosed in 1987–1996, i.e. before HAART introduction, were
compared with 100 patients diagnosed in 1997–2002, i.e. after
HAART introduction. Differences in categorical variables were
analysed with the use of the chi squared test or Fisher’s exact
test, as appropriate.
Results: At onset, patients diagnosed in 1997–2002 were more
likely to have TB as the ﬁrst AIDS deﬁning illness (79% vs. 56%,
P < 0.005), to be foreign born (37% vs. 12%, P < 0.005), and had a
higher CD4+ count (median 126 vs. 72/mm3, P < 0.005). More-
over, post-HAART patients had more frequently a ‘typical’ chest
X-ray pattern with upper-lobe inﬁltrate and/or cavitation (55%
vs. 35%, P < 0.005), and M. tuberculosis resistant to at least both
isoniazid and rifampin (12% vs. 5%; P ¼ 0.09). We observed 20
cases of TB among post-HAART patients. By the end of the
study period (September 30, 2003), 113 patients (51%) had died,
93 patients (42%) were alive and healthy, while 15 patients (7%)
were lost to follow-up after TB diagnosis; 21 patients had died
(21%) in post-HAART group and 92 patients (76%) in pre-
HAART group ( P < 0.001). TB was recorded as the cause of
death in 34 patients (30%). The survival proportion at 1 and
3 years was 87% and 82% in patients diagnosed in the post-
HAART era, while it was 59% and 26% respectively in pre-
HAART patients. Univariate analysis showed that pre-HAART
patients had a signiﬁcantly decreased survival compared with the
other patients (P < 0.001, log-rank).
Conclusions: We found that, after HAART became widely avail-
able, patients tended to be diagnosed with TB at lower level of
immunosuppression, to have TB more frequently as the ﬁrst AIDS
deﬁning illnesses, and to have more frequently a ‘typical’ chest
X-ray pattern. Moreover, patients diagnosed in the HAART era
had a signiﬁcantly longer survival. Our data suggest that the
increasing use of HAART has modiﬁed the clinical presentation
of HIV-associated TB and the survival of patients presenting with
this disease.
O419 Treatment of tuberculosis in HIV-infected patients
A. Matteelli, C. Casalini, A.-C. Carvalho, M. Manfrin, R. Poni
Gore, N. Saleri, G. De Iaco, C. Pizzocolo, S. Capone, G. Carosi
Brescia, I
Objective: To describe treatment practices and outcomes of tuber-
culosis and HIV infection in dually infection persons.
Methods: We retrospectively reviewed the medical records of all
HIV-1 positive patients with TB, identiﬁed from December 1997 to
October 2003 at the Infectious and Tropical Diseases Institute of
the University of Brescia, Italy, collected on demographic para-
meters, viro-immunological status, TB site, treatment adminis-
tered, response to treatment and side-effects and cases of AIDS-
deﬁning illness.
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Results: A total of 42 HIV+ patients with tuberculosis were iden-
tiﬁed. Among them 59.5% were immigrants, 14.3% injection
drug users; 54.1% were unaware of their HIV infection at the
time of the TB diagnosis. All TB cases were classiﬁed as new
cases and the diagnosis was based on isolation of M. tuberculosis
or identiﬁcation of acid-fast bacilli were detected on 91.3%. The
17.4% shown extrapulmonary involvement (23.9% TB lympho-
node), 21.7% disseminated TB, 82.6% pulmonary (PTB) involve-
ment with a smear positive in 45.6% of cases. Rifampin was
administered in 93.5% of the cases, 95.3% of whom concluded
the TB treatment; 6.5% were treated with rifabutine. The 43.5%
of the cases developed the tuberculosis with a CD4 count <300/
mm3 L, and the 71.8% with a CD4 count <100/mm3 L, accord-
ing with the rate found of 21.7% of disseminated TB in patients
with a low CD4 count. 76.1% of all TB and HIV co-infection
cases received HAART; 62.8% of whom with NNRTI. During
the follow-up, three patients developed an AIDS deﬁning illness.
Adverse events were recorded on 17.4% of all cases, none inter-
rupt treatment because of side-effects. 4.7% failed, and 7.2%
died. Comparing the CD4 cell count and HIV viral load at the
beginning and end of TB treatment, we observed an increasing
of CD4 cell count (P ¼ 0.07) and reduction of the viral load
(P, not signiﬁcant).
Conclusions: 76.1% of dually infected patients in this study
received HAART in combination with TB treatment. Side-effects
occurred in 17.4%, but no one case interrupted HAART.
Infection in the immunocompromised host: diagnostic tools, treatment and monitoring
O420 A negative procalcitonin test as an indicator of
noninfectious fever in neutropenic cancer patients with FUO
O.J. Robinson, T. Calandra, F. Bally, M. Knaup, W. Beier,
O. Marchetti
Lausanne, CH; Hennigsdorf, D
Objectives: FUO accounts for 25–50% of all febrile episodes (FE) in
neutropenic cancer patients and may reﬂect the presence either of
a noninfectious fever or of an occult infection. Given that infection
cannot be ruled out, most patients with FUO are treated with
broad-spectrum antibiotics for extended periods of time (IDSA,
CID, 2002). Identiﬁcation of patients with NIF, in whom antibio-
tics could be stopped rapidly (i.e. within 48–72 h of fever onset),
would help to reduce treatment costs, adverse events and mini-
mise the risk of development of resistance. In children with
meningitis and in critically ill patients, PCT has been shown to
distinguish bacterial from viral infections or from inﬂammatory
diseases. The aim of the present study was to evaluate the utility
of PCT for the management of neutropenic FUO.
Methods: 171 FE in 125 consecutive neutropenic patients under-
going intensive chemotherapy for haematological malignancies
were studied prospectively over 18 months. FE were classiﬁed as
microbiologically (MDI) or clinically (CDI) documented infections
and FUO according to standard deﬁnitions (ICHS, JID, 1990).
Plasma concentrations of PCT (LUMItest,BRAHMS, Germany)
were measured twice weekly in the absence of fever and daily
within 4 days of a FE test was considered to be negative if PCT
was <0.5 ng/mL.
Results: Forty-six of 171 FE (27%) were classiﬁed as FUO. Among
these, PCT remained negative in 32 (median 0.2 ng/mL) and
became positive within 72 h in 14 (median 0.7) (P < 0.001) reach-
ing levels comparable with those measured in MDI (median 0.8)
and CDI (median 0.5). Apart from PCT levels at day 3, these two
subgroups of FUO patients were clinically indistinguishable: peak
temperature (38.5 vs. 38.6C), time to defervescence (2 days, range
1–9 vs. 2 days, range 1–6) and duration of antibiotic therapy
(8 days vs. 7 days). Thus, PCT was the only parameter capable of
distinguishing FUO patients likely to have a NIF (low PCT) from
those likely to have an occult bacterial infection (elevated PCT).
Conclusions: A negative PCT (<0.5 ng/mL) within 72 h after onset
of fever in neutropenic cancer patients with FUO is an indicator
of a noninfectious aetiology of fever suggesting that empirical
antibiotic therapy might be discontinued in these patients. This
strategy should be tested prospectively.
O421 Prevalence and impact of adenovirus viraemia in
adult stem-cell transplant recipients treated with Campath-1H
A. Geretti, E. Nieto, S. Ramalingam, A. Ho, M. Smith, G. Mufti,
S. Devereux, A. Pagliuca, M. Zuckerman, D. Cubitt
London, UK
Objective: Determine the incidence and impact of ADV viraemia
in adult recipients of peripheral or bone marrow stem-cell trans-
plantation (PSCT, BMT) who received Campath-1H-based condi-
tioning.
Methods: Whole blood and serum samples collected weekly were
tested by PCR (Hexon gene). Stool, urine, nasopharyngeal aspi-
rates and throat swabs were tested by PCR and culture (A549
cells) to assess virus excretion. Blood viral load kinetics were
determined by real-time PCR.
Results: The study included 49 consecutive patients (30M, 19F;
mean age 50 years, range 19–69) who received PSCT (n ¼ 34) or
BMT ( n ¼ 15) for haematological disease in May 2002–May 2003.
Donor status was sibling HLA-identical (n ¼ 12), unrelated (UD)
HLA-identical (n ¼ 26) and UD HLA-mismatched (n ¼ 11). Over
748 person-weeks of follow-up and a mean follow-up to day 113+
(median 102+), ADV viraemia was detected in four patients. All
had lymphocyte counts <0.25; two had failed a previous SCT, two
others were recipients of UD HLA-mismatched grafts. All pro-
gressed to disseminated infection, with virus excretion at two or
more sites, viral load >10  6 c/mL, and symptomatic disease
(fever, gastroenteritis, pneumonia, haematuria or hepatitis). Two
patients became viraemic at day 12+ (types C, A12) and died with
multi-organ failure at day 15+ and 30+, respectively. A third
patient became viraemic at day 26+ (type C) and reactivated CMV
at day 33+. The ADV viral load declined during anti-CMV ther-
apy with i.v. ganciclovir, but rebounded once therapy was discon-
tinued. The patient died with multi-organ failure at day 76+. The
fourth patient became viraemic at day 48+ (type E4)and pro-
gressed to disseminated infection with hepatitis. The viral load
declined following the beginning of i.v. cidofovir at day 67+ and
coinciding with lymphocyte count increasing >0.25. ADV PCR
became negative in serum and subsequently in whole blood; virus
excretion ceased at all sites and the patient made a full recovery
by day 114+. ADV was detected in the stool of four additional
patients in the absence of viraemia, but the infection resolved
spontaneously.
Conclusions: In this cohort of heavily immunocompromised
patients the incidence of ADV viraemia was 8.2%. Viraemia was
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highly predictive of virus dissemination and morbidity and was
associated with the entire mortality (three of 49) observed in the
ﬁrst 100 days post-SCT. Blood viral load dynamics correlated well
with disease progression and response to antiviral therapy and/or
immune reconstitution.
O422 Efﬁcacy of caspofungin against invasive Candida or
Aspergillus infections in neutropenic patients: review of the
caspofungin database
N. Kartsonis, H. Teppler, A. Taylor, R. Lupinacci, C. Sable
West Point, USA
Objectives: Neutropenia is an indicator of poor prognosis in
patients (pts) with fungal infections. In vivo models demonstrate
that the echinocandin caspofungin (CAS) is effective against both
Candida and Aspergillus infections even in persistently neutropenic
animals. We reviewed the current Merck database to ascertain the
efﬁcacy of CAS in neutropenic pts with documented invasive
aspergillosis (IA) or invasive candidiasis (IC).
Methods: This review was limited to neutropenic pts with pro-
ven/probable IA or IC at study entry. Data are available from
four clinical trials: the salvage IA study (Protocol 019, P019), the
comparative IC study (P014), the IA/IC compassionate use study
(P024), and the empirical therapy (Rx) study in febrile neutropenic
pts (P026). P026 included a subset of pts who had IC or IA based
on clinical/radiology evidence of infection at study entry but in
whom the diagnosis was not conﬁrmed until after CAS was
initiated. All pts had an ANC <500/mm3 at CAS onset. In all pts,
CAS was administered as monotherapy at 50 mg/day following a
70-mg loading dose on day 1. CAS was administered as salvage
Rx in P019 and P024, and as ﬁrst-line Rx in P014 and P026. Efﬁ-
cacy was assessed at the end of CAS Rx. Success included com-
plete or partial responses.
Results: A total of 75 neutropenic pts were identiﬁed with proven/
probable invasive infection, including 29 pts with IC and 46 pts
with IA. Most had acute or chronic leukaemia. IC: A total of 25 pts
had proven candidemia; two pts each had chronic disseminated
candidiasis (CDC, one proven/one probable) or other disseminated
Candida infections (one proven/one probable). Favourable response
was noted in 62% (18/29), including a 58% (15/26) response as
ﬁrst-line Rx and a 100% (three of three) response as salvage Rx. Suc-
cess in candidaemia was 68% (17/25); success in CDC and other
disseminated infections was 25% (one of four). Outcome across the
different Candida species was similar. IA: 35 (76%) pts had pulmon-
ary IA (15 proven, 20 probable). Other sites of infection (all proven)
included sinus (15%), skin (2%), and disseminated (7%). Favour-
able responses were noted in 35% (16/46), including a 42% (ﬁve of
12) response as ﬁrst-line Rx and 32% (11/34) response as salvage
Rx. Success by site of infection was pulmonary 34% (12/35), sinus
43% (3/7), and skin/disseminated 25% (1/4).
Conclusions: Review of the CAS database demonstrates that CAS
is effective in neutropenic pts with either proven/probable cases
of IC or IA.
O423 Impact of resolution of fever on the overall
composite endpoint in a phase III study of caspofungin vs.
liposomal amphotericin B as empirical therapy for neutropenic
patients with persistent fever
B. de Pauw, C. Sable, T. Walsh, R. Lupinacci, M. Bourque,
H. Teppler
Nijmegen, NL; West Point, Bethesda, USA
Objectives: An exploratory analysis was conducted within a recent
phase III trial of caspofungin (CAS) vs. liposomal amphotericin B
(L-AmB) to determine the impact of the endpoint deﬁnition for
the resolution of fever (RF) on the overall response rate using a
ﬁve-part composite endpoint.
Methods: The primary analysis used a ﬁve-part composite end-
point: successful outcome of baseline invasive fungal infection
(IFI), no breakthrough IFI to 7 day post-Rx, survival to 7 day
post-Rx, no discontinuation of study drug for toxicity or lack of
efﬁcacy, and RF deﬁned as afebrile (<38C) for 48 h during neu-
tropenia and before the end of study Rx. A favourable response
required success in each endpoint component. This analysis
demonstrated noninferiority of CAS to L-AmB. Subsequently,
three prespeciﬁed exploratory analyses were performed using
less conservative deﬁnitions for RF: 24 h afebrile during neutro-
penia before end of Rx, afebrile at 7 day post-Rx, and exclusion
of RF from the composite analysis. All other endpoint compo-
nents were handled consistently with the primary analysis. The
impact of risk category, a stratiﬁcation parameter at study entry,
was examined. High-risk patients (pts) had allogeneic haemato-
poietic transplant or relapsed acute leukaemia; all others were
low-risk.
Results: Stratum-adjusted overall response rates are shown in
the Table 1 below. In each analysis, CAS met noninferiority cri-
teria. When RF was excluded from the composite endpoint,
CAS was superior to L-AmB. Low-risk pts in both Rx groups
had shorter duration of neutropenia (by 3–4 days). Due to less
opportunity to demonstrate 48 h afebrile during a shorter per-
iod of neutropenia, low risk patients failed the RF endpoint in
the primary analysis more often than high-risk pts (RF rates
37–39% for low vs. 50–52% for high risk). In the exploratory
analyses, a greater increase in response rates was seen for low
than high-risk pts.
Conclusions: Overall response rates for the composite endpoint in
this empirical therapy study are driven by low response rates for
RF, especially in low-risk pts due to their shorter duration of neu-
tropenia. Noninferiority of CAS to L-AmB was conﬁrmed in each
analysis. When RF was not included as part of the composite end-
point, CAS was superior to L-AmB in the empirical therapy of
persistently febrile neutropenic pts.
O424 Monitoring of Epstein-Barr virus (EBV) DNA load
after haematopoietic stem-cell transplantation for prevention,
early diagnosis as well as antiviral and immune therapy of
EBV-associated lymphoproliferative diseases
A. Meerbach, B. Gruhn, R. Haefer, F. Zintl, P. Wutzler
Jena, D
Objective: The development of a life-threatening EBV-associated
lymphoproliferative disease (LPD) is a serious complication in
patients after haematopoietic stem-cell transplantation (HSCT).
Monitoring of viral load is a useful and sensitive parameter in the
surveillance of EBV reactivation for prevention and treatment of
EBV-associated LPD.











CAS 33.9 51.6 55.3 81.7
L-AmB 33.7 47.8 53.5 74.7
Difference 0.2 3.8 1.8 7.0
(95:2% CI) (5:6; 6:0) (2:4; 9:9) (4:3; 8:0) (1.9, 12.1)
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Methods: A semiquantitative PCR for evaluating EBV-genome copy
numbers in plasma and peripheral blood mononuclear cells
(PBMC) was established. The method bases on a nested PCR using
primers of the structural protein region p23 and an end-point dilu-
tion. Using this assay in 65 patients undergoing HSCT EBV DNA
load was prospectively screened weekly after transplantation.
Results: EBV reactivations (>1000 EBV-genome copies measured in
100 000 PBMC) were observed in 11 patients (16.9%). Three
patients developed LPD with extremely high EBV-genome copy
numbers in PBMC (>100 000) and plasma. The rapid increase of
EBV-genome copies occurred 1–4 weeks before the onset of the
disease. After combined antiviral and immune therapy two of
three patients showed a dramatic decrease of EBV load and sur-
vived, while the third patient died of lymphoma. A subclinical
EBV reactivation was observed in ﬁve cases with EBV-genome
copies ranging from 1000–10 000. After reduction of immunosup-
pression the EBV levels normalised. In three patients the high
copy number of >10 000 and plasma positivity prompted the phy-
sicians to start pre-emptive therapy with rituximab and cidofovir
for prevention of EBV-associated LPD. After drug administration
the high EBV load in plasma and PBMC reduced dramatically.
The decrease of EBV-genome copies was associated with a
decrease of B lymphocytes and an increase of CD8+ and CD4+ T
lymphocytes. The 54 patients who had copy numbers of <1000
did not develop EBV-associated LPD.
Conclusions: Monitoring of EBV DNA load is a useful method for
early diagnosis and treatment of EBV-associated LPD and for fol-
low-up the efﬁcacy of therapy.
O425 Real-time PCR quantiﬁcation of EBV, CMV and
HHV6 in patients after allogeneic haematopoietic stem cell
transplantation
P. Hubacek, O. Cinek, M. Zajac, S. Voslarova, P. Sedlakova,
P. Keslova, J. Stary, P. Sedlacek
Prague, CZ
Objectives: Herpesvirus infections cause serious complications in
patients after haematopoietic stem-cell transplantation (HSCT).
Recently, real-time PCR monitoring of viral load has become the
method of choice for distinguishing between benign and
life-threatening herpesvirus infections and thus for indication of
antiviral therapy. The aim was to investigate the frequency and
outcome of infection with EBV, CMV and HHV6 in a consecutive
group of children undergoing allogeneic HSCT.
Methods: We tested 1566 samples collected from 58 children trans-
planted between January 2001 and August 2003. The samples
were drawn weekly by day +100 after HSCT, and biweekly there-
after until day +365. DNA was extracted from whole blood, and
tested for EBV, CMV and HHV6 by real-time PCR techniques.
The viral load was normalised to 100 000 human genomic equiva-
lents (GE) as assessed by albumin gene quantiﬁcation. A provi-
sional cut-off level of the quantity was set to 1000 copies of viral
DNA per 100 000 GE.
Results: The quantity threshold for either of the three viruses was
crossed in 17 of 58 (29%) children. The proportion of children
with EBV, CMV and HHV6 activation was identical, Eight of 58
(14%) for each virus. Three children required anti-CD20 adminis-
tration due to prolonged or rising EBV viral load. No child died
of EBV-related complications. Therapy with foscavir or ganciclovir
was instituted in seven of eight CMV-positive patients. Five of the
patients experienced repeatedly treated reactivations, one of them
died of CMV pneumonia. One child had CNS symptoms attribu-
table to HHV6 infection (documented in blood and cerebrospinal
ﬂuid), and was therefore treated with acyclovir and ganciclovir.
All remaining children with HHV6 had long lasting low-to-inter-
mediate viral loads without detectable effects on the post-trans-
plant course.
Conclusion: Our report conﬁrms usefulness of frequent monitoring
of EBV and CMV viral load in routine post-transplant care. Since
we had instituted the quantitative monitoring, no patient died of
post-transplant EBV lymphoproliferation (EBV-LPD) in contrast to
four deaths of EBV-LPD in the preceding year. To our best knowl-
edge, this is the ﬁrst report on longitudinal monitoring of HHV6
in an unselected consecutive group of children after allogeneic
HSCT, showing that HHV6 frequently accompanies, but rarely
complicates the post-transplant course. Supported by the Minis-
try of Health grant 7459.
O426 Contamination of bone marrow products with a
Mycobacterium mucogenicum-related pathogen
I. Kassis, I. Oren, R. Finkelstein, G. Rabino, T. Katz, H. Sprecher
Haifa, IL
Background: Contamination of bone marrow products (BMP) occurs
in 8–20% of cases, mostly by nonpathogenic microorganisms,
usually without signiﬁcant morbidity among bone marrow trans-
plant (BMT) recipients. Contamination can occur in the course of
BMP collection or during processing for cryopreservation. BMP
contamination with mycobacteria is rare and poses a signiﬁcant
diagnostic and therapeutic challenge. In our institution, samples of
BMP are cultured before cryopreservation as a part of quality assur-
ance process. Usually these samples are incubated for 5–6 days.
Objectives: To describe an outbreak of contamination of BMP by
an unusual microorganism, the microbiological identiﬁcation and
infection control measures taken to investigate and contain the
outbreak.
Methods: BMP samples were inoculated into aerobic bottles and
cultured using a continuously monitored broth system (BAC-
TEC). Initial identiﬁcation was carried out by subculturing on
5% sheep blood agar Gram and Ziehl-Nielsen staining. Final
identiﬁcation was carried out by PCR-restriction fragment length
polymorphism (RFLP) analysis of the 65-kDa heat shock protein
gene and sequencing of 16s rRNA gene. BMP preservation pro-
cedure practices were observed, and environmental samples
were cultured.
Results: The ﬁrst case was incidentally detected after prolonged
incubation. Following that, subsequent samples were incubated
for at least 10 days. A Gram-positive rod was isolated from ﬁve
of 45 BMP samples during May–July, 2003. Sequencing of the
pathogen 16s rRNA revealed 90% identity to the published
sequence of Mycobacterium mucogenicum. During the BMP proces-
sing, ice cubes generated by ice machine using general water sup-
ply were used for cooling. The same mycobacterium was isolated
from the ice machine, ice cubes and tap water. Substitution of ice
cubes by cooling trays, aborted the outbreak. Two patients were
transplanted by the contaminated BMP with no clinical and
microbiological consequences.
Conclusion: Water may be a source of mycobacterial contamination
of BMP. BMP samples should be routinely cultured before cryo-
preservation and incubated for a prolonged period. Molecular
methods are invaluable tools for identifying unusual pathogens.
A thorough epidemiological investigation is essential for control-
ling an outbreak.
O427 Lack of association between CMV-viraemia and
bronchiolitis obliterans syndrome in lung transplant recipients
I.A. Forrest, A. Krause, P.A. Corris, J.H. Dark, C.E. Taylor,
F.K. Gould
Newcastle upon Tyne, UK
Purpose: CMV infection is considered by many to be one of the
probable risk factors for developing BOS. Published evidence is
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controversial. Some transplant centres employ aggressive CMV-
prophylaxis regimes to prevent early or late CMV-related compli-
cations. We describe our experience with prospective CMV sur-
veillance using quantitative PCR (QPCR) and the subsequent
development of BOS.
Method: Case note survey of adult lung transplant recipients (LTx)
between January 2000 and November 2001. Patients who were
CMV-positive prior to transplantation (IgG+) and CMV mis-
matches (MM ¼ D+/R-) were followed with weekly CMV QPCR.
MM received prophylaxis with oral ganciclovir for 3 months.
Spirometry and ﬂow volume measurements were performed at
regular intervals. Development of BOS was assessed by ISHLT cri-
teria during follow-up period (22–45 months). Bronchoalveolar
lavage and transbronchial biopsies were performed at 1, 4, 12, 26
and 52 weeks and whenever clinically indicated. CMV D-/R- LTx
served as control group. Recipients were divided into three
groups according to CMV QPCR values (copies/ml) (i) 103–104,
(ii) 104–105 and (iii) 105–107.
Results: Nine of 50 patients were MM, eight of these had positive
QPCRs: one in group (i), three in (ii), and four in (iii). Three
patients developed CMV disease and were treated. One asympto-
matic patient in group (iii) developed BOS at 6 months. 16 of 22
IgG+ patients were QPCR-positive: Five in group (i), six in
(ii), and ﬁve in (iii). Five patients were symptomatic, four of these
were treated. Three asymptomatic patients (one QPCR-negative,
two in group (i) developed BOS at 20, 29 and 6 months, respec-
tively. Five of 19 patients from the D-/R- control group developed
BOS.
Conclusion: We did not ﬁnd any correlation between either CMV-
QPCR results or CMV disease and BOS development in our sur-
veillance group. Although the ﬁgures are small, we are encour-
aged that oral ganciclovir prophylaxis is only justiﬁed to protect
the CMV-MM high risk group.
O428 Correlation between HHV8 infection and Kaposi’s
sarcoma in a group of heart and lung transplant recipients
B. Nocita, F. Poletti, B. Castiglioni, F. Farchi, S. Perrotta,
M. Vigano`, M. Andreoni, L. Minoli
Pavia, Rome, I
Objective: The aim of this retrospective study was to evaluate the
seroprevalence of human herpesvirus 8 (HHV8) in a group of 77
solid organ recipients (63 heart, 13 lung and one heart–lung)
transplanted at our Division of Cardiosurgery from 1997 to 2002
and in 62 donors, to detect seroconversion after transplantation
and to assess the risk of developing KS in pretransplant positive
patients, post-transplant seroconverted patients and seronegative
patients.
Methods: Serum samples of recipients and donors, collected before
transplantation, were tested by an immunoﬂuorescence assay
based on BCBL-1 cell line to detect HHV-8 anti-lytic antibodies.
After transplantation at least one serum sample was tested for
each patient seronegative before transplant to detect seroconver-
sion. Diagnosis of KS was made clinically during follow-up vis-
its and conﬁrmed by hystological examination.
Results: Of the 77 pretransplant serum samples, 13 (16.9 %) were
positive for HHV8 antibodies. The donor’s serum was tested in 62
cases and resulted positive in ﬁve (8%). Post-transplant serocon-
version was observed in 15 organ recipients. Among these four
received an organ from a seropositive donor (D+/R-). Only one of
the mismatched patients is still seronegative (follow-up of
8 months). Four of 13 patients who were HHV8-seropositive
before transplantation developed KS, corresponding to an inci-
dence of 30.7%; in these patients the immunosuppressive regimen
was standard with cyclosporin or tacrolimus plus prednisone and
the median interval between transplantation and diagnosis of KS
was 2 months (range 1–35 months). However none of the 49 ser-
onegative patients and none of the 15 seroconverted patients at
the moment have developed clinical KS (medium follow-up of
35.7 months).
Conclusion: This study suggests that HHV8 antibody detection is a
useful means to recognise heart and lung transplanted patients at
higher risk of KS, particularly in geographical areas where sero-
prevalence is higher than average, because HHV8 seropositivity
appears to have predictive value for an early onset of KS. How-
ever, D+/R- mismatch does not seem to represent a risk of iatro-
genic KS. Reducing the degree of immunosuppression
prematurely could play a critical role in preventing KS in HHV8-
infected recipients.
O429 Documented bacterial and fungal infections in
orthotopic liver transplant recipients: an Italian multicentre
study in 416 patients
C. Viscoli, B. Bucci, M. Machetti, M. Spada, P. Amoroso, P. Burra,
A. De Gasperi, G. Ferretti, G. Guaraldi, A. Pellizzari, E. Regalia,
G. Sangiorgi, P. Toniutto, L. Boni
Genoa, Bergamo, Naples, Padua, Milan, Rome, Modena, Bologna,
Udine, I
Objectives: The aim of this study was to understand the natural
history of infection in liver transplant recipients.
Methods: We prospectively studied incidence, main clinical
characteristics, aetiology and outcome of documented infections
developing during the ﬁrst 4 months after transplant in 416
patients. who underwent liver transplantation from 1999 to 2001
in 10 liver transplant centers in Italy.
Results: The patients’ mean age was 46 years and the UNOS score
was 1 in 5% (22/416), 2a in 46% (192/416), 2b in 1.7% (109/416),
and 3 in 21% (86/416) of the patients (21% missing data). Among
patients with liver cirrhosis, 12% were Child A, 25%, Child B and
44% Child C. Sixty-one of 416 patients (15%) received a split
transplant, and 328 (78%) a whole transplant (27 missing). The
overall number of patients who had at least one documented
infection was 162/416 (39%). A total of 287 episodes were identi-
ﬁed, according to strict clinical and microbiological deﬁnitions
(6% of the patients had four or more episodes). Of 287 isolated
pathogens, 147 (51%) were Gram-positive cocci, 115 (40%) Gram-
negative rods and 25 (9%) fungi. Enterococci, staphylococci and
Pseudomonas accounted for 21, 28 and 23% of all pathogens iso-
lated. The overall crude mortality rate at 120 days after transplan-
tation was 12% (50/416).
Conclusions: The infection was considered to be the main or an
associated cause of death in 28/416 patients (7%), while the
remaining 22 patients died from other reasons.
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